



RANGER MEDIC HANDBOOK 2019

MEDICAL DIRECTION

Hemorrhage remains the number one cause of preventable death on the battlefield. Evaluate and treat each patient in accordance with protocols. Ranger medics must apply thought and cannot blindly follow algorithms. Since hemorrhage accounts for approximately 90% of preventable battlefield death always consider and treat for hemorrhagic shock when in doubt. Although medics should follow the MARCH algorithm always ask yourself, "What is killing my patient now?" Act on that question regardless of the algorithm if there is a clear cause. Patients may stop breathing because of hemorrhage. Treating hemorrhage remains a higher priority than airway control or breathing assistance.

Ranger medics will always train and master the basics before pursuing more advanced skills, procedures, or techniques. While these skills are care enhancing the basics of TCCC will save the most lives on the battlefield.

COMMONLY ASKED QUESTIONS

1. TXA may be predrawn into a STERILE 10cc syringe. This should be replaced every 7 days due to bacterial infection risk.
2. Although the data is not clear at this time it is likely best practice to administer TXA 2 grams IV/IO flush as the initial dose and then do not redose. Ranger medics are approved to pre-draw 2 grams TXA and give this as an initial dose. However, the standard 1 gram dose followed by a 2nd gram after blood products is still acceptable until the data becomes more clear. We anticipate changing this protocol to reflect the initial 2 gram bolus with the 2020 updates.
3. Do not clamp chest tubes after an arbitrarily defined output. The chances of clamping causing tamponade are low but the bleeding will continue. Clamping will make it impossible to measure the bleeding and will also cause ventilatory complications.
4. In hemorrhagic shock the priority and focus of the Ranger medic should be administering blood products; do not delegate this important task. TXA, calcium, and other adjuncts should not delay blood products.
5. Cold stored blood products should be warmed. However, cold blood is better than no blood. If warming will cause delays then start transfusing without a warmer. DO NOT PLAN TO NOT HAVE A WARMER.
6. Your medical direction only comes from those within Ranger Regiment. While we appreciate the experts that give advice and learn from them they will never dictate your scope of practice. Do not contradict your Ranger medical leadership by following outside advice.
7. The 75th Ranger Regiment does not promote commercial products or companies. No medic will be mandated to carry a specific product unless a clear, overwhelming, significant advantage can be proven.
8. Product specific protocols have been removed from this handbook. Follow specific product instructions and train with each product that will be used in combat prior to deployment. This handbook will not instruct on every product available for use.
9. Annual updates will be clarified in this section.

TABLE OF CONTENTS

1. CASUALTY RESPONSE SYSTEMS

| | |
|--|----|
| Forward | 2 |
| Ranger Medic Charter | 3 |
| Regimental Medical Charter | 3 |
| Senior Medic Duties & Responsibilities | 4 |
| Scope of Practice | 5 |
| 8 Critical RFR Tasks | 5 |
| Standing Orders and Protocol Guidance | 8 |
| Tactical Combat Casualty Care (TCCC) | 12 |

2. PRIMARY TRAUMA PROTOCOLS

| | |
|---|----|
| Tactical Triage Protocol | 15 |
| Tactical Trauma Assessment | 17 |
| Hemorrhage Management Protocol | 19 |
| Tourniquet Application Procedure | 21 |
| Tourniquet Conversion Procedure | 22 |
| Airway Management Protocol | 23 |
| Surgical Cricothyroidotomy Procedure | 25 |
| Thoracic Trauma Management Protocol | 26 |
| Needle Chest Decompression Procedure | 28 |
| Chest Tube Insertion and Finger Thoracostomy Procedure | 29 |
| Tactical Damage Control Resuscitation Protocol | 30 |
| Shock Management Protocol | 32 |
| Saline Lock & Intravenous Access Procedure | 33 |
| External Jugular Intravenous Cannulation Procedure | 34 |
| Sternal Intraosseous Infusion Procedure | 35 |
| Intraosseous Infusion Procedure (Non-Sternal) | 36 |
| Hypothermia Prevention & Management Procedure | 37 |
| Head Trauma Management Protocol | 38 |
| Traumatic Brain Injury (Concussion) Management Protocol | 40 |
| Abdominal Trauma Management Protocol | 42 |
| Hemostatic Agent Application Procedure | 43 |
| IV Fluid Warmer Procedure | 44 |
| Abdominal Trauma Management Protocol | 46 |
| Blast Injury Assessment | 44 |
| Eye Injury Management Protocol | 45 |
| Lateral Canthotomy Procedure | 47 |
| Seizure Management Protocol | 48 |
| Spinal Cord Trauma Management Protocol | 50 |
| Orthopedic Trauma Management Protocol | 52 |
| Burn Management Protocol | 54 |
| Pain Management Protocol | 56 |
| Procedural Analgesia Protocol | 58 |
| Regional Anesthesia | 59 |
| Extended Austere Care Protocol | 60 |
| Blood Transfusion Procedure | 63 |
| Foley Catheterization Procedure | 66 |
| Crush Syndrome Management Protocol | 67 |
| Evacuation Protocol | 68 |
| MEDEVAC Request, MIST, & SIT Report | 70 |
| Evacuation Patient Packaging | 71 |
| Evacuation Patient Handover | 72 |
| Skedco Horizontal Hoist Procedure | 73 |
| Skedco Vertical Hoist Procedure | 74 |
| CBRN | 75 |
| CBRN CCP | 76 |
| TICs/TIMs Box | 77 |
| Chemical Casualty Triage Table | 78 |
| CBRN – Nerve Agents | 79 |
| CBRN – Vesicant Agents | 80 |

| | |
|--------------------------------|----|
| CBRN – Cyanide Agents | 80 |
| CBRN – Pulmonary Agents | 81 |
| CBRN Quick Reference Cards | 82 |
| Chemical Agent Treatment Guide | 85 |
| Notes | 86 |

3. TACTICAL MEDICAL EMERGENCY PROTOCOLS (TMEPs)

| | |
|---|-----|
| Medical Patient Assessment Protocol | 91 |
| Altitude Medical Emergency Management Protocol | 93 |
| Anaphylactic Shock Management Protocol | 95 |
| Behavioral Emergency Management Protocol | 97 |
| Assessment and Management of Suicidal Risk | 99 |
| Hyperthermia (Heat) Management Protocol | 104 |
| Hypothermia Prevention & Management | 106 |
| Abdominal Pain (includes Surgical Abdomen, GERD, Dyspepsia) | 108 |
| Allergic Rhinitis / Hay Fever | 108 |
| Asthma (Reactive Airway Disease) | 108 |
| Barotrauma | 109 |
| Bronchitis | 109 |
| Cellulitis / Cutaneous Abscess | 110 |
| Chest Pain | 110 |
| Compartment Syndrome | 111 |
| Conjunctivitis | 111 |
| Constipation / Fecal Impact | 111 |
| Contact Dermatitis | 112 |
| Corneal Abrasion / Corneal Ulcers | 112 |
| Cough | 113 |
| Deep Vein Thrombosis (DVT) | 113 |
| Dehydration | 113 |
| Dengue Fever | 114 |
| Dental Pain | 114 |
| Determination of Death / Discontinuing Resuscitation | 114 |
| Electrocution | 115 |
| Envenomation – Arthropod (Spider & Scorpion) | 115 |
| Envenomation – Insect, Hymenoptera (Bee, Wasp, Hornet) | 115 |
| Envenomation – Marine | 116 |
| Envenomation – Snake | 116 |
| Epistaxis | 117 |
| Flank Pain (includes Renal Colic, Pyelonephritis, Kidney Stones) | 117 |
| Frostbite & Frostnip | 117 |
| Fungal Skin Infection | 118 |
| Gastroenteritis (Diarrhea / Nausea / Vomiting) | 118 |
| Headache | 119 |
| Headache (Migraine Origin) | 119 |
| HIV Post-Exposure Prophylaxis | 120 |
| Ingrown Toenail | 120 |
| Insomnia | 121 |
| Joint Infection | 121 |
| Laceration | 121 |
| Loss of Consciousness (without Seizure) / Syncope | 122 |
| Malaria | 122 |
| Meningitis | 123 |
| Motion Sickness & Prevention | 123 |
| Nausea & Vomiting | 123 |
| Otitis Externa (Outer Ear Infection or Swimmer's Ear) | 124 |
| Otitis Media (Middle Ear Infection) | 124 |
| Pharyngitis (Oral Pharyngeal Infections including Viral, STREP, Epiglottitis, Peritonsillar Abscess, Mononucleosis) | 125 |
| Pneumonia | 125 |
| Pulmonary Embolism | 126 |
| Rabies Post-Exposure Prophylaxis | 126 |
| Rectal Bleeding | 126 |
| Rhabdomyolysis | 127 |
| Sepsis / Septic Shock | 127 |
| Smoke Inhalation | 127 |

| | |
|---|-----|
| Spontaneous Pneumothorax | 128 |
| Subungal Hematoma | 128 |
| Testicular Pain | 128 |
| Upper Respiratory Infection / Common Cold | 129 |
| Urinary Tract Infection | 129 |
| Notes | 130 |

4. RANGER PHARMACOLOGY

| | |
|--|-----|
| Ranger Medic Pharmacology Standards | 133 |
| Pharmacology Guidelines | 134 |
| Acetaminophen (Tylenol) | 135 |
| Acetazolamide (Diamox) | 135 |
| Acetylsalicylic Acid (Aspirin) | 136 |
| Albuterol (Proventil) | 136 |
| Amoxicillin/Clavulanate (Augmentin) | 137 |
| Atavaquone-Proguanil (Malarone) | 137 |
| Atropine Sulfate | 137 |
| Azithromycin (Zithromycin, Z-Pak) | 138 |
| Bacitracin | 138 |
| Benzathine-Penicillin-G (Bicillin) | 138 |
| Benzonatate (Tessalon Perles) | 139 |
| Bisacodyl (Dulcolax) | 139 |
| Bupivacaine (Marcaine) | 139 |
| Cefazolin Sodium (Ancef) | 140 |
| Ceftriaxone (Rocephin) | 140 |
| Cetirizine (Zyrtec) | 140 |
| Cimetidine (Tagamet) | 141 |
| Ciprofloxacin (Cipro) | 141 |
| Clindamycin (Cleocin) | 142 |
| Cyclobenzaprine (Flexeril) | 142 |
| Dexamethasone (Decadron) | 143 |
| Dextrose (D50) | 143 |
| Diazepam (Valium) | 144 |
| Diphenhydramine (Benadryl) | 145 |
| Docusate (Colace) | 145 |
| Doxycycline | 146 |
| Epinephrine (including Epi-Pen) | 146 |
| Ertapenem (Invanz) | 147 |
| Erythromycin Ophthalmic Ointment | 147 |
| Eszopiclone (Lunesta) | 147 |
| Fentanyl Oral Lozenge (Actiq) | 148 |
| Fexofenadine (Allegra) | 148 |
| Colace (see Docusate) | 157 |
| Fluconazole (Diflucan) | 148 |
| Fluticasone (Flonase) | 149 |
| Gatifloxacin Ophthalmic Solution (Zymar) | 149 |
| Guaifenesin | 150 |
| Hydrocortisone Cream | 150 |
| Hydromorphone (Dilaudid) | 151 |
| Ibuprofen (Motrin, Advil) | 151 |
| Ketoconazole | 152 |
| Ketamine | 152 |
| Ketorolac (Toradol) | 153 |
| Lactated Ringers (LR) | 153 |
| Levetiracetam (Keppra) | 153 |
| Levofloxacin (Levoquin) | 154 |
| Lidocaine (Xylocaine) | 154 |
| Loperamide (Imodium) | 155 |
| Loratadine (Claritin) | 155 |
| Maalox (Aluminum Hydroxide, Magnesium Hydroxide) | 155 |
| Meclizine (Antivert) | 156 |
| Melatonin | 156 |
| Meloxicam (Mobic) | 156 |
| Methocarbamol (Robaxin) | 157 |

| | |
|--|-----|
| Methylprednisolone (Solu-Medrol) | 157 |
| Metronidazole (Flagyl, Metrogel) | 157 |
| Midazolam (Versed) | 158 |
| Modafinil (Provigil) | 158 |
| Morphine Sulfate (MSO4) | 159 |
| Moxifloxacin (Avelox) | 159 |
| Mupirocin (Bacroban) | 160 |
| Naloxone (Narcan) | 160 |
| Naphazoline (Naphcon, Vascon, Clear Eyes) | 161 |
| Naproxen (Naprosyn) | 161 |
| Nitrofurantoin (Macrobid) | 162 |
| Ofloxacin Otic (Floxin) | 162 |
| Omeprazole (Prilosec) | 162 |
| Ondansetron (Zofran) | 163 |
| Oxymetazoline (Afrin) | 163 |
| Plasma-Lyte A | 163 |
| Polyethylene Glycerol (Miralax) | 164 |
| Prednisone | 164 |
| Primaquine | 164 |
| Promethazine (Phenergan) | 165 |
| Pseudoephedrine (Sudafed) | 165 |
| Rabeprazole (Aciphex) | 166 |
| Ranitidine (Zantac) | 166 |
| Rizatriptan (Maxalt) | 166 |
| Scopolamine (Transderm-Scop) | 167 |
| Sodium Chloride, 0.9% (Normal Saline) | 167 |
| Sodium Chloride, 3% (Hypertonic Saline) | 167 |
| Sumatriptan (Imatrex) | 168 |
| Terbinafine (Lamisil) | 168 |
| Tetracaine | 168 |
| Tranexamic Acid (TXA) | 169 |
| Trimethoprim-Sulfamethazole (TMP-SMZ, Bactrim, Septra) | 169 |
| Zolpidem (Ambien) | 170 |
| Tylenol (see Acetaminophen) | 156 |
| Ultram (see Tramadol) | 170 |
| Valium (see Diazepam) | 177 |
| Versed (see Midazolam) | 151 |
| Zantac (see Ranitidine) | 174 |
| Zithromycin / Z-Pak (see Azithromycin) | 181 |
| Zofran (see Ondansetron) | 161 |
| Notes | 172 |
| Drug Quick Reference | 174 |

5. SPORTS MEDIC SCOPE OF PRACTICE

| | |
|---------------------------------------|-----|
| Shoulder – Traumatic & Acute Pain | 176 |
| Arm / Elbow – Traumatic & Acute Pain | 177 |
| Hand / Wrist – Traumatic & Acute Pain | 178 |
| Hip – Traumatic & Acute Pain | 179 |
| Leg – Traumatic & Acute Pain | 180 |
| Knee – Traumatic & Acute Pain | 181 |
| Ankle – Traumatic & Acute Pain | 182 |

6. MWD / CANINE TRAUMA & EMERGENCY PROTOCOLS

| | |
|--|-----|
| Canine Patient Assessment | 185 |
| Canine Trauma & Shock Management Protocol | 186 |
| Canine Field Blood Transfusion Procedure | 189 |
| Canine Injection & IV Sites | 190 |
| Canine Heat Injury | 191 |
| Canine Gastric Dilatation Volvulus (GDV) | 191 |
| Canine Altitude Sickness and Pulmonary Edema | 192 |
| Canine Seizure Management | 192 |
| Canine Toxicities – Explosives, Others | 192 |
| Canine CBRNE | 193 |

| | |
|--------------------|-----|
| MPC Reference Card | 197 |
|--------------------|-----|

7. MEDICAL PLANNING & CCP OPERATIONS

| | |
|--|-----|
| Casualty Response Planning | 199 |
| Pre-Deployment Requirements | 200 |
| Medical Threat Assessment | 200 |
| Higher Headquarters Orders and Guidelines | 201 |
| Determine Medical Assets | 202 |
| Tactical Medical Support Plan Development | 208 |
| Briefs, Rehearsals and Pre-Combat Inspections | 213 |
| Sustained Combat Operations & Time Sensitive Targets | 215 |
| Casualty Collection Point Operations | 218 |
| Relief-in-Place Operations | 225 |

8. HAZARDOUS TRAINING MEDICAL COVERAGE

| | |
|---|-----|
| Hazardous Training Medical Coverage Duties & Responsibilities | 228 |
| Hazardous Training Medical Coverage Planning | 229 |
| Medical Coverage During Tactical Exercises | 230 |
| Pre-Coverage Inspections | 230 |
| Hazardous Training Medical Coverage Equipment Requirements & Checklists | 231 |

9. PACKING LISTS

| | |
|--|-----|
| Kit / Aid Bag Minimum Stock | 233 |
| Advanced Ranger First Responder Medical Kit Contents | 234 |
| Ranger Bleeder Control Kit Contents | 234 |

10. REFERENCES & ABBREVIATIONS

| | |
|----------------------------|-----|
| Abbreviations & Acronyms | 236 |
| MACE 2 | 242 |
| Reference Charts | 256 |
| Conversion Charts | 257 |
| Neuro Exam Reference Chart | 258 |
| Ketamine Drip Table | 259 |
| ARDSNET Vent Settings | 260 |
| Ranger Casualty Card | 263 |
| Prolonged Field Care Card | 264 |
| TBI RTD Card | 266 |

SECTION ONE

**THE RANGER MEDIC
&
CASUALTY RESPONSE
SYSTEMS**



FORWARD

The 75th Ranger Regiment has been continuously engaged in combat operations since the beginning of the Global War on Terrorism. Since Oct 2001, the Regiment has remained the standard for pre-hospital care. Ranger medics continue to be at the cutting edge of battlefield medicine driving changes to TCCC. Given the Ranger mission, life threatening injuries will still be encountered as we continue prosecuting our nation's enemies.

Though we have lost too many Ranger brethren, executing the fundamentals of the unit's casualty response and medical programs has produced astounding results. Based on the principles that have evolved in the last two decades, the 75th Ranger Regiment standard of medical care is no deaths from preventable causes of combat death. This hallmark is a direct result of the intense medical training and enabling capability of individual Rangers, Ranger Leaders, and Ranger Medical personnel.

The success of Ranger medicine is the success of the 75th Ranger Regiment. The Ranger First Responder, Advanced Ranger First Responder, Ranger Medic, and Ranger leaders have made casualty scenarios into a battle drill. Survivability does not depend solely on the Ranger medic but on the effectiveness of the Ranger team to respond to a fallen comrade. The chain of survival starts in training and allows for both success of the mission and care for the casualty.

"Mastery of the Basics" is and always has been a standard to live by within the 75th Ranger Regiment. The mastery of casualty response and medical skills at all levels has saved numerous Ranger lives. Rangers are continuously self-critical and use every training or real casualty scenario to improve. The unit also looks for emerging technology and techniques and swiftly adapts them to the combat environment.

The foundation of the unit's medical programs remains based on the integrated tenets of Tactical Combat Casualty Care (TCCC), innovative medical planning, and casualty response training for Ranger leaders, which when employed to their fullest saves lives on the battlefield. Through the continuous evolution of our training and equipment programs, the Regiment will always strive to be the tip-of-the-spear for developing the battlefield medicine standard of care for the Infantry and Special Operations communities.

The 75th Ranger Regiment and Ranger Medical Team will continue to hold true the Ranger Creed and the unit charters, and complete any mission placed before it.

I will never leave a fallen comrade...

RANGER MEDIC CHARTER

Shoot and engage targets to defend casualties and self while tactically remaining a combat multiplier with highly-dispersed and highly-mobile combat formations in an austere environment.

A competent provider of advanced trauma management care whose absolute mastery of the basics sustains casualties using pre-hospital trauma life support and tactical combat casualty care protocols and an advanced scope of practice.

An Advanced Tactical Paramedic who assists licensed medical providers with medical emergencies and routine health care encountered while in garrison, training, and during deployments.

REGIMENTAL MEDICAL CHARTER

Provide optimal tactical health care support in accordance with TCCC and the Ranger Medic Handbook.

“Absolute Mastery of the Basics”

Train and operate medics that are relatively independent with highly-dispersed highly mobile combat formations in an austere environment.

“Advanced skills within a Scope of Practice”

Train and operate medics to move tactically through unsecured areas that can communicate, engage targets and remain a combat multiplier.

“Be a Ranger on the battlefield”

Provide training to individual Rangers and leaders to provide first responder care and command/control of casualty response operations.

“Teach and mentor Rangers and Leaders in Combat Medicine”

Evaluate and develop casualty response tactics, techniques, equipment and procedures as the standard bearer of tactical medicine for the armed forces.

“Set the Standard for the Armed Forces in Tactical Medicine”

SENIOR ENLISTED MEDICAL ADVISOR DUTIES AND RESPONSIBILITIES

The SEMA is customarily known as a company senior medic, and he traditionally functions in the capacity of a squad leader. However, in the context of the Ranger Medic Handbook the senior medic duty description will be used to define the responsibilities of the highest ranking and most experienced medic present at any given location and time. This medic is designated as the “senior medic” at that specific location and thus is responsible for the duties and responsibilities as listed below.

- ❖ **Principal medical advisor to the commander and senior enlisted advisor**
- ❖ **Provide and supervise advanced trauma management within protocols and sick call within scope-of-practice**
- ❖ **Lead, supervise, and train junior medics**
 - Individual training
 - Health and welfare
 - Development and counseling
 - Troop leading procedures and pre-combat inspections (PCIs)
- ❖ **Plan, supervise, and conduct casualty response training for Rangers and Leaders**
 - Ranger First Responder (RFR)
 - Casualty Response Training for Ranger Leaders (CRTRL)
 - Opportunity training / Spot-checking
- ❖ **Maintain company/platoon-level medical equipment and supplies**
 - Accountability / Inventory
 - Maintenance / Serviceability
 - PCI of Individual Ranger Bleeding Control Kits
 - PCI of Squad Casualty Response Kits
 - Requisition and receive Class VIII from appropriate source
- ❖ **Plan, coordinate, and execute medical planning for company level operations**
 - Task organization of company medics
 - On-Target casualty response plan
 - CASEVAC from target to next higher medical capability
- ❖ **Conduct after action reviews and report and archive medical lessons learned**
- ❖ **Monitor the status of health in the unit / element**
 - Physically limiting profiles
 - Command health reporting and tracking
 - MEDPROS data entry and information review

SCOPE OF PRACTICE

CASUALTY RESPONSE SYSTEM – The Regiment’s solution for managing combat casualties is to recognize that the problem is solved by the entire unit, not just medics, and that a casualty can occur during any phase of an operation. The principles of the casualty response system are the first responder to a casualty can be any Ranger in the unit; that medical personnel manage casualty care; and that leaders run the mission. When a casualty is incurred, it immediately becomes a component of the unit’s mission to extract, treat, and evacuate the casualty while still completing the assigned combat mission as an integrated team. Thus, every member of the unit must maintain first responder medical skills, medics must be highly proficient, and leaders must know how to properly integrate casualty management into any phase of an operation.

RANGER FIRST RESPONDER (RFR) – A Ranger First Responder is the baseline for all Rangers. This level of training equips all Rangers with treatment skills as a secondary mission to their primary mission role. The RFR medical capability provides a tactical combat casualty care skillset with specific trauma skills. A RFR is always trained and employed in conjunction with a platoon medic or higher but has the skill set to provide basic medical interventions independent of any trained medical personnel. This skillset will be trained and verified annually.

| THE 8 CRITICAL RFR TASKS | |
|---------------------------------|--|
| CARE UNDER FIRE | <p>Contain Scene and Assess Casualties</p> <ul style="list-style-type: none"> ○ Return Fire and Secure Scene ○ Direct Casualties to Cover ○ Evaluate for Life Threatening Injuries ○ Triage – Immediate, Delayed, Minimal, Expectant ○ Call Medical Personnel for Assistance as Required <p>Rapidly Identify and Control Massive Hemorrhage</p> <ul style="list-style-type: none"> ○ Direct & Indirect Pressure ○ Tourniquet ○ Emergency Trauma Dressing |
| TACTICAL FIELD CARE | <p>Inspect and Ensure Patent Airway</p> <ul style="list-style-type: none"> ○ Open and Clear Airway ○ Nasopharyngeal Airway <p>Treat Life Threatening Torso Injuries</p> <ul style="list-style-type: none"> ○ Occlusive Seal Dressing ○ Needle Decompression ○ Abdominal wound management <p>Inspect for Bleeding, Gain IV Access, Manage Shock</p> <ul style="list-style-type: none"> ○ Head to Toe Blood Sweeps ○ 18 Gauge Saline Lock ○ IV Fluids when dictated by Shock ○ Prevent Hypothermia <p>Control Pain and Prevent Infection</p> <ul style="list-style-type: none"> ○ Combat Wound Pill Pack |
| TACTICAL EVACUATION | <p>Aid and Litter Team</p> <ul style="list-style-type: none"> ○ Package and Prepare for Transfer ○ SKEDCO, Litters, Manual Carries <p>Leader Coordinated Evacuation</p> <ul style="list-style-type: none"> ○ Command & Control of casualty evacuation integrated with ongoing combat operation ○ Request & coordinate evacuation asset and establish evacuation site (HLZ) ○ Casualty Precedence – Critical (Urgent), Priority, Routine CASEVAC or MEDEVAC Coordination |

ADVANCED RANGER FIRST RESPONDER (ARFR) – The Advanced Ranger First Responder medical capability is a non-medical Ranger trained on specific first responder medical skills beyond the RFR level, to provide a higher level of trauma response during Ranger operations. This is the highest level of capability for non-medical Rangers. The ARFR is expected to provide limited scope trauma and emergency care in a tactical or austere setting; they may work independently or in support of a medical provider. They are proficient at advanced medical procedures and basic medication administration.

PLATOON MEDIC – The Ranger Platoon Medic is the minimum standard for an individual serving as sole medical support for a Ranger mission. The Ranger Platoon Medic is a Special Operations-Advanced Tactical paramedic (SO-ATP). The Ranger Platoon Medic provides advanced emergency medical care for critical and emergent casualties in a tactical setting with a specific focus on trauma for patient care less than 4 hours duration. These personnel are employed in disaggregated operations to ensure tactical elements have adequate advanced trauma medical capabilities. The Ranger Platoon Medic also provides medical support to the platoon outside of tactical operations, is able to treat basic medical conditions independently, and difficult medical conditions with oversight or medical direction. Ranger Platoon Medics are responsible for training and validating Ranger First Responders.

COMPANY SENIOR MEDIC – The Company Senior Medic is a Ranger Medic serving in the capacity of Provider-Extender Primary Medic for a special operations maneuver element. The Company Senior Medic is expected to independently manage multiple complex traumatic and medical problems on the modern battlefield and in remote or austere conditions. While deployed, the Company Senior Medic independently delivers a selected level of health care normally provided by mid-level practitioners. The Company Senior Medic is expected to manage and lead the company level casualty collection point (CCP). The Company Senior Medic is responsible for training and validating Ranger Platoon Medics and Advanced Ranger First Responders.

BATTALION SENIOR ENLISTED MEDICAL ADVISOR – The Battalion SEMA is a Ranger Medic capable of providing critical care and advanced resuscitative care to a Ranger maneuver element. He is an integral member of the Ranger Resuscitation Team who provides far forward critical care for complex trauma and medical patients. The Battalion SEMA is expected to manage and lead the battalion level CCP. He also trains, validates, and employs all Ranger Medics and non-medical providers.

RANGER RESUSCITATION TEAM – The Ranger Resuscitation Team provides a team-based approach capable of providing critical care and advanced procedures during SOF missions. The team is composed of the Medical Officer, Physician Assistant, and SEMA. The team can care for 2 critical care patients simultaneously for up to 6 hours while providing advanced airway interventions, ventilation, cardiovascular support, and advanced hemorrhage control.

Ranger medics provide routine garrison care to include assisting unit medical officers with daily sick call. This requires advanced knowledge in common orthopedic problems, respiratory illnesses, gastrointestinal disorders, dermatological conditions, and environmental hazard illnesses. Ranger Medics train non-medical personnel on first responder skills and preventive medicine. Ranger Medics conduct their scope of practice under the licensure of a medical director and are not independent health care providers. Ranger Medics should always obtain medical director advice and supervision for all care provided. However, on rare occasions Ranger Medics may be required to operate relatively independently with only indirect supervision in remote, austere, or clandestine locations. In these cases, it is still extremely rare that a Ranger Medic will be unable to communicate by radio, phone, or computer.

STANDING ORDERS – Advanced life support interventions, which may be undertaken *before* contacting on-line medical control.

PROTOCOLS – Guidelines for out of hospital patient care. Only the portions of the guidelines, which are designated as “standing orders”, may be undertaken before contacting an on-line medical director.

MEDICAL CONTROL / MEDICAL DIRECTOR / MEDICAL OFFICER – A licensed and credentialed medical provider, physician or physician assistant, who verbally, or in writing, states assumption of responsibility and liability and is available on-site or can be contacted through established communications. Medical care, procedures, and advanced life-saving activities will be routed through medical control in order to provide optimal care to all sick or injured Rangers. Medical Control will always be established, regardless of whether the scenario is a combat mission, a training exercise, or routine medical care. **Note that, ultimately, all medical care is conducted under the licensure of an assigned, attached, augmenting, or collocated PHYSICIAN.**

STANDING ORDERS AND PROTOCOLS

As published, these standing orders and protocols will be used ONLY by Ranger Medics currently assigned to the 75th Ranger Regiment who have demonstrated competency through Ranger Medic Assessment & Validation (RMAV) and expressly given a scope of practice by their supervising Medical Director.

PURPOSE

The primary purpose of these protocols is to serve as a guideline for tactical and non-tactical pre-hospital trauma and medical care. Quality out-of-hospital care is the direct result of comprehensive education, accurate patient assessment, good judgment, and continuous quality improvement. The protocols contained within this handbook make the following specific assumptions on when and how they are employed.

Ranger Medics may often find themselves in austere tactical environments where evacuation of a unit member to a medical treatment facility for a medical emergency would entail either significant delays to treatment or compromise the unit's mission. The disorders chosen have one of the following properties in common: they are relatively common, acute in onset; the Ranger Medic is able to provide at least initial therapy that may favorably alter the eventual outcome; the condition is either life-threatening or could adversely affect the mission readiness of the injured or ill Ranger; immediate evacuation may not be possible and, even if it is, may still entail significant delays to definitive treatment; the medical problem may worsen significantly if treatment is delayed. The Ranger Medic will contact a consulting physician as soon as feasible. Treatment will be done under the appropriate protocol.

Medical Director approved medication regimens are designed to provide the Ranger Medic the ability to manage multiple conditions without compromising standards of care. Appropriate documentation of diagnosis and treatment rendered in the patient's medical record will be accomplished when the unit returns to their forward operating base.

Unit Protocols are not designed to conduct Medical/Civic Action (MEDCAP) missions independently. Evacuation recommendations are based on the appropriate therapy per protocol being initiated on diagnosis. The definitions of Urgent, Priority, and Routine evacuations are based on the times found in Joint Publication 4-02.2 of 2, 4, and 24 hours respectively.

Unit medical officers use protocols to develop the knowledge base and capability of Ranger Medics during unit sick call. Ranger Medics should not perform any step in a standing order or protocol if they have not been trained to perform the procedure or treatment in question.

Emergency, trauma, and tactical medicine continues to evolve at a rapid pace. Accordingly, this document is subject to change as new information and guidelines become available and are accepted by the medical community. The Ranger Medic must continuously expand and sustain his knowledge base.

STANDING ORDERS AND PROTOCOLS

These standing orders and protocols are ONLY for use by Ranger Medics while providing emergency care under the license of their Medical Director. Ranger Medics who are authorized to operate under the Trauma Management Team guidelines may not utilize these standing orders outside of their military employment. Revocation of privileges will be considered by the granting authority if these standards are violated.

COMMUNICATION

In a case where the Ranger Medic cannot contact Medical Control due to an acute time-sensitive injury or illness, a mass casualty scenario, or communication difficulties, all protocols become standing orders. Likewise, in the event that Medical Control cannot respond to the radio or telephone in a timely fashion required to provide optimal care to a patient, all protocols are considered standing orders. In the event that Medical Control was not contacted, and treatment protocols were carried out as standing orders, Medical Control will be contacted as soon as feasible following the incident and the medical record (Casualty Card, SF 600 or Trauma SF 600) will be reviewed and countersigned by Medical Control. Retroactive approval for appropriate care will be provided through this process.

When communicating with medical control, a medical officer or a receiving facility, a verbal report will include the following essential elements:

1. **Provider** – name, unit, and call back phone number
2. **Patient** – name, unit, age, and gender
3. **Subjective** – findings to include chief complaint and brief history of event
4. **Objective** – findings to include mental status, vital signs, and physical exam
5. **Assessment** – to include differential diagnosis, presumed diagnosis, and level of urgency
6. **Plan** – to include treatment provided, patient response to treatment, and patient status updates

NEVER HESITATE TO CONTACT A MEDICAL DIRECTOR AT ANY TIME FOR ASSISTANCE, QUESTIONS, CLARIFICATION, OR GUIDANCE THROUGH ANY COMMUNICATIONS MEANS AVAILABLE.

PATIENT CARE DOCUMENTATION

Patient care documentation is of paramount importance and will be performed for every patient encounter using a Tactical Combat Casualty Card, Trauma SF 600 Medical Record, SF 600 Medical Record or a designated electronic health record and transported with the patient to a medical treatment facility or provider. Lack of a card or form is not an excuse for lack of documentation. Rangers Medics will use all resources available to attempt documentation for the next level provider. Documentation by writing on dressings, tape or even the patient himself is completely acceptable if other resources are not available. If time constraints that might delay the evacuation of the patient prevent real time documentation, then the Ranger Medic will document at the first available opportunity.

MEDICAL PERSONAL PROTECTIVE EQUIPMENT (PPE) AND UNIVERSAL PRECAUTIONS

Medical PPE and the concepts of universal precautions will be used whenever possible and indicated. When the circumstances allow, utilize a minimum of non-sterile exam gloves. If possible, actions normally considered sterile procedures will be conducted in as clean an environment as can be maintained. Awareness of patient protection from infection must be maintained during the execution of any protocol or procedure. Ranger Medics will conduct pre-combat inspections of all invasive or sterile materials prior to every mission and replace accordingly.

RESUSCITATION CONSIDERATIONS

Resuscitation is not warranted in patients who have sustained obvious life-ending trauma, or patients with rigor mortis, decapitation, decomposition or mass casualty situations. When reasonable, consider performing resuscitation efforts when this is your only patient. The perception of fellow Rangers and family members in this instance should be that every effort was made to sustain life. When possible, use ultrasound to confirm no cardiac activity or place EKG leads to confirm asystole in three leads and attach a copy of this strip to the medical record. Also note that, technically, only a medical officer can pronounce a patient as deceased. Refer to the protocol *Determination of Death/Discontinuing Resuscitation*.

GENERAL GUIDELINES FOR PROTOCOL USAGE

1. Documentation should not delay the treatment of the injured patient. Life-threatening problems detected during the primary assessment must be treated first.
2. Cardiac arrest due to trauma is not treated by medical cardiac arrest protocols. Trauma patients should be transported promptly to the previously coordinated Medical Treatment Facility with control of external hemorrhage, blood product resuscitation, bilateral finger thoracostomies, and other indicated procedures attempted en-route. CPR should be a last resort.
3. In patients who require a saline lock or intravenous fluids, only two attempts at IV access should be attempted in the field. Intraosseous infusion should be considered for life-threatening emergencies. Patient transport to definitive care **must not be delayed** for multiple attempts at IV access or other advanced medical procedures.
4. Medics will verbally repeat all orders received and given prior to their initiation. It is preferable that medical personnel work as Trauma Teams whenever practical.
5. Due to the high level of physical fitness of Rangers and special operations personnel, there may be a prolonged period of mental lucidity and apparent stable vital signs despite a severe injury. Always treat the injury at hand and be prepared under the assumption that the patient's condition will worsen.
6. It is understood that though oxygen is only indicated for respiratory distress or SpO2 desaturations. It will be a rare occasion in which oxygen is available during a ground tactical operation. If oxygen is available and indicated, the expectation is that a medic will administer it appropriately.
7. Highly trained Ranger Medics have a clear understanding of the circumstances to determine the

appropriate level of protocol usage. During combat operations in an austere environment, a medic will fully utilize the protocols contained within this handbook and within his scope of practice. In the non-deployed training environment within CONUS, a Ranger Medic is expected to implement the U.S. standards of care and evacuate to an appropriate medical treatment facility as previously planned. However, whether executing protocols in an austere environment or at a training exercise on a military installation, the goal of the Ranger Medic is to provide the most up to date Standard of Care.

AFTER ACTION REVIEWS (AAR) AND RANGER PRE-HOSPITAL TRAUMA REGISTRY (PHTR)

In accordance with RTC 350-29, Ranger medical personnel will submit a casualty after action review for any injury/illness that occurs on a combat target. The timeframe for reporting begins upon departing the staging base, through the combat operation, and ends upon return to staging base. Medical personnel are required to submit the Casualty AAR no later than 72 hours post mission. Casualty AARs will also be completed for injuries that occurred during the mission but are not reported or observed until after returning to the staging base. All casualty AARs are to be self-critical and lead to medical education. No comments in an AAR will be used in disciplinary matters against a medic.

TACTICAL COMBAT CASUALTY CARE (TCCC)

Trauma is the leading cause of death in the first four decades of life. Current protocols for civilian trauma care in the US are based on the Advanced Trauma Life Support (ATLS) course, which was initially conducted in 1978. Since that time, ATLS protocols have been accepted as the standard of care for the first hour of trauma management that is taught to both civilian and military providers. ATLS is a great approach in the civilian setting; however, it was never designed for combat application.

Historically, most combat-related deaths have occurred in close proximity to the point of injury, prior to a casualty reaching an established medical treatment facility. The combat environment has many factors that affect medical including temperature and weather extremes, severe visual limitations, delays in treatment and evacuation, long evacuation distances, a lack of specialized providers and equipment near the scene, and the lethal implications of combat weapons. Thus, a modified approach to trauma management must be utilized while conducting combat operations.

The tactical environment and causes of combat death dictate a different approach for ensuring the best possible outcome for combat casualties while sustaining the primary focus of completing the mission. CAPT Frank Butler and LTC John Hagmann proposed such an approach in 1996. Their article, “***Tactical Combat Casualty Care in Special Operations***”, emphasized three major objectives and outlined three phases of care.

Objectives:

- ✓ **Treat the patient**
- ✓ **Prevent additional casualties**

Phases of Care:

- 1. Care Under Fire**
- 2. Tactical Field Care**
- 3. Combat Casualty Evacuation (CASEVAC) Care**

The 75th Ranger Regiment adopted the principles of TCCC in the late 1990's and institutionalized them with training programs prior to combat operations in Afghanistan and Iraq. Today, mastering the basics of TCCC remains the bedrock of the Ranger Medic. This, along with Casualty Response Training for Ranger Leaders and dedication to meticulous medical planning, produce astounding casualty survival rates on the modern battlefield.

CARE UNDER FIRE

Care under fire is the care rendered by the first responder or combatant at the scene of the injury while he and the casualty are still under effective hostile fire. Available medical equipment is limited to that carried by the individual or by the medical provider in his aid bag.

Major goals of CUF are to move the casualty to safety, prevent further injury to the casualty and provider, stop life threatening external hemorrhage, and **gain and maintain fire superiority – the best medicine on the battlefield!**

TACTICAL FIELD CARE

Tactical Field Care is the care rendered by the first responder or combatant once he and the casualty are no longer under effective hostile fire. TFC may consist of rapid treatment of the most serious wounds with the expectation of a re-engagement with hostile forces at any moment, or there may be ample time to render whatever care is possible in the field. It also applies to situations in which an injury has occurred, but there has been no hostile fire. Available medical equipment is still limited to that carried into the field by unit personnel. Time to evacuation to a medical treatment facility may vary considerably. Remember – effective hostile fire could resume at any time.

TACTICAL EVACUATION CARE

Tactical Evacuation Care is the care rendered once the casualty has been picked up by an aircraft, vehicle or boat. Additional medical personnel and equipment that may have been pre-staged should be available in this phase of casualty management. The term "Tactical Evacuation" encompasses both Casualty Evacuation (CASEVAC) and Medical Evacuation (MEDEVAC).

TCCC Concepts

Casualty scenarios in combat usually entail both a medical as well as a tactical problem. We want the best possible outcome for both the casualty and the mission. Good medicine can sometimes be bad tactics; bad tactics can get everyone killed or cause the mission to fail. Doing the **RIGHT THING** at the **RIGHT TIME** is critical.


Hypotensive Resuscitation

Goals of Fluid Resuscitation Therapy: 1) Improved state of consciousness, 2) Palpable radial pulse, 3) Avoid over-resuscitation of shock. Basing the titration of fluids upon a monitored physiologic response may avoid the problem of excessive blood pressure elevation and fatal re-bleeding from previous clotted injury sites. **BLOOD** and blood products are the only fluid for trauma resuscitation!

Preventing the Trauma Lethal Triad

Hypothermia is a significant concern in any trauma victim because it leads to hypothermia-induced coagulopathy by both decreasing platelet function and slowing enzyme activity in the coagulation cascade.

Prevention of hypothermia, along with hemorrhage control and fluid resuscitation, will help maintain the casualty's ability to generate heat.



SECTION TWO
PRIMARY TRAUMA
PROTOCOLS



Triage



Triage

Triage is the process for sorting casualties into groups based on their need for or likely benefit from immediate medical treatment. Obviously, all casualties need treatment. However, accurate triage aids the provider in deciding which casualties have the greatest likelihood of survival if immediate care is rendered and which casualties can wait until the immediate care is completed. Triage ensures the greatest care for the greatest number and the maximal utilization of medical personnel, equipment, evacuation and facilities. At any location or CCP, the most experienced provider assumes the role of triage officer. All casualties, including traumatic brain injury, must be assumed to have multi-system trauma until proven otherwise.

Triage is a dynamic and continuous process the must continue as the casualty's status changes.

TCCC Application

Care Under Fire: CUF is primarily self-aid and buddy-aid. If a patient is conscious, then direct to seek cover and provide self-treatment. If a patient is non-responsive, when tactically feasible, move the patient to cover. Address only immediate life-threatening hemorrhage if possible. Continue the mission/fight. Leave a Ranger Buddy or report the GPS location of any patients who are separated from the maneuver element for later recovery.

Tactical Field Care: Direct all casualties through a choke point and triage into the CCP to provide appropriate treatment and accountability. Perform initial tactical trauma assessments on casualties. Separate casualties into 4 distinct categories using the UPR method. If a casualty can walk and talk (can follow instructions or describe injuries), then they are most likely going to be categorized as Routine. Routine casualties should tend to their own wounds if possible. Routine casualties may also assist with other casualties. If a casualty has obvious signs of death, then they should be categorized as Expectant. Casualties who require life-saving interventions, cannot obey simple commands, have abnormal (or no) radial pulses, or are in respiratory distress are categorized as Urgent. All others will most likely fall into the Priority category. As soon as initial triage is completed, the primary effort is the life-saving interventions for the Urgent casualties. When moving from patient to patient, each is rendered a complete trauma assessment in a head-to-toe-treat-as-you-go manner. When the provider has completed with one category group, he moves to the next. The provider should return to the Urgent category group routinely, or after each other group is completed, to assess and provide continued resuscitation as needed. When all category casualties have been completed, the provider starts over with the Urgent group and cycles back through all casualties in each category. Triage is a constantly continuing process until all casualties have been evacuated. In some cases, depending on injuries, interventions completed, or emerging complications, a casualty may be downgraded to a lower category or upgraded to a higher category. There may be instances of a small number of casualties in which a single patient is obviously Expectant while others are obviously minimal. In this case, a patient normally classified as Expectant may be the focus of your attention. This action is for the benefit of the patient's comrades in that you attempted everything possible to save his life. Expectant casualties receive comfort measures and pain medications.

Tactical Evacuation: Triage is again conducted as casualties are packaged and prepared for evacuation. In this phase, triage is categorized into evacuation precedence of Urgent, Priority, or Routine. Urgent casualties are those that require surgical or advanced medical intervention within 2 hours to save life, limb or eyesight. Priority casualties are those that require evacuation to a higher level of care within 4 hours. Routine casualties are those that remain including minimal, expectant, and depending on the tactical situation, KIA or DOW. Some minimal casualties may not require evacuation and can exfiltrate with the unit for further medical treatment upon return to base. It is critical that the medic has a good understanding of the evacuation assets/capabilities and receiving facility's capabilities. When evacuation is imminent, casualties should be arranged in evacuation precedence keeping in mind the capability of the evacuation asset. In cases of a small asset (MEDEVAC or MH60) that can carry only a few of your casualties, then urgent casualties are loaded and evacuated first while remaining casualties are evacuated on subsequent turns of the asset. In cases of a large asset (MH47), then priority litter casualties are loaded first followed by urgent litter casualties. This is so that the urgent casualties will be the first unloaded at the receiving facility. Minimal or walking wounded are loaded last. In all cases, the evacuation medic/ provider will over-ride the ground medic in casualty loading based on placement of resuscitation equipment on the vehicle or aircraft.

Extended Care: Triage continues through extended care as casualty conditions may improve or deteriorate and require less or more medical care over time. TCCC management does not stop until a casualty is turned over to an equal or higher level of care.

Triage Categories & Evacuation Precedence

Urgent: This category includes those casualties who require an immediate life-saving intervention or surgery. Example casualties include those that are hemodynamically unstable, have airway complications, chest or abdominal injuries, massive external hemorrhage, shock or burns >20% TBSA. Casualties require evacuation within 2 hours.

Priority: This category includes those wounded who may need surgery, but whose condition permits delay in treatment without unduly endangering life, limb or eyesight. Example casualties include those with no evidence of shock, large soft tissue wounds with controlled bleeding, fractures of major bones, torso wounds with controlled bleeding or burns <20% TBSA. Casualties require evacuation within 4 hours.


Routine: This category is for casualties often referred to as —walking wounded. These casualties have minor injuries such as small burns, lacerations, abrasions, and small bone fractures. Casualties require evacuation within 12 hours.

Expectant (Routine): This category is for casualties who have wounds so extensive that even if they were the only casualty they would have little hope for survival. Examples of expectant casualties are those that are unresponsive with massive penetrating head trauma, massive torso trauma or no signs of continued life.


Tactical Triage Protocol



CARE UNDER FIRE PHASE



TACTICAL FIELD CARE PHASE



Tactical Trauma Assessment



Tactical Patient Assessment

Follow TCCC Guidelines of Care Under Fire, Tactical Field Care, and Tactical Evacuation Care.

The acronym MARCH is recommended to guide the priorities in the Care Under Fire (control of life-threatening hemorrhage only) and Tactical Field Care phases:

Massive hemorrhage – control life-threatening bleeding.

Airway – establish and maintain a patent airway.

Respiration – decompress suspected tension pneumothorax, seal sucking chest wounds, and support ventilation/oxygenation as required.

Circulation – establish IV/IO access and administer blood products as required to treat shock.

Head injury / **H**ypothermia – prevent/treat hypotension and hypoxia to prevent worsening of traumatic brain injury and prevent/treat hypothermia.

TCCC Application

Care Under Fire: Return fire and take cover. Direct or expect casualty to remain engaged as a combatant if appropriate. Direct casualty to move to cover and apply self-aid if able. Try to keep the casualty from sustaining additional wounds. Casualties should be extricated from burning vehicles or buildings and moved to places of relative safety. Do what is necessary to stop the burning process. Tactical patient assessment during this phase is limited to identifying life threatening hemorrhage in a rapid head to toe survey taking less than 10-15 seconds or as tactically feasible. Airway management, other than positioning, is generally best deferred until the Tactical Field Care phase. Stop *life-threatening* external hemorrhage if tactically feasible with an approved tourniquet.

Tactical Field Care: Consolidate casualties in CCP. Initially, conduct triage to identify which patient needs attention first and who can wait. Identify any life-threatening hemorrhage not already controlled. In this phase, the first priority is to conduct a rapid trauma assessment. A more deliberate and traditional head-to-toe MARCH survey is completed on each casualty after all life threats have been addressed. Casualties with an altered mental status should be disarmed immediately, including communications equipment. Injuries are managed in a head-to-toe-treat-as-you-go manner. Triage reoccurs during this entire phase. Delegate treatment of minor injuries to ARFRs or RFRs freeing the medic to focus on more seriously injured. Provide instructions to ARFRs or RFRs if tasked to assist you with multi-system trauma casualties. Communicate casualty status and evacuation requirements to C2. Consolidate medical supplies in CCP. Prepare and package casualties for evacuation.

Trauma Assessment Principles

Massive Hemorrhage: Obvious external sources of bleeding should be controlled with tourniquets, direct pressure and pressure dressings. Clamping of injured vessels is not indicated unless the bleeding vessel can be directly visualized. Sources of internal hemorrhage should be identified. Initial tourniquets are to be placed “high and tight”. Effort should be made to convert these as distally as possible or to a pressure dressing as soon as the tactical situation allows.

Airway: A conscious and spontaneously breathing patient rarely requires immediate airway intervention. If the patient is able to talk normally then his airway is intact. If the patient is semi-conscious or unconscious, the tongue is the most common source of airway obstruction. Patient positioning and airway adjuncts (NPA/OPA) should be the first choice to maintain a patent airway. Ranger medics train extensively in order to proficiently conduct a surgical cricothyroidotomy. This should be the first choice for any patient requiring a definitive airway. Penetrating trauma causing c-spine fractures is almost universally fatal. One should consider c-spine fracture in blunt trauma and take appropriate precautions.

Respirations: In the conscious patient, who is alert and breathing normally, no interventions are required. If the patient has an appropriate mechanism of injury and signs of respiratory distress such as tachypnea, dyspnea, or cyanosis, which may be associated with agitation or decreasing mental status, then a presumption of tension pneumothorax management is indicated.

Circulation: Important information can be rapidly obtained regarding perfusion and oxygenation from the level of consciousness, pulse, skin color, and capillary refill time. Decreased cerebral perfusion may result in an altered mental status. Skin color and capillary refill will provide a rapid initial assessment of peripheral perfusion. Pink skin is a good sign versus the ominous sign of white or ashen, gray skin depicting hypovolemia. Pressure to the thumb nail or hypothenar eminence will cause the underlying tissue to blanch. In a normovolemic patient, the color returns to normal within two seconds. In the hypovolemic, poorly oxygenated patient and/or hypothermic patient this time period is extended or absent.

Head Injury/Hypothermia: Clothing and protective equipment such as helmets and body armor should only be removed as required to evaluate and treat specific injuries. If the patient is conscious with a single extremity wound, only the area surrounding the injury should be exposed. Unconscious patients may require more extensive exposure in order to discover potentially serious injuries but must subsequently be protected from the elements and the environment. Hypothermia is to be avoided in trauma patients. A brief neurological assessment should be performed and LOC can be described through preferably AVPU or alternately by the Glasgow Coma Scale (GCS) method. If the pupils are found to be sluggish or nonreactive to light with unilateral or bilateral dilation, one should suspect a head injury and/or inadequate brain perfusion. Assessment for any fractures or deformities of extremities or joints.


Vital Signs: Vital signs should be assessed frequently, especially after specific therapeutic interventions, and before and after moving patients. As a group, Ranger patients are in excellent physical condition and may have tremendous physiological reserves. They may not manifest significant changes in vital signs until they are in severe shock. Technology can fail and Ranger medics must be capable of obtaining manual vital signs. EtCO₂ monitors attached to a facemask are inaccurate and the trend is often more important than the number.

Tactical Trauma Assessment



CARE UNDER FIRE PHASE

TACTICAL FIELD CARE PHASE



Tactical Casualty Assessment

M MASSIVE HEMORRHAGE
A AIRWAY
R RESPIRATION
C CIRCULATION
H HEAD INJ/HYPOTHERMIA

MIST

M Mechanism of Injury
I Injury
S Signs/Symptoms
T Treatments

SIT

S Stable/Unstable
I Injuries
T Treatments

Hemorrhage Management



Hemorrhage Control

Extremity trauma hemorrhage is the most frequent cause of preventable combat death which can generally be prevented by the early use of a tourniquet. The use of compression dressings and/or hemostatic agents to control bleeding or convert tourniquets is imperative in continued casualty management. For internal or uncontrollable hemorrhage of the chest or abdomen, the most crucial life-saving intervention is rapid evacuation to a surgical capability. Measures that will enhance the possibility of survival of these casualties are early resuscitation with blood products, avoidance of aggressive crystalloid/colloid fluid resuscitation, prevention of clotting dysfunction caused by hypothermia and acidosis and avoidance of platelet-impairing medications.

TCCC Application

Care Under Fire: Stop *life-threatening* external hemorrhage if tactically feasible. Direct casualty to control hemorrhage by self-aid/ buddy-aid if able. Use a CoTCCC-recommended tourniquet for hemorrhage that is anatomically amenable to tourniquet application. Apply the tourniquet proximal to the bleeding site, over the uniform, tighten, and move the casualty to cover. Initial tourniquet placement should be as high as possible on the limb.

Tactical Field Care & Tactical Evacuation: Assess for unrecognized hemorrhage and control all sources of bleeding. If not already done, use a CoTCCC-recommended tourniquet to control life-threatening external hemorrhage that is anatomically amenable to tourniquet application or for any traumatic amputation. Apply directly to the skin 2-3 inches above wound and never over a joint. For compressible hemorrhage not amenable to tourniquet use or as an adjunct to tourniquet removal (if evacuation time is anticipated to be longer than two hours), use a pressure dressing with a hemostatic agent. Hemostatic gauze should be packed into cavitation of wound with at least 3 minutes of direct pressure. Before releasing any tourniquet on a casualty who has been resuscitated for hemorrhagic shock, ensure a positive response to resuscitation efforts (i.e., a peripheral pulse normal in character and normal mentation if there is no traumatic brain injury). Reassess prior tourniquet application. Expose wound and determine if tourniquet is needed. If so, move tourniquet from over uniform and apply directly to skin 2-3 inches above wound. If a tourniquet is not needed, use other techniques to control bleeding. When time and the tactical situation permit, a distal pulse check should be accomplished. If a distal pulse is still present, consider additional tightening of the tourniquet or the use of a second tourniquet, side by side and proximal to the first, to eliminate the distal pulse. Expose and clearly mark all tourniquet sites with the time of tourniquet application. Use a permanent marker.

- a. Reassess patient and verify bleeding is controlled.
- b. Verify distal pulses are absent in extremities with tourniquets.
- c. Reassess if tourniquet is required or other hemorrhage control means are appropriate.

Advanced Hemorrhage Control: Consider the early use of a junctional tourniquet for high femoral or axillary bleeding not amenable to tourniquet application. Any improvised junctional technique must be trained and practiced to ensure proper application. Other advanced hemorrhage control techniques such as REBOA should only be performed by those with extensive training and experience in the individual tasks required to successfully complete the procedure.

Extended Care

TOURNIQUET CONVERSIONS: If a tourniquet is applied, loosened or re-applied, ensure the approximate time is recorded on the tourniquet and the casualty card. Re-evaluate all applied tourniquets for efficacy and further need. Perform tourniquet conversion procedure as applicable, as early as possible, and if hemorrhage control is achieved otherwise.

WOUND MANAGEMENT: Change and/or reinforce all hemorrhage control dressings as applicable and dependent on medical supplies. Irrigate and redress wounds (any potable water can be used for irrigation). Debride only **obviously** devitalized tissue. Change dressings every 24 hours or as needed. Consider converting to silver impregnated dressings to reduce frequency of dressing changes. Continue antibiotics. Repeat moxifloxacin 400 mg PO or ertapenem 1 gm IV/IO/IM every 24 hours.


ABDOMINAL INJURIES: Control any visible hemorrhage from bowel. Irrigate gross debris off of exposed bowel. Attempt to gently reduce bowel back into abdominal cavity. If bowel is reduced, approximate skin (sutures or staples) and cover abdominal wound with dressing. If bowel is unable to be reduced, cover bowel with moist dressing and keep covered.

Hemorrhage Control Protocol



CARE UNDER FIRE PHASE

TACTICAL FIELD CARE PHASE




1. If bleeder is visualized or palpated, apply hemostatic agent directly to site.
2. For truncal bleeding, assume the possibility of intra-abdominal and thoracic injury.
3. If a tourniquet is applied, loosened or re-applied, ensure the approximate time is recorded on the tourniquet and the casualty card.
4. Lower extremity injuries often require a second tourniquet proximal to the initial tourniquet.

All hemorrhage control measures should be confirmed and reconfirmed to be intact before and after any movement of patient.

TRANEXAMIC ACID ADMINISTRATION:
If a casualty is anticipated to need a blood transfusion (for example: presents with hemorrhagic shock, one or more major amputations, penetrating torso trauma, or evidence of severe bleeding). Administer 1-2 gram of tranexamic acid IV/IO flush. Administer second infusion of 1 gm TXA IV/IO (if required) after blood product resuscitation.

Tourniquet Application Procedure




DOCUMENTATION:

- Detailed Assessment
- Vital Signs
- SpO2
- Complications Encountered

1. Depending on injury patterns, consider assessment of tourniquet tightness by eliminating a distal pulse as opposed to only stopping arterial bleeding.
2. Initial CUF tourniquets are to be placed as high and tight as possible on long bones of extremities to ensure adequate hemorrhage control during rapid evacuation. When feasible, such tourniquet applications should be converted 2-3" proximal to the wound directly over the skin.
3. Tourniquet Pain is difficult to manage – titrate pain medication to desired effect. Do not allow casualty to loosen for pain relief.
4. Tourniquet Conversion is to only be performed by a Ranger Medic or ARFR.

Tourniquet Conversion Procedure



EQUIPMENT NEEDED:

- Tourniquet
- Pressure dressing

DOCUMENTATION:

- Detailed Assessment
- Vital Signs
- Date/Time of procedure
- Skin Color
- Capillary Refil
- Response to procedure
- Complications Encountered

Tourniquet Pain is difficult to manage. Titrate pain medications to appropriate effect.

Airway Management



Airway Management

Airway management must be of prime concern for any trauma casualty. The setting, conditions, and injuries must be taken into account for every casualty. In the tactical setting, hemorrhage control and shock resuscitation are more important than definitive airway management. Aggressive airway management is warranted in some casualties. However, in many casualties, simple repositioning of an airway may solve airway, breathing and oxygenation problems. Assess every patient's airway based on the setting, patient condition, and patient's pending condition and take the appropriate action. **A patient that can breathe on his own should be allowed to breath on his own unless the injury pattern or predicted clinical course warrants a more aggressive action.**

TCCC Application

Care Under Fire: Airway management, other than patient positioning, is generally best deferred until the Tactical Field Care phase.

Tactical Field Care:

Unconscious casualty without airway obstruction:

- Inspect oropharynx and remove any foreign body from airway or lip. Do not conduct blind finger sweeps.
- Chin lift or jaw thrust maneuver
- Nasopharyngeal airway
- Place casualty in the recovery position

Casualty with airway obstruction or impending airway obstruction:

- Inspect oropharynx and remove any foreign body from airway or lip. Do not conduct blind finger sweeps.
- Chin lift or jaw thrust maneuver
- Nasopharyngeal airway
- Allow casualty to assume any position that best protects the airway, including sitting up.
- Place an unconscious casualty in the recovery position.
- If previous measures are unsuccessful: Surgical cricothyroidotomy (with pain control if conscious)

Tactical Evacuation:

With every evacuation movement of a casualty, confirm airway placement and reassess airway patency.

Unconscious casualty without airway obstruction:

- Inspect oropharynx and remove any foreign body from airway or lip. Do not conduct blind finger sweeps.
- Chin lift or jaw thrust maneuver
- Nasopharyngeal airway
- Place casualty in the recovery position

Casualty with airway obstruction or impending airway obstruction:


- Inspect oropharynx and remove any foreign body from airway or lip. Do not conduct blind finger sweeps.
- Chin lift or jaw thrust maneuver
- Nasopharyngeal airway
- Allow casualty to assume any position that best protects the airway, to include sitting up.
- Place unconscious casualty in the recovery position.
- If above measures are unsuccessful:
 - Surgical cricothyroidotomy (with pain control if conscious)
 - Supraglottic Airway

Spinal immobilization is not necessary for casualties with penetrating trauma.

Extended Care

1. Monitoring: Maintain continuous pulsoximetry and ETCO₂; document serial vital signs.
2. Verify airway patency and with any evacuation or movement of the patient.
3. Suction: Consider periodic suctioning of the oropharynx and established airway tube.
4. Ventilation: The SAVe II Ventilator is a small, lightweight ventilator that automatically recommends ARDSnet lung protective settings based on the patient's height. The default settings do not have PEEP and medics must manually set the vent to a PEEP of 5 at a minimum. The SAVe II does not require an external O₂ source, but supplemental O₂ can be attached and set at no higher than 6L/m which provides 62% oxygen. Any ventilator battery lasts for a limited amount of time. For extended periods, consider alternating between a ventilator and BVM assisted ventilations with an attached PEEP valve. **Keep in mind that positive pressure ventilation is a known cause of tension pneumothorax.**
5. Consider local wound care and further securing of cricothyroidotomy site if applicable.

Airway Management Protocol



DOPE

D Dislodgement – Check tube placement
 O Obstruction – Consider suctioning
 P Pneumothorax – Consider NCD
 E Equipment failure – Disconnect vent and BVM

Airway Placement Verification

Visualization
 Misting of the Tube
 Auscultation
 End tidal CO2 monitor
 Increase in SpO2 if hypoxic

* DO NOT rely on auscultation or visual misting as sole placement confirmation.

Glasgow Coma Scale


| | | |
|-----------------|------------------------|---|
| Eye Opening | Spontaneous | 4 |
| | To Voice | 3 |
| | To Pain | 2 |
| | None | 1 |
| Verbal Response | Oriented | 5 |
| | Confused | 4 |
| | Inappropriate Words | 3 |
| | Incomprehensible Words | 2 |
| | None | 1 |
| Motor Response | Obeys Commands | 6 |
| | Localizes Pain | 5 |
| | Withdraws (Pain) | 4 |
| | Flexion | 3 |
| | Extension | 2 |
| | None | 1 |

Document as: E__ + V__ + M__ = __

Surgical Cricothyroidotomy Procedure



1. Severe Airway Obstruction due to trauma, edema, excess secretions, foreign body, or tongue
2. Failure of airway positioning, chin-lift or jaw-thrust
3. Failure of Nasopharyngeal Airway
4. Unable to manually ventilate



- EQUIPMENT NEEDED:**
- Scalpel
 - Tracheal Hook or Bougie
 - Povidine/Chlorhexidine/Alcohol Swab
 - Gloves
 - Sterile 4X4 Sponge
 - ET Tube
 - Bag-Valve-Mask (BVM)
 - Curved Hemostats if required
 - Securing Device, Tape, or Suture
 - Suction (recommended)

- DOCUMENTATION:**
- Detailed Assessment
 - Vital Signs
 - SpO2
 - Glasgow Coma Scale
 - Tube Check Results
 - Lung Sounds
 - Complications Encountered

- ETCO2**
 Tube Misting
 Breath against cheek/wrist
 Auscultate Breath Sounds
 Monitor SpO2

Any airway adjunct(s) should be confirmed and reconfirmed to be intact before and after any movement of patient.

1. Maintain strict C-Spine precautions if concerned for C-Spine injury.
2. Anytime the patient desaturates (SpO2<90%), stop the procedure and ventilate for 30-60 seconds before procedure is re-attempted.
3. Secure the tube by securing device, suture in place, or IV tubing. An adhesive seal can be used as an adjunct but not as a sole securing device.

Thoracic Management



Thoracic Trauma

Penetrating and blunt chest trauma remains a threat regardless of the use of body armor. The primary life-threat that is preventable is tension pneumothorax. Always consider presumptive diagnosis of tension pneumothorax when progressively worsening respiratory distress develops in a casualty with a known or suspected torso trauma. The late signs of decreased breath sounds, tracheal deviation, and jugular vein distention may not always be present and may be difficult to assess on the battlefield. Relief of tension pneumothorax requires release of air under pressure within the chest cavity. Constant reassessment of patients with chest trauma is imperative to identify progression or reemergence of tension pneumothorax. The management of an open chest wound with an occlusive dressing sealing the wound may lead to the development of a pneumothorax. Once sealed, patients must be monitored for development of tension pneumothorax. Continued assessment for hemothorax, flail segments, or cardiac tamponade should follow management of tension.

TCCC Application

Care Under Fire: No specific action.

Tactical Field Care: In a casualty with progressive respiratory distress and known or suspected torso trauma, consider a tension pneumothorax and decompress the chest on the side of the injury with at least a 14-gauge, 3.25 inch needle/catheter unit inserted in the 5th intercostal space, anterior axillary line or second intercostal space, midclavicular line. Ensure that the needle entry into the chest is not medial to the nipple line and is not directed towards the heart. All open and/or sucking chest wounds should be treated by immediately applying an occlusive material to cover the defect and securing it in place. Monitor the casualty for the potential development of a subsequent tension pneumothorax. Casualties with evidence of torso trauma and no vital signs should have bilateral needle decompression or finger thoracostomy performed to ensure they do not have a tension pneumothorax prior to all resuscitation efforts being halted.

Tactical Evacuation: Consider finger thoracostomy or chest tube insertion if multiple needle decompressions, no improvement, life-threatening complications and/or long transport is anticipated. Most combat casualties do not require supplemental oxygen, but administration of oxygen may be of benefit for the following types of casualties: low oxygen saturation, injuries associated with impaired oxygenation, casualties with TBI (maintain oxygen saturation > 90%), casualties in shock, and casualties at altitude.

Extended Care

Reassess patient for development of tension pneumothorax. Consider finger thoracostomy or chest tube if: patient requires multiple needle decompressions **OR** no improvement with needle decompression **OR** evacuation time is prolonged (greater than 1 hour) **OR** evacuation requires transport at high altitude in unpressurized aircraft. If available, provide oxygen as needed to maintain O2 saturation > 90% (> 95% for TBI). Apply negative pressure to chest tube if available, not exceeding -20 cm water. Consider rib blocks for pain management. If patient is being ventilated, maintain strict bagging cycles (1 breath every 5 seconds) and a tidal volume of approximately 500 ml to allow for complete exhalation and avoid stacking breaths. Always use a PEEP valve when bagging. Consider the use of a ventilator if available and add physiologic positive end-expiratory pressure PEEP (3-5 cm water). Consider sedation for casualties requiring prolonged intubation/ventilation if no shock or hypotension. If sufficient supply of chest seals are available, then consider removing seals, "burping" wounds, and re-sealing with a new occlusive dressing. Resuscitative fluids should be managed very conservatively unless there noted significant blood lost from other injuries. Regardless, maintain resuscitation fluids to only to maintain a systolic pressure of 90-100.

FLAIL CHEST MANAGEMENT: Monitor for developing hypoxia secondary to pulmonary contusions. Casualty may require positive pressure ventilation. Ensure adequate analgesia or procedural sedation as required. Consider rib blocks for pain management, if trained. These casualties frequently fatigue and require definitive surgical airway.


HEMOTHORAX: Identification of hemothorax is difficult to assess in the field. MOI, reduced breath sounds, difficulty breathing, and unexplained shock should lead to suspicion of hemothorax. Rapid evacuation to surgical capability, ventilation support, judicious fluid therapy, and chest tube is indicated for hemothorax.

CARDIAC TAMPONADE: Bleeding or fluid collection into the pericardium may often be expected from hard frontal trauma to the chest or small puncture wounds creating a compression upon the heart. Little can be accomplished in the field if this injury is suspected. The suspicion of this injury should elevate the urgency of evacuation and should be communicated to receiving facility if possible. If properly trained, a pericardiocentesis may be performed in extremis situations.

CARDIAC DYSRHYTHMIAS: If patient is being monitored with ECG capability, cardiac dysrhythmias with chest trauma (especially blunt trauma) may occur. Manage any such dysrhythmias as with any such cardiac patient IAW ACLS guidelines.


ACCOMPANYING ABDOMINAL INJURIES: Any injury between the nipple and the navel may be assumed to be a thoracoabdominal injury. Consider the use of occlusive dressings over these wounds if concerned for tension pneumothorax. Subsequently, assess patient for development of tension pneumothorax physiology. Diaphragmatic rupture or injuries may occur and have a significant effect on respiratory effort. Control any visible hemorrhage from bowel using approved hemostatic agent or gauze. Irrigate gross debris off of exposed bowel. Attempt to gently reduce bowel back into abdominal cavity. If bowel is reduced, approximate skin (sutures or staples) and cover abdominal wound with an occlusive dressing. If bowel is unable to be reduced, cover bowel with moist dressing.

Thoracic Trauma Management Protocol



1. Re-Assess vital signs after each intervention – including SpO2 and EtCO2.
2. If in a multiple casualty situation, consider bilateral needle decompression or finger thoracostomy on all significant chest injuries.
5. Casualties with thoracoabdominal trauma and no vital signs should have bilateral needle decompression or finger thoracostomy performed to ensure they do not have a tension pneumothorax prior to all resuscitation being halted.

Needle Chest Decompression Procedure



EQUIPMENT NEEDED:
- 10G to 14G 3.25" Needle with catheter

DOCUMENTATION:

- Detailed Assessment
- Vital Signs
- SpO2
- Lung Sounds before and after decompression
- Chest rise/excursion
- Skin Color
- Capillary refill
- Response to treatment
- Complications Encountered


1. The provider will make determination on site selection based on injury pattern and overall patient condition.
2. If you have a limited supply of needle/catheters, then remove catheter with needle. Inspect catheter before any reinsertions. If needle supply is adequate, then leave catheter in place to provide limited decompression and to provide indication of previous intervention to the next provider.

Chest Tube Insertion and Finger Thoracostomy Procedure



FINGER THORACOSTOMY PROCEDURE

TUBE THORACOSTOMY PROCEDURE



MINIMUM EQUIPMENT NEEDED:

- 6" or 9" Peans Forceps (clamp)
- Chlorhexidine Gluconate Solution/swab
- Scalpel, #10
- 28 Fr to 36 Fr Chest Tube
- Heimlich Valve
- Sterile Gloves
- Securing device

DOCUMENTATION:

- Detailed Assessment
- Vital Signs
- SpO2 / EtCO2
- Lung Sounds before and after tube insertion
- Chest rise/excursion
- Skin Color
- Capillary refill
- Response to treatment
- Complications Encountered

Monitor for changes in respiratory status:

1. Frequently assess vital signs including SpO2 and EtCO2
2. Assess lung sounds and ventilatory status
3. Check tubing for seals, connections or tube dislodgement and suction frequently.
4. Assess the insertion site for subcutaneous emphysema.
5. Assess and document color and amount of drainage; Surgical intervention is required if blood loss is 1000-1500mL immediately or 200-300mL/hr in the adult patient.

ALL CHEST TUBES SHOULD BE PLACED WITH STERILE TECHNIQUE.

Repeat NCD or finger thoracostomy if unable to place a sterile chest tube

If available: Connect the free end of the chest tube to an underwater seal drainage system (Pleur-Evac), and then suture into place with nylon 2-0. If an underwater seal drainage system is unavailable, make a field expedient version by securing the free end of the tube in a container of water that is lower than the level of the inserted end of the tube. This system prevents the patient drawing air back into the chest cavity. Bubbles coming out of the free end of the tube are a positive sign, indicating that the patient is expelling free air.

TACTICAL DAMAGE CONTROL RESUSCITATION



Extended Care

Prevention of hypovolemic shock (inadequate tissue perfusion) is critical in a trauma casualty. Shock can be thought of as a pause in the act of dying and requires aggressive actions to prevent its progression. Once a casualty has progressed to shock, he is susceptible to the lethal triad of coagulopathy, hypothermia and acidosis. Early preventative actions can delay hypothermia. Controlling blood loss and appropriate blood product administration can delay the progress of coagulopathy.

TCCC Application

Care Under Fire: Stop life-threatening bleeding.

Tactical Field Care: The first priority is to stop any active hemorrhage. Initiate Intravenous (IV) access if indicated. Start an 18-gauge or larger IV or saline lock. If resuscitation is required and IV access is not obtainable, use the intraosseous (IO) route. Assess for hemorrhagic shock; decreased mental status (in the absence of head injury) and weak or absent peripheral pulses are the best field indicators of shock. If indicated by assessment, initiate fluid resuscitation. If not in shock, resuscitation is not necessary. If in shock, administer whole blood or blood products in a 1:1 ratio. Repeat if still in shock. Warm fluids are preferred if IV fluids are required. Be aware of warmer constraints as applying pressure to increase flow may cause ineffective warming and cell lysis. Continued efforts to resuscitate must be weighed against logistical and tactical considerations and the risk of incurring further casualties. If a casualty with TBI is unconscious and has no peripheral pulse resuscitate to restore the radial pulse. Prevention of hypothermia is critical in a shock patient. Minimize casualty's exposure to the elements. Keep protective gear on or with the casualty if feasible. Replace wet clothing with dry if possible. Get the casualty onto an insulated surface as soon as possible. Apply the Ready-Heat Blanket from the Hypothermia Prevention and Management Kit (HPMK) to the casualty's torso (not directly on the skin) and cover the casualty with the Heat-Reflective Shell (HRS). If a HRS is not available, the combination of any blanket and the Ready Heat blanket may also be used. If the items mentioned above are not available, use dry blankets, poncho liners, sleeping bags, or anything that will retain heat and keep the casualty dry.

TXA Administration: If a casualty is anticipated to need a blood transfusion (for example: presents with hemorrhagic shock, one or more major amputations, penetrating torso trauma, or evidence of severe bleeding). Administer 1-2 gram of tranexamic acid as an IV/IO flush as soon as possible but not later than 3 hours after injury. If initial dose of TXA was 1 gram, administer second infusion of 1 gm TXA after the first unit of blood or blood product treatment. Record on CAX Card "1-2 gm TXA given". Drug must be properly maintained between 15-30 °Celsius / 59-86° Fahrenheit. Consider administration of CaCl or CaGluc 1gm slow IV/IO push, if possible, after 2 gms of TXA using a second IV/IO site. **Do not delay blood product resuscitation for a trauma patient in shock in order to administer TXA and/or calcium.** Repeat calcium after every 4th unit of blood.


Tactical Evacuation: Reassess need for IV access if not previously established. Reassess for hemorrhagic shock. If not in shock then no IV fluids are necessary. Avoid PO fluids for casualties requiring surgical intervention. Continue resuscitation with whole blood, packed red blood cells (PRBCs) and plasma in a 1:1 ratio as indicated. If a casualty with TBI is unconscious and has a weak or absent peripheral pulse, resuscitate as necessary to maintain a systolic blood pressure of 110 mmHg or above. Prevention of hypothermia is even more critical for a trauma patient in moving vehicles or aircraft. Keep protective gear on or with the casualty if feasible. Remove and replace wet clothing with dry if possible. Get the casualty onto an insulated surface as soon as possible. Apply external warming devices as depicted in tactical field care if not already accomplished. Use a portable fluid warmer capable of warming all IV fluids including blood products. Protect the casualty from wind if doors must be kept open.

Extended Care

Fluid management: Continue resuscitation with whole blood or blood products as indicated. Maintain a palpable radial pulse or systolic blood pressure of 90-100 mm Hg in all unconscious patients with non-compressible, internal hemorrhage. Maintain a normal radial pulse character or systolic blood pressure > 110 mm Hg in TBI patients with altered mental status. If available, insert Foley catheter and titrate IV/IO/NG/PR crystalloid fluids to maintain urine output of 30-50 ml per hour.

ROLO Transfusion: All life saving TCCC protocols and procedures should be completed while ARFRs obtain blood for transfusion. Evacuation should not be delayed for field transfusions. ROLO may be considered for trauma casualties showing signs of hemorrhagic shock; shock from internal, non-compressible, or uncontrollable bleeding; massive blood loss with tachypnea, tachycardia, systolic hypotension and altered mental status; or extended evacuation.

TACTICAL DAMAGE CONTROL RESUSCITATION PROTOCOL



TXA Indications:
 Presence of Hemorrhagic Shock
 One or more major amputations
 Penetrating torso trauma
 Evidence of severe bleeding
 Evidence of pelvic fracture

TXA Instructions:
 Only store inside and within temperature range.
 If pre-drawn – replace every 7 days
 Draw TXA into 10cc syringe in a sterile fashion, cap, and clearly label
 Do not delay blood product resuscitation for TXA administration

1. The goal of this protocol is to prevent the lethal triad of hypothermia, acidosis and coagulopathy.
2. Fluid of choice for shock resuscitation is whole blood then component therapy in a 1:1 ratio.
3. Patient Warming procedures are to be initiated as soon as possible.
4. ARFRs are expected to initiate the ROLO protocol independent of a medic and resuscitate with stored blood products if available.
5. Foley catheters should be packed in vehicle-based trauma bags and utilized based on extended evacuation time

Shock Management



Hypotensive Resuscitation

The employment of Hypotensive Resuscitation is meant to avoid over-resuscitation of shock. Basing the titration of fluids upon a monitored physiologic response may avoid the problem of excessive blood pressure elevation and fatal re-bleeding from previously clotted injury sites.

Shock Assessment

Important information can be rapidly obtained regarding perfusion and oxygenation from the level of consciousness, pulse, skin color, and capillary refill time. Mental status is the most important indicator of shock. Decreased cerebral perfusion may result in an altered mental status. The patient may progress from anxious to confused to unresponsive. Beware of the patient with an impending sense of doom. The patient's pulse is easily accessible, and if palpable, the systolic blood pressure in millimeters of mercury (mm HG) can be roughly estimated as follows:

RADIAL PULSE: PRESSURE 80 mm Hg
 FEMORAL PULSE: PRESSURE 70 mm Hg
 CAROTID PULSE: PRESSURE 60 mm Hg

It is important to state, that the above pressure ranges are merely quick estimates of systolic blood pressures and are generally OVER-ESTIMATED and inaccurate. They are to be used during the rapid initial assessment of a trauma patient. Actual blood pressure measurement and a complete patient assessment should direct your trauma and shock management decisions.

Skin color and capillary refill will provide a rapid initial assessment of peripheral perfusion. Pink skin is a good sign versus the ominous sign of white or ashen, gray skin depicting hypovolemia. Pressure to the thumb nail or hypothenar eminence will cause the underlying tissue to blanch. In a normovolemic patient, the color returns to normal within two seconds. In the hypovolemic, poorly oxygenated patient and/or hypothermic patient this time period is extended or absent.

The classic classes of shock are inaccurate and misleading but are often referred to in trauma literature. Ranger medics should consider mechanism of injury, mental status, pulse, and other signs when making decisions on triage, treatments, and evacuation priority.


The following table is provided for educational purposes only and should not be relied upon.

Estimate of Fluid and Blood Requirements in Shock*

| | <u>Class I</u> | <u>Class II</u> | <u>Class III</u> | <u>Class IV</u> |
|------------------------------|------------------|-----------------|------------------|--------------------|
| Blood Loss (ml) | Up to 750 | 750-1500 | 1500-2000 | > 2000 |
| Blood Loss(%BV) | Up to 15% | 15-30% | 30-40% | > 40% |
| Pulse Rate | < 100 | > 100 | > 120 | > 140 |
| Blood Pressure | WNL | WNL | Decreased | Decreased |
| Pulse Pressure (mmHg) | WNL/increased | Decreased | Decreased | Decreased |
| Capillary Blanch Test | Normal | Positive | Positive | Positive |
| Respiratory Rate | 14-20 | 20-30 | 30-40 | > 35 |
| Urine Output (mL/hr) | > 30 | 20-30 | 5-15 | Negligible |
| CNS-Mental Status | Slightly anxious | Mildly anxious | Anxious/confused | Confused/lethargic |

* modified from ATLS


Saline Lock & Intravenous Access Procedure




- EQUIPMENT NEEDED:**
- Constricting Band
 - Chlorhexidine Gluconate Solution/ Swab
 - 2 X 18-G or 16-G IV Catheter/Needle
 - Needleless Saline Lock
 - Tegaderm (at least 2.5" X 2.5")
 - IV Tubing
 - IV securing device
 - Gloves

- DOCUMENTATION:**
- Detailed Assessment
 - Vital Signs
 - SpO2 / ETCO2
 - IV Site Location
 - IV Catheter Gauge
 - Date/Time Started
 - Fluids Infused / Rate
 - Complications Encountered

1. Never delay evacuation or other treatments to gain IV access unless needed to perform a life saving procedure.
2. Warmed IV fluids will always be the preferred infusion to prevent hypothermia.




External Jugular Intravenous Cannulation Procedure



- MINIMUM EQUIPMENT NEEDED:**
- Constricting Band
 - Chlorhexidine Gluconate Swab
 - 2 X 14-G IV Catheter/Needle
 - 10 cc Syringe
 - Needleless Saline Lock
 - Tegaderm (at least 2.5" X 2.5")
 - Gloves

- DOCUMENTATION:**
- Detailed Assessment
 - Vital Signs
 - SpO2
 - IV Site
 - IV Gauge
 - Date/Time Started
 - Fluids Infused / rate
 - Complications Encountered

Sternal Intraosseous Infusion Procedure



MINIMUM EQUIPMENT NEEDED:

- 38.5mm 15ga manual IO device
- OR
- Spring-loaded IO device
- Flush


DOCUMENTATION:

- Detailed Assessment
- Vital Signs
- SpO2
- IV Site
- IV Gauge
- Date/Time Started
- Fluids Infused / rate
- Complications Encountered

CAUTIONS:

1. Do not rock or bend during manual needle insertion. Maintain a 90° angle.
2. Do not leave catheter inserted for longer than 24 hours.
3. Do not attach .asyringe directly to the IO catheter hub.
4. Consider 5-10cc lidocaine flush for pain control

Intraosseous Infusion Procedure (Non-Sternal)



MINIMUM EQUIPMENT NEEDED:

- 45mm 15ga IO device (Humeral)
- 38.5mm 15ga IO device (Sternal)
- 25mm 15ga IO device (Tibial)
- Flush

CONTRAINDICATIONS:

- Fracture or injury to site
- Absence of landmarks
- Injury proximal to IO site

Use each device and needle size ONLY for its indicated site


DOCUMENTATION:

- ABC's
- Detailed Assessment
- Vital Signs
- SpO2
- Complications Encountered

CAUTIONS:

1. Do not rock or bend during manual needle insertion. Maintain a 90 degree angle.
2. Do not leave catheter inserted for longer than 24 hours.
3. If patient withdraws during bolus, consider 20-40mg 2% lidocaine over 30 seconds.

Hypothermia Prevention & Management Kit Procedure



EQUIPMENT NEEDED:
- Hypothermia Kit

DOCUMENTATION:
- Detailed Assessment
- Vital Signs
- SpO2
- Skin Color
- Complications Encountered

NOTE:
- Circumstances may preclude use of HPMK (ie, MASCAL). If this occurs, use whatever means available to keep casualty warm to include blizzard blankets, clothing from uninjured personnel, blanket found on target, etc.

Head Trauma



Head Trauma

Open head injury results from application of force with penetration of the skull. The most common agents are missiles and blunt instruments. The lethality is proportional to the energy of the missile (which in turn is proportional to the square of the velocity). Injuries caused by blunt instruments can cause open depressed skull fractures, but are usually of relatively low energy and cause only local injury to the brain. Nonetheless, these are serious wounds and have a high potential for infection.

Closed head injury results from application of force to the head that does not involve penetration of the skull but may involve scalp lacerations and facial fractures. The degree of injury to the brain is dependent on the energy transferred to the brain as a result of the force applied to the head. Closed head injury most often results from falls and motor vehicle accidents, even in an operational environment. Alteration of consciousness is the hallmark of brain injury, and may be mild or severe, immediate or delayed, brief or permanent. Delayed deterioration of consciousness may occur as a result of hematoma formation within the skull or worsening swelling of the brain. The mechanism for this impairment of consciousness is increasing intracranial pressure, with subsequent impairment of brain perfusion (blood flow).

Assessment & Management

Generally, with head injuries the primary damage is done and there is little that can be done to correct that damage. The primary goal of head injury management is to prevent secondary injuries associated with hypoxia, hypotension, anemia, hyperthermia and hypothermia. This equates to aggressive bleeding control and airway management. Avoid hypoxia (any $SPO_2 < 90\%$), hypotension (any $SBP < 100$), and reacting to the signs of brain edema, herniation, or seizures.

The hallmark of head injury is alteration of consciousness. This is best assessed using the Glasgow Coma Scale. Additionally, the MACE 2 examination, particularly for mild TBI, should be performed. Pupillary function is also important to assess, and this can be done with any light source. In bright sunlight conditions, closing the eye for 30 seconds and observing while quickly opening demonstrates pupillary reactivity. Regular reassessment, as the tactical situation permits, is critical as a neurologic status may vary significantly over time.

Inspection: Vital signs should be assessed in any patient with a head injury and patency of the airway confirmed. The head should be inspected for signs of open injury or skull fracture. Open injury will be accompanied by a defect, and basal skull fracture may be associated with Battle's sign (retroauricular ecchymosis) or raccoon eyes (periorbital ecchymoses). Leakage of cerebrospinal fluid from the ears or nose may also be present. The pupils should be inspected for equality or reactivity. Unequal or non-reactive pupils in an unconscious patient are ominous signs.

Auscultation: Auscultation is generally not helpful in the evaluation of the head injury itself, but in a patient with impaired consciousness, a full exam, including auscultation of the lungs, should be performed.

Palpation: Palpation of the head may reveal an underlying closed depressed skull fracture (an "ashtray" feel). The cervical, thoracic and lumbar spine should be palpated to assess for tenderness or deformity, possibly indicated an associated spinal injury.

Management: Treatment involves securing the airway, maintaining systolic blood pressure > 110 , maintaining oxygen saturation $> 92\%$, stabilizing the cervical spine if indicated, dressing any wound, and establishing an intravenous line. Prevent seizures IAW seizure protocol and treat, if indicated, with hypertonic saline.

Extended Care

Key aspects of field management of severe TBI are the prevention of hypoxia and hypotension. Ensure early establishment of a definitive airway, aggressively treat respiratory compromise, administer oxygen if available (to maintain saturation $> 92\%$), and fluid resuscitate hypotension. **DO NOT** hyperventilate unless indicated for signs of herniation. Controlled hyperventilation may be considered as a temporizing measure for evidence of increasing intracranial pressure (ICP) and herniation (deteriorating mental status, unequal pupils, posturing). Ventilate to achieve pCO_2 of 25-30 mm Hg for 15-20 minutes. If end tidal CO_2 monitor is not available, ventilate at a rate of 20 per minute and a tidal volume of approximately 500 ml. Prevent seizures as per seizure protocol. Administer Levetiracetam 1g IV to prevent seizure or 4g IV for seizure treatment. Elevate the head 30 degrees. Prevent hypo/hyperthermia. Antibiotic prophylaxis for penetrating head trauma: Ertapenem 1 gm IV/IO **OR** Ceftriaxone 2 gm IV/IO. Ensure casualty is evacuated to a facility with a neurosurgeon available.

Head Injury Management Protocol



Obvious Mech of Injury
 Altered Mental Status or LOC
 Disorientation
 Sudden/Prolonged Headache/Pain
 Blurred Vision
 Sudden Nausea/Vomiting
 Anxiety/Irritability
 Sensitive to Light/Loud Noise
 Unexplained Seizures
 Neurological Deficits

Neurological Assessment

Mental Status
 Orientation
 Affect
 Speech (Content & Process)


Cranial Nerves
 I Olfactory (Identify an odor or distinguish between 2 odors)
 II Optic (Visual Acuity test)
 III Oculomotor (Assess 6 cardinal eye movements & pupillary reaction)
 IV Trochlear (Assess 6 cardinal eye movements)
 V Trigeminal (Facial Sensitivity & Biting/Clinching teeth)
 VI Abducens (Eye movement looking left and right)
 VII Facial (Smile, frown, raise brows, and taste)
 VIII Acoustic (Hearing-rubbing fingers & Equilibrium)
 IX Glossopharyngeal (Gag reflex and identify tastes)
 X Vagus (Gag reflex and speech)
 XI Spinal Accessory (Head movement and shoulder shrugging)
 XII Hypoglossal (stick out tongue and move left and right)

Motor Status
 Posture
 Strength in basic muscle movements
 Resistance to passive movement
 Tremors or Involuntary Movements

Sensation Status
 Senses light touch
 Senses pain or pricks
 Senses temperature
 Senses vibration (tuning fork)

Coordination
 Gait and Stance
 Finger to nose
 Heel to shin

Reflexes
 Deep tendon reflexes (biceps, triceps, knees, ankles)
 Plantar reflexes



Signs of Impending Herniation

Asymmetric Pupils
 Fixed Dilated Pupil
 Extensor/Flexor Posturing
 GCS decrease of > 2

1. Oxygen 100% per NRB Mask or BVM if available for SpO2<92%.
2. Consider emergency cricothyroidotomy or ETI for GCS<9.
3. Do not allow BP to drop below 110mmHg.
4. Hyperventilation is not indicated unless signs of herniation syndrome are present. This will be a gentle hyperventilation of 20 breaths/min to EtCO2 25-30 for 15-20 minutes.
5. Isolated head injuries do not cause shock. If shock is present, look for other causes.
6. Generally, head injuries should be evacuated by air using low altitude or pressurized cabin.
7. Any casualty with mTBI should undergo Ranger mTBI Return to Duty Protocol.
8. Perform serial GCS exams every 5-10 minutes.
9. All head injuries will be reported to a medical officer and require a MACE2 exam (if conscious)

CONDUCT POST-INJURY TBI ASSESSMENT UPON RETURN TO BASE FOR ANY INDICATED CASUALTIES

MTBI / Concussion



CONCUSSION

A concussion is a blow or jolt to the head or a penetrating head injury that disrupts the function of the brain. Not all blows or jolts to the head cause a brain injury. In combat, concussions are usually caused by a bullet, fragment, blast, fall, direct impact, or motor vehicle crash. Some, but not all, persons with a concussion lose consciousness.

S/S: Headache; fatigue; sensitivity to noise and light (phonophobia and photophobia); difficulty concentrating; loss of balance; nausea/vomiting; insomnia/sleep disturbances; vision changes/blurred vision; ringing ears; excessive tiredness; dizziness; drowsiness; difficulty remembering; confusion; irritability.

TCCC Application

Care Under Fire: Manage life-threatening hemorrhage. No specific action for TBI/Concussion.

Tactical Field Care: Treat other injuries in accordance with TCCC guidelines. For patients with S/S of traumatic brain injury or potential for blast injury, assess for RED FLAG symptoms, administer MACE2 and neurological evaluation.

S/S of RED FLAG Evacuation:

Tactical Evacuation: Evacuate based on appropriate protocol of other injuries or red flag symptoms.

Special Considerations

Mandatory events requiring MACE2:

- Personnel in a vehicle associated with a blast, collision or rollover
- Personnel within 150 meters of a blast
- Personnel with a direct blow to the head
- Command directed evaluation

All Return-to-Duty must be evaluated and approved by an MD/PA.

mTBI is primarily a clinical diagnosis. If you do not feel that a patient is back to their baseline, do not allow them to RTD and re-consult your medical provider.

Management

1. Consider mTBI (concussion) in anyone who is dazed, confused, "saw stars", lost consciousness (even if just momentarily) or has memory loss that results from a fall, explosion, motor vehicle crash or any other event involving abrupt head movement, a direct blow to the head or other head injury
2. Triage and treat other injuries as required. As soon as tactically feasible evaluate for mTBI
3. If red flags are present - consult with medical provider for possible urgent evacuation.
4. Administer MACE2, initiate 24 hour rest and consult with medical provider.
5. Treatment: Treat symptoms with acetaminophen, NSAIDS, and ondansetron as needed. **DO NOT** use narcotics or tramadol for symptom management. Not all symptoms will respond to conservative management as the brain heals. This is to be expected. Refer to the Ranger mTBI Return to Duty Protocol for clearance.

Extended Care

Extended Care: All patients with TBI/Concussion injuries are to be evaluated by a MD/PA as soon as tactically feasible. If evacuation is delayed then remove patient from an active tactical role. If no RED FLAG indications, then place patient in a limited duty role that will allow for rest and sleep if possible. Identify a Ranger Buddy who will remain in close proximity and monitor patient status – DO NOT allow patient to be left alone while remaining in a tactical situation. Medical personnel should assess patient frequently for general responsiveness, vitals signs and any indication of red flag symptoms. Explain to patient and Ranger Buddy the importance of alerting medical personnel of any red flag symptoms. If possible, rest will be the best recovery. Ensure patient remains well hydrated as dehydration will aggravate recovery. Allow patient to eat small light meals if not affected by nausea or vomiting. Avoid exertion and any kind of strenuous events or situations that will hinder healing. Limit work to mundane tasks that are not critical to tactical situation but still allow a feeling of importance.


mTBI Management Protocol



All personnel exposed to or involved in a blast, fall, vehicle crash or direct head impact who becomes dazed, confused or loses consciousness (even momentarily) will be evaluated for brain injury.

IMMEDIATE EVACUATION CRITERIA
 LOC > 5 minutes
 GCS decrease > 2
 Seizure
 Asymmetric Pupils
 Repeated vomiting (>3 times)
 Weakness to extremities
 Clinical concerns

All Return-to-Duty must be evaluated and approved by MD/PA.



RESPONSIVENESS ASSESSMENT (AVPU)
 Alert
 Verbal: Responds to verbal stimuli
 Pain: Responds to painful stimuli
 Unconscious: No response to any stimuli

mTBI Red Flags
 Deteriorating level of consciousness
 Double vision
 Increased restlessness, combative, or agitated behavior
 Repeat vomiting
 Results from a structural brain injury detection device (if available)
 Seizures
 Weakness extremities

Abdominal Trauma



Abdominal Trauma

Penetrating abdominal injuries are characterized by a violation of the peritoneal or retroperitoneal spaces by any variety of low to high velocity objects. Injuries represent a spectrum that includes impalement with foreign objects, stab, gunshot and fragment wounds. Tissues are crushed and torn by the penetrating missile or they are injured indirectly by stretching and cavitation. Multiple abdominal organs are commonly damaged as a result of penetrating trauma. The management of abdominal trauma in the field centers on adequate resuscitation, pain control and intravenous antibiotics with the goal of evacuating the patient to a location where surgical care is available. Wound care and other supportive measures should also be given.

Initial Assessment & Management

Visible evidence of abdominal trauma may not always be immediately present (especially when associated with blunt mechanisms of injury). Abdominal pain is not always a reliable indicator of abdominal injury as it may be mimicked by fractures of the ribs and pelvis or not be readily evident because of decreased mental status due to associated head or spinal cord injury. Furthermore, severe pain from other injuries such as extremity fractures may mask the patient's perception of pain in the abdominal area.

Inspect for: Entrance and exit wounds, contusions and abrasions, distention, protruding bowel or omentum, gastrointestinal hemorrhage (bloody emesis or rectal bleeding), hematuria, signs of shock.

Palpation: Palpation of the abdomen can reveal tenderness, guarding, and rigidity. Assess all abdominal quadrants for superficial, deep and rebound tenderness. If an obvious evisceration is present, palpation in that quadrant should be deferred. Involuntary guarding is a reliable sign of peritoneal irritation. Pelvic stability should be assessed especially when blunt trauma is the mechanism of injury. A pelvis which is determined to be unstable should not be subjected to repeated manipulation to test for stability. If possible, a rectal examination should be done in all patients with suspected abdominal injuries. Gross blood indicates gastrointestinal hemorrhage or perforation of the bowel; a high riding prostate is suspicious for urethral injury and poor rectal tone indicates neurological injury.


Auscultation: Auscultation is difficult and misinterpreted in the tactical setting and should not be used as singular diagnostic measure. Absent or decreased bowel sounds are commonly associated with injury to abdominal viscera. However, patients with audible bowel sounds can still have significant underlying abdominal injuries. Auscultation of bowel sounds in the thorax is suggestive of diaphragmatic injury.

Control any visible hemorrhage from bowel using approved hemostatic agent or gauze. Irrigate gross debris off of exposed bowel. **Attempt to gently reduce bowel back into abdominal cavity. If bowel is reduced, approximate skin (sutures or staples) and cover abdominal wound with dressing.** If bowel is unable to be reduced, cover bowel with moist dressing. If uncontrolled abdominal hemorrhage is suspected, massive infusions of intravenous fluid to correct an abnormal blood pressure should be avoided. Resuscitation efforts should instead be directed at maintaining cerebral perfusion as indicated by patient's mental status if there is no associated head injury. If there is no associated head injury, a systolic blood pressure of 90-100mm Hg is adequate and will prevent rebleeding from over resuscitation. The patient who is hemodynamically unstable and requires ongoing large volume resuscitation is probably bleeding from an intraabdominal or intrathoracic source.

Extended Care

Eviscerated bowel and omentum should be covered with a bandage moistened with saline or Ringer's lactate solution. Purified drinking water may be used if sterile fluids are not available. The wound should be reassessed and re-moistened every 1-2 hours. Clamps for hemorrhage control should be applied only to easily seen bleeding vessels. Do not attempt to pull out more bowel or omentum. A nasogastric (NG) tube should be placed to decompress the stomach in order to decrease the risk of vomiting and aspiration. The NG tube may be reserved for those patients that are vomiting or have a distended abdomen. A Foley catheter may be useful in patients who are unstable in order to monitor urine output and to obtain urine samples to evaluate for blood. Worsening pain, or worsening signs of shock, peritonitis, or sepsis indicate deterioration and should accelerate efforts to evacuate the patient to a location where surgical care is available. Antibiotic therapy should be initiated as soon as a penetrating injury is suspected. Administer Ertapenem 1gm IV.

Abdominal Trauma Management Protocol



Blast Injury Assessment



Blast Injuries

TCCC: INITIAL EVALUATION AND TREATMENT PER APPROPRIATE TRAUMA PROTOCOL

All unit members exposed to blast will be assessed for blast injuries as soon as tactically feasible with documentation if possible. Any indications or complications from blast injuries should warrant immediate evacuation for evaluation at a more capable facility.

Blast injuries have a wide range from minor tympanic membrane ruptures to hollow organ over-pressure injuries. All personnel must be evaluated and monitored for at least 6 hours for injuries. Submersion or confined space environments significantly increase the incidence of injury. Special caution should be taken when examining these patients.

Signs & Symptoms

HEENT - Careful inspection for Tympanic Membrane (TM) rupture during examination. Intact TMs do NOT exclude significant blast injury to other parts of the body. Check for ear discharge, tinnitus, hearing loss.

Pulmonary – Evaluate for shortness of breath and abnormal breath sounds.

Neurologic – Evaluate for TBI with MACE 2 and neurological exam.

Abdomen – Monitor until 48-72 hours post injury.

Management

1. All asymptomatic patients should be monitored for at least 6 hours after the event to rule out late presenting complications.
2. Tympanic Membrane: Keep ear canal dry/covered (use cotton balls if possible) in case of TM rupture. Refer to ENT for evaluation when possible.
3. MACE 2 examination needs to be accomplished on all personnel affected by the blast.
4. Pulmonary Decompensation: High flow O₂ if available. Use caution with high pressure ventilation, this may worsen the patient's condition. Follow rules for hypovolemic resuscitation given risk for pulmonary edema. Have high suspicion for tension pneumothorax. Be prepared for needle decompression. Consider tube thoracostomy: recurrence or persistence of respiratory distress after 2 needle decompressions **OR** evacuation time > 1 hr **OR** Patient requires positive pressure ventilation. For air evacuation, fly at the lowest tactically feasible altitude.
5. Abdomen: Any abdominal pain or tenderness within 48-72 hours of a blast exposure should be presumed to be a bowel perforation and warrants urgent surgical evaluation. Follow *Abdominal Pain Protocol* for urgent evacuation.
6. Consider possibility of Arterial Gas Embolism (AGE) in patients with focal neurological deficits after pulmonary blast injury. AGE may require recompression therapy. See *Barotrauma Protocol*.
7. Spine Injury: Patients involved in vehicular blasts or thrown by explosions are at high risk for spinal injury. Maintain a high index of suspicion for spinal injury, especially in unconscious patients. Manage IAW *Spinal Trauma Protocol*.

DISPOSITION & EVACUATION

1. TM rupture without complications – Return To Duty after 6 hrs of observation
2. TM rupture with hearing loss – *Routine* evacuation
3. Neurologic Injury - *Urgent for neurosurgical evaluation*
4. Pulmonary Complications- *Urgent* evacuation
5. Abdominal Pain - *Urgent* evacuation
6. AGE or Barotrauma – *Urgent* evacuation
7. Spinal Injury – *Urgent* evacuation to neurosurgical capability.

Eye Injury



Eye Injuries

Penetrating injuries to eye globe or fracture of the orbit must be assessed with any facial trauma in the combat setting. In the combat setting, penetrating wounds of the eye may be very common from shrapnel and debris. Blunt trauma that may disrupt the integrity of the globe may be seen during facial trauma from falls, PLF, FRIES landings, hand-to-hand combat or MVA-type collisions. The primary management in any setting includes a rigid eye shield that does not put pressure on the globe of the eye. Avoid any manipulation of eye or eye globe if penetrating injury is suspected. Infection may cause later permanent loss of vision, so early broad-spectrum systemic antibiotic therapy is critical to prevent post-traumatic endophthalmitis.

TCCC Application

Care Under Fire: Stop life-threatening bleeding.

Tactical Field Care/Tactical Evacuation: If a penetrating eye injury is noted or suspected: Perform a rapid field test of visual acuity and document findings. Cover the eye with a rigid eye shield (NOT a pressure patch.) Give Ondansetron 4-8mg IV/IM/ODT/PO to prevent vomiting and the subsequent increase in IOP. Ensure that the 400 mg moxifloxacin tablet in the combat pill pack is taken if possible. If able to take PO: Moxifloxacin, 400 mg PO onCe a day. If unable to take PO: Ertapenem, 1 g IV/IM once a day.

Extended Care

Extended Care:

Retrobulbar Hematoma: Blunt or penetrating periocular trauma may result in orbital bleeding. As the pressure in the orbital compartment is progressively elevated, the intraocular pressure will also rise. If intraocular pressure rises to a high enough level, either central retinal artery occlusion or damage to the optic nerve may ensue and vision may be permanently lost in the eye. Signs/symptoms of retrobulbar hemorrhage include pain, periorbital ecchymosis, progressive proptosis (bulging forward of the eye), decreased vision, diffuse subconjunctival hemorrhage, and an afferent papillary defect. The definitive management for this disorder is a lateral canthotomy.

Rapid Field Visual Acuity Test

Visual acuity is the vital sign of the eye in your assessment. Vision in affected eye should be checked with unaffected eye closed. A simple quantification is from best to worst:

1. Able to read print
2. Can count the number of fingers held up
3. Can see hand motion
4. Can see light

Document the finding on casualty card.

Eye Examination (TRAUMA)

Inspect surrounding structures: Inspect the symmetry of the eyes, eyebrows, and orbital area for any abnormalities.

Eyelids: Inspect the patient's lightly closed eyelids for symmetry, fasciculation, tremors, and presence of eyelashes. While closed, look to ensure eyelids close completely.

Pupils: PERRLA, Distortion, Size

Iris: Details clear, blood in anterior chamber, evidence of iris tissue in cornea or limbus, laceration or indication of penetrating trauma

Sclera: Obvious lacerations, dark iris or uveal tissue, redness, subconjunctival hemorrhage

Cornea: Obvious defects (laceration or penetration), iris tissue in cornea

Ocular Motion: Inability to move eye


Standard Visual Acuity Test

Distant visual acuity is tested using a Snellen chart with patient 20 ft away in a well-lighted area. Test each separately, with one eye being covered while testing the opposite eye. Allow a few moments for eyes to adjust between tests. If patient wears corrective vision, record 2 separate tests; 1 with and 1 without correction. Documentation is recorded as a fraction in which the numerator indicates the distance from the chart (20) and the denominator indicates at which the average eye can read the line. (i.e. 20/40 indicates the patient is reading at 20 ft what the average eye can read at 40 ft. Tell patient to read the line most clear to them and then proceed to the next distance level. Record the distance in which the patient can still accurately read the text.


Near visual acuity is tested using the same principles as distant vision, but with Rosenbaum pocket vision screener. The patient holds the card a approximately 14 inches from the eye and reads the smallest line possible.

Peripheral visual acuity is tested using the confrontation test. Stand facing the patient at eye level and test each eye separately. While the patient covers one eye, you cover the opposing eye (PT-L, Examiner-R). Fully extend your arm midway between yourself and the patient and then move it centrally with the fingers moving. Have the patient tell you when the moving fingers are first seen. Compare the patient's response with your response in the upper, lower, left and right spectrums. Record as the estimated degrees of vision with directly ahead being 0 degrees.

Eye Injury Management Protocol



Lateral Canthotomy



EQUIPMENT NEEDED:

Mosquito clamp, hemostats, or needle driver
Lidocaine 1% w/Epi (preferred) or w/o/Epi
Syringe w/25G 5/8" Needle
Iris scissors
Tissue forceps

CONTRAINDICATIONS:



Globe Rupture

CAUTION:

All aspects of procedure should be performed lateral to the eye

DOCUMENTATION:

- ABC's
- Detailed assessment
- Vital signs
- Complications Encountered



Seizures



Seizures

A seizure is an uncommon event that can be caused by many different ailments and processes. Not all convulsions become an epileptic condition, and most are brief and self-limited. Seizures are characterized by abrupt onset of abnormal muscle activity, or prodrome of confusion, peculiar behavior, automatisms, or vivid sights/smells.

Assessment & Management


Assessment: May have sudden onset of loss of consciousness, followed by abnormal motor activity such as tonic rigidity, clonic rhythmic movements of the limbs, urinary incontinence, frothing at the mouth, and biting the tongue and mouth; may last seconds to minutes, and is usually followed by a period of weakness, somnolence and confusion (post-ictal state). Seizures will often spontaneously stop without any intervention after a few minutes. The differential diagnosis of a convulsive event is extensive: idiopathic epilepsy, alcohol or drug associated seizures, post concussive syndrome, convulsive syncope, heat stroke, infectious (meningitis), brain mass lesions, nerve gas exposure, metabolic abnormalities, and eclampsia in pregnancy. Wellbutrin, INH, Tramadol and other medications may lower seizure threshold.

Management: Remove the patient from an area where he could injure himself or others. Keep sharp and breakable objects away from the patient. Pad objects to avoid injury. Do not put anything in the patient's mouth. Never put your fingers in the patient's mouth. Medications are rarely required to break a first time seizure. After the seizure, evacuate the patient to an appropriate treatment facility for a neurological examination and further evaluation. The exam will usually be normal, other than confusion and somnolence in the immediate post-ictal period, which may last for hours. After focal motor seizures, there may be a period of Todd's paralysis, which is focal weakness of the affected limb. If seizure lasts more than ten minutes there is the possibility of status epilepticus. These seizures must be stopped ASAP. This is a life-threatening event and may produce significant brain injury if the patient survives. Emergency medical assistance and intervention must be rapidly sought. Begin an IV access line. Administer benzodiazepines until the seizure stops or the patient requires airway management. **Midazolam** 2-5mg IV/IO or 5mg IM q5m or Diazepam 5-10mg IV/IO. Administer Levetiracetam 1-4g IV x1 for further prophylaxis and treatment. Evacuate for further imaging and EEG monitoring if available.

Extended Care

Attempt to identify and manage underlying condition prompting the seizure activity. **NO DRIVING, WEAPONS HANDLING, OR OTHER DANGEROUS ACTIVITIES UNTIL MEDICALLY CLEARED.** Urgent evacuation is not normally required for a patient with a single seizure that spontaneously resolved. Patients should ultimately be referred for a non-emergent, ROUTINE Neurological Consultation.

Seizure Management Protocol



Spinal Cord Injury Management



Spinal Injuries

While cervical spine (CS) injuries are relatively common in major trauma, they receive less attention in the combat environment due to the prevalence of penetrating injury mechanisms. With the high incidence of explosive injury in present conflicts, providers must pay attention to the indications for and methods of ruling out cervical or spinal injury. IED blasts and jump injuries have a high risk for lumbar fractures. Physical exam is essential for cervical spine clearance, but most patients will require some form of imaging. If possible, ground assault force vehicles should carry spinal immobilization equipment.

Spine boards have never been proven to provide any benefit to the patient and often cause harm through prolonged pressure. Even patients with suspected spinal injuries are best cared for on a rigid litter and not on a spine board. If used, patients should spend no more than 10 minutes on a spine board as they make transferring/moving patients easier. Remove the patient as soon as possible from a spine board and place on a padded rigid litter. Do not place a suspected spine injured patient on a SKEDCO or other flexible litter.

Likewise, cervical collars are also known to cause harm by interfering with lifesaving interventions and hiding other injuries. Use NEXUS Criteria to aid in cervical spine clearance and only place a collar when necessary. Penetrating trauma patients rarely require cervical collars. If required, perform all lifesaving interventions with an assistant preventing unnecessary cervical spine movement prior to placing a cervical collar.

TCCC Application

Care Under Fire: Manage life-threatening hemorrhage. No specific action. On the battlefield, preservation of the life of the casualty and medic are of paramount importance. In these circumstances, evacuation to a more secure area takes precedence over spine immobilization.

Tactical Field Care: All patients who have sustained injuries through the following mechanisms should have a cervical collar placed with spinal immobilization in the pre-hospital environment if the tactical situation allows: Trauma resulting in loss of consciousness; major explosive or blast injury; mechanism that produces a violent impact on the head, neck, torso or pelvis; mechanism that creates sudden acceleration/deceleration or lateral bending forces on the neck or torso; fall from height (vs. fall from standing); ejection or fall from any motorized vehicle. Autopsy data shows patients with penetrating cervical injury in war almost never survive the injury. Therefore, spinal stabilization should only be performed after all other life saving interventions. All providers must be aware that the collar may hide other injuries, increase the difficulty of airway management, and mask developing pathology such as expanding hematoma. Patients with isolated penetrating cervical injury who are conscious and have no neurologic signs should not have a cervical collar placed in the pre-hospital environment. Patients with isolated penetrating brain injury do not require a cervical collar unless the trajectory suggests cervical spine involvement. During spinal immobilization, ensure adequate precautions are taken to prevent hypothermia using external warming devices. Field expedient cervical immobilization methods include IV bags, rolled poncho liner, stacked/taped MRE package, rolled up uniform shirt or snivel gear.

Tactical Evacuation: Evacuate as determined by other significant injury protocols. Evacuate as *Urgent* patients with gross neurological deficits. Evacuate as *Priority* patients without other significant injuries or without neurological deficit. Consider padding of litter for extended distance evacuations. Ensure hypothermia prevention measures are rendered.


Extended Care

Extended Care: In the event of extended care, there is little that can be done for known spinal injuries. If possible, avoid repeated litter movements of the casualty. If extended spinal immobilization is expected, then attempt to pad the litter prior to placement of the patient to reduce the risk of development of pressure ulcers. Attempt to pad any areas near bony prominences. Immobilized patients are at risk of aspiration. Be prepared for emergency suction and/or the ability to tip the immobilized patient if vomiting is imminent. Use prophylactic antiemetics to help reduce risk. High spinal cord injuries may affect the diaphragm and put the patient at risk for respiratory failure. Be prepared for ventilation procedures. These patients may also display hypotension (from neurogenic shock) and bradycardia. Fluid challenge within normal guidelines. If tachycardia is present, then assume hypovolemic shock and attempt to determine cause. Patient comfort while immobilized will become a greater concern as time passes. Urination may be controlled by use of Foley catheterization or tipping the immobilized casualty.

Spinal Injury Assessment

1. Do not administer procedural sedation until after completion of neurovascular check and assessment of GCS.
2. Report & document GCS, paralysis, and any neurologic deficit.
3. Concerning mechanisms of injury:
 - a. Any mechanism that produced a violent impact to the head, neck, torso, or pelvis.
 - b. Incidents producing sudden acceleration, deceleration or lateral bending forces to neck or torso.
4. Distracting injuries are any injury that may potentially impair the patient's ability to recognize other injuries or neurological deficit.

Spinal Cord Injury Management Protocol



| Glasgow Coma Scale | | |
|--------------------|------------------------|---|
| Eye Opening | Spontaneous | 4 |
| | To Voice | 3 |
| | To Pain | 2 |
| | None | 1 |
| Verbal Response | Oriented | 5 |
| | Confused | 4 |
| | Inappropriate Words | 3 |
| | Incomprehensible Words | 2 |
| Motor Response | None | 1 |
| | Obeys Commands | 6 |
| | Localizes Pain | 5 |
| | Withdraws (Pain) | 4 |
| | Flexion | 3 |
| | Extension | 2 |
| | None | 1 |

Document as: E ___ + V ___ + M ___ = ___

NEXUS
 Focal neurologic deficit?
 Midline spinal tenderness?
 Altered level of consciousness?
 Intoxication?
 Distracting injury?

If all are "no" then a cervical collar is not necessary

1. In Care Under Fire phase, do not jeopardize mission/men to attain spinal immobilization.
2. Do not administer pain control drugs until after completion of neurovascular check.
3. Report & Document GCS, Paralysis of Neurovascular deficit.
4. There are relatively few "spinal" injuries in the combat environment.

Orthopedic Trauma



Orthopedic Trauma

Trauma to the extremities is common and can range from simple sprains to massive soft tissue injury and bony destruction associated with explosive devices. The sensation of a “pop” or “crack” is often misleading and should not be relied upon. The patient’s exam is often the key to diagnosis and initiating proper treatment. Any bleeding, even a small amount, should indicate an open fracture. Examine joints for dislocation and splint any obvious deformity in two planes.

TCCC Application

Care Under Fire: Control massive life-threatening hemorrhage.

Tactical Field Care: Initially splint any fractures in position of function or immobilize in current position. Generally, splinting in position of function will reduce overall pain to patient. Use traction on indicated fractures but stop if it is causing worse pain. By splinting and reducing fractures, attempt to restore any vascular compromise. If possible, clean and irrigate any gross contaminated wounds/fractures. If conscious, administer combat wound pill pack. Administer antibiotics: Ertapenem 1g IV/IM qd or Cefazolin 1-2g IV q8h for open fractures. Re-assess neurovascular status every 5-10m and document changes. Dislocations with distal pulse may be reduced based on evacuation time and training/experience in procedure. Consider pain management, local/regional anesthesia, or dissociative agents prior to manipulating dislocations. Splint and/or sling/swathe as appropriate.

Tactical Evacuation: Re-Assess splints, interventions and neurovascular status after any evacuation movements. If previously unable to provide traction or adequate splinting, apply as appropriate.


Extended Care

Orthopedic injuries often accompany other significant injuries. Prioritize patient management based on severity of multiple injuries. Vital signs should be monitored regularly to include color, temperature, motor and sensory function. Conduct repeat motor and sensory exams in conjunction with vital sign checks. IV fluids administered to maintain SBP of 90-100mm/hg or as indicated by other conditions. Focus extended care efforts on extremity perfusion. Splinting in anatomical position of function will optimize improved blood flow. If tourniquets have been applied, consider tourniquet conversion if hemorrhage can be controlled through other means.

Consider patient comfort for extended timeframes and re-splint as necessary. Use hematoma blocks, local, or regional anesthesia for pain control. Consider padding points of contact on splinting devices. Pain management IAW protocol and consideration of effect on other injury patterns. Contaminated wounds should be flushed with normal saline or clean water. The intent is to remove gross contamination such as dirt and debris.

Monitor for development of compartment syndrome. Be suspicious of compartment syndrome in the following conditions: Fractures, crush injuries, vascular injuries, or multiple penetrating injuries (fragmentation). The classic clinical signs of compartment syndrome: pain out of proportion to injury, pain with passive motion of muscles in the involved compartment, pallor, paresthesias, and pulselessness are late findings. Be aware that peripheral pulses are present in 90% of patients with compartment syndrome. Monitor closely and be aware of any pain out of proportion. Compartment syndromes make take hours to develop. For patients with suspected compartment syndrome, reevaluate every 30 minutes for 2 hours, then every hour for 12 hours, then every 2 hours for 24 hours, then every 4-6 hours for 48 hours. Extremity compartment syndromes may occur in the thigh, lower leg/calf, foot, forearm, and hand. Compartment syndrome management: maintain extremity at level of heart. **Do not elevate.** Loosen encircling dressings. Urgent evacuation. Only attempt fasciotomy if evacuation is delayed 6 hours or longer and with online medical direction. Fasciotomy is not within the independent scope of the Ranger medic.

Orthopedic Trauma Management Protocol



Burn Management



TCCC Application

Care Under Fire: Casualties should be extricated from burning vehicles or buildings and moved to places of relative safety. Do what is necessary to stop the burning process.

Tactical Field Care: Facial burns, especially those that occur in closed spaces, may be associated with inhalation injury and/or carbon monoxide inhalation. Aggressively monitor airway status and oxygen saturation in such patients and consider early surgical airway for respiratory distress or oxygen desaturation. Estimate total body surface area (TBSA) burned to the nearest 10% using the Rule of Nines. Cover the burn area with dry, sterile dressings. For extensive burns (>20%), consider placing the casualty in the Blizzard Survival Blanket in the Hypothermia Prevention Kit in order to both cover the burned areas and prevent hypothermia. Initiate fluid resuscitation (USAISR Rule of Ten): If burns are greater than 20% of Total Body Surface Area, fluid resuscitation should be initiated as soon as IV/IO access is established. Resuscitation should be initiated with crystalloids. Do not use more than 3L of NS due to the risk of causing hypochloremic metabolic acidosis. Initial IV/IO fluid rate is calculated as %TBSA x 10cc/hr for adults weighing 40-80 kg. For every 10 kg ABOVE 80 kg, increase initial rate by 100 ml/hr. If hemorrhagic shock is also present, resuscitation for hemorrhagic shock takes precedence over resuscitation for burn shock. Pain management for the burn patient is per the Pain Management Protocol. Prehospital antibiotic therapy is not indicated solely for burns, but antibiotics should be given as indicated for other traumatic injuries. All TCCC interventions can be performed on or through burned skin in a burn casualty.

Tactical Evacuation: Initiate any tactical field care interventions not previously performed. Burn patients are particularly susceptible to hypothermia. Extra emphasis should be placed on barrier heat loss prevention methods and IV fluid warming in this phase.

Extended Care

Extended Care: Extended care in the pre-hospital environment will remain focused on prevention of hypothermia, airway and vital signs monitoring as well as initiation of fluid resuscitation avoiding bolus fluids if possible. Elevate injured extremities 30-45°. Documentation of input/out of fluids must be initiated and evacuated with patient to the next higher facility. Fluid resuscitation will be in accordance with the USAISR Rule of Ten. Assess distal circulation of all extremities by palpating the radial, dorsalis pedis, and posterior tibial arteries. If a pulse is palpable in one or more arteries in each extremity escharotomy is not indicated.



Inhalation burns should be assumed with any burns to the face and neck and may require aggressive airway management. Inhalation injury is further exacerbated by retained soot and chemicals. Not every patient with soot in the airway will require airway management. Use clinical judgement and assess the patient before taking the airway. Remember, inhalation injury is mostly a chemical injury that will benefit from removing the chemical. Suction the airway carefully using the endotracheal suction tubing if available to remove both secretions and soot or chemical materials. Irrigation of any kind in the field is not warranted and will most likely move materials to unaffected airways or pulmonary tissue.

Burn Guidelines: Do not administer prophylactic antibiotics for burns without other combat wounds. Splint burned hands and feet in position of function with dressings separating digits. Aggressively manage pain and hypothermia for critical burn patients. Commercial burn dressings are not required and add little to patient care. In the acute phase do not be distracted by a burn. **DO NOT OVER-RESUSCITATE WITH IV FLUIDS. RECORD STRICT IOS AND MAINTAIN 0.5-1CC/KG/HR UOP.**

Escharotomy: The requirement for escharotomy usually presents in the first few hours following injury. If the need for either procedure has not presented in the first 24 hours, then circulation is likely to remain adequate without surgical intervention. Escharotomy is normally performed when an extremity has a circumferential full thickness burn. If the burn is superficial or not circumferential and pulses are absent, consider inadequate circulation from other causes such as hypovolemia, hypotension, or occult traumatic injury. If indicated, extend escharotomy incisions the entire length of the full-thickness burn and carry across the joint when the burn extends across the joint. In the lower extremity, make a mid lateral or mid axial incision with a surgical knife through the dermis to the level of fat. It is not necessary to carry the incision to the level of fascia. Although full thickness burn is insensate, the patient will often require intravenous narcotics and benzodiazepines during this procedure. Perform pain management or sedation as required. On completion of midlateral or midmedial escharotomy reassess the pulses. If circulation is restored, bleeding should be controlled and the extremity dressed and elevated at a 30-45° angle. Assess pulses hourly for at least 12-24 hours. If circulation is not restored, perform a second incision on the opposite side of the extremity. For upper extremities, place the hand in the anatomic position (palm facing forward) and make an incision in the mid radial or mid ulnar line. Ulnar incisions should stay anterior (volar) of the elbow joint to avoid the ulnar nerve, which is superficial at the level of the elbow. If pulses are not restored, a second incision may be necessary on the opposite side of the extremity. If both the hand and arm are burned, continue the incision across the mid ulnar or midradial wrist and onto the mid ulnar side of the hand or to the base of the thumb and then the thumb webspace. Following escharotomy, late bleeding may occur as pressure is decompressed and circulation restored. Examine the surgical site every few minutes for up to 30 minutes for signs of new bleeding.

PEDIATRIC BODY SURFACE AREA: Head = 18%, Torso Front = 18%, Torso Back = 13%, Unilateral Buttock = 2.5%, Arm = 9%, Leg = 15% (7.5% per side).

Burn Management Protocol




1. Consider other traumatic injuries
2. Other life-threatening injuries take priority over burn management
3. Treat other injuries IAW TCCC or appropriate protocol

BAMC-ISR Formula:
 = %TBSA X 10cc/hour for adults weighing 40-80 kg. For every 10kg above 80kg, increase rate by 100ml/hr. For burns >20% TBSA, initiate fluid resuscitation ASAP.

Parkland Formula:
 · The IV fluid required for the first 24 hours = 4 ml/kg of LR x % area burned.
 · Give half of the total fluid within the first 8 hours of the burn. -- Give the second half over the next 16 hours.

Document:
 · Degree of Burn
 · % of Body Burned
 · Respiratory Status
 · EtCO2
 · SpO2
 · Type of Burn
 · Medical History
 · Confined Space?

1. Remove clothes, flood with water ONLY if flames or smoldering is present.
2. Consider Carbon Monoxide poisoning if victim was within a confined space. If potential for CO poisoning exists administer Oxygen 100%.
3. If shock is present consider underlying causes.
4. Note: the patient's palm represents 1% of their BSA. Use this as a reference.
5. Critical burn = · any degree >20% TBSA · 3rd degree > 10% · respiratory injury · involvement of face, hands, feet, or genitalia · circumferential burns · associated injuries · electrical or deep chemical burns · underlying medical history (cardiac, diabetes) · age < 10 or > 50 years.
6. Start IVs within unburned areas if possible. Burned areas may be used if needed.
7. Consider HPMK to cover burns >20%, to protect burns, and prevent hypothermia.
8. Treat other traumatic injuries prior to addressing a burn.



Chemical Burns
 1. Irrigate wound if possible with copious amounts of water to stop burning process and/or to remove chemical from wound.
 2. If chemical is solid, brush off of skin and do not apply water.

Ocular Burns
 1. Irrigate wound if possible with copious amounts of water or saline.
 2. Consider administration of ocular anesthetic.

Pain Management



Basic Pain Management

Severity of pain is subjective and should be based on individuals and injuries and not this protocol alone. Any use of narcotic medications will be sedating and degrade the mission performance of patients. Avoid IM or SQ injections of narcotic medications due to the potential for delayed absorption. Apnea can occur at any dose of opioids and ketamine when pushed too quickly. Slow IV push is mandatory and completed over 30s-1min. Always closely monitor patients receiving these medications.

TCCC Application

Care Under Fire: No action required.

Tactical Field Care:

1. Able to fight: Administer combat wound pill pack (CWPP) pain management components (Meloxicam, 15 mg PO once a day and Acetaminophen, 650-mg bilayer caplet, PO every 8 hours) as soon as possible after wounding.

Have a BVM or naloxone readily available whenever administering opiates.

2. Unable to fight but does not otherwise require IV/IO access: Oral transmucosal fentanyl citrate (OTFC), 800-1600 mcg transmucosal (tape lozenge-on-a-stick to casualty's finger as an added safety measure). Reassess in 15 minutes. Add second lozenge, in other cheek, as necessary to control severe pain. Monitor for respiratory depression. **OR** Ketamine 0.2-0.6mg/kg IN **OR** Fentanyl 0.5-1mcg/kg IN (using nasal atomizer device). Repeat dose every 30 minutes to 1 hour as necessary to control severe pain.

3. Unable to fight but IV or IO access obtained: Ketamine 0.1-0.3mg/kg slow IV/IO push over 1 minute **OR** Hydromorphone 0.5-1mg IV/IO **OR** Fentanyl 0.5-1mcg/kg. Reassess in 10 minutes. Repeat dose every 30 minutes as necessary to control severe pain. Monitor for respiratory depression. Continue to monitor for respiratory depression and agitation. Avoid 0.3-0.8mg/kg IV/IO and rapid administration.

Administer Ondansetron 4-8 mg IV/IO/ODT q1 hr as needed for nausea/vomiting.

Tactical Evacuation: No change to tactical field care actions.

TMEP Application

Start in sequential manner to maximize pain control with mission performance.

1. Acetaminophen 1000 mg PO q 6 hr.

2. Non-steroidal anti-inflammatory drugs: Meloxicam 15 mg PO qd prn **OR** Ibuprofen 800 mg PO q 8 hr prn **OR** Ketorolac 30 mg IM (15mg IV) q8 hr prn.

3. Narcotic Medications: Oral Transmucosal Fentanyl Citrate 400 – 800 mcg orally over 15 minutes **OR** Hydromorphone 0.5-1 mg IV **OR** Ketamine 0-1-0.3mg/kg IV/IO q30 min.


4. Procedural sedation with available medications.

5. Treat per *Nausea and Vomiting Protocol*.


Considerations

Pain should be assessed at its onset and reassessed frequently. **Do not** give insufficient pain medication to achieve relief. **Do not** give pain medication only after the pain has returned. Anticipate the onset of pain, and give the medication 30 minutes BEFORE the pain returns to provide effective relief. **Do not** fail to consider all classes of pain medications and their side effects before administering. Narcotics can cause apnea and the patient's respiratory status needs monitoring closely.

Pain Management Protocol



Procedural Analgesia



EQUIPMENT NEEDED:

- Saline Lock
- Needle/Syringe
- Medications
- Airway management equipment

SPECIAL CONSIDERATIONS:

1. Intended for performing brief, significantly painful procedures such as chest tube insertion or fracture reduction.
2. Prior to initiating this protocol, the following should be accomplished:
 - A. Vascular access
 - B. Airway equipment, suction, and bag valve mask device immediately available and within reach
 - C. Monitoring equipment (if available) on and attached to patient (if tactically feasible)
3. Concomitant administration of narcotics and benzodiazepines increases the risk for respiratory depression and hemodynamic instability. Use caution in patients with shock or hypotension.
4. Once the protocol has been initiated monitor patient continuously.

Regional Anesthesia



Digital Nerve Block

Approach & Indications

The digital nerve block provides anesthesia to clean and repair wounds to any digit or assist with management of severe pain of the digit. Current literature classifies injectable anesthetics with epinephrine as contraindicated due to risk of vascular compromise. Follow maximum dosing and pharmacology protocols for the injectable anesthetic utilized. Generally, administer 2-5cc of anesthetic when performing block.

Indications: Laceration or other wound cleansing and repair of digit, nail removal or trephination, or pain relief (ensure to document detailed neurovascular exam to include intact flexor and extensor tendon exam prior to anesthetizing digit).

Technique

The procedure can be best accomplished using the transthecal (palmar/plantar) technique. Using standard sterile precautions, place the patient's hand on the procedure surface palm up. Locate the flexor tendon sheath just proximal to the distal palmar crease. Insert the small gauge needle at 90-degrees, hit bone, slightly withdraw and inject in standard fashion ensuring medication is not administered intravenously. During the injection, you can use the nondominant hand to apply pressure just proximal to the injection site, to direct the flow distally. The procedure can be performed on the digits of the feet as well using similar landmarks and methodology.

Hematoma Block

Approach & Indications

The hematoma block provides local anesthesia to assist with management of fracture reduction without the need and risks associated with procedural sedation. Subcutaneous injection of anesthetic prior to actual nerve block will lessen discomfort. Follow maximum dosing and pharmacology protocols for injectable anesthetic utilized. Use standard PPE precautions.

Indications: Long bone fracture requiring anesthesia to assist with reduction of fracture prior to splinting. Most commonly used for metacarpal or forearm fractures.

Technique

The hematoma block injection site is identified through palpation of the deformity and then cleansed in standard sterile fashion. The needle is then inserted generally perpendicular to the skin into the fracture site. This may be accomplished blindly through readjustments until the needle "falls" into the fracture with loss of resistance. Confirmation of needle location within the fracture site can be obtained by drawing back on the syringe plunger and aspirating hematoma. The hematoma can then be infiltrated with 8-12 cc of anesthetic.

Wrist Block

Approach & Indications

The wrist block provides anesthesia to clean and repair large wounds to the hand or assist with management of severe pain or crush injury during further treatment or transfer to higher level of care. Ensure proper and accurate documentation of time and medication used to properly inform the receiving facility and providers. Follow the maximum dosing and pharmacology protocols for the injectable anesthetic utilized. Always use standard sterile precautions and withdraw prior to injection to ensure anesthetic is not administered intravenously. Review wrist and hand nerve distributions to determine appropriate single or combination of blocks indicated for the patient. Subcutaneous injection of anesthetic prior to actual nerve block will lessen discomfort. Generally, administer 5cc of anesthetic when performing block.

Indications: Multiple digit/large hand laceration or other wound cleansing and repair of digits, multiple nail removal or trephination, or pain relief (ensure to document detailed neurovascular exam to include intact flexor and extensor tendon exam prior to anesthetizing digit).

Technique

The ulnar nerve block procedure is accomplished by inserting the needle at 90-degrees at the proximal wrist crease and just ulnar and deep to the flexor carpi ulnaris tendon. Ensure needle is not within the ulnar artery by aspirating without blood return prior to injection. The median nerve block procedure is accomplished by inserting the needle at 90-degrees at the proximal palmar crease in between these two tendons. The median nerve runs between the flexor carpi radialis and palmaris longus tendons. A pop is often felt when through the fascia, or withdraw the needle after hitting bone to verify position. A fan technique of anesthetic administration will ensure complete anesthesia. The radial nerve block procedure is accomplished by inserting the needle at 90-degrees just distal due to the radial styloid in the anatomic snuff box over the radial side of the wrist.

Fascia Iliaca Block

Approach & Indications

This block allows for anesthesia of at least two of the three major nerves that supply the medial, anterior and lateral thigh with one simple injection, namely the femoral and lateral femoral cutaneous nerves. Ensure proper and accurate documentation of time and medication used to properly inform the receiving facility and providers. Subcutaneous injection of anesthetic prior to actual nerve block will lessen discomfort. Do not exceed 400mg of lidocaine with this injection or 40mLs 1% Lidocaine and follow maximum dosing and pharmacology protocols for the injectable anesthetic utilized. Use standard sterile precautions.

Indications: The fascia iliaca nerve block provides anesthesia to assist with management of hip fracture or dislocation reduction without the need and risks associated with procedural sedation.

Technique

Draw a line between the anterior superior iliac spine (ASIS) and pubic tubercle on the side of the planned block. Divide this line into thirds. Using a blunt tipped needle, insert the needle one cm distal to the junction of the lateral 1/3 and 2/3 marks. Verify this is lateral to the femoral artery and expected to be lateral to the femoral nerve that is adjacent to the artery laterally. Two distinct pops should be felt during needle insertion as it penetrates the two fascia layers. Insert the needle 1-2mm past the second pop. Withdraw to ensure the needle is not located intravascularly and slowly inject the anesthetic. The medication should flow easily, if not, slightly withdraw as the needle is likely within the muscle. Inject 20-30 mLs of long acting anesthetic slowly.

Extended Austere Care



Extended Evacuation in Austere Environment

Extended Austere Care – Due to the extreme nature of special operations, the Ranger Medic may find himself in a situation in which prompt evacuation of casualties to a surgical facility is not possible for long periods of time. In these situations, the medic is limited to what he is carrying and the contingencies previously considered and planned for. Essentially, **extended care begins at the point in which you thought you were going to evacuate your casualties**. The medic should make all possible attempts to make contact with higher medical capability to confirm extended care measures.

Extended Care Considerations

Principles of Extended Care: Once the Medic has identified that he/she has transitioned into extended care a tactical pause must be taken. Additional factors may become priorities and to remain effective the Medic must have a plan for treatment. There are several key principles which aid in preparation and execution of Extended Austere Care.

- Plan appropriately
- Understand Resuscitation goals
- Proper pain management and understanding potential drug interactions
- Monitor/Trending vitals to include UOP and physical exams
- Create an effective plan for treatment and identify possible procedures
- Performing surgical procedures, within scope of practice, in the absence of timely evacuation
- Prevent any damage done by treatments and provide effective nursing care
- Utilize telemedicine as early as possible
- Effective team dynamics and utilize a rest cycle for sustainability
- Prepare an effective handover

Extended Care Capabilities: Utilizing the Good, Better, Best model and having a strong understanding of both physical limitations (ie. Equipment) and mental limitations (ie. Knowledge) will aid the Medic in preparing and executing effective Extended Care.

- Monitor Vitals
- Resuscitate
- Definitive Airway Control
- Be able to Ventilate/Oxygenate
- Utilize Sedation/Pain Control
- Perform Physical Exams
- Execute Nursing Care
- Perform Surgical Interventions
- Understand and Execute Telemedicine
- Package and Prepare for Evacuation

Patient Assessment: After completing the initial MARCH assessment and being alerted of extended evacuation times, the Medic must transition to completing a more comprehensive assessment and focus on additional tasks. **MARCH-E PAWS-B** and **RAVINES** are two potential options.

- **MARCH-Eyes, Pain, Antibiotics, Wounds, Splinting, Burns**
- **Resuscitation/Reduce Tourniquets, Airway (Definitive/Sedation), Ventilation/Oxygenation, Initiate Telemedicine, Nursing Care, Environmental Considerations, and Surgical Procedures**

Vital Signs: Vital signs should be assessed frequently, especially after specific therapeutic interventions, and before and after moving patients. Any change in vital signs should prompt an assessment to determine the cause and appropriate action should be taken. Documentation of vital signs in Extended Care will help with gaining a better understanding of where your casualty is trending.

- **Good:** BP cuff, stethoscope, Pulse Oximeter
- **Better:** ETCO2, Foley
- **Best:** Monitor for vital signs

Airway Management: Airway assessments should be done at regular intervals to ensure patency and provide suction as needed. This is of particular importance after performing any patient movement. Remember to assess cuff pressures.

- **Good:** Supraglottic Airway
- **Better:** Definitive Airway Management
- **Best:** Long Duration Sedation and Definitive Airway Control

Extended Austere Care



Extended Care Considerations

Breathing/Respiratory Management: If ventilation support is required, place patient on SaVE or SaVE 2 mini-vent or ventilate with BVM. Consider alternating between SaVE and BVM to conserve battery strength. Continue needle decompressions as indicated and change chest seals as required to ensure occlusion. Establish thoracotomy as required. If chest tube established, routinely check, reinforce, and suction as needed.

- **Good:** BMV with PEEP
- **Better:** Supplemental Oxygen
- **Best:** Portable Ventilator

Wound Management: Particular emphasis must be placed on several aspects of long-term wound care to achieve ideal outcomes for wound management in Extended Care

- **Physical Examination:**
 - Inspection of the wound and surrounding tissues for necrosis/infection
 - Passive/Active Range of Motion
 - Ultrasound
 - Labs
- **Irrigation/Debridement**
 - Clean water from bottles or canteens may be used to washout wounds
- **Dressing Changes/Reassessments**
 - Tourniquets and dressings should be checked and reinforced. Convert tourniquets to pressure dressing as soon as possible
- **Splinting/Reduction of fractures**
- **Telemedicine**

Damage Control Resuscitation (DCR): The goal is to maintain a systolic blood pressure above 100 and patient mentation. Continue fluid resuscitation IAW appropriate protocols. A Foley catheter should be placed as soon as possible. Record Ins/Out and shoot for 30-50ml/hour (.5-1mg/kg/hr).

Pain Management/Sedation: It is important to have an understanding of your goals with pain management and sedation.

1. Keep the casualty alive. Do not give analgesia or sedation if there are no other priorities
2. Sustain adequate physiology to maintain perfusion. Avoid medications that cause hypotension/bradypnea for patients with hemorrhagic shock or respiratory distress
3. Relieve Pain first
4. Maintain safety. Agitation and anxiety may result in damage to interventions/equipment/patient
5. During painful procedures amnesia may be required. Titrate to effect and duration with a limited amount of medication, the Medic must get the most out of what he/she carries. Start low and go slow, the less blood volume means less medication to achieve desired effects. Utilize Regional Anesthesia when able and trained appropriately.
 - **Background Pain:** the pain that is always present because of an injury or wound. Keep the patient comfortable at rest and do not impair breathing/circulation/mentation.
 - **Breakthrough Pain:** acute pain from movement/manipulation. Manage as needed.
 - **Procedural Pain:** associated with a procedure. Anticipate and medicate appropriately both before, during, and after the procedure.


Nursing Care: Utilize passive movement of uninjured extremities to prevent DVT or PE (BPT to manage as applicable). Also, consider position change on the litter and padding of pressure points. Hypothermia management will remain a constant concern for the traumatized patient. Apply the HITMAN mnemonic when remembering nursing care:

- Hydration
- Infection
- Tubes
- Medications
- Analgesia
- Nutrition

Equipment & Battery Management: Check battery strengths every time equipment is activated. Consider alternating between manual and mechanical VS check or ventilation for periods of time. Turn on devices only when needed. Keep devices as clean and protected as possible. Ensure you train with equipment you plan on using in potential Extended Care scenarios. Understand how to troubleshoot your equipment.

Documentation: Maintain consistent and accurate documentation. Upon eventual evacuation, your management and interventions will be critical to receiving medical facilities. Record vital signs trends and all fluids infused along with estimations of blood loss and urine output.

Extended Austere Care Protocol



Extended Care Considerations:

1. Inventory all Class VIII available
2. Check batteries on all equipment
3. Contact Medical Officer if possible

Blood Transfusion



WARNINGS

1. **Confirmed O Low Titer** is the only universally compatible FWB type. Second choice should be non-titered O. Otherwise, transfusions of FWB must be an ABO match. All attempts should be made to transfuse blood from pre-identified ROLO donors. For female casualties, do not delay transfusion for Rh- blood if needed.
2. Blood and blood components should only be administered by personnel who are trained in the proper procedure and the identification and management of transfusion reactions.
3. Use only collection bags designed for the collection of whole blood (WB) and administration sets designed for the administration of blood and blood components. Failure to do so may lead to fatal thromboembolic events.
4. 0.9 percent normal saline (NS) is the IV fluid of choice for administering with blood or blood components. Ringer's Solution can be used if Normal Saline is unavailable. Colloids (Hextend) or dextrose-based fluids should NOT be used at any time.
5. Great care should be taken to practice aseptic technique when performing transfusions in the field to prevent subsequent infection.
6. The largest bore IV catheter should be used. An IO device may be used. Ensure that a strong flush is done and good flow is obtained prior to using an IO infusion.

S/S of Reactions

Allergic Reaction S/S: Diffuse, itchy rash most common. Anaphylaxis may also occur.

Anaphylactic Reaction S/S: Shock, hypotension, angioedema, respiratory distress

Acute Hemolytic Reaction S/S: 1. Acute Hemolytic reaction usually has onset within 1 hour. 2. Evidence of disseminated intravascular coagulopathy (DIC) – oozing from blood draw, IV sites. 3. Flushing, especially in the face. 4. Fever, an increase in core temp of more than 2 degrees F (1 degree C). 5. Shaking, chills (rigor). 6. Flank pain or the acute onset of pain in the chest (retrosternal), abdomen and thighs. 7. Wheezing, dyspnea. 8. Anxiety, feeling of impending doom. 9. Nausea and vomiting. 10. Hypotension. 11. Pain, inflammation, and or warmth at the infusion site. 12. Red or Brown Urine (hemoglobinuria)-The onset of red urine during or shortly after a blood transfusion may represent hemoglobinuria (indicating an acute hemolytic reaction) or hematuria (indicating bleeding in the lower urinary tract).

Febrile Nonhemolytic Reactions S/S: Fever not as severe with an acute hemolytic reaction; chills; dyspnea

Transfusion Related Acute Lung Injury (TRALI) S/S: Development of ARDS following transfusion. Often presents with hypoxemia, hypotension, and frothy, pink pulmonary secretions. Avoid female donors to reduce chances of TRALI.

Management of Reactions

The first step in treating ALL transfusion related issues is to STOP the transfusion and save all of the blood products and equipment used for administration and typing for follow up testing.


Febrile Reaction: Diphenhydramine 25-50mg PO, PR, or IV for urticaria.

Anaphylactic Reaction: Treat IAW Anaphylactic Management Protocol. 1. Epinephrine 0.3ml of 1:1000 IM or push dose 1:100,000 epinephrine to maintain blood pressure. 2. Airway maintenance and oxygenation. 3. Resuscitate hypotensive patients with IV fluids.


Acute Hemolytic Reaction: 1. Secure and maintain airway. 2. Begin IV infusion of crystalloids. 3. Goal of fluid replacement is to infuse 100-200ml/hr in order to support a urine output of 1-2cc/kg/hr. 4. The patient should receive a foley catheter to monitor urine output. 6. Consider using Acetaminophen 1gm PO, PR, or IV (every 6 hours to treat discomfort associated with fevers. (Avoid the use of aspirin or other NSAIDS). 7. Administer 25-50mg of Diphenhydramine IM or IV to treat the associated histamine release from AHTR. Antihistamines should not be mixed with blood or blood products. 8. SAVE the rest of the donor blood and any typing information available and evacuate with the patient. This will allow for ABO and further diagnostic testing at the medical treatment facility.

Febrile Nonhemolytic Reactions: Treat with antipyretics. Acetaminophen 1gm PO, PR, or IV (avoid the use of aspirin and other NSAIDS). If symptoms abate and there is no evidence of an acute hemolytic reaction consider restarting the transfusion.

TRALI: Secure and maintain the airway. Administer supplemental oxygen and maintain continuous pulse oximetry monitoring. Use suction to remove secretions.



Fresh Whole Blood Transfusion (DONOR PROCEDURE)



WARNING!

Confirmed O Low Titer is the only universal donor for whole blood. Second choice is non-titered type O. Otherwise whole blood MUST be ABO-identical.

Refer to Anaphylaxis Management Protocol if S/S present of hemolytic reaction.


NOTE:

1. Donor is not restricted from duty unless symptomatic.
2. Donor should only donate once every 60 days
3. Start donor on iron supplementation 325mg QD


1. All ROLO Donors should be confirmed prior to deployment. ROLO Donor should be used to decrease the chances of a transfusion reaction and increase the speed of the procedure.
2. All blood typing should be confirmed prior to deployment. The Eldon card test is meant to be a pre-transfusion confirmation. ID (dog) tags should only be used as a last resort for blood type confirmation.
3. Attempt to monitor patient temperature during and after entire procedure as it may be the first indicator of transfusion reaction.
4. For female recipients Rh- blood is preferred but this should not delay transfusion if required.

- EQUIPMENT NEEDED:**
- Eldon blood typing card
 - Constriction band
 - 16-18G needles
 - Alcohol, Iodine or Clorhexidine swabs
 - 2x2 sponges
 - Tape, 1 or 2"
 - 450ml blood collection system with Citrate/Phosphate/Dextrose (CPD)
 - Hemostat
 - Blood transfusion IV tubing with 180 micron filter

Fresh Whole Blood Transfusion (RECIPIENT PROCEDURE)



Foley Catheterization Procedure



EQUIPMENT NEEDED:
- Foley Catheterization Set

DOCUMENTATION:
- ABC's / Airway Status
- Detailed Assessment
- Vital Signs
- Date/Time of procedure
- Amount of urine collected (hourly)
- Response to procedure
- Complications Encountered

1. Inflate with 10cc of normal saline.
2. The catheter must be advanced to the Y-junction as to avoid urethral injury due to the balloon being inflated in the urethra. Care must be taken to ensure the balloon is in the bladder. You may try to irrigate the catheter with >10 cc of sterile saline. If the solution does not easily return, you may not have the catheter far enough in the bladder.

Intake and output (I&O) measurements are used to determine if a patient is retaining fluid or diuresing (putting out more fluid than is being taken in). Initial Foley output is not included in this measurement. The patient retaining fluid is at risk for respiratory failure due to pulmonary edema, cardiac compromise due to congestive heart failure and increased risk of skin breakdown due to increased fluid in the tissue. I&O also gives the medic a quick snapshot of renal function and perfusion. Urinary output that averages less than 0.5cc/kg/hour is marginal and may be an indicator of decreased renal perfusion and/or function.

1. Measure and record all input, which is any fluid that goes into the patient; IV fluids, fluids by mouth, fluids via NG tube, and IV medications.
2. Measure and record all output, which is urine, emesis, liquid stool, and anything coming out of a drainage tube.
3. The output is subtracted from the input. If input is larger the patient is positive, and if output is larger the patient is negative in balance.
4. Do not over or underestimate the volumes of intake and output.

Crush Syndrome Management Protocol



CRUSH SYNDROME MANAGEMENT CONSIDERATIONS

Definition: Massive, prolonged crush injury resulting in profound muscle and soft tissue damage places the patient at significantly increased risk for developing circulatory and renal complications.

1. The principles of hypotensive resuscitation according to TCCC DO NOT apply in the setting of extremity crush injury requiring extrication.
2. In the setting of a crush injury associated with non-compressible (thoracic, abdominal, pelvic) hemorrhage, aggressive fluid resuscitation may result in increased hemorrhage.
3. With extremity crush injuries, tourniquets should NOT be applied during Phase 1 unless there is hemorrhage which is not controllable by other means.
4. Be aware of development of cardiac dysrhythmias due to hyperkalemia immediately following extrication.
5. BE AWARE OF DEVELOPMENT OF CRUSH SYNDROME STARTING AS EARLY AS 4 HOURS POST INJURY.

THESE MEDICATIONS ARE NOT PART OF THE STANDARD AID BAG AND REQUIRE DEVELOPMENT OF A SEPARATE CRUSH INJURY KIT.

PHASE 1: IMMEDIATE MANAGEMENT (while attempting to extricate)

The following management measures are to be initiated if time from initial crush to extrication exceeds four hours, while still trying to extricate the patient, and complete prior to extrication when crush has been > 4 hours:

1. Maintain patent airway and adequate ventilation.
2. Monitor O2 sat with pulse ox and administer high flow oxygen if indicated.
3. Give initial bolus of 1-2 L of crystalloid solution **PRIOR** to attempts at extrication and continue at 1.5 L/hr. Ringer's lactate or other potassium containing solution is not recommended due to the potassium content and risk for hyperkalemia and cardiac events.
4. Maintain urine output at greater than or equal to 1-2cc/kg/hr and monitor urine output volume. If indicated, insert Foley catheter.
5. Assess and reassess mental status.
6. Follow *Pain Management Protocol*
7. Treat with prophylactic antibiotics – Ertapenem 1 gm IV if time and tactical situation allows.

Utilize cardiac monitoring if available to monitor for signs of hyperkalemia. Treat suspected emergent hyperkalemia accordingly. Cardiac arrest should be treated per standard ACLS protocol with addressing early hyperkalemia as likely cause with calcium, sodium bicarbonate, insulin with glucose, and albuterol treatments.

PHASE 2: IMMEDIATELY PRIOR TO EXTRICATION

The following management measures are to be attempted immediately after extricating the patient:

1. **Cardiac Dysrhythmias or Arrest are likely immediately following extrication.**
2. CPR should be initiated if cardiac arrest develops following extrication IAW ACLS protocol. DO NOT follow the TCCC guidelines on cardiac arrest.
3. If extrication is greater than 4 hours OR in the presence of dysrhythmias, administer 1 amp of Calcium Chloride or Calcium Gluconate slow IV push. Calcium should not be given in a bicarbonate containing solutions due to precipitation of calcium carbonate.
4. Additional dosing of 1 amp of Sodium bicarbonate slow IV push may be required if dysrhythmias or cardiac arrest persist after giving calcium chloride or gluconate.

Following extrication, once the patient is stabilized, be prepared to treat recurrent dysrhythmias or hyperkalemia. Monitor for compartment syndrome of the crushed extremity with evidence of pain out of proportion, paresthesia, pallor, paresis, pulselessness, and poikilothermia. Compartment syndrome can only be treated surgically by a trained medical provider.

PHASE 3: EVACUATE

Urgent Evacuate to a surgical facility. If compartment syndrome develops likelihood of loss of limb increases with time to fasciotomy by a trained medical provider.

Evacuation



SOF Aircraft Capacities

MH-60 – 2 X Litter, 1 X Ambulatory (Optimal) **OR** 2 X Litters Only with Auxiliary Fuel Tank **OR** 3 X Litter (minimal en route treatment) **OR** 1 X Litter and 2-3 X Ambulatory.

MH-47 – 8 X Litter (Floor-loaded)

MH-6 – 1 X Litter (Floor-loaded) for emergency contingency only. Never plan an MH6 as a primary CASEVAC platform.

HH-60 – With carousel – 4 X Litter; Without carousel – 2 X Litter, 1 X Ambulatory

CV-22 – 5 X Litter (Floor-loaded)

General Principles of Rescue

During all rescue operations, tactical security and prevention of additional injuries (patients and rescuers) must be under constant consideration by all participants. The principles or phases of tactical rescue include: security of area/force; assessment of rescue situation; gaining access; rendering emergency care; disentanglement/extrication; removal; stabilization medical care; and evacuation. Contingency planning, training and rehearsals should always be a consideration. Consider anchoring of rolled vehicle to prevent shifting of weight. If possible, CCP should be established upwind from the site. Timing of evacuation requests must be synchronized to expected timeframes of extracting and packaging of casualties. Keep C2 informed.

Downed Aircraft Casualty Extraction Considerations

A downed aircraft can occur during any phase of tactical operation having a dramatic effect on the operation and should always be an assumed contingency. The immediate concern is securing the site and suppression of enemy actions. Rescuers should identify themselves as friendly when approaching a downed aircraft. Immediate casualty care is focused on coinciding extraction from burning aircraft and treatment of life-threatening injuries. Casualty collection points must be at a minimum safe distance from potential ammunition cook-off. CCP should be established upwind from site, if possible, as burning aircraft materials can be toxic. Buddy-team search parties conduct methodical searches around crash site for thrown victims. If possible, anchor the aircraft to the ground to prevent shifting or rolling. CSAR link-up and assumption of C2 should be rehearsed as contingency for all aircraft operations. N-95 masks should be included in CSAR kits to protect rescuers.

Vehicular Casualty Extraction Considerations

Vehicle rollovers, IED events, and driving accidents can occur during any phase of a tactical operation. Scene security and C2 must be established as soon as possible with the understanding that a combat engagement may continue during rescue attempts. Suppression of enemy fire remains the primary mission at all times. Ensure the safety of rescuers and casualties. Assess the scene situation to determine the need for additional assets. Recognize the kinematics that produced injuries and consider the treatments/equipment required to manage casualties. Identify and manage life-threatening conditions and defer non-life threats to later stage. Consider cervical spine stabilization as applicable if kinematics or MOI indicate potential spine injuries. Consider threats to rescuers and casualties to include fire in vehicle, leaking fuels/products, ammunition cook-off, and other environmental conditions. Manage injuries IAW tactical trauma protocols with deference to use of conventional/civilian techniques when indicated.


Confined Space/Building Collapse Extraction Considerations

Confined space rescues in the tactical setting include casualties who have fallen into wells, storage tanks, drainage systems or trenches. Aside from the injuries incurred on initial trauma, closed spaces may contain low amounts of oxygen or potentially hazardous gases or materials. Key information requirements are number of casualties and potential hazards to patients and rescuers.

Building collapse rescue is complex, usually involves large numbers of personnel and specialized equipment, requires knowledge of building design and will likely take an extended period of time. Security of the site is paramount. Key information requirements are the last known positions of personnel prior to the collapse. The organization of small search teams covering sectors is critical. Aside from trauma injuries involved with the collapse, rapid cardiovascular compromise is the greatest life threat as victims are extracted. Sudden cardiac arrest may occur from acidosis and hyperkalemia. Refer to the Crush Syndrome Management Protocol.

Constant awareness of the security situation, flammable materials, and additional hazards are paramount during rescue operations.

Evacuation Protocol



MH-60 CASEVAC / UH-60 MEDEVAC:
 - Always approach aircraft from 3 o'clock or 9 o'clock
 - Wait for Crew Chief or Flight Medic to signal you to approach aircraft.

MH-47 CASEVAC:
 - Always approach aircraft from 6 o'clock
 - Wait until the ramp drops and for Crew Chief or Flight Medic to signal you to approach aircraft.

MH-6 CASEVAC:
 - Always approach aircraft from 3 o'clock or 9 o'clock
 - Wait for the pilot to signal you to approach aircraft.

HLZ GUIDELINES:

1. To prevent further injury to patient, injury to the other personnel, and damage to the aircraft, ensure there is little to no debris on the HLZ.
2. The HLZ should be as flat/level as possible. If the surface does not meet these conditions, and advisory must be given and the aircraft must either terminate at a hover or touch down while under power.
3. Never approach the aircraft on a downhill slope.

HLZ DIMENSION REQUIREMENTS:

| | | |
|--------|-------------|--|
| Size 1 | 80ft (25m) | Light observation A/C (OH6 or OH-58) |
| Size 2 | 125ft (35m) | Light Utility/Attack A/C (UH-1H, H-65) |
| Size 3 | 160ft (50m) | Medium Utility/Attack A/C (UH60) |
| Size 4 | 265ft (80m) | Cargo A/C (CH-47 or CH-53) |

NOTE: Rehearse and train with receiving providers and platforms ahead of missions to identify pertinent handover procedures (radio frequencies, casualty loading procedures, MASCAL contingencies, etc)

CASUALTY MARKING

RED – Urgent
GREEN – Priority
BLUE – Expectant or Routine

NATO MEDEVAC Request




| MEDEVAC REQUEST 9-LINE | |
|---|---|
| LINE 1: LOCATION OF UNIT | HLZ GRID (MGRS): |
| LINE 2: CALLSIGN AND FREQUENCY AT THE PZ | CALLSIGN: FREQUENCY: |
| LINE 3: NUMBER AND PRECEDENCE OF CASUALTIES | A: Number of Urgent Casualties B: Number of Priority Casualties C: Number of Routine Casualties |
| LINE 4: SPECIAL EQUIPMENT REQUIRED | A: None B: Hoist C: Extraction D: Ventilator E: Other (specify) |
| LINE 5: NUMBER OF CASUALTIES BY TYPE | L: Number of Litter Casualties A: Number of Ambulatory Casualties E: Number of Escorts |
| LINE 6: SECURITY AT PZ | N: No enemy P: Possible enemy E: Enemy in area X: Armed escort required |
| LINE 7: PZ MARKING | A: Panels B: Pyrotechnics C: Smoke (designate color) D: None E: Other (specify) |
| LINE 8: CASUALTIES BY NATIONALITY/STATUS | A: US/Coalition Military B: US/Coalition Civilian C: Non-Coalition D: Non-Coalition Civilian E: Opposing Forces/Detainee F: Child |
| LINE 9: NBC CONTAMINATION (In peacetime, description of terrain) | N: Nuclear B: Biological C: Chemical In peacetime: Brief description of significant obstacles on approach / departure headings and type of predominant terrain for the HLZ |

NOTE: Lines 1-5 required to initiate MEDEVAC spin up

| MIST REPORT | |
|--|---|
| M – MECHANISM OF INJURY AND TIME OF INJURY (IF KNOWN) | Mechanism of Injury and time of injury (if known) |
| I – INJURY OR ILLNESS | Injury or Illness |
| S – SYMPTOMS AND VITAL SIGNS | A – Airway status B – Breathing rate C – Pulse rate D – Conscious/Unconscious E – Other signs |
| T – TREATMENT GIVEN | Such as Tourniquet/Time Applied Drugs administered |


| SIT REPORT (Used when communicating with PSG/1SG or other key personnel on the ground) | |
|---|--|
| S | STABLE/UNSTABLE |
| I | NOTABLE INJURIES |
| T | TREATMENTS RENDERED (Emphasis on medications, fluids, or procedures that cannot be seen by subsequent medics/providers) |

Evacuation Patient Packaging



CASUALTY MARKING
RED - Urgent
GREEN - Priority
BLUE - Routine

Evacuation Patient Handover



EQUIPMENT NEEDED:
 - Casualty Card
 - Communications Equipment

MINIMUM PATIENT HANDOVER INFORMATION:

Stable vs Unstable: With one arm, give a thumbs DOWN and an exaggerated downward arm motion.

Injuries/MOI: Quick summary of life threatening injuries and MOI (GSW, blast, fall, etc).

Treatments / Drugs Administered: Interventions and Type, Dose, Route of any narcotics, antibiotics or fluids administered, emphasizing treatments that cannot be seen by receiving provider.

STANDARD PATIENT HANDOVER INFORMATION:

Mechanism of Injury: Quick summary of how the casualty was injured.

Stable vs Unstable: With one arm, give a thumbs DOWN and an exaggerated downward arm motion.

Drugs Administered: Type, Dose, Route of any pertinent medications administered

Pertinent Vital Signs: Last pertinent VS and any trends identified.


Interventions: Identify and describe results or complications.

Fluids Given: Relate type, amount and time.

HANDOVER INFORMATION FLOW:
 Due to excessive noise, it is key to have the casualty card completed. The flight medic will not be able to hear everything that is said.

NOTE: Rehearse and train with receiving providers and platforms ahead of missions to identify pertinent handover procedures (radio frequencies, casualty loading procedures, MASCAL contingencies, etc)

Skedco Horizontal Hoist Procedure



EQUIPMENT NEEDED:

- SKEDCO Litter (Full-size ONLY)
- 2x Horizontal lifting straps (one long/foot end and one short/foot end)
- 10,000 lbs D-ring
- Tag-line carabiners and Y-connector

HAND & ARM SIGNALS:

Hoist Up: With one arm, give a thumbs UP and an exaggerated upward arm motion.

Hoist Down: With one arm, give a thumbs DOWN and an exaggerated downward arm motion.

Stop Hoist: With one arm, make a fist and hold arm straight out.


Emergency During Hoist: Arm held directly out 90 degrees to side of body moving continuously to and from body.

Deploy Hoist: One arm held straight up and one arm held straight out 90 degrees to side of body (3 O'clock position).

CAUTIONS:

1. Never attempt to grab the hoist cable when it is in mid air. Always wait for the cable to touch the ground and discharge its static charge.
2. Wear gloves when controlling the tag line.
3. Shield the casualty from rotor wash.
4. Ensure all locking D-rings are oriented in a gate down position to prevent gravity and vibrations from unscrewing the threaded lock.
5. Do not drag or grab or maneuver the Skedco using the hoist straps to prevent fraying or damage.
6. Avoid nylon on nylon friction points.

Skedco Vertical Hoist Procedure



EQUIPMENT NEEDED:

- SKEDCO Litter (Full-size ONLY)
- 30' 3/8" rope
- 10,000 lbs D-ring
- Tag-line with carabiners and Y-connector

HAND & ARM SIGNALS:

Hoist Up: With one arm, give a thumbs UP and an exaggerated upward arm motion.

Hoist Down: With one arm, give a thumbs DOWN and an exaggerated downward arm motion.



Stop Hoist: With one arm, make a fist and hold arm straight out.

Emergency During Hoist: Arm held directly out 90 degrees to side of body moving continuously to and from body.

Deploy Hoist: One arm held straight up and one arm held straight out 90 degrees to side of body (3 O'clock position).

CAUTIONS:

1. Never attempt to grab the hoist cable when it is in mid air. Always wait for the cable to touch the ground and discharge its static charge.
2. Wear gloves when controlling the tag line.
3. Shield the casualty from rotor wash.
4. Ensure all locking D-rings are oriented in a gate down position to prevent gravity and vibrations from unscrewing the threaded lock.
5. Do not drag or grab or maneuver the Skedco using the hoist straps to prevent fraying or damage.
6. Avoid nylon on nylon friction points.



CBRN



CBRN

The goals of CBRN trauma medicine are to limit and minimize exposure/contamination, treat the immediate life threats, and administer appropriate antidotes or countermeasures. Assessment and treatment of CBRN casualties follows the modified MARCH algorithm (MARCH)². Combat the mentality of a CBRN patient dipped in agent as a “candied apple”. Instead, think of these patients as stepping in a mud puddle.

Massive hemorrhage, **M**ask check – control life-threatening bleeding.

Airway, Administer **A**ntidotes (ATNAA, CANA) – establish and maintain a patent airway.

Respiration, **R**apid Spot Decontamination (RSDL) – decompress suspected tension pneumothorax, seal sucking chest wounds, and support ventilation/oxygenation as required.

Circulation, Administer **C**ountermeasures – establish IV/IO access and administer blood products as required to treat shock.

Head injury / **H**ypothermia – prevent/treat hypotension and hypoxia to prevent worsening of traumatic brain injury and prevent/treat hypothermia.

Use **CRESS** to quickly determine the agent of concern, conduct triage and recognize symptoms.

C – Consciousness (unconscious, convulsing, altered)

R – Respirations (present, labored, absent)

E – Eyes (pupil size, PERRLA)

S – Secretions (absent, normal, increased)

S – Skin (diaphoretic, cyanotic, dry, hot)

CBRN casualties present unique challenges and the medic must constantly ask what is killing the casualty now.

These patients can suffer from trauma, poisoning, or both trauma and poisoning. Always treat the most immediate life threat.

TCCC Application

Hot Zone: Depending on the agent, consider any area with agent to be the same as receiving effective fire. Always wear multiple sets of nitrile gloves when operating in a CBRN environment. Treatments in this zone are limited to (MAR)². Prevention of additional casualties, medic safety, and removing the patient from the area are the highest priorities. Check and find massive hemorrhage. Only expose on the casualty what is needed to save a life. Use the DRY-WET-DRY technique and RSDL for decontamination.


Warm Zone: These treatments begin when moved to the Dirty CCP, are in conjunction with decontamination, and consist of (CHE)². All Hot Zone treatments should be reassessed and possibly replaced with clean ones. Use the command, “Expose to treat” in order to quickly communicate to any assistants the immediate need to decontaminate the head/face and chest to facilitate mask removal and sternal IO placement. This allows ventilatory support and rapid dosing of countermeasures. Removing contamination by any means available may mean the difference between life and death, as this limits continued dosing. Do NOT perform any unnecessary procedures in the Warm Zone. Only address immediate threats to life that cannot wait for decontamination to be completed. The Warm Zone is for DECON, not medical care.

Trauma Assessment Principles

Hot Zone: Tourniquets placed over a CBRN suit are prone to fail. Check the casualties mask and ensure it is in place. Assess the patient’s airway and determine if it makes sense to unmask the casualty to provide an airway in a contaminated environment. If the medic is breathing filtered air the casualty should be too. Use a Resuscitator Device Individual Chemical (RDIC) as needed. Administer Antidotes based on the presumed agent. Use ATNAA/CANA for nerve agent and CyanoKit for cyanide once removed from the exposure. Assess respiratory changes and determine if they are due to an agent or trauma. Rapid Spot Decontamination for any visible agent, around breaches in the suit, and any exposed skin. Use the DRY-WET-DRY technique and RSDL or soap and water for decontamination.

Warm Zone: Administer countermeasures if required – IV/IO drips, suction, and ventilatory support. Respiratory difficulty due to poisoning should be treated with ventilatory support if required. Treatment with nebulized albuterol, solumedrol 125mg IV, and/or racemic epinephrine should wait until the Cold Zone. Assess circulation and provide resuscitation if required. Nerve agent poisonings may require atropine drips for treatment. Preventing hypothermia is critical and decontamination should occur quickly as the patients will be exposed and wet. Manage head wounds as required.

Schematic – DIRTY CCP



Notes:

- Triage flows from left to right in the hot zone
- Casualty flow moves from top to bottom in this diagram
- Medical Personnel, at least one designated clean and one designated dirty

TICS/TIMS Toxic Inhalation/ Eye Exposure Box

This kit is meant to be carried as an adjunct in aid bag as mission dictates the threat to personnel. The surplus of drugs is meant to provide continuous care and re-dosing as symptoms persist. Be mindful that nebulizers don't work if they are not kept upright. Collapsible and bendable airway tubes may be needed to provide nebulizer treatment to a casualty that is prone. If you use the Omron Nebulizer, read the directions for use and maintenance before you pack it in your aid bag.

1ea Pelican 1150 Case

1ea Toxic Inhalation SOP Quick Ref Card
1ea Omron Micro Air Nebulizer w/ batteries
1ea Extension Tubing
1pkg (5 vials) 5mL 4% Lidocaine HCl 40mg/mL
1ea 8.4% Sodium Bicarbonate 50mEq/mL – Dilute 1:1 with Normal Saline for use
15ea bullets 2.5mg Albuterol in 3mL
4ea vials Dexamethasone IV 20mg/5mL
5ea 3mL NS Pre-Filled Syringes
3ea 18g Hard Needles
2ea Neomycin or Gentamicin Ophthalmic Oint.
2ea Tetracaine Ophthalmic

Eye treatment not in case, carried in Aid Bag:

1ea 1000cc bag of NS or Lactated Ringers
2ea Morgan's Lens
1ea Morgan's Lens Admin Set

Carried on Vehicle

2ea D Cylinders of O₂
5ea NRB Masks
5ea Nebulizer Masks

Supplemental items:

1ea Peak Flow Meter
1ea Capno Check

Toxic Industrial Chemicals/Materials Inhalation Injury Treatment SOP

Administration via Nebulizer (in order)

1. 1 Albuterol bullet, 2.5mg in 3mL, by nebulizer
2. 1cc 4% lidocaine w/ 1 cc normal saline or 2cc 2% lidocaine w/o NS by nebulizer (for cough / pain suppression)

3. Administration via IV/IO:

- Dexamethasone: 8mg q6hrs (Preferred) Or
- 125mg Solumedrol IV/IM q6hrs

If no resolution of symptoms (efficacy is unproven by research) attempt

- 1cc 8.4% Sodium Bicarbonate w/ 1cc normal saline by nebulizer. Do not use undiluted 8.4% Sodium Bicarbonate

- for acidic inhalation
- do not mix with other drugs

TIC/TIMS

Eye Injury Treatment SOP

1. Tetracaine Eye Drops for Pain
2. 20 min NaCl Flush with Morgans Lens
3. Neomycin Eye Drops Prevent Eyelids Sticking Shut
4. Allow Eyes to Drain. Avoid Tight Bandaging.





Chemical Casualty Triage Table

| AGENT | URGENT | PRIORITY | ROUTINE | EXPECTANT |
|---|--|--|--|--|
| NERVE | Symptoms in 2 or more organ systems i.e. respiratory, GI, skeletal (seizure activity) (NOT including miosis or rhinorrhea) OR serious CNS involvement; unconscious, seizing, or apneic | Recovering from moderate / severe exposure, asymptomatic liquid exposure | Walking and talking after vapor exposure, consider miosis or residual effects on RTD | Loss of vital signs |
| VESICANT | Acute airway problems (coughing, hoarseness, secretions), agent in wounds | Liquid burn greater than 1% of BSA or critical areas*, eye involvement, pulmonary symptoms with an onset greater than 4 hours after exposure | Liquid burn LESS than 1% BSA (no critical areas*) | Severe pulmonary edema or clinical signs of respiratory compromise within 4 hours after exposure |
| PULMONARY | Acute airway problems (coughing, hoarseness, secretions, wheezing) | Onset of symptoms greater than 4 hours after exposure | 8 hours since exposure with no signs | Laryngeal obstructions or bronchospasms and/or severe pulmonary edema within 4 hours of exposure |
| CYANIDE | Serious Cardiopulmonary symptoms (bradypnea or hypotensive), serious CNS involvement, unconscious, seizing, or apneic | Recovering from mild exposure or post-treatment | Walking and talking after vapor exposure | Co-exposure with other toxicants (pulmonary edema, miosis, vesicant exposure area of 1% or more), signs of anoxic encephalopathy |
| <p>Notes: Triage category will increase for trauma + poisoning.</p> | | | | |

CBRN – Nerve Agents



Nerve Agents

Nerve agents are considered the primary agents of threat to the U.S. military because of their high toxicity and effectiveness through multiple routes of entry. They are absorbed through the eyes, respiratory tract, and skin. Nerve agents are generally referred to a group of chemicals known as organophosphates. These compounds inhibit acetylcholinesterase (AChE) thus having Acetylcholine (Ach) accumulating in the body causing multiple organ overstimulation. Then this produces a cholinergic crisis from the excessive amounts of Ach. Muscarinic effects of smooth muscle contraction in airways, GI tract, pupils (miosis). Glandular effects from eyes, nose, mouth, sweat, airways and GI tract. Effect on vagus nerve causing bradycardia. Nicotinic effects of skeletal muscles with fasciculations, seizures, fatigue, and flaccid paralysis (late sign). Preganglionic effects of tachycardia, hypertension.

LD₅₀ or LCT₅₀- The amount of solid, liquid, or vapor sufficient to kill the average person.

Persistent- last longer than 24 hours; Non-persistent- gone in 24 hours or less

TABUN (GA), SARIN (GB), SOMAN (GD), G, AND VX

S/S: Mild to moderate vapor exposure s/s: CNS-slowness in thinking and decision making. HEENT-miosis, blurred or dim vision, rhinorrhea, salivation. Respiratory-SOB, chest tightness.

Large vapor exposure s/s: CNS-LOC, seizures, flaccid paralysis. Respiratory-apnea GI- involuntary NVD, abdominal pain.

Liquid on skin exposure: Small -local effects such as sweating and fasciculations. Medium -systemic effects, potential miosis. Large -CNS and respiratory effects such as respiratory failure, LOC, seizures, apnea, flaccid paralysis, miosis

MGMT: 1xATNAA for any patient with miosis. Mild-1 x ATNAA (self-aid) or 3 x ATNAA (buddy-aid). Moderate/Severe-3 x ATNAA plus 1 x CANA injector even if seizure activity is not evident. Atropine 6mg IM or 8mg IV/IO should be repeated q 3-5 mins until the drying of secretions is noted. One additional dose of 2 PAM CL should be given 1 hour after the initial 3 doses if patient is still symptomatic. Severe nerve agent casualties may need more than 2-3 CANA auto injectors to relieve seizure activity.

Disposition: Refer to chemical casualty triage table

Special Considerations: Heart rate should not be a distinguishing sign due to its ability to be normal, tachycardia, or bradycardia. Once removed from exposure form vapor nerve agent effects do not worsen.

Packaging:

The Antidote Treatment Nerve Agent Auto injector (ATNAA) (NSN: 6505-01-362-7427) is an auto injector with 2mg of atropine and 600 mg of 2PAM CL combined.

The Convulsant Antidote for Nerve Agents (CANA) (NSN: 6505-01-274-0951) contains 10 mg of diazepam.

CBRN – Vesicant Agents



Vesicant Agents

Blister or Vesicant agents are second only to nerve agents as a concern to the U.S. Military. These are a concern as there are large stockpiles of them; they are easily manufactured; and they are both incapacitating and lethal. The severity of vesicant agents will, in part, be affected by the environmental conditions at the time of exposure. Warm, humid conditions increase the severity of blister agents damage and shorten the time of symptom onset. Cold weather may slow the onset and lessen blister severity. M8 Chemical Detection paper will turn red in the presence of liquid mustard. Precursors and impure agents are also hazardous and are easily manufactured.

MUSTARDS-SULFAR, MUSTARD (H) OR (HD) AND NITROGEN MUSTARD (HN₁, HN₂, HN₃)

S/S: Skin-erythema, small vesicles, bullae, direct coagulation necrosis and skin sloughing with high-dose. Eyes-conjunctivitis with epithelial necrosis, subcorneal edema and sloughing. Airway-hoarseness, cough, throat, nasal irritation. Severe patients can have laryngospasms.

MGMT: Immediate decontamination by any means available (Contact time should be less than 2 mins.) and symptomatic management.

Disposition: Refer to chemical casualty triage table

Special Considerations: Sulfur mustard is a very potent, persistent agent which produces relatively few deaths but will require a lengthily convalescence of personnel affected. Liquid mustard may be seen as amber (HD) or dark brown (H) colored oily liquid that has an odor comparable to onions or garlic. Liquid Mustard absorption can be enhanced by thin epithelial barriers, heat, moisture, and oils on the skin. The fluid in mustard blisters does not contain mustard. The LD₅₀ of mustard liquid is equivalent to 3-7 grams (about a teaspoon). H₁₋₃ will have shorter latent periods and more severe systemic effects.

ARSENICALS-LEWISITE (L), MD, ED, PD

S/S: similar s/s to HD with the distinct differences being pain within seconds to minutes after contact, "Lewisite Shock" will have capillary leakage, pulmonary edema (ARDS), hypotension, circulatory failure.

MGMT: Immediate decontamination by any means available and symptomatic management. British Anti-Lewisite 3mg/kg IM x1 for exposure with immediate pain.

Disposition: Refer to chemical casualty triage table

OXIME-PHOSGENE (CX)

S/S: urticaria with immediate pn. Produces skin lesions similar to acid burns. Blanching or erythematous ringing of contact site, and wheal formation.

MGMT: Immediate decontamination by any means available and symptomatic management.

Disposition: Refer to chemical casualty triage table

CBRN – Cyanide Agents

HYDROGEN CYANIDE (AC), CYANOGEN CHLORIDE (CK)

S/S: Rapid symptom onset, seizures, respiratory arrest, incontinence, normal pupils or mydriasis.

MGMT: Remove from exposure area, restore ventilation, and if symptomatic give 1 CyanoKit. May be redosed every 5 minutes for persistent symptoms. If not available, use Sodium nitrite 300mg of 3% solution IV over 5-20 minutes.

Disposition: Refer to chemical casualty triage table

Special Considerations: Cyanide is classified as a blood agent which can affect all systems in the body. Decontamination is usually not required due to the patients "off gassing". Cyanide can affect people by inhalation, ingestion, or percutaneous routes. Hydrogen Cyanide (AC) can smell like bitter almonds or peach pits but, most people cannot detect the odor due to it being so faint. Cyanogen Chloride can be a pungent, biting odor which can irritate the eyes, nose, and respiratory tract. The onset of symptoms from cyanide is within seconds of exposure. The difference between nerve agent symptoms and cyanide symptoms are the lack of secretions and normal pupils or mydriasis; whereas nerve agent poisonings have copious secretions and meiosis. Any Nitrate given within minutes, with mechanical ventilation, can be very effective in improving patient health.

CBRN – Pulmonary Agents



Pulmonary Agents

Lung-damaging agents are not commonly mentioned as major chemical threats. However, troops may be exposed to these threats through enemy actions or mitigating side effects such as explosions/fires involving vehicles or manufacturing areas, industrial hazards or accidents, or various burning materials.

The Four Hour Rule states that if a patient shows breathing difficulty within four hours of exposure, prognosis is poor, versus patients who do not become symptomatic until after four hours.

24 hours is the minimum time for observation and no physical exertion after an exposure to a pulmonary agent.

Agents that are liquids at room tend to give off vapors that can become trapped in clothing. Thus the agent then begins to "off-gas" which could affect personnel without respiratory protection. Therefore, decontaminating a patient with exposure to one of these agents is still needed. Always wear multiple pairs of nitrile gloves when conducting decontamination. Decon with either RSDL or soap and water. Use the DRY-WET-DRY technique for decon. Irrigate the patient's eyes to a pH 7.0 and provide Tetracaine for pain relief.

Treat respiratory symptoms with nebulized albuterol 3mL 0.083% and solumedrol 125mg IV x1. Consider nebulized racemic epinephrine for no respiratory improvement. Aggressive airway and respiratory support with PPV and suctioning may be required.

AMMONIA (NH₃)

S/S: Mild exposure- eye complaints, hoarseness, strider, cough, SOB, chest pain, wheezing
Moderate-Severe exposure-Hypoxia, chemical pneumonia, hemorrhage

MGMT: Remove from exposure, decontaminate, and consider advanced airway protocol

Disposition: Refer to chemical casualty triage table

SULFAR MUSTARD (HD)

S/S: Mild Mild exposure- eye complaints, hoarseness, strider, cough, SOB, chest pain, wheezing
Moderate-Severe exposure-hypoxia, chemical pneumonia, hemorrhage

MGMT: British anti-Lewisite 3mg/kg IM x1 for vesicant exposure and immediate pain. Respiratory treatments.

Disposition: Refer to chemical casualty triage table

CHLORINE

S/S: Mild-suffocation, choking sensation, ocular and/or nasal irritation, chest tightness, cough, exertional dyspnea, Moderate-aforementioned s/s plus hoarseness, stridor, pulmonary edema within 2-4 hours, Severe-dyspnea at rest, can cause pulmonary edema in 30-60 seconds, copious airway secretions, sudden death may occur with laryngospasms

MGMT: Remove from exposure, decontaminate, and respiratory treatments.

Disposition: Refer to chemical casualty triage table

PERIPHERAL ACTING AGENTS (Phosgene or CG, Perfluoroisobutylene or PFIB, HC Smoke, Nitrogen Oxides)

S/S: Mild-cough, SOB, chest tightness, Moderate-ocular irritation and aforementioned, Severe-dyspnea at rest, onset of pulmonary edema in 30 secs to four hours, copious upper airway secretions, sudden death may occur with laryngospasms

MGMT: Remove from exposure, decontaminate, respiratory/airway treatments.

Disposition: Refer to chemical casualty triage table

Special Considerations: Phosgene can be found in foam plastics, herbicides, pesticides, and dyes. It can be present in the burning objects like plastics, degreasers, and paint strippers. PFIB can be found in "Teflon" or burning military vehicles. Nitrogen Oxides can be found in arc welding areas specifically with enclosed areas and diesel engine exhaust.

CBRN

| CBRN | | | |
|---|---|---|--|
| <p style="text-align: center; margin: 0;">MARCH</p> <p>M – Massive hemorrhage/Mask check: always treat these situations as CUF. Apply TQ's, pts mask, and move from danger area. A – Airway/Antidote: always ensure early and proper airway management with quick antidote administration R – Respirations/Rapid DECON: positive pressure ventilations and rapid spot DECON C – Circulation/Counter measures: start IV/IO drips if needed H – Hypothermia/Head injury</p> | <p style="text-align: center; margin: 0;">SIGNS AND SYMPTOMS OF NERVE AGENTS</p> <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>MUSCARINIC</p> <ul style="list-style-type: none"> • Diarrhea • Urination • Miosis • Bronchorhea/Bronchospasms • Bradycardia • Emesis • Lacrimation • Salivation/Secretions/Sweating </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>NICOTINIC</p> <ul style="list-style-type: none"> • Mydriasis • Tachycardia • Weakness • Hypertension • Fasciculations </td> </tr> </table> | <p>MUSCARINIC</p> <ul style="list-style-type: none"> • Diarrhea • Urination • Miosis • Bronchorhea/Bronchospasms • Bradycardia • Emesis • Lacrimation • Salivation/Secretions/Sweating | <p>NICOTINIC</p> <ul style="list-style-type: none"> • Mydriasis • Tachycardia • Weakness • Hypertension • Fasciculations |
| <p>MUSCARINIC</p> <ul style="list-style-type: none"> • Diarrhea • Urination • Miosis • Bronchorhea/Bronchospasms • Bradycardia • Emesis • Lacrimation • Salivation/Secretions/Sweating | <p>NICOTINIC</p> <ul style="list-style-type: none"> • Mydriasis • Tachycardia • Weakness • Hypertension • Fasciculations | | |
| <p>PPE AND DECON CONSIDERATIONS</p> <ul style="list-style-type: none"> • Use of mask always required. • Wearing a minimum of two (2) pairs of nitrile exam gloves will provide needed protection IOT put hands on patient - as always ensure that you protect yourself first. • Ensure patient is masked or has protected airway to prevent inhalation injuries • When removing clothing and equipment ensure they are bagged and disposed of properly • DECON with RSDL, to include wounds and eyes if needed, soap and water also works well with most CBRN agents and precursors. DRY-WET-DRY for decon. • Place bleach in suction reservoir (if able) to ensure that body fluids are DECONed as well | | | |

NERVE AGENTS (G and V SERIES AGENTS)

| | |
|--|---|
| <p style="text-align: center; margin: 0;">MARCH</p> <p>M – Massive hemorrhage/Mask check: ensure the patient has good mask seal A – Airway/Antidote: ATNAA and CANAA R –Respirations/Rapid Decon: positive pressure ventilations and rapid decon with physical removal of clothing and any liquids on skin C – Circulation/Counter measures: Atropine and 2Pam Drips H – Hypothermia/Head injury</p> | <p style="text-align: center; margin: 0;">PPE AND DECON CONSIDERATIONS</p> <ul style="list-style-type: none"> • WEAR MASK. • CBRN gloves needed IOT put hands on patient. • Ensure patient is masked or has protected airway to prevent inhalation injuries • DECON with RSDL, to include wounds and eyes if needed. Soap and water also works well. |
| <p style="text-align: center; margin: 0;">IMMEDIATE CONSIDERATIONS</p> <ul style="list-style-type: none"> • Miosis is a highly variable sign of contamination and does not dictate treatment • Suction will be needed for excess secretions • Pts with mild s/sx should receive 1 x ATNAA (self-aid) and 2 x ATNAA (buddy-aid) • Pts with severe s/sx should receive 3 x ATNAA and 1 x CANA • BPT treat q 3-5 mins with Atropine auto injectors • If no CANA can treat with Versed 10mg IM for seizures | <p style="text-align: center; margin: 0;">PFC CONSIDERATIONS</p> <ul style="list-style-type: none"> • Atropine drip = Draw air from 250mL bag of saline and inject 50mL of 20/8 Atropine. Mark bag with "Atropine 300mL/20mg. Set drip rate to 300mL/hr (or 1ggt/sec with 15ggt set line). Once atropinization has been achieved reduce to 10-20% of original dose. • 2-PAM 500mg bolus an drip rate should be started 30 minutes after original 1200mg dose (ATNAA) AND symptoms persist. Add 20mL/1g 2-PAM to 250mL bag of saline. Set drip rate to 270mL/hr (or 1ggt/sec with 15ggt drop set). |

VESICANTS

MUSTARD (H) and LEWISTITE (L)

| | |
|---|--|
| <p style="text-align: center;">MARCH</p> <p>M – Massive hemorrhage/Mask check: ensure the patient has good mask seal A – Airway/Antidote: ATNAA and CANAA R –Respirations/Rapid Decon: positive pressure ventilations and rapid decon with physical removal of clothing and any liquids on skin C – Circulation/Counter measures: Atropine and 2Pam Drips H – Hypothermia/Head injury</p> | <p style="text-align: center;">PPE AND DECON CONSIDERATIONS</p> <ul style="list-style-type: none"> • WEAR MASK. • CBRN gloves needed IOT put hands on patient. • Ensure patient is masked or has protected airway to prevent inhalation injuries • DECON with RSDL, to include wounds and eyes if needed. Soap and water also works well. |
| <p style="text-align: center;">IMMEDIATE CONSIDERATIONS</p> <ul style="list-style-type: none"> • Miosis is a highly variable sign of contamination and does not dictate treatment • Suction will be needed for excess secretions • Pts with mild s/sx should receive 1 x ATNAA (self-aid) and 2 x ATNAA (buddy-aid) • Pts with severe s/sx should receive 3 x ATNAA and 1 x CANA • BPT treat q 3-5 mins with Atropine auto injectors • If no CANA can treat with Versed 10mg IM for seizures | <p style="text-align: center;">PFC CONSIDERATIONS</p> <ul style="list-style-type: none"> • Atropine drip = Draw air from 250mL bag of saline and inject 50mL of 20/8 Atropine. Mark bag with “Atropine 300mL/20mg. Set drip rate to 300mL/hr (or 1gtt/sec with 15gtt set line). Once atropinization has been achieved reduce to 10-20% of original dose. • 2-PAM 500mg bolus an drip rate should be started 30 minutes after original 1200mg dose (ATNAA) AND symptoms persist. Add 20mL/1g 2-PAM to 250mL bag of saline. Set drip rate to 270mL/hr (or 1gtt/sec with 15gtt drop set). |

TOXIC INDUSTRIAL CHEMICALS/MATERIALS

(CHLORINE/PHOSGENE/CYANOGENS)

| | |
|---|--|
| <p style="text-align: center;">MARCH</p> <p>M – Massive hemorrhage/Mask check: ensure the patient has good mask seal A – Airway/Antidote: no antidote for chlorine or phosgene, however, ensure good and early airway management, O2 ASAP and Cyanokit for Cyanide if available R –Respirations/Rapid Decon: positive pressure ventilations and rapid decon with physical removal of clothing and any liquids on skin C – Circulation/Counter measures: circulatory support H – Hypothermia/Head injury</p> | <p style="text-align: center;">PPE AND DECON CONSIDERATIONS</p> <ul style="list-style-type: none"> • As always use of mask recommended. • Wearing a minimum of two (2) pairs of nitrile exam gloves will provide needed protection IOT put hands on patient. • Ensure patient is masked or has protected airway to prevent inhalation injuries • DECON with RSDL, to include wounds and eyes if needed. Soap and water also works well. |
| <p style="text-align: center;">IMMEDIATE CONSIDERATIONS</p> <ul style="list-style-type: none"> • One immediate finding is CNS depression due to hypoxia, however, cyanogens will cause a drop in BP so ensure proper circulatory support. Give CyanoKit (x 2 if inadequate response to first) • 92% O2 (titrate to effect) with positive pressure ventilations due to pulmonary edema, supportive care • Manage airway aggressively if evidence of upper airway burns or fluid accumulation: Nebulized Albuterol – 3mL (0.083%) nebulized albuterol, Consider: Nebulized Racemic Epinephrine 2.25% in 15, 30ml, Solu-Medrol 125mg IM/IV • Flush eyes saline/water to pH 7.0, Tetracaine 2gtts OU | <p style="text-align: center;">PFC CONSIDERATIONS</p> <ul style="list-style-type: none"> • Multiple patients: (may run out of CyanoKit, use Sodium nitrite) Consider Sodium nitrite: 300mg of a 3% solution (10ml of a 3% solution) over 5-20min • Absolute bed-rest 36 hours • Monitor patient for ARDS, may be delayed up to 72 hours • If patient survives first 48 hours, recovery is likely |

RADIATION POISONING

| | |
|---|---|
| <p style="text-align: center;">MARCH</p> <p>M – Massive hemorrhage/Mask check: ensure the patient has good mask seal A – Airway/Antidote: As needed R –Respirations/Rapid Decon: Rapid decon with physical removal of clothing and any particulates on skin C – Circulation/Counter measures: Prussian Blue, Zinc/Calcium DTPA for internal contamination H – Hypothermia/Head injury</p> | <p style="text-align: center;">PPE AND DECON CONSIDERATIONS</p> <ul style="list-style-type: none"> Airway protection as needed based on isotope. Wearing one(1) pair of nitrile gloves will provide needed protection IOT put hands on patient. Ensure patient is masked or has protected airway to prevent inhalation injuries (goggles and mask would suffice). DECON with Tape or Baby Wipes and removal of clothing. Wounds should be irrigated to less than 2 x background. Time, Distance and Shielding are the three major factors in the amount of radiation the patient will receive. Doubling patients distance from the source with quarter amount of radiation received. |
| <p>IMMEDIATE CONSIDERATIONS</p> <ul style="list-style-type: none"> Time to emesis is key to dosage and patient outcome (<1hr is expectant, 1-4hrs is immediate/delayed, >4hrs minimal). Dosage should be kept as low as reasonably possible. BPT suction airway post vomiting. Removal of any foreign objects should be done so with instruments only and placed as far from personnel as reasonably possible. | <p style="text-align: center;">PFC CONSIDERATIONS</p> <ul style="list-style-type: none"> Supportive Care |

RADIATION POISONING

| | |
|---|---|
| <p>λ Gamma Emitters: <u>Industry Use, of Terrorist Interest. RDD or RED</u> Cobalt 60 Chelating agent: DTPA Calcium or Zinc, 1g in 5ml in 250ml of NS over 30min Cesium 137 Chelating agent: Prussian Blue (Radiogardase), 3g tid β Beta Emitters Strontium 90 Aluminum Hydroxide 10 Calcium Chloride Suspension IV: 200mg to 1g every 1-3days, slow 1mL min Calcium Gluconate PO: 10g powder in 30cc water Iridium 192 DTPA Calcium or Zinc, 1g in 5ml in 250ml of NS over 30min for internal contamination Tritium H3 Beer. Increase Diuresis α Alpha Emitters Uranium 235, 238 Sodium Bicarbonate Oral or IV Americium 241/Plutonium 239 DTPA Calcium or Zinc, 1g in 5ml in 250ml of NS over 30min</p> | <p style="text-align: center;">Radiation Pearls</p> <ul style="list-style-type: none"> Radiation Exposure <ul style="list-style-type: none"> – From existing sources or small scale criticality incident – Detection, dosimetry, conduct bio-assay post mission with medical evaluation – Radioactive gasses may be present in reprocessing facility or at a damaged nuclear reactor – Reverse isolation for severely irradiated casualties Corrosive Liquids and Gasses <ul style="list-style-type: none"> – Uranium Hexafluoride can off gas Hydrogen Fluoride Gas – Nitric Acid used in reprocessing Heavy Metal Toxicity <p><u>Acute Radiation Syndrome (ARS)</u> Whole body dose of greater than 100 cGy or 100 rad Hematopoietic Syndrome > 200-300 cGy Gastrointestinal Syndrome > 600 cGy Neurovascular Syndrome > 1200cGy ARS symptoms do not manifest immediately, our role involves treating immediate life threats and administration of chelating agents and decontamination. Dose estimation determines prognosis. We have the ability to perform blood collection for later bio dosimetry. We do not have Cytokines. Initiate stem cell banking recall for sick personnel. Prolonged evacuation times may necessitate the treatment of ARS.</p> |
|---|---|

Chemical Agent Treatment Guide

| Agent | Signs & Symptoms | Management | Decontamination |
|---|---|---|---|
| Nerve | Mild , miosis, rhinorrhea, slight difficulty breathing, sweating, nausea, vomiting Severe , LOC, apnea, convulsions, copious secretions, flaccid paralysis | ATNAA CANA ABCDD | RSDL, M291, soap & water, water in large amounts, 0.5% hypochlorite |
| Vesicants | Erythema, blisters, conjunctivitis, cough, | Immediate decontamination, symptomatic management | RSDL, M291, soap & water, water in large amounts, 0.5% hypochlorite |
| Mustard-HD, H Lewisite-L Phosgene Oxime-CX | | | |
| Pulmonary | Eye & airway irritation, delayed onset SOB or chest tightness, pulmonary edema | ABCDD, oxygen with or without positive airway pressure, rest | Vapor: fresh air Liquid: water irrigation |
| C, CG | | | |
| Cyanide | Seizures, respiratory, and cardiac arrest | ABCDD, inhaled amyle nitrite, IV sodium nitrite, sodium thiosulfate, hydroxocobalamin | Usually not needed |
| AC, CK | | | |
| Riot | Burning and pain on mucous membranes, skin, & eyes; respiratory discomfort | Usually none, effects are self limiting | Water, alkaline soap |
| CS, CN | | | |

Acronyms: (ABCDD: Airway, Breathing, Circulation, Drugs, Decontamination), (ATNAA: Antidote Treatment-Nerve Agent Autoinjector), (CANA: Convulsant Antidote for Nerve Agent), (LOC: Loss of Consciousness), (RSDL: Reactive Skin Decontamination Lotion), (SOB: Shortness of Breath)

Notes:



Notes:



Notes:



Notes:



SECTION THREE

**TACTICAL MEDICAL
EMERGENCY PROTOCOLS
(TMEP)
&
SICK CALL**



Medical Patient Assessment




Medical Patient Assessment

Documentation of all health care provided is inherent with any form of care provided by Ranger Medical Personnel. Ranger Medics will document any and all assessments, health care, treatments, or procedures as appropriate to the situation and setting. In the non-tactical situation, health care will be documented on an SF 600, AHLTA electronic note or trauma run sheet. In the tactical situation, care will be documented on the Ranger Casualty Card, DA5767 (TCCC Card), or may be maintained in a notebook until subsequent annotation to the appropriate format. Referral to, communication with or review by a primary provider is required for all patients and notes.

SOAP NOTE FORMAT

| | |
|--|---|
| Pertinent Information (to side of SOAP) | Chief Complaint |
| A simple list of Allergies, Current Medications and Vital Signs. EXAMPLE: NKDA Azithromycin P – 68 B/P – 118/72 R – 16 T – 99.2 | C/C: One sentence identifying PT age, gender, race, occupation and using the patient's words describing their primary problem. EXAMPLE: <i>C/C: 21y/o M Cau Ranger c/o Dry Cough X7d.</i> |
| | S - Subjective |
| | S: Description of problem based on patient's history. Do not put words in their mouth, but ask specific questions regarding their complaint. Use OPQRST and AMPLE as a guideline in your questions and notes. Identify any pertinent social or family history as related to the complaint. Give a simple logical timeline and description followed by pertinent positives and negatives based on the review of systems that relate to their complaint. Include any previous self-treatments or medical treatments from previous encounters. EXAMPLE: <i>S: Non-productive Cough started 7days ago upon return from leave in Mexico, treated with a Z-Pak by MO with no improvement. No PMHx of pneumonia or bronchitis. Non-smoker. ROS – NO hemoptysis, fever, dyspnea, wheezing, malaise.</i> |
| Work-Up Results (if applicable) | O – Objective/Observations |
| A simple list of findings from any previous labs, x-rays, or tests including the date done. EXAMPLE: CXR-WNL (09 Sep 10) | O: Description of your pertinent vital signs findings, mental status, observations and examinations with pertinent positives and negatives. Record the results or outcomes of any labs, imaging, test, or procedures done as part of this visit. EXAMPLE: <i>O: A&OX3, (-) fever, VS – WNL Normal Lung Sounds (-) rales, (-) rhonchi, (-) crackles (-) cervical lymphadenopathy Non-productive cough and nasal congestion witnessed</i> |
| | A – Assessment |
| Patient Information (on form) | A: Sum up your assessment or diagnosis based on the subjective and objective/observations. Paint a textual picture what you are thinking the condition is and why. A single-word diagnosis is not required as long as you explain your rationale in your decision. Provide a differential diagnosis to explain why you think it is not another diagnosis. EXAMPLE: <i>A: Viral URI – given non-productive cough, congestion, rhinorrhea, VS-WNL, unremarkable exam, and no evidence of serious bacterial infection, viral URI is most likely.</i> DDx: Pneumonia – doubt given with no dyspnea, no fever, VS WNL, on no concerning findings on auscultation. GERD – doubt given sudden onset and no reflux symptoms. Asthma – doubt given no PMHx, no wheezing on exam |
| | P – Plan of Action |
| NAME (L, F, MI) SSN DOB UNIT SEX Contact Number Student Status (if applicable) | P: Provide the details of the course of treatment for today. Include any immediate or future work-up requirements (lab, x-ray, tests). Include instructions to patient if condition worsens or does not improve within a specified time period or if patient is to return for follow-up. Include any modification or profile to duty/training status. EXAMPLE: <i>A: Stop taking azithromycin Pseudoephedrine 1 q12h X 7d, Acetaminophen q6h PRN If cough persists >72h, RTC for CXR, PFT, and consider trial of Albuterol PT at own pace/distance X5d</i> |

Medical Patient Assessment Protocol



Altitude Medical Emergencies



ALTITUDE ILLNESSES

ACUTE MOUNTAIN SICKNESS (AMS): Typically occurs at altitudes > 8,000 ft (2,500 m). Onset typically occurs 6-12 hours after ascent but can occur as quickly as 3 hours after ascent. The key to prevention is prophylactic acetazolamide and a combination of slow, graded ascent and staged ascent. A slow, graded ascent is no more than 1,650 ft/day (500 m) when above 10,000 ft (3,000 m) and limit sleeping altitude to 1,000 ft above previous night's altitude. A staged ascent is spending 2-3 days at moderate altitude 8,000-10,000 ft (2,500-3,000 m).

HIGH ALTITUDE CEREBRAL EDEMA (HACE): Rare below 11,500 ft. Headache is common at altitude. Ataxia and altered mental status at altitude are HACE until proven otherwise.

HIGH ALTITUDE PULMONARY EDEMA (HAPE): Caused by the hypoxia of altitude, HAPE is the most common cause of death from altitude illness. Usually occurs above 8,000 ft. Respiratory distress at high altitude is HAPE until proven otherwise.

HACE AND HAPE MAY COEXIST IN THE SAME PATIENT!

SIGNS/SYMPTOMS

AMS is generally benign and self-limiting, but symptoms may become debilitating. Worsening condition should prompt consideration of a more life-threatening condition (HAPE or HACE). AMS Diagnosis: recent ascent > 8,000 ft (2,500 m), plus a headache AND at least one of the following: anorexia, nausea, vomiting, insomnia, dizziness, lightheadedness, lassitude, weakness, or fatigue. No correlation with fitness level (likely genetic predisposition).

HACE: Unsteady, wide, and unbalanced (ataxic) gait and altered mental status are hallmark signs.

HAPE: Dyspnea at rest is the hallmark sign. Other symptoms may include cough, crackles upon auscultation, tachypnea, tachycardia, fever, central cyanosis, or decreased physical exercise tolerance. Measure SpO₂% and compare to other people around. If measured SpO₂% is less than others and the patient has symptoms then descent must be initiated.

INITIAL MANAGEMENT & EXTENDED MANAGEMENT

1. Halt ascent. Immediately descend at least 1,500 ft for HACE, HAPE, or refractory AMS if tactically feasible.
2. **IF AMS SYMPTOMS PRESENT:** Acetazolamide 250 mg PO bid **UNLESS PATIENT IS ALLERGIC TO SULFA** or is already taking as prophylaxis. Dexamethasone 4 mg PO / IV / IM q 6h if patient is allergic to sulfa. If Dexamethasone is administered, no further ascent until asymptomatic for 18 hours after last Dexamethasone dose. Descend if symptoms worsen.
3. **IF HACE SYMPTOMS PRESENT: ATAXIA OR ALTERED MENTAL STATUS:** Dexamethasone 10 mg IV/IM STAT, then 4 mg IV/IM q 6h. Individuals with HACE should not be left alone and especially not be allowed to descend alone. Administer supplemental oxygen, if available.
4. **IF HAPE SYMPTOMS PRESENT: SHORTNESS OF BREATH AT REST:** Nifedipine 10 mg PO / SL STAT; then 20 mg q 6h if blood pressure is stable. For extended management, consider sildenafil 50 mg q 8h, **OR** tadalafil 10 mg q 12h (Do not use in HACE; the drop in blood pressure will worsen the symptoms of this disease). Administer supplemental oxygen, if available. Consider Salmeterol 2 inhalations q 12h. **OR** albuterol 2 inhalations q 6h.
5. Minimize patient exertion during descent for HAPE since this will exacerbate symptoms.
6. Treat per *Pain Management Protocol*, but avoid the use of narcotics since they may depress respiratory drive and worsen high altitude illness. Treat per *Nausea and Vomiting Protocol*.
7. For signs or symptoms of either HAPE or HACE, if immediate descent is not tactically feasible and a GAMOW bag is available, use a GAMOW bag in 1 hour treatment sessions with bag inflated to a pressure of 2 psi (approximately 100mmHg) above ambient pressure. Four or five sessions are typical for effective treatment. **GAMOW BAG TREATMENT IS NOT A SUBSTITUTE FOR DESCENT.**
8. Treat per *Dehydration Protocol*.

DISPOSITION: Most cases of AMS are relatively mild, resolve in 2-3 days, and do not require evacuation. Avoid vigorous activity for 3-5 days. *Priority* evacuation for AMS patients that worsen despite therapy. *Urgent* evacuation for patients with suspected HACE or HAPE. Individuals who have recovered from HACE or HAPE should not re-ascend without medical officer clearance.

PROPHYLAXIS & PRE-TREATMENT


AMS Emergency Rapid Ascent / HAF Insertion at altitude > 11,500 ft; With prior medical officer approval, consider pretreatment of unit personnel with Acetazolamide 125mg PO bid **OR** Dexamethasone 4 mg PO/IV/IM q 6h (for operations < 48 hours). Dexamethasone prevents symptoms but does not help with acclimation. AMS Prevention/Pretreatment: Acetazolamide 125 mg PO bid, started 24 hours before ascent to altitude > 8,000 ft. Takes 8 hours after the first dose to have efficacy. Cease pretreatment after 2-3 days at target altitude or during descent. If true Sulfa allergy, do not use Acetazolamide and supplement with Dexamethasone. If Sulfa ABX allergy continue to use Acetazolamide with medical officer approval. For personnel who have a history of previous HAPE, Nifedipine, Acetazolamide, Sildenafil, Tadalafil, Salmeterol, and Albuterol may be used (individually or in combination).

Altitude Medical Emergency Management Protocol



Headache
Nausea/Vomiting
Insomnia
Altered Mental Status
Dyspnea
Dry Cough or Hemoptysis
Fatigue/Weakness
Ataxia
Disoriented/
Hallucinations
Cranial Nerve Palsy
Hemiparesia
Unconsciousness

HACE Clinical Presentation:
HA, N/V, Visual Changes and papilledema, Hallucinations, Hemiparesis/Hemiplegia, Focal neurologic signs, or Seizures (rare)
Hallmarks of HACE:
Ataxia, Altered Mental Status, and Severe lassitude
HACE Diagnosis:
AMS plus one of the following: Ataxia, Altered Mental Status, OR Presence of both CNS abnormalities in a person who recently ascended to altitude



Early Signs:
Decreased exercise tolerance, Nonproductive cough, especially at night, Dyspnea at rest, Increased dyspnea with exertion, O2 Saturation > 10 points less than rest of party, Desaturation with exertion, Low grade fever
Late Signs:
Frothy pink sputum or hemoptysis, Numerous rales and wheezing, Severe dyspnea, Cyanosis, Confusion, Hallucinations, Coma

- Altitude emergencies are usually preceded by 6-12 hours latent period after ascent.
- HACE is rare below 11,500 ft
- HAPE usually occurs > 9,000 ft and typically 2-4 days after arriving at high altitude.
- Any respiratory distress at high altitude should be assumed as HAPE until proven otherwise.
- Do not reascend until asymptomatic for 18 hours and/or until cleared by a medical officer
- Consider prophylactic Acetazolamide (125-250 mg PO bid) OR Dexamethasone 4 mg PO qid beginning 24 hours out (or minimum 8 hours if TST) if mission is planned at/above 10,000 ft or if drastic rapid ascent (HAF) with medical officer approval. Note that frequent urination will disrupt sleep cycle and may cause dehydration.

ANAPHYLAXIS REACTION EMERGENCIES



ANAPHYLAXIS

Anaphylactic shock is a life-threatening medical emergency that is caused by a generalized allergic reaction affecting the cardiovascular, respiratory, cutaneous, and gastrointestinal systems. It is a severe immune-mediated reaction that occurs when a previously sensitized patient is reexposed to an offending allergen such as: bee/wasp stings, penicillin or other drug allergies (especially when given IM/SC/IV), seafood (especially shrimp/shellfish) and nuts of various types. Allergens may produce an allergic reaction by being ingested, inhaled, injected, or absorbed through the skin/mucous membranes. Shock is produced by the release of histamine that causes "leaky" vessels resulting in hives/edema and hypotension; it also causes bronchospasm/wheezing. This produces both a volume problem and a vascular resistance problem. Anaphylactic shock differs from less severe allergic reactions in that it is characterized by hypotension and obstructed airflow (upper and/or lower) that can be life-threatening.

SIGNS/SYMPTOMS

Wheezing (bronchospasm), dyspnea, stridor (laryngeal edema), angioedema, urticaria (hives), hypotension, tachycardia. clinical observation is the only diagnostic test. Use rapidity of onset and constellation of symptoms to suggest the diagnosis. A prior history of similar symptoms may be the only other clue. Observe closely with frequent assessment/reassessment of mental status, vital signs, and pulse oximetry. Anaphylaxis is likely if ANY of the following 3 criteria are met:

Acute onset (minutes to several hours) with involvement of skin and or mucosal tissue (hives, pruritus, swollen lips/tongue) plus 1 of the following: respiratory compromise (eg, dyspnea, wheezing, stridor or other signs of bronchospasm) or cardiovascular compromise (eg, decreased blood pressure, syncope).

Two or more of the following that occur quickly (minutes to several hours) after exposure to a likely allergen: involvement of skin-mucosa, respiratory compromise, reduced blood pressure, persistent GI symptoms (eg, vomiting, abdominal pain).

Reduced blood pressure (systolic <90 for adult) after exposure to a known allergen for the patient.

INITIAL MANAGEMENT & EXTENDED MANAGEMENT

For patients with signs and symptoms of airway involvement and/or circulatory collapse:

1. Epinephrine is the mainstay of therapy. Administer Epi-Pen **OR** epinephrine 0.3 to 0.5 mg (0.5 ml of 1:1000 IM into the anterolateral thigh. **DO NOT USE INTRAVENOUSLY.**) Repeat epinephrine q5 minutes prn. Administer oxygen with pulse oximetry monitoring. If severe respiratory distress exists, aggressive airway management with bag-valve-mask and airway adjuncts (oral and nasopharyngeal airways). Control airway early if no response to epinephrine. IV normal saline TKO (saline lock). Administer Diphenhydramine 50 mg IV/IM/PO/SL. Administer 1 - 2 liter crystalloid bolus for hypotension then titrate to establish systolic blood pressure > 90 mm Hg or palpable radial pulse if BP cuff not available. Administer Dexamethasone 10 mg IV/IM/PO. If wheezing is present after epinephrine administration, consider Albuterol, 2-3 puffs q 5 minutes, repeat up to 3 times. The metered dose inhaler works best when used with a spacer (e.g. – rolled up piece of paper, cardboard from toilet paper roll, etc). Administer Ranitidine 150 mg PO bid.


Considerations

Immediate definitive airway if impending airway obstruction from angioedema is suspected. Delay may lead to complete obstruction, difficult intubation and cricothyroidotomy. Give 6-8L oxygen per minute via face mask if required or up to 100% if airway controlled.

Albuterol metered dose inhaler (2-3 puffs) for bronchospasm. Place patient in recumbent position and elevate lower extremities. Crystalloid (saline) fluid bolus IV titrated to restore and maintain blood pressure. Monitor patient: at least 24 hours following treatment: Recurrence of symptoms may occur in up to 20% of patients (generally within 8 hours but recurrences up to 72 hours following initial resolution of symptoms have been reported).

Apply ice to, and consider injecting small dose of epinephrine (0.1- 0.2mL 1:1,000) into the injection site unless contraindicated. If due to bee/wasp sting(s), carefully remove all stingers. Avoid applying pressure to venom sac while stinger is inserted in patient.

Anaphylactic Shock Management Protocol



- H1 Antihistamines**
Cetirizine 10mg PO qd
Fexofenadine 180mg PO qd
Loratadine 10mg PO qd
Diphenhydramine 25-50mg PO/IM/IV q4-6h
- H2 Antihistamines**
Ranitidine 300mg PO/IM/IV q6-8h
Cimetidine 150mg PO bid
Promethazine 25 mg PO/IM/IV

1. Bee sting: gently remove stinger if still present
2. All cases of suspected anaphylaxis will be reported to a medical officer.
3. Urgent evacuation if symptoms do not resolve after aggressive treatment with epinephrine or any airway compromise.
4. Priority evacuation if mild/moderate/localized symptoms have not resolved after 6 hours.

Behavioral Emergency Management



BEHAVIORAL CONDITIONS

Includes psychosis, depression and suicidal impulses. In a tactical setting consider sleep deprivation as a cause. Etiologies are numerous and will often dictate the management; thus mental status changes could be caused by head trauma, metabolic and endocrine disease processes, environmental toxins, infections, combat stress disorder, hypoxia, hyperthermia, hypothermia, pharmaceutical agent use (i.e. mefloquine) or withdrawal. Consider diabetic hypoglycemia as a cause of altered mental status.

SIGNS/SYMPTOMS

Acute behavioral changes include withdrawal, depression, aggression, confusion, or other behavioral patterns atypical for the individual.


Psychosis is an acute change in mental status characterized by altered sensory perceptions that are not congruent with reality: auditory and/or visual hallucinations; may include violent or paranoid behavior; disorganized speech patterns are common; may include severe withdrawal from associates.

INITIAL MANAGEMENT & EXTENDED MANAGEMENT

1. Remove all weapons or potential weapons from patient AND treating medic.
2. Check pulse oximetry.
3. Place patient in safe environment under continuous surveillance
4. Give contents of 1 sugar packet sublingually to treat for possible hypoglycemia.
5. Take core temperature. If Temperature is below 95 degrees, treat per *Hypothermia Protocol*. If Temperature is above 101 degrees, treat per *Meningitis Protocol*. If Temperature is above 103 degrees, treat per *Meningitis and Hyperthermia Protocols*
6. For acute agitation, combativeness, or violent behavior, restrain patient with at least four individuals and give Midazolam 5 mg IM OR diazepam 10 mg IM. Repeat after 30 minutes prn.
7. If sedated or restrained, maintain constant vigilance for a change in the hemodynamic status or loss of airway reflexes.
8. Evacuate *Urgent* as tactically feasible.

| <u>AMSIT Patient History</u> | <u>Glasgow Coma Scale</u> | <u>Neurological Assessment</u> | | | | | | | | | | | | | | | | | | |
|--|---|--|----------------|---|--|----------------|---|--|---------------------|---|--|------------------------|---|--|-----------|---|--|------|---|---|
| <u>Appearance, Behavior & Speech</u> (ill or distressed, posture & body language, willingness to talk, manner, evidence of emotions, attention span, speech patterns) | <table border="0"> <tr> <td>Eye Opening</td> <td>Spontaneous</td> <td>4</td> </tr> <tr> <td></td> <td>To Voice</td> <td>3</td> </tr> <tr> <td></td> <td>To Pain</td> <td>2</td> </tr> <tr> <td></td> <td>None</td> <td>1</td> </tr> </table> | Eye Opening | Spontaneous | 4 | | To Voice | 3 | | To Pain | 2 | | None | 1 | Mental Status Orientation Affect Speech (Content & Process) | | | | | | |
| Eye Opening | Spontaneous | 4 | | | | | | | | | | | | | | | | | | |
| | To Voice | 3 | | | | | | | | | | | | | | | | | | |
| | To Pain | 2 | | | | | | | | | | | | | | | | | | |
| | None | 1 | | | | | | | | | | | | | | | | | | |
| <u>Mood and Affect</u> (anger, fear, anxiety, elation, intensity and changes in mood) | <table border="0"> <tr> <td>Verbal Response</td> <td>Oriented</td> <td>5</td> </tr> <tr> <td></td> <td>Confused</td> <td>4</td> </tr> <tr> <td></td> <td>Inappropriate Words</td> <td>3</td> </tr> <tr> <td></td> <td>Incomprehensible Words</td> <td>2</td> </tr> <tr> <td></td> <td>None</td> <td>1</td> </tr> </table> | Verbal Response | Oriented | 5 | | Confused | 4 | | Inappropriate Words | 3 | | Incomprehensible Words | 2 | | None | 1 | Cranial Nerves I Olfactory (Identify an odor or distinguish between 2 odors) II Optic (Visual Acuity test) III Oculomotor (Assess 6 cardinal eye movements & pupillary reaction) IV Trochlear (Assess 6 cardinal eye movements) V Trigeminal (Facial Sensitivity & Biting/Clinching teeth) VI Abducens (Eye movement looking left and right) VII Facial (Smile, frown, raise brows, and taste) VIII Vestibulocochlear (Hearing-rubbing fingers & Equilibrium) IX Acoustic (Gag reflex and identify tastes) X Vagus (Gag reflex and speech) XI Spinal Accessory (Head movement and shoulder shrugging) XII Hypoglossal (stick out tongue and move left and right) | | | |
| Verbal Response | Oriented | 5 | | | | | | | | | | | | | | | | | | |
| | Confused | 4 | | | | | | | | | | | | | | | | | | |
| | Inappropriate Words | 3 | | | | | | | | | | | | | | | | | | |
| | Incomprehensible Words | 2 | | | | | | | | | | | | | | | | | | |
| | None | 1 | | | | | | | | | | | | | | | | | | |
| <u>Sensorium</u> (oriented to time and place, recent and remote events, concentration and calculation) | <table border="0"> <tr> <td>Motor Response</td> <td>Obeys Commands</td> <td>6</td> </tr> <tr> <td></td> <td>Localizes Pain</td> <td>5</td> </tr> <tr> <td></td> <td>Withdraws (Pain)</td> <td>4</td> </tr> <tr> <td></td> <td>Flexion</td> <td>3</td> </tr> <tr> <td></td> <td>Extension</td> <td>2</td> </tr> <tr> <td></td> <td>None</td> <td>1</td> </tr> </table> | Motor Response | Obeys Commands | 6 | | Localizes Pain | 5 | | Withdraws (Pain) | 4 | | Flexion | 3 | | Extension | 2 | | None | 1 | Motor Status Posture Strength in basic muscle movements Resistance to passive movement Tremors or Involuntary Movements |
| Motor Response | Obeys Commands | 6 | | | | | | | | | | | | | | | | | | |
| | Localizes Pain | 5 | | | | | | | | | | | | | | | | | | |
| | Withdraws (Pain) | 4 | | | | | | | | | | | | | | | | | | |
| | Flexion | 3 | | | | | | | | | | | | | | | | | | |
| | Extension | 2 | | | | | | | | | | | | | | | | | | |
| | None | 1 | | | | | | | | | | | | | | | | | | |
| <u>Intellectual Function</u> (education, vocabulary use, appropriate for age) | Document as: E ___ + V ___ + M ___ = ___ | Sensation Status Senses light touch Senses pain or pricks Senses temperature Senses vibration (tuning fork) | | | | | | | | | | | | | | | | | | |
| <u>Thought</u> (logical, reasonable, speed, hallucinations, self-image, insight awareness) | | Coordination Gait and Stance Finger to nose Heel to shin Reflexes Deep tendon reflexes (biceps, triceps, knees, ankles) Plantar reflexes | | | | | | | | | | | | | | | | | | |

Behavioral Emergency Management Protocol



AVPU Responsiveness Assessment

ALERT
 VERBAL – Responds to verbal stimuli
 PAIN – Responds to painful stimuli
 UNCONSCIOUS – Does not respond to any stimuli

| Glasgow Coma Scale | | | |
|--------------------|------------------------|------|---|
| Eye Opening | Spontaneous | 4 | |
| | To Voice | 3 | |
| | To Pain | 2 | |
| | | None | 1 |
| Verbal Response | Oriented | 5 | |
| | Confused | 4 | |
| | Inappropriate Words | 3 | |
| | Incomprehensible Words | 2 | |
| | | None | 1 |
| Motor Response | Obeys Commands | 6 | |
| | Localizes Pain | 5 | |
| | Withdraws (Pain) | 4 | |
| | Flexion | 3 | |
| | Extension | 2 | |
| | | None | 1 |

Document as: E__ + V__ + M__ = __

- Withdrawal
- Depression
- Aggression
- Confusion
- Atypical patterns of individual behavior
- Hallucinations
- Violent
- Paranoid
- Disorganized speech

AMSIT Patient History

Appearance, Behavior & Speech (ill or distressed, posture & body language, willingness to talk, manner, evidence of emotions, attention span, speech patterns)

Mood and Affect (anger, fear, anxiety, elation, intensity and changes in mood)

Sensorium (oriented to time and place, recent and remote events, concentration and calculation)

Intellectual Function (education, vocabulary use, appropriate for age)

Thought (logical, reasonable, speed, hallucinations, self-image, insight awareness)

Assessment and Management of Suicidal Risk



Suicide

Suicide remains a serious public health problem with more than 44,000 people taking their lives every year (CDC, 2017). Suicide was the tenth leading cause of death for all ages in 2016 and the second leading cause of death for persons aged 24 and younger. Among military members and veterans, suicide and other forms of suicidal self-directed violence have steadily increased over the past decade. According to estimates from the Centers for Disease Control and Prevention (CDC, 2013), Veterans account for approximately 20% of the deaths from suicide in the United States. While even the most accurate suicide data does not predict suicide in a given individual, thorough clinical assessment informed by demographic and other suicide-related associations may improve risk-appropriate management. The following protocol represents the VA/DoD Clinical Practice Guidelines for the assessment and management of suicidal risk.

Table 1: Warning Signs

Warning Signs: Observations that signal an increase in the probability that person intends to engage in suicidal behavior in the immediate future (i.e. minutes and days). Warning signs present tangible evidence to the clinician that a person is at heightened risk for suicide in the short term. Warning signs may be experienced in the absence of risk factors.

Direct Warning Signs portend the highest likelihood of suicidal behaviors occurring in the near future:

Suicidal communication: Writing or talking about suicide, wish to die, or death (threatening to hurt or kill self) or intention to act on those ideas.

Preparations for suicide: Evidence or expression of suicide intent, and/or taking steps towards implementation of a plan. Makes arrangements to divest responsibility for dependent others (children, pets, elders), or making other preparations such as updating wills, making financial arrangements for paying bills, saying goodbye to loved ones, etc.

Seeking access or recent use of lethal means: Owning or planning to acquire weapons, medications, toxins, or other lethal means.

Other Indirect Warning Signs presentation(s) or behavioral expressions that may indicate increased suicide risk and urgency in a patient at risk for suicide:

- Substance abuse:** Increasing or excessive substance use (alcohol, drugs, smoking)
- Hopelessness:** Expresses feeling that nothing can be done to improve the situation
- Purposelessness:** Express no sense of purpose, no reason for living, decreased self-esteem
- Anger:** Rage, seeking revenge
- Recklessness:** Engaging impulsively in risky behavior
- Feeling Trapped:** Expressing feelings of being trapped with no way out
- Social Withdrawal:** Withdrawing from family, friends, society
- Anxiety:** Agitation, irritability, angry outbursts, feeling like wants to “jump out of my skin”
- Mood Changes:** Dramatic changes in mood, lack of interest in usual activities/friends
- Sleep:** Insomnia, unable to sleep or sleeping all the time
- Guilt or Shame:** Expressing overwhelming self-blame or remorse

Assessment and Management of Suicidal Risk



| Table 2: Risk Factors | |
|---|--|
| <p>Acute Risk Factors: Acute (of brief duration) and stressful episodes, illnesses, or life events. While not usually internally derived, these events can build upon and challenge a person's coping skills.</p> <p>Chronic Risk Factors (Pre-Existing): Relatively enduring or stable factors that may increase a person's susceptibility to suicidal behaviors, such as genetic and neurobiological factors, gender, personality, culture, socio-economic background and level of isolation.</p> | |
| Psychological Factors: | |
| <ul style="list-style-type: none"> -Suicide of relative, someone famous, or peer -Suicide bereavement -Loss of loved one (grief) -Loss of relationships (divorce, separation) -Loss of status/respect/rank (public humiliation, being bullied or abused, failure work/task) | |
| Social Factors: | |
| <p>Stressful Life Events (acute experiences)</p> <ul style="list-style-type: none"> -Breakups and other threats to prized relationships -Other events (e.g. fired, arrested, evicted, assaulted) -Chronic stressors (ongoing difficulties) <p>Financial Problems</p> <ul style="list-style-type: none"> -Unemployment, underemployment -Unstable housing, homeless -Excessive debt, poor finances (foreclosure, alimony, child support) | <p>Legal Problems (difficulties)</p> <ul style="list-style-type: none"> -DUI/DWI, lawsuit, criminal offense, incarceration <p>Lack of Social Support</p> <ul style="list-style-type: none"> -Poor interpersonal relationships (partner, parent, children) -Geographic isolation from support -Recent change in level of care (discharge from inpatient psychiatry) |
| Medical Conditions | Medical Conditions |
| <ul style="list-style-type: none"> -History of Traumatic Brain Injury -Terminal disease -HIV/AIDS -New diagnosis of major illness -Having a medical condition -Worsening of chronic illness -Intoxication -Substance withdrawal (alcohol, opiates, cocaine, etc.) -Use of prescription medication with warning for increased risk of suicide -Chronic pain | <ul style="list-style-type: none"> -Mood or affective disorder (major depression, bipolar disorder) -Personality disorder (especially borderline) -Schizophrenia -Anxiety -PTSD -Panic Disorder -Substance Use Disorder -Eating Disorder -Insomnia or other sleep disorder |
| Military-Specific | Pre-existing & Non-modifiable |
| <ul style="list-style-type: none"> -Disciplinary actions (UCMJ) – Reduction in rank -Career threatening change in fitness for duty -Perceived sense of injustice or betrayal (unit/command) -Command/leadership stress, isolation from unit -Transferring duty station -Administrative separation from service/unit -Adverse deployment experience | <ul style="list-style-type: none"> -Gender (male) -Race (white) -Marital status (divorce, separate, widowed) -Family history of suicide/attempt or mental illness -Child maltreatment (physical/psychological/sexual) -Sexual trauma -Lower education level -Same sex orientation (LGBT) -Cultural or religious beliefs |




| Table 3: Protective Factors |
|---|
| Capacities, qualities, environmental and personal resources that increase resilience; drive an individual toward growth, stability, and/or health and/or to increase coping with different life. |
| Social Context Support System |
| <ul style="list-style-type: none"> -Strong interpersonal bonds to family/unit members and community support -Employed -Intact marriage -Child rearing responsibilities -Responsibilities/duties to others -A reasonably safe and stable environment |
| Positive Personal Traits |
| <ul style="list-style-type: none"> -Help seeking -Good impulse control -Good skills in problem-solving, coping and conflict resolution -Sense of belonging, sense of identity, and good self-esteem -Cultural, spiritual, and religious beliefs about the meaning and value of life -Optimistic outlook - Identification of future goals -Constructive use of leisure time (enjoyable activities) -Resilience |
| Access to Health Care |
| <ul style="list-style-type: none"> -Support through ongoing medical and mental health care relationships -Effective clinical care for mental, physical and substance use disorders -Good treatment engagement and sense of the importance of health and wellness |

Assessment and Management of Suicidal Risk



| Table 4: Level of Risk for Suicide | | |
|---|--|--|
| Risk for Suicide Attempt | Indicators for Suicide Risk | Contributing factors |
| High Risk | <ul style="list-style-type: none"> • Persistent suicidal ideation or thoughts • Strong intention to act or plan • Not able to control impulse <li style="text-align: center;">OR • Recent suicide attempt | <ul style="list-style-type: none"> • Acute state of psychiatric disorder or acute psychiatric symptoms • Acute precipitating event(s) • Inadequate protective factors |
| Intermediate Risk | <ul style="list-style-type: none"> • Current suicidal ideation or thoughts • No intention to act • Able to control the impulse • No recent attempt or preparatory behavior or rehearsal of act | <ul style="list-style-type: none"> • Existence of warning signs or risk factors <li style="text-align: center;">AND • Limited protective factors |
| Low Risk | <ul style="list-style-type: none"> • Recent suicidal ideation or thoughts • No intention to act or plan • Able to control the impulse • No planning or rehearsing a suicide act • No previous attempt | <ul style="list-style-type: none"> • Existence of protective factors <li style="text-align: center;">AND • Limited risk factors |

Assessment and Management of Suicidal Risk



Hyperthermia



Heat Injuries

Heat injuries fall into a continuum of heat cramps to heat exhaustion to heat stroke. While the mechanism of heat cramps is not fully understood, there is convincing evidence to suggest it is the result of sodium depletion or over hydration. Heat exhaustion and heat stroke represent a spectrum of disorders, which range in intensity and the severity of tissue damage. The pathophysiology of heat exhaustion and heat stroke are so similar that they may represent a continuum of disease rather than separate, distinct diseases and both are characterized by sodium and water depletion. Heat cramps, heat exhaustion and heat stroke are all illnesses related to a failure of the body to maintain fluid and electrolyte balance to the challenge of adapting to added heat loads. These conditions may develop over several days, allowing adequate time for effective intervention. The maintenance of adequate diet and fluid intake is essential. The use of dietary supplements can lead to dehydration and increased likelihood of heat injury. When faced with increased heat loads, the body is dependent on sweating to maintain a constant body temperature. The sources of the heat load may be external (a hot day), internal (a road march with 50 pounds of gear) or both (a road march in the desert sun). If the heat load exceeds the body's ability to lose heat, a heat injury will result.

Heat Cramps

The term "heat cramps" is actually a misnomer, as muscle cramping more likely results from sodium depletion during intense activity, not heat. In fact, cooling of a fatigued muscle is often a contributing factor. Heat cramps typically occur in individuals undergoing prolonged, intense activity in a hot and humid environment. Heat cramps are brief, intermittent, and very painful, but can be largely prevented by maintaining an adequate salt and fluid balance prior to and during exertion.

S/S: Painful, tonic contractions of skeletal muscles frequently preceded by palpable or visible fasciculation. Fatigue, dizziness, nausea, vomiting are common.

MGMT: Obtain hydration and diet history to guide management and identify likely electrolyte cause. Use iSTAT or similar point of care lab testing device to evaluate electrolytes if available. Oral electrolyte rehydration and foods are the initial management of choice. IV crystalloid solution is indicated if more rapid treatment is needed. Mild stretching and massage of the contracting muscle will provide some relief to the intense discomfort. May return to activity after symptoms resolve but patient is at risk for return of heat cramps or other heat injury.

Heat Exhaustion/Stroke

Heat exhaustion is the most common heat illness. Although heat exhaustion in a military setting often manifests after extreme exertion, in reality, it likely develops over several days and is a result of cardiovascular strain as the body tries to maintain normothermia in a hot environment. Heat exhaustion occurs when the demands for blood flow (to the skin for temperature control through convection and sweating, to the muscles for work, and other vital organs) exceed the cardiac output. A body that has developed a state of salt depletion over several days, in combination with extreme exertion, is at risk for heat exhaustion.

S/S: Profound fatigue, chills, nausea/vomiting, tingling of the lips, shortness of breath, orthostatic dizziness, headache, syncope, hyperirritability, anxiety, piloerection, heat cramps, heat sensations in head and upper torso. Casualty may or may not feel thirsty. Tachypnea, tachycardia, orthostatic hypotension may be present. Cor temperature may be normal or greater than 104°F. Heat stroke can be defined as a heat injury with central neurologic symptoms such as altered mental status or seizures.

MGMT HEAT EXHAUSTION: Reduce the load on the heart with rest and cooling. Place casualty in shade and remove heavy clothing. Apply cool water to the skin, if available. Correct water and electrolyte depletion by administering oral or IV fluids. IV fluids replenish the volume and correct symptoms quickly. Patients with resting tachycardia or orthostatic hypotension should initially receive up to 1-2 L boluses of crystalloid solution and monitored for these vital signs to correct. If patient can tolerate oral fluids, use an oral electrolyte solution or sports drink. SM should limit activity for minimum of 24 hrs and ease into return in activity in slow stepwise approach.

MGMT HEAT STROKE: Heat stroke is a true emergency and needs to be managed by rapid active cooling (ice bath immersion or rotation of ice sheets). In a patient with an undefined heat injury and temperature >104°, or hyperthermia and AMS treat as heat stroke per the protocol. Do not rely solely on temperature to diagnose but have a high index of suspicion with appropriate risk factors and clinical setting and treat presumptively.

Hyponatremia

In addition to these standard heat injuries, hyponatremia, or emergently low serum sodium, may be classified as a heat injury. Hyponatremia in our population most commonly occurs due to excessive free water intake that overwhelms the body's ability to maintain a normal serum electrolyte concentration. This excessive free water leads to a dilution of the serum sodium and can have central nervous system effects such as seizures or AMS.


Treat all apparent heat injuries with primary concern for heat stroke. After treating or ruling out heat stroke, evaluate and treat as indicated for hypoglycemia. In a patient thought to have a heat injury due to environmental factors with AMS or seizures with a core temperature <104°F and normal or treated glucose level, attempt to gain history of excessive free water intake or recurrent clear vomiting. With a negative evaluation for heat stroke and hypoglycemia in patient with AMS or seizures, treat for presumptive hyponatremia. Treatment includes continuing emergent evacuation and administering a single 250cc hypertonic saline (3%) bolus. Ensure large IV access for administration and be cognizant of venous extravasation and risk with hypertonic saline.

Hyperthermia (Heat) Management Protocol



Steps should be performed concurrently if possible

Altered Mental Status
Nausea/Vomiting
Cramps to Extremities/
Abdomen
Sweaty, Hot, Flushed or Dry
Skin, Fatigue, Seizures
Ataxia



1. Evac as early as possible
2. Treat presumptively as heat stroke while working through protocol and evaluation
3. Can initiate up to 2L IVF bolus for heat stroke while awaiting evacuation
4. IVF for heat stroke should be cold stored to 29C or in ice sheet cooler
5. Seizure likely due to hyponatremia, treat accordingly
6. Hyponatremia patient often has history of excessive fluid intake and repeated clear vomiting
7. Document initial and serial core temps and times
8. Ensure patency of IV and large vein access for 3% NS due to increased extravasation risk

9. All heat related patients must be documented and reported to a medical officer.
10. Key Documentation includes: PT Hx and Hx leading up to the event; medications or supplements ingested; last meal type and time; any cardiac dysrhythmias.
11. DO NOT delay evacuation process to render treatment – treat en route.
12. Oral Electrolyte Fluids include Drip drop or 1:1 dilution with sports drinks.
13. Titrate rehydration to establish normal urinary frequency and volume, restoration of pale urine color, restoration of normal skin turgor, and restoration of mucosal moisture.
14. All heat injury patients will be documented and reviewed by a medical officer.

Hypothermia Management



HYPOTHERMIA

Hypothermia, acidosis, and coagulopathy constitute the "triad of death" in trauma patients. The understanding of hypothermic coagulopathy with increased mortality is critical. Prevention of hypothermia **must** be emphasized in combat operations and casualty management, and all levels of care. Hypothermia occurs regardless of the ambient temperature; hypothermia can, and does, occur in both hot and cold climates. Prevention of hypothermia is much easier than treatment of hypothermia; therefore prevention of heat loss should start as soon as possible after the injury. Keep in mind that hypothermia becomes a cardiac event as much as a temperature event.

TCCC Application

Care Under Fire: No specific action.


Tactical Field Care: All attention should be directed towards preventing heat loss. Stop bleeding and resuscitate appropriately. If available, warm fluids should be used. This will start generating internal heat that facilitates re-warming. Minimize the casualty's exposure to the elements. Keep protective gear on or with the casualty if feasible. Remove and replace wet clothing with dry if possible. Get the casualty onto an insulated surface as soon as possible. Apply the Ready-Heat Blanket from the Hypothermia Prevention and Management Kit (HPMK) to the casualty's torso (not directly on the skin) and cover the casualty with the Heat-Reflective Shell (HRS). If an HRS is not available, the previously recommended combination of the Blizzard Survival Blanket and the Ready Heat blanket may also be used. If the items mentioned above are not available, use dry blankets, poncho liners, sleeping bags, or anything that will retain heat and keep the casualty dry. Warm fluids are preferred if IV fluids are required. Placement of a temperature dot on the forehead of the patient will assist in monitoring changes in the patients' response to treatment, and will serve as a visual "clue" to remind providers to monitor the patient's temperature throughout the evacuation process

Tactical Evacuation: Use a portable fluid warmer capable of warming all IV fluids including blood products. Protect the casualty from wind if doors must be kept open.

Extended Care

Extended Care: Hypothermia will result in decreased clotting ability in the trauma casualty. Prevention is the key to management, since only limited rewarming is possible in the field. Minimize the casualty's exposure to the elements. Keep protective gear on or with the casualty if feasible. Remove wet clothing and replace with dry garments if possible. Wrap the casualty with available insulating material (e.g.: CoTCCC recommended commercial systems, sleeping bags, or anything that will retain heat and keep the casualty dry). If resuscitation is required, use warmed IV fluids if possible.

Hypothermia Prevention & Management Protocol



1. Other Methods include: electrical, hot water baths, heating pads, radiant heat sources and warming beds.
2. Give IV medications at longer than standard intervals.
3. Do not defibrillate a second time until core temperature >86F

- Document:**
- Signs & Symptoms
 - Vital Signs, SpO2
 - Cardiac Rhythm
 - Core Temp
 - Mechanism of injury
 - Treatment
 - Response to treatment

ABDOMINAL PAIN (INCLUDES SURGICAL ABD, GERD, DYSPEPSIA)

Definition: Common causes in young healthy adults include appendicitis, cholecystitis, pancreatitis, perforated ulcer, and diverticulitis. Consider constipation/ fecal impaction as a potential cause of abdominal pain.

S/S: Epigastric burning pain, Present bowel sounds, Nausea and/ or vomiting, Absence of rebound tenderness, If diarrhea is present, treat per *Gastroenteritis Protocol*.

MGMT: ; 1. Ranitidine 150 mg PO bid **OR** Rabeprazole 20 mg PO qd **OR** Proton Pump Inhibitor of choice. 2. Increase PO Hydration. 3. Avoid triggers (acidic/spicy foods/tobacco); wait 3h between eating and lying down. 4. Antacid of choice (antacids will mask other S/S). Treat per nausea/vomiting protocol as required.

***Determine pregnancy status of females with abdominal pain to evaluate for ectopic pregnancy. Follow appropriate protocol only after ruling out ectopic pregnancy.**

Disposition: Observation and re-evaluation; *Priority* evacuation if symptoms not controlled by this management within 12 hours.

ACUTE SURGICAL ABDOMEN

S/S SUGGESTING URGENT EVAC: Severe, persistent or worsening abdominal pain is the key sign, rigid abdomen, rebound abdominal tenderness, fever, absence of bowel sounds, focal percussive tenderness, uncontrollable vomiting, presence of bloody vomitus or stools, presence of black tarry stools, presence of coffee ground vomitus, positive findings of Murphy's, McBurney's or Grey-Turner Signs.

MGMT: 1. Start IV with crystalloid, 1 liter bolus, followed by crystalloid 150 cc/hr. 2. Keep NPO except for medications or PO hydration. 3. Ertapenem 1 gm IV qd **OR** Ceftriaxone 1 gm IV qd. plus Metronidazole 500 mg PO q 8h. 4. Treat per *Pain Protocol*. 5. Treat per *Nausea and Vomiting Protocol*

Disposition: *Urgent* evacuation to a surgical facility.

ALLERGIC RHINITIS / HAY FEVER

Definition: Inflammation of the nasal passages due to environmental allergy

S/S: Clear nasal drainage; Pale, boggy or inflamed nasal mucosa; With or without complaints of nasal congestion; Watery or red eyes; Sneezing; Normal temperature; History of environmental allergy

MGMT: 1. Fluticasone 1 spray each nare BID +/- Loratadine 10mg PO qd **OR** Fexofenadrine 180 mg PO qd **OR** Cetirizine 5-10 mg PO qd **AND/OR** ; If no previous available, then Diphenhydramine 25 – 50 mg PO q 6h if tactically feasible (Drowsiness is a side-effect). 2. Increase oral fluid intake. 3. If prolonged management, consider Fluticasone 2 sprays in each nostril daily. Nasal saline spray may be very helpful in clearing upper airway secretions.

Disposition: Evacuation usually not required

ASTHMA (REACTIVE AIRWAY DISEASE)

Definition: Inflammatory disorder of the airway with bronchiolar hyper-responsiveness and narrowing of the distal airways; acute exacerbation seen with change in environment or level of allergen or irritant.

S/S: Wheezing, dyspnea, difficulty with speaking in full sentences, chest tightness, decreased oxygen saturation, respiratory distress

MGMT: 1. Initiate Pulsoximetry monitoring. 2. Albuterol (metered dose inhaler – works best when used with spacer), 2 - 3 puffs q 5 min, up to 3 times and assess. 3. If there is no response to Albuterol, initiate urgent evacuation and continue Albuterol MDI 4 puff q10m **AND/OR** consider Epinephrine 0.5 mg (0.5ml of 1:1000 solution) IM (**DO NOT INJECT INTRAVENOUSLY**). 4. May repeat one dose in 5 - 10 min. 5. Initiate IV access with saline lock. 6. Dexamethasone 10 mg IV / IM OR Methylprednisolone 125 mg IV/IM. 7. Administer oxygen if SpO2 <92%. 8. If there is fever, pleuritic chest pain and productive cough, treat per *Bronchitis/Pneumonia Protocol*. 9. If airway compromise, refer to airway management protocol. 10. If available, administer medications via nebulizer (Albuterol 2.5mg TID over 5-15m).

Disposition: If the patient responds to management, observe for 4 hours. Return-To-Duty if there is no wheezing or dyspnea and normal oxygen saturation. Continue Albuterol (2 puffs q 6 h) and re-evaluate in 24 hours. Continue Prednisone 60mg qd X 4d. Consider Fluticasone 250mg/Salmeterol 50mg (Advair) 1 puff bid X 14d. *Urgent* evacuation if no response to treatment. *Urgent* evacuation if symptoms persist.

Special Considerations: Other disorders to consider: anaphylactic reaction, spontaneous pneumothorax, HAPE, and pulmonary embolism.

BAROTRAUMA

Definition: Physical damage to body tissues caused by difference in pressure between an air space inside or beside the body and surrounding fluid.

S/S: Pain/pressure in the ear(s), sinuses, teeth; pulmonary over-inflation syndrome may present with chest pain, dyspnea, mediastinal emphysema, subcutaneous emphysema, pneumothorax, and arterial gas embolism (AGE).

MGMT: Middle ear - If a tympanic membrane rupture is present or suspected: 1. Protect the ear from water, diving, flying or further trauma, **DO NOT** use ear drops. 2. Pseudoephedrine 60 mg PO q4–6 hr prn AND/OR Oxymetazoline 2-3 sprays each nostril bid (no longer than 3d). Refer to higher level of care when feasible. Consider Moxifloxacin 400 mg PO qd only if gross contamination is suspected.

Paranasal Sinus barotraumas – Pseudoephedrine 60 mg PO q 4 - 6 hr prn. 3. Pulmonary barotraumas to include subcutaneous emphysema - If no respiratory distress, monitor patient closely. Use pulse oximetry if available. If respiratory distress occurs – Treat per *Spontaneous Pneumothorax Protocol*. 3. If arterial gas embolus is suspected, administer 100% oxygen and 1 liter normal saline IV 150cc/hr. *Urgent* evacuation to recompression chamber. If an unpressurized airframe is used, avoid altitude exposure greater than 1000 ft. 4. Treat per *Pain Management Protocol*. (Avoid narcotics if recompression is anticipated.)

Disposition: *Urgent* Evacuation for cerebral arterial gas embolus or pneumothorax with respiratory distress. Mild to moderate middle ear, sinus, or pulmonary barotraumas without respiratory distress, observation and *Routine* evacuation. *Routine* evacuation for consultation for Tympanic Membrane rupture.

Special Considerations: 1. Pulmonary Over-Inflation Syndrome (POIS) may occur from ascent from depth if compressed air was used or exposure to blast overpressure. 2. The most commonly affected site is the middle ear and tympanic membrane, but paranasal sinuses and teeth may be affected. 3. Pulmonary barotrauma occurs when compressed air is breathed at depth followed by ascending with a closed airway (i.e. breath-holding), and can cause pneumothorax or arterial gas embolism.

BRONCHITIS

Definition: Inflammation of trachea, bronchi, and bronchioles resulting from upper respiratory tract infection (URI) or chemical irritants; viruses are the most common cause.

S/S: Preceding URI symptoms, cough (initially unproductive, then productive), fatigue, +/- fever > 100.4, +/- dyspnea, injected pharynx, may have wheezing or unremarkable lung sounds, sputum (color does not differentiate between viral or bacterial)

MGMT: 1. Increase PO fluids. 2. Acetaminophen 1000mg PO q6h prn fever and Ibuprofen 800mg PO q8h, 3. Treat symptoms with antitussive, decongestants, expectorant, as needed. 3. If wheezing present, Albuterol MDI 2 puffs q4-6hrs. Ensure smoking cessation and enforce hydration. Consider throat lozenges for accompanying pharyngitis. Consider O2 if SpO2 <92%. If symptoms worsen or persist, consider treatment as per *Pneumonia* protocol.

Disposition: Evacuation usually not required. *Observation or Routine evacuation* as necessary. *Urgent* evacuation for severe dyspnea or hypoxia.

Special Considerations: Consider high altitude pulmonary edema (HAPE) at high altitudes. Consider pulmonary embolism (PE) and pneumothorax (fever and productive cough are atypical for these). Acute bronchitis is a common and generally self-limiting condition that usually does not require antibiotics. Cough may linger for several weeks.

CELLULITIS/CUTANEOUS ABSCESS

Definition: Acute superficial bacterial skin infection due to trauma, scratching or other lesions. Generally begins about 24 hours following a break in the skin, but more serious types of cellulitis may be seen as early as 6 – 8 hours following animal or human bites.

S/S: Local warmth; painful, erythematous, swollen, tender area; induration, regional lymphadenopathy, Fever may or may not be present; Typically, erythema spreads without treatment; Rapidly spreading and very painful infections suggest the possibility of necrotizing fasciitis, a life-threatening infection of the deeper tissues that should be treated per *Sepsis/ Septic Shock Protocol* and URGENT evacuation to a surgical facility; Fluctuant, tender, well-defined mass indicates abscess formation.

MGMT: 1. Clean and dress wound and surrounding area. 2. Use a pen to mark the demarcation border of the infection and re-evaluate in 24 hours. 3. Mild: Doxycycline 100 mg PO bid **OR** Trimethoprim-Sulfamethoxazole 1 tab PO bid X10d **OR** Cephalexin 500 mg PO qid x10d (for adequate staph and strep coverage) **OR** Clindamycin 450mg PO q8h X10d for first line failure (if human/animal bite, replace with Amoxicillin/Clavulanic Acid 875 mg PO bid). 4. If no other antibiotics available, then Moxifloxacin 400 mg PO qd for 10 days. 5. Limit activity until infection resolves. 6. Add Ertapenem 1 gm IV / IM qd if worsening at 48 hours or no improvement after 48 hours of treatment and seek evac/higher care and look for abscess. 7. Treat per *Pain Management Protocol*. **Cellulitis will not resolve if there is an abscess present.** 8. **IF ABSCESS IS PRESENT:** Incise and drain (I&D) if the environment permits: (a) Establish sterile incision site with Chlorhexidine or comparable antiseptic. (b) Local anesthesia using Lidocaine. (c) Incise the length of the abscess cavity, but no further. (d) Incision should be parallel to skin tension lines if possible. (e) irrigate with adequate crystalloid solution or potable water. (f) Pack the wound loosely with iodoform or dampened gauze, if available. On subsequent dressings, you can wick the wound. Bandage site and perform wound checks daily. **DO NOT SUTURE THE SITE.**

Disposition: Re-evaluate daily and watch for progression of erythema while on antibiotics. Cellulitis in critical areas (head, neck, hand, joint involvement, perineal) requires *Priority* evacuation. Use of IV antibiotics requires *Priority* evacuation or medical officer consultation. Instruct PT to keep area covered and avoid close contact to prevent spreading infection to others or swimming to worsen infection.

Special Considerations: If abscess formation occurs, only attempt I&D in the tactical setting IF: a. Pt is compromising mission due to inability to perform. b. Delay in I&D until MC is not possible. c. The abscess is clearly well demarcated and superficial. d. Local anesthesia and antiseptic are available.

CHEST PAIN

****Refer to Current ACLS Protocols if tactically feasible and if ACLS equipment and drugs are available.** This Protocol assumes no access to ACLS medications or monitoring/defibrillation equipment. Do not delay evacuation if tactically feasible.

Definition: Possible myocardial infarction or reason to rule out cardiac-related chest pain.

S/S (Cardiac): The presence of one or more of the following risk factors increases the likelihood of coronary artery disease: smoking, diabetes, hypertension, elevated cholesterol, obesity, family history of MI at a young age, and patient age over 40.

The following are signs and symptoms suspicious for myocardial infarction as the etiology for chest pain: Substernal chest pain that may radiate to the left arm, neck, or jaw; Pain described as pressure or squeezing; Pain exacerbated with exertion and relieved with rest; Associated dyspnea, diaphoresis (sweating), nausea, lightheadedness, or syncope; Tachycardia, irregular heart rhythm, or severe bradycardia; Bilateral rales/crackles in the lungs on auscultation; Significant hypertension or hypotension.

MGMT: 1. Aspirin 324 mg PO (non-enteric coated) – chew to speed absorption. 2. Oxygen (if indicated) and Pulse oximetry monitoring. 3. If available, Nitroglycerin 0.4mg SL initially, repeat q5min for total of 3 doses if not contraindicated (not hypotensive and not taking medications to treat erectile dysfunction) 4. IV access with saline lock. Administer 250 – 500 cc crystalloid solution as needed to correct hypotension with frequent reassessment. 5. After above, treat per *Pain Management* protocol. 6. Avoid all exertion. Allow the patient to rest in a position of comfort. Frequently reassess the patient including hemodynamic status.

Disposition: *Urgent* evacuation. Evacuation platform should include ACLS certified medical personnel and the equipment, supplies, and medications necessary for ACLS care. Do not delay evacuation if unsure of chest pain etiology. Strongly consider early contact with a medical officer or medical treatment facility for consultation. Frequently reassess the patient suspected of a non-cardiac etiology to ensure stability and accuracy of the diagnosis.

Special Considerations/Other Etiologies of Chest Pain:

1. The following signs and symptoms **MAY** suggest a GI etiology such as gastroesophageal reflux disease (GERD): dyspepsia, dysphagia, burning quality to chest pain, exacerbated by laying flat, foul or brackish taste in mouth. A trial of antacids or Ranitidine 150mg PO bid may be useful if evacuation will be delayed.
2. Severe chest pain following forceful vomiting may indicate esophageal rupture. Administer IV crystalloid solution 150 cc/hr and Ertapenem 1 gm IV and evacuate as *Urgent*.
3. Sudden onset of pleuritic chest pain with dyspnea may indicate pulmonary embolus or spontaneous pneumothorax. Auscultate the lungs; unilaterally diminished breath sounds suggest pneumothorax which may require decompression. Administer oxygen, establish IV access, administer Aspirin 324mg PO for suspected PE, and evacuate as *Urgent*.
4. The following signs and symptoms **MAY** suggest a musculoskeletal etiology: pain isolated to a specific muscle or costochondral joint pain exacerbated with certain types of movements, non-central chest pain reproduced upon palpation. A trial of NSAIDs such as Ibuprofen 800 mg PO tid may be useful if evacuation will be delayed.
5. Chest pain with gradual onset and exacerbated by deep inspiration and accompanied by fever and productive cough **MAY** indicate lower respiratory tract infection. Consider treatment per *Bronchitis/ Pneumonia Protocol*.

COMPARTMENT SYNDROME

Definition: A progressive ischemic injury to tissue and muscle that results from increased pressure within a closed compartment of the body. A serious complication following wound closures, deep contusions, and long bone fractures resulting in necrotic tissue, nerve and vascular damage. May be seen in shrapnel wounds within 48-96h of trauma.

S/S: Pain that is disproportionate from original injury; persistent deep ache or burning pain; paresthesia (onset 30m to 2h due to ischemic nerve dysfunction; muscle weakness in affected area; tense with swollen shiny skin; pain with passive stretch of muscles; tense compartment with firm feeling, decreased sensation and muscle weakness (onset generally over 24h; pain with pressure over the compartment area; feeling of pressure in affected area; late symptoms are diminished sensation distal to compartment area and diminished or absent pulses distal of to the injury.

MGMT: 1. Remove any constricting clothing, splints or bandages. 2. Closed or partially closed wounds should be opened, irrigated and dressed with wound remaining open. 3. Manage pain as per pain management protocol. 4. Gain IV access. 5. Ertapenem 1 gm IV qd **OR** Ceftriaxone 2 gm IV qd **OR** Moxifloxacin 400 mg PO qd. 5. Fasciotomy only if properly trained and online medical direction.

Disposition: *Urgent* evacuation to a surgical facility.

CONJUNCTIVITIS

Definition: Eye conjunctiva inflammation due to allergic, viral, or bacterial cause.

S/S: All causes (burning, irritation, tearing); allergic (bilateral, serous or mucoid discharge, itching, redness, accompanying sneezing); viral (bilateral or unilateral, redness, watery discharge, conjunctiva swelling, tender preauricular node, sandy/gritty/foreign body sensation, associated URI); bacterial (bilateral or unilateral, eye injection, mucopurulent or purulent discharge)

MGMT: 1. Remove contact lens if worn. 2. Assess for visual acuity and document before/after all treatments. 3. Tetracaine 0.5%, 2 drops in the affected eye one-time only for exam and pain relief. **DO NOT dispense to patient.** 4. Check for foreign body to include eyelid eversion of upper and lower lids and assess using fluorescein stain for abrasion/ulcer. Irrigate with normal saline prn. 4a (Allergy) Attempt initial treatment with Artificial Tears, then if no resolution X2d Naphazoline 2 drops q6h X 3d **OR** Naphazoline/Pheniramine 1 drop q6h prn X 3d. 4b. (Viral) Natural Tears and treat per Upper Respiratory Tract Infection/Common Cold. 4c. (Bacterial) Erythromycin 0.5% ophth oint q4h x 3-5d **OR** Fluroquinolone ophth drops – 1 drop in the affected eye q6h while awake for 5d. 5. Treat per pain management protocol (Rare). 6. Reassess q24h until resolved.

Disposition: Generally, does not require evacuation. Evacuate *Routine* if S/S do not resolve with treatment.

CONSTIPATION / FECAL IMPACT

Definition: Infrequent, hard, dry stools.

S/S: Recent history of infrequent passage of hard, dry stools or straining during defecation; Abdominal pain, which is typically poorly localized with cramping; If pain becomes severe and is associated with nausea / vomiting and complete lack of flatus or stools, consider a bowel obstruction.

MGMT: Generally, dietary modification to include increased fiber intake will resolve simple constipation conditions. First line is 30 gm dietary fiber daily along with 80-120oz of water. 1. If severe pain, rigid board-like abdomen, fever, and/ or rebound tenderness develop, or moderate to large amounts of blood are present in the stool, then treat per *Abdominal Pain Protocol*. 2. Polyethylene Glycol 17g in 4-8 oz of water PO qd titrated to effect. 3. If no relief, Bisacodyl (Dulcolax) 10 mg PO tid prn **OR** Docusate 100 mg PO bid. 4. If above measures fail, perform digital rectal examination to check for fecal impaction. If fecal impaction is present, perform digital disimpaction, if trained. 5. Treat per *Pain Management Protocol (no narcotics – they cause constipation)*. With all treatments, increase PO fluid and fiber (fruits, bran, and vegetables) intake (both episodically and continuing lifestyle).

Disposition: Evacuation is usually not required for this condition. *Routine* evacuation if no response to therapy.

Special Considerations: Differential diagnosis include acute appendicitis, volvulus, ruptured diverticulum, bowel obstruction, pancreatitis, or parasitic infections. Acute onset, severe pain, point tenderness, and fever indicate etiologies other than constipation or fecal impaction.

CONTACT DERMATITIS

Definition: Skin reaction to external substance (plants, chemicals, topical medications, metals).

S/S: Acute onset of skin erythema and intense itching (pruritis); may see edema, papules, vesicles, bullae, discharge, and/or crusting may be visible.

MGMT: 1. Remove offending agent and evaluate pattern. 2. Change clothes when possible and bag original clothes until they can be machine washed. 3. Wash area with mild soap and water. 4. Apply cold wet compress to affected area to help decrease itching. 5. If available, apply Triamcinolone Cream 0.1% (OR if on face, 1% Hydrocortisone cream) to the affected area **OR** if suspected poison ivy/oak/sumak, then Zanafel cream bid. 6. Give Diphenhydramine 25 – 50 mg PO / SL q 6 hr prn itching, if tactically feasible. (Sedation may occur). 7. In severe cases (hands/feet/face/genital or >30% BSA), Prednisone 60 mg PO daily X 5 days burst or taper dose down every 3 days for 14-21 day course **OR** Dexamethasone 10 mg IM qd for 5 days **OR** Methylprednisolone 125 mg IM X 5d.

Disposition: *Priority* evacuation for severe symptoms: intra-oral or eye involvement, or >50% body surface area (BSA) involvement. *Routine* evacuation for any cases not showing improvement <24h after steroids. Monitor for secondary infection; treat per *Cellulitis Protocol* if suspected on the basis of increasing pain, redness, or purulent crusting.

Special Considerations: 1. Insect bite(s) as a differential diagnosis - also accompanied by itching, but with discrete red papular lesions(s). 2. Cellulitis as a differential diagnosis - bright red, painful, non-pruritic, and typically becomes steadily worse without antibiotics. 3. Fungal infection as a differential diagnosis – not always pruritic; infection site(s) slowly enlarge without therapy. 4. Effects are particularly dangerous if contact in or around the eyes.

CORNEAL ABRASIONS / CORNEAL ULCERS

Definition: A traumatic disruption of the epithelial covering of the cornea with three major concerns: intense eye pain, corneal ulcer (vision-threatening infection), and potential for ruptured globe.

S/S: History of eye trauma or contact lens wear; severe eye pain; tearing; blurred vision; light sensitivity; fluorescein stain positive; white or gray spot on cornea for corneal ulcer (usually need tangential penlight exam to see); for sudden onset of eye pain after trauma in a patient with LASIK surgery, consider LASIK flap dislocation.

MGMT: 1. Remove contact lens if worn. 2. Assess for visual acuity and document before/after all treatments. 3. Tetracaine 0.5%, 2 drops in the affected eye one-time only for exam and pain relief. DO NOT dispense to patient. 4. Check for foreign body to include eyelid eversion of both upper and lower lids and assess using fluorescein stain for abrasion/ulcer. Irrigate with normal saline prn. 5. Moxifloxacin 0.5% drops (1 drop four times a day) **OR** Erythromycin 0.5% ophth oint q4h x 3-5d **OR** Flouroquinolone ophth drops – 1 drop in the affected eye q6h while awake for 5d **OR** Bacitracin ointment four times a day – all applied until the corneal epithelium is healed. 6. Treat per *Pain Management Protocol*. 7. Reduce light exposure, stay indoors if possible - sunglasses if not possible. 8. For corneal abrasions: monitor daily for worsening signs and symptoms of a corneal ulcer (increasing pain and development of a white or grey spot at abrasion site). **DO NOT PATCH.** 9. Assess using fluorescein stains daily — abrasions should get progressively smaller. Continue antibiotic drops until 24 hours after cornea becomes fluorescein negative (no bright yellow spot). 10. PO analgesics PRN IAW pain management protocol. 11. **IF CORNEAL ULCER PRESENT:** Flouroquinolone 1 drop in the affected eye q6h while awake for 5d. *Urgent* evacuation to ophthalmologist. Moxifloxacin 400 mg PO once a day may be added if evacuation is delayed or the victim's pain is becoming worse.

Disposition: Reassess q24h to ensure improvement. Evacuation may not be needed for corneal abrasion if improving with treatment. *Priority* evacuation for Corneal Ulcer. *Urgent* evacuation for LASIK flap dislocation.

Special Considerations: 1. Contact lens corneal abrasions are at a high risk for development of a corneal ulcer. They should not be patched and require more intensive antibiotic therapy. 2. Consider LASIK Flap dislocation for anyone that sustains eye trauma after LASIK surgery. 3. Consider Herpes Simplex or Fungal infections as well and contact a medical officer.

COUGH

Definition: Usually viral etiology, but may also occur with high altitude pulmonary edema (HAPE) and pneumonia.

S/S: Cough with or without scant sputum production; often accompanied by other signs and symptoms of upper respiratory tract infection (i.e. sore throat and rhinorrhea).

MGMT: 1. If associated with Upper Respiratory Infection S/S, treat per protocol. 2. If absence of fever and URI S/S, treat per bronchitis protocol. 3. If fever, tachycardia, tachypnea, shortness of breath, treat per pneumonia protocol. 4. If at altitude, treat per altitude medical emergency protocol.

Disposition: Correlate signs/symptoms to medical condition and manage by appropriate protocol. Differential: Causes of chronic cough include GERD, Asthma, and PND.

DEEP VEIN THROMBOSIS (DVT)

Definition: Potentially life-threatening condition in which a clot is present in the large veins of a leg and may dislodge and localize in the pulmonary system, a pulmonary embolism.

S/S: History of recent trauma, air travel, altitude exposure, birth control pills, or family history of DVT; asymmetric pain and swelling in a lower extremity (often the calf muscles); warmth over affected area; increased pain in the affected calf muscles with dorsiflexion of the foot; palpable venous "cord".

MGMT: 1. Monitor patient with pulse oximetry (sudden decrease in oxygen saturation or new chest pain/shortness of breath suggests a pulmonary embolism). 2. Acetylsalicylic acid (Aspirin) 325mg PO q4-6h. 3. Immobilize the affected extremity and do not allow to walk. 4. For associated respiratory distress (tachypnea, tachycardia, dyspnea, chest pain) consider Pulmonary Embolus and treat per *Chest Pain Protocol*.

Disposition: *Priority* evacuation if no respiratory distress or chest pain. *Urgent* evacuation if respiratory distress or chest pain are present

Special Considerations: May be confused with a ruptured Baker's cyst in a tactical setting.

DEHYDRATION

Definition: Inadequate fluid intake exacerbated by physical exertion or illness.

S/S: Lightheadedness (worse with sudden standing); mild headache (especially in the morning); dry mucosa; decreased urinary frequency and volume; dark urine (tea colored); degradation in performance

MGMT: 1. Assess for underlying condition and treat as per appropriate protocol in conjunction with this protocol. 2. Increase oral fluids if tolerated. (a) If available, use carbohydrate/ electrolyte drink mixes for fluid replacement diluted to a 1:4 solution. (b) Avoid fluids containing caffeine. 3. If unable to tolerate PO fluids, use an initial bolus of 1 liter crystalloid IV, followed by repeat attempt at PO hydration. If still unable to tolerate PO hydration, repeat 1 liter bolus of crystalloid IV. 4. Treat per *Nausea/Vomiting Protocol* as needed.

Disposition: Monitor closely for recurrence of dehydration. *Priority* evacuation if dehydration persists after treatment.

Special Considerations: 1. Troops in the field are often chronically dehydrated. 2. Prolonged missions, acute diarrhea (gastroenteritis), viral / bacterial infections, and environmental factors (heat stress or strenuous activity) all may exacerbate dehydration. 3. May also occur in cold or high altitude environments.

DENGUE FEVER

Definition: A flaviviral disease transmitted by the *Aedes aegypti* and *albopictus* mosquitoes.

S/S: Can be dormant for 1-7 days. Patients will have high fever with at least two of the following: severe HA, severe retro orbital PN, arthralgias, myalgias, rash, or petechiae. **Hemorrhagic manifestations may include purpura/ecchymosis, epistaxis, gum bleeding, blood in emesis, urine, or stool, or vaginal bleeding.**

MGMT: Refer to higher medical care if suspected DF. Management is mostly supportive focusing mostly on maintaining blood pressure and perfusion. Initiate Tylenol 1000mg q 6hrs.

Disposition: *Urgent* evacuation for suspected DF, Dengue Hemorrhagic Fever (DHF), or Dengue Shock Syndrome (DSS).

Special Considerations: Most commonly found in tropical Asia, Central and South America, and the Caribbean Dengue is the leading mosquito-borne infection. The *Aedes* prefers to feed in the day time. Their bites can go unnoticed. One mosquito can infect multiple people. Dengue can be transmitted by blood transfusions and organ transplants but no recorded person-to-person transmission. Someone can be infected with any of the Dengue viruses and never develop DF. There is no vaccine or chemoprophylaxis for any of the Dengue Viruses. The primary means of prevention is eliminating the mosquito breeding habits, wearing clothing properly, using insect repellent, and mosquito nets. If a person has been infected with the Dengue Virus previously and is exposed again they are at risk for either DHF or DSS which could be fatal.

DENTAL PAIN

Definition: Most common causes are deep decay, fractures of tooth crown/root, acute periapical (root end) abscesses, or pericoronitis (pain associated with an impacted wisdom tooth).

S/S: Intermittent or continuous pain (usually intense), heat or cold sensitivity; Visibly broken / cracked tooth; severe pain on percussion; intraoral swelling / abscess; partially erupted wisdom tooth.

MGMT: 1. Treat per *Pain Management Protocol*. Consider application of clove oil soaked gauze for pain relief. 2. If signs and symptoms of infection are present, administer Amoxicillin/Clavulanic Acid 875 mg PO bid for 7 days **OR** Ceftriaxone 1 gm IV / IM qd x 7 days **OR** if previous unavailable, then Azithromycin 500mg PO initially followed by 250mg PO qdX4d. 3. If gums appear swollen and red, encourage increased oral hygiene and warm saline rinses bid. Consider local or regional anesthesia if trained.

Disposition: Evacuation usually not necessary. *Routine* evacuation if not responding to therapy or requiring IV antibiotics

DETERMINATION OF DEATH

Definition: Immediate determination of death is appropriate in a trauma patient without pulse or respirations in the setting of multiple casualties when resuscitative efforts would hinder the care of more viable patients. It is assumed that personnel do not have access to ECG, or other monitoring equipment to evaluate heart rhythm, or deliver counter-shocks.

S/S: Obvious Death -- Persons who, in addition to absence of respiration, cardiac activity and neurologic reflexes have one or more of the following: decapitation; massive crushing and/or penetrating injury with evisceration of the heart, lung or brain; incineration; decomposition of body tissue; rigor mortis or post-mortem lividity.

MGMT: 1. In the setting of obvious death, resuscitative efforts should not be initiated. 2. If resuscitative efforts have been initiated, discontinuation should be considered: A. After 15 minutes (if the cause is unknown or due to trauma) or after 30 minutes (when the cause is due to hypothermia, electrical injury, lightning strike, cold water drowning, or other cause known to require a prolonged resuscitative effort) when: There is persistent absence of pulse and respirations despite assuring airway and ventilation as well as administration of resuscitative fluids and medications; pupils are fixed and dilated; no response to deep pain above or below the clavicles; absence of SpO₂ and EtCO₂, from a correctly placed endotracheal tube or alternative airway. 3. If there is any question as to the discontinuation of resuscitative efforts, then a medical officer should be contacted for guidance.

Disposition: Evacuation of the remains when tactically feasible. In the event of return of spontaneous circulation, *Urgent* Evacuation.

Special Considerations: Patients that are struck by lightning, have hypothermia, cold-water drowning, or intermittent pulses may require extended cardiopulmonary resuscitation.

ELECTROCUTION

Definition: Death or serious injury caused by electric shock, electric current passing through the body. Injury can occur through both direct electrocution and from blast/blunt trauma injuries.

MGMT: Follow standard trauma assessment protocol with additional key notes outlined in this protocol. Lightning strikes deliver direct current (DC) electrocution and domestic electrocution is classically alternating current (AC). Maximal injury due to DC is usually cardiac and respiratory arrest, and AC injury can cause ventricular fibrillation. Fixed and dilated pupils are often due to transient autonomic disturbance, but be sure to rule out closed head injury first. Rhabdomyolysis and compartment syndrome can develop. For lightning strike casualties conduct reverse triage as apnea/asystole is commonly transient and can resolve with BLS/ACLS support until return of respirations and pulse.

Disposition: Evacuate any patients with systemic symptoms to higher level of care.

ENVENOMATION - ARTHROPOD (SPIDER & SCORPION)

Definition: Toxic envenomations from arthropods are generally not life threatening, but can cause conditions requiring treatment and potential hospitalization. Most suspected "spider bites" are MRSA abscesses. Assume abscess unless the spider bite was witnessed.

BLACK WIDOW

S/S: Pinching bite followed by local swelling and burning; large muscle group spasms/tremors; abdominal pain and/or rigidity within 60 minutes (may mimic appendicitis or acute surgical abdomen); nausea and vomiting; diaphoresis; hypertension; tachycardia.

MGMT: 1. Treat per *Pain Management Protocol (narcotic analgesia)*. 2. Midazolam 2-5mg IV/IM for relief of muscle spasm. 3. Diphenhydramine 25–50mg q 6hr prn PO / IV. 4. In cases of suspected black widow spider bites, consider other causes for acute abdominal pain.

BROWN RECLUSE

S/S: Local pain and ulceration at site within 2-8 hours with surrounding erythema; Hemorrhagic vesicle progressing to slowly enlarging eschar; Fever, chills, nausea, joint pain.

MGMT: 1. Elevate bite site. 2. Avoid strenuous activity. 3. Treat per *Pain Management Protocol (narcotic analgesia)*. 4. Diphenhydramine 25–50mg q 6hr prn PO / IV. 5. Monitor and treat per *Cellulitis* protocol.

SCORPION

S/S: Local pain, swelling, and erythema; nausea and vomiting; paresthesias; tongue fasciculations; sympathetic (tachycardia, hypertension, hyperthermia) or parasympathetic (hypotension, bradycardia, hypersalivation, incontinence) overdrive can develop; seizures; agitation; blurry vision/rotary eye movements.

MGMT: 1. Treat per *Pain Management* protocol. 2. Treat per *Nausea and Vomiting* protocol. 3. Supportive care as necessary per appropriate protocol. 4. Diphenhydramine 25–50mg q 6hr prn PO / IV. 5. Apply ice or cold water.

Disposition: *Urgent* evacuation for development of abdominal rigidity, development of systemic signs, or for anaphylaxis. *Routine* evacuation for tissue necrosis of brown recluse bite. *Evacuation typically not required for localized insect stings and scorpion bites.*

ENVENOMATION – INSECT, HYMENOPTERA (BEE, WASP, HORNET)

Definition: Toxic envenomations from bees, wasps, and hornets are all capable of causing life-threatening anaphylaxis, especially in personnel with known hypersensitivity. Personnel with known reactions should maintain their own epinephrine administration kit (Epi-Pen).

S/S: Pain; swelling / edema; puncture site(s) from stinger or fangs; warmth; erythema; signs of anaphylaxis

MGMT: 1. If signs and symptoms of anaphylaxis present, treat per *Anaphylaxis* protocol.

HYMENOPTERA (BEE, WASP, HORNET): 2. Remove stinger by scraping from side. 3. Apply ice or cold water. 4. Apply topical 1% hydrocortisone cream. 5. Apply topical lidocaine. 6. Ibuprofen 800mg PO tid x 7 days. 7. Diphenhydramine 25–50mg q 6hr prn PO / IV.

Disposition: *Urgent* evacuation for development of systemic signs or for anaphylaxis. Evacuation typically not required for localized insect stings and scorpion bites.

Special Considerations: Tactical medics must always be aware of unit personnel with known insect hypersensitivities.

ENVENOMATIONS - MARINE

Definition: Marine envenomation results from stings by jellyfish, fire corals, sting rays, sea urchins, bristle worms, fish spines, and sea snakes. All of these envenomations are more likely to occur in intratidal regions, reefs and surf zones.

JELLYFISH STING: Contact with jellyfish tentacles causes immediate, intense sharp and burning pain, followed by local, linear erythematous eruption; Severe stings can cause anaphylactic reaction, hematuria, vomiting, syncope, hypotension, or paralysis; (Envenomation by fire coral is similar to jellyfish, but less severe and rarely causes complications. Pain symptoms usually resolve within 12 hours).

BRISTLEWORM STING: Is caused by contact with bristle-like setae on feet of animal. Contact is like brushing against a cactus plant and may result in many fine bristles embedded in the skin. Causes painful inflammation, which is almost never serious.

STINGRAY PUNCTURE: Spine on tail contains retro-serrated teeth, with a venom gland along the groove. Envenomation causes immediate, intense pain at site of injury out of proportion to what it looks like, edema. Pain tends to peak 30-60 minutes after puncture and can last for several days. Rare systemic symptoms include limb paralysis, hypotension, and bradycardia.

SEA URCHIN PUNCTURE: Frequently cause multiple deep puncture wounds when stepped on. Puncture and envenomation causes immediate, intense pain, erythema and local swelling. If more than 15-20 punctures are present then severe systemic symptoms can occur.

FISH SPINE PUNCTURE: First symptom is usually immediate localized pain out of proportion to clinical manifestations, lasting minutes to hours. Puncture wound is usually cyanotic, with surrounding erythema and edema. Pain is often noted in proximal lymph nodes. Symptoms can progress to delirium, malaise, nausea, vomiting, and elevated temperature. Infrequently leads to shock and death.

SEA SNAKE BITE: Fang and teeth marks consist of small puncture wounds and may number from 1–20. Latent period of 10 minutes to several hours between bite and onset of symptoms. May initially present with mental status changes, including euphoria, anxiety or restlessness. Progresses to dry throat, nausea, vomiting, generalized weakness and paralysis, leading to respiratory distress/failure.

BLUE RINGED OCTOPUS BITE: Bite is painless and may go unnoticed. Patient may become paralyzed with respiratory distress. Symptoms are usually rapid in onset and extremely variable in severity.

STING MANAGEMENT (Jellyfish, Sea Wasp): 1. Remove stinger, tentacles, etc if possible with gloved hand, forceps or tape. 2. Immediately flush with dilute acetic acid (vinegar). Alternative flush is isopropyl alcohol and seawater. Do not use fresh water. 3. Topical lidocaine. 4. Topical steroids. 5. Follow *Pain Management* protocol.

BITE MANAGEMENT (Sea Snakes, Blue-Ringed Octopus): 1. Treat as a snake envenomation.

PUNCTURE MANAGEMENT (Sea urchin, stingray, fish spines, bristleworms): 1. Remove all penetrating foreign bodies with gloved hand, forceps or tape. 2. Irrigation with cold seawater. 3. Soak the affected area in non-scalding water (110–115 degrees) for 30-90 minutes to inactivate toxins. 4. Ultrasound or xray (if available for retained foreign body). 5. Antibiotics for deep puncture wounds: Moxifloxacin 400mg qd. 6. Follow *Pain Management Protocol*.

Disposition: *Urgent* evacuation if evidence of severe envenomation (cardiovascular collapse, anaphylaxis, paralysis, ascending edema of limb). Evacuation not required if signs and symptoms do not indicate severe envenomation after 24 hours of observation.

ENVENOMATION - SNAKE

Definition: Snake bites and actual envenomation is rare. More care should be taken to avoid snakes and potential bites than the likelihood of an actual envenomation.

S/S: **Crotalidae (Pit vipers, rattlesnake, moccasin, bush master):** Sudden pain; erythema; ecchymosis; hemorrhagic bullae; bleeding from site; metallic taste; hypotension/ shock; swelling/edema.

Elapids (Coral snake, sea snake, mamba, cobra, taipan, kraits): Cranial Nerve dysfunction (i.e., ptosis, difficulty swallowing); paresthesias; fasciculations; weakness; altered mental status

MGMT: 1. If signs and symptoms of anaphylaxis present, treat per *Anaphylaxis* protocol. 2. General supportive care as necessary through emergency protocols. 3. Treat per *Pain Management* protocol using *narcotics*. Avoid NSAID use. 4. Treat per *Nausea and Vomiting* protocol. 5. If toxic snakebite suspected (significant pain, edema, evidence of coagulopathy or neurologic signs/symptoms):
A. Minimize activity and place on a litter. B. Remove all constricting clothing and jewelry. C. Initiate saline lock in unaffected extremity. D. Monitor and record vital signs and extent of edema every 15–30 minutes. E. IV crystalloid for hypotension as necessary. F. Immobilize affected limb in neutral position. G. A compression wrap (proximal to distal) may be helpful with an elapidae (neurotoxic) snake (cobra, mamba, coral snake), but is not indicated with crotalidae (pit viper) bites. H. The need for a fasciotomy is difficult to determine in a snake bite unless compartment pressures have been taken. I. Cold therapy and suction therapy is contraindicated in snakebites.

Disposition: *Urgent* evacuation if treated for anaphylaxis. *Urgent* evacuation for elapidae bites or if evidence of severe envenomation (systemic signs and symptoms, progressive ascending edema) exists. Evacuation not required for crotalidae bites if signs and symptoms do not indicate anaphylaxis or development of severe envenomation after four hours of observation.

Special Considerations: 1. Only a minority of snakebites from toxic snakes involve severe, life-threatening envenomations. 2. Incision, excision, electrical shock, tourniquet, oral suction, and cryotherapy should **NOT** be performed to treat snakebites. 3. Suction device is not effective for removing snake venom from a wound. If previously placed, it should be left in place until patient reaches higher level of care.

EPISTAXIS

Definition: Anterior or Posterior Nosebleed

S/S: Nosebleed, Often previous history of nosebleeds

MGMT: 1. Clear nares/airway by having PT sit up and lean forward and blow nose. 2. Oxymetazoline nasal spray 2 squirts in each nostril. 3. Pinch anterior area of nose firmly for full 10 minutes **WITHOUT RELEASING PRESSURE**. 4. Assess for continued bleeding and have PT clear/blow nose. 5. If bleeding continues, pack with Afrin-soaked gauze bilaterally along floor of nasal cavity X24h. 6. Once bleeding has stopped (after 30 minutes), remove the Afrin nasal sponge and apply Bactroban to the affected nostril bid – tid x7days. 7. Clear clots and other material from airway (if required) by having patient sit up, lean forward, and blow his/her nose. 8. If bleeding continues, pack with TXA-soaked gauze bilaterally along floor of nasal cavity x 30 min then execute step 6. 9. **IF BLEEDING CONTINUES despite packing or re-bleeding occurs after 24h** : Prepare 14 French Foley catheter. (Tip is cut to minimize distal irritation). Advance catheter along floor of nose (straight in) until visible in mouth. Fill balloon with 5 cc of normal saline. Retract catheter until well opposed to posterior nasopharynx. Add an additional 5 cc of normal saline to balloon. Clamp in place without using excessive anterior pressure. Moxifloxacin 400 mg PO qd until packing is removed. **Leave balloon and packing in place for 72 hours.**

Disposition: Evacuation may not be required if epistaxis is mild, anterior, and resolves with treatment. *Urgent* evacuation for severe epistaxis not responding to therapy or if Foley catheter is used.

Special Considerations: 1. Common at high altitude and in desert environments due to mucosal drying. 2. May be anterior or posterior. 3. Posterior epistaxis may be difficult to stop and may cause respiratory distress due to blood flowing into the airway. This type of epistaxis is uncommon in young healthy adults. It is more commonly seen in older, hypertensive patients.

FLANK PAIN (INCLUDES RENAL COLIC, PYELONEPHRITIS, KIDNEY STONES)

Definition: Flank pain possibly caused by renal colic, pyelonephritis, or kidney stones.

S/S: Flank Pain; urinary tract infection (dysuria and/or polyuria); back pain; nausea/ vomiting; costovertebral angle tenderness; fever; hematuria.

MGMT: 1. Treat per *Pain Management* protocol with **Ketorolac if kidney stone suspected**. 2. Treat per *Nausea and Vomiting* protocol. 3. Treat per *Dehydration* protocol. 4. If fever present treat with antibiotics and evacuate: A. Ciprofloxacin 500 mg PO bid **OR** Moxifloxacin 400 mg PO qd **OR** Trimethoprim-Sulfamethoxazole 1 tab PO bid **OR** Amoxicillin/Clavulanic Acid 875 mg PO bid. **B.** Ceftriaxone 1 gm bid IV / IM **OR** Ertapenem 1 gm IV / IM if unable to tolerate PO or unresponsive to oral treatment.

Disposition: *Priority* evacuation

Special Considerations: 1. May progress to life-threatening systemic infection. 2. May be associated with testicular torsion. Ensure normal external GU exam first.

FROSTBITE & FROSTNIP

Definition: FROSTNIP: superficial freezing of the skin, a precursor to frostbite, that produces reversible skin changes that usually resolve with warming. FROSTBITE: occurs when tissue freezes and crystals form in the extracellular space between cells.

S/S: Edema; Tenderness; Loss of sensation (often loss of previous painful sensation); Inability to move or flex affected areas; Blisters (clear-fluid blisters indicate less severe/hemorrhagic blisters indicate a deeper, more severe injury); Skin color may be pale, yellowish, or waxy-looking; Frozen area will feel solid or wooden and may have a lifeless appearance.

MGMT: 1. Prevent additional freezing and/or progression of injury. 2. DO NOT attempt re-warming or thawing if there is a chance that refreezing will occur. 3. Treat per *Pain Management* protocol prior to attempting re-warming. FROSTNIP: A. Administer passive re-warming with warming devices such as warm blankets, insulated ready-heat, or HPMK. B. Manage mild to moderate pain as per *Pain Management* protocol. C. After re-warming, assess every 6h for tissue damage or signs of infection. D. Give NSAIDs prn x 5d. FROSTBITE: A. Administer passive re-warming with warming devices as above OR if available, preferred is rapid re-warming in 104-108F (40C) water. B. Gain IV access. C. Administer warmed crystalloid fluids (1000-1500 ml) to reduce blood viscosity and capillary sludging. D. For pain, treat with narcotics or for severe pain as per *Pain Management* protocol. E. Clean and dress any blisters that have burst while avoiding bursting any intact blisters. F. Splint fingers/toes and separate digits with non-adherent gauze. G. Elevate extremities to reduce edema. H. Initiate NSAID regimen until evacuated.

Disposition: *Urgent* evacuation if risk of refreezing or re-warming is not an option. *Priority* evacuation for frostbite. Frostnip generally will not require evacuation if resolved (any indication of infection or tissue damage should be evacuated as *routine*).

Special Considerations: 1. Ensure complete differential diagnosis from hypothermia (hypothermia may occur in conjunction with frostbite and should be managed first). 2. Do not allow patient any type of tobacco product. 3. Do not rub or massage injured tissue in the re-warming process. 4. Troops are more susceptible to cold at high altitudes or windy conditions below 32F.

FUNGAL SKIN INFECTION

Definition: Dermatophyte (Tinea) Infections are common worldwide and are common causes of Tinea Corporis, Tinea Pedis, Tinea Cruris, and Tinea Capitis.

TINEA CORPORIS: A dermatophyte infection of the skin that occurs predominantly on the core (body surfaces other than the feet, groin, face, scalp hair, and beard hair), also known as ringworm. Tinea Corporis is typically acquired by skin-to-skin contact. **S/S:** Initially: Pruritic, circular or oval, erythematous, scaling patch or plaque that spreads centrifugally. An annular, raised border, plaque appears after a few days in a "ringed appearance". **Treatment:** Apply Terbinafine or Itraconazole once to twice per day x1-3 weeks.

TINEA PEDIS: An infection of the skin that occurs on the feet (also known as athlete's foot). Tinea Pedis is typically acquired by direct skin contact, usually from showers or locker rooms. **S/S:** Pruritus; erythematous erosions or scales between toes, soles, medial, or lateral aspect of the foot. **Treatment:** Apply topical Terbinafine 1% once to twice daily x4 weeks.

TINEA CRURIS: A dermatophyte infection of the skin that occurs in the crural fold (also known as jock itch). Tinea Cruris is typically associated with an active Tinea Pedis infection. **S/S:** Initially begins with an erythematous patch on the proximal medial thigh, then spreads centrifugally with slightly elevated erythematous, sharply demarcated borders with tiny vesicles possibly present. The infection may spread to the perineum, gluteal cleft, buttocks, but sparing the scrotum in males. **Treatment:** Apply Terbinafine or Itraconazole once to twice per day x1-3 weeks.

TINEA CAPITIS: A dermatophyte infection of the skin that occurs in the scalp. Tinea Capitis is typically associated with direct contact from an infected person or object (i.e. hat or comb). **S/S:** Pruritus and scaly patches present on scalp. **Treatment:** Oral systemic antifungal therapy (Griseofulvin, Terbinafine, Fluconazole, or Itraconazole). Topical antifungal creams are ineffective.

Special Considerations: Dermatophyte infections that do not resolve with topical antifungal creams should be treated with Oral systemic antifungals. Consult a Medical Provider for any dermatophyte infections that do not respond to topical antifungal creams. A boggy, pustular area on the scalp (kerion) can develop secondary to tinea capitis. Do not confuse with abscess and do not I&D. Treatment is oral antifungals in consultation with a Medical Provider. Note: fungal infections can be complicated and diverse in nature, so consult a Medical Provider if you are unsure of the nature of the infection.

GASTROENTERITIS (DIARRHEA / NAUSEA / VOMITING)

Definition: Usually due to an acute viral infection of the GI tract, but bacteria or parasite infections are common in deployed environments.

S/S: Acute onset of nausea, vomiting, and diarrhea; Fever may or may not be present; Abdominal cramping, discomfort, or distension may or may not be present; possible S/S of dehydration.

MGMT: 1. If severe pain, rigid board-like abdomen, fever, and/ or rebound tenderness develop, or moderate to large amounts of blood are present in the stool, then treat per *Abdominal Pain* protocol. 2. Treat per *Nausea and Vomiting* protocol and/or *Dehydration* protocol. 3. Either allow diarrhea to pass for 24h **OR** if diarrhea has already persisted for >24h, then administer Loperamide 4 mg PO initially, then 2 mg PO after every loose bowel movement with a maximum dose of 16mg per day (Do not use loperamide in the presence of fever or bloody stools). 4. If bloody diarrhea, fever >100.4F at onset/development or persists >48h after initial treatment, Azithromycin 500 mg PO qd for 3 days **OR** Ciprofloxacin 500 mg PO bid X 3d **OR** Moxifloxacin 400 mg PO qd for 3 days. 5. If diarrhea persists after 3-5 days of therapy, or diarrhea develops while already on antibiotics, give Metronidazole 500 mg PO tid for 5 days.

Disposition: *Urgent* evacuation if grossly bloody stools or circulatory compromise. *Priority* evacuation if dehydration occurs despite above therapy. *Routine* evacuation if diarrhea persists after 3 days of therapy or if it develops while already on antibiotics,

Special Considerations: 1. Antibiotics are generally not needed for routine bacterial causes. 2. Emerging fluoroquinolone resistance among enteropathogenic E. Coli and Campylobacter makes azithromycin the new primary agent for therapy. 3. Consider antibiotic-related diarrhea if on antibiotics at onset. 4. Consider parasitic infection if symptoms persist for 3 or more days. 5. Must rule out malaria if fever and GI symptoms exist in a malarious area. 6. Azithromycin is considered treatment of choice for Traveler's Diarrhea.

HEADACHE

Definition: Headache

S/S: Headache; If the headache is atypical for the patient or "thunderclap/worst HA of life" or neurological exam changes, check for elevated blood pressure (if possible), fever, neck rigidity, visual symptoms, mental status changes, weakness, and dehydration.

MGMT: 1. Perform full neurological exam and document. 2. If history of trauma or blast proximity, treat per *Concussion/mTBI* protocol. 3. If the patient has fever, signs of AMS while not at altitude, nuchal rigidity, photophobia, or petechial rash, then assess per *Meningitis* protocol. 4. If at altitude, treat per *Altitude Medical Emergency* protocol. 5. If atypical or "thunderclap/worst HA of life", evacuate urgent for CT Scan to rule-out life-threatening intracranial pathology. 6. If headache is accompanied by nausea and / or vomiting, treat per *Nausea and Vomiting* protocol. 7. Treat per *Pain Management* protocol. 8. If dehydration is suspected, treat per *Dehydration* protocol. 9. Oxygen can be attempted to treat cluster headache.

Disposition: Evacuation is usually not required if the headache responds to therapy. Acute headache in the presence of fever, severe nausea and vomiting, mental status changes, focal neurological signs, or preceding seizures, loss of consciousness, or a history of "thunderclap/it's the worst headache of my life" constitutes a true emergency and requires *Urgent* evacuation. Also consider *Urgent* evacuation for anyone without a prior history of headaches if their pain is severe.

Special Considerations: The number of differential diagnoses for the acute headache is large and includes disorders that encompass the spectrum of minor to severe underlying disorders.

HEADACHE (MIGRAINE ORIGIN)

Definition: Chronic episodic headache disorder capable of altering daily function lasting 4-72 hours.

S/S: Prior history of diagnosed migraines; Headache that begins with mild pain that escalates into a unilateral and throbbing pain lasting 4-72 hours; no immediate history of head trauma or blast exposure; headache intensified with physical movement; may have accompanying nausea, vomiting, photophobia, phonophobia; may be preceded by an aura of visual disturbances, sensory disruption in arms or face, and speech difficulties.

MGMT: 1. Perform a complete neurological exam to exclude other etiologies (If patient is compliant enough) and refer to appropriate protocol if indicated. 2. If suspected migraine, move to a dark, cool, quiet environment (if possible). 3. Initiate treatment with available triptan: Rizatriptan 5-10 mg PO (may repeat 1 dose in 2h prn) **OR** Sumatriptan 6 mg subcutaneous (may repeat 1 dose in 2h prn). 4. Acetaminophen 1000 mg q6h **AND** Aspirin 325 mg q6h **AND** Caffeine 200 mg q6h (Single combined drug option is Excedrin Migraine). 5. Consider prevention or management of nausea and vomiting with Promethazine 25 mg IV/IM/PO q 6 hr prn **AND** Diphenhydramine 25-50 mg IV/IM/PO q 6 hr prn. 6. Encourage sleep, hydration and light meals if possible.

Disposition: Priority evacuation if condition does not improve with continual repeat treatments, condition worsens, a single episode is persistent greater than 24 hours, or individual becomes a risk to the mission.

Special Considerations: 1. Do not assume new headache with neurologic abnormalities is a migraine. Treat per stroke/ACLS guidelines or Meningitis protocol based on clinical scenario. 2. Generally avoid the use of narcotics, but if primary management is unresolved with intense pain that is compromising mission, consider IAW Pain Management protocol. 3. NSAIDs are generally ineffective, but may provide some relief if no other options are available. 4. Migraine-prone individuals should be identified before deployment.

HIV POST EXPOSURE PROPHYLAXIS

HIGH RISK EXPOSURES: Percutaneous injury (needle stick or other contaminated penetrating injury); exposure or exchange of body fluids with persons at high risk for HIV; transfusion of blood products that have not undergone standard US blood bank or equivalent testing for transmissible diseases; when attempting to evaluate a high risk exposure, take into account the source of the bodily contamination. For example, blood from a fellow soldier would fall into a low risk category for exposure.

MGMT: 1. Immediately wash area with soap and water to clean area and minimize exposure. 2. Use a Rapid HIV Test Kit (if available) to determine if therapy should be initiated. **In high risk situations, do not delay initiation of therapy if the test kit is not available. HIV PEP should be started within 1 – 2 hours of exposure.** 3. Consult with unit medical officer ASAP to discuss the case and obtain further guidance after any significant exposure. A. If the Rapid HIV Test is positive, initiate PEP. B. If high-risk exposure occurs and a Rapid HIV Test is unavailable, initiate PEP. C. If a Rapid HIV Test is negative, seek medical officer guidance to determine the need for PEP. 4. Initiate antiretroviral triple therapy according to the following priority of drugs. **Choose only 1 of the following drug treatment options:** Tenofovir disoproxil 300 mg/emtricitabine 200 mg (Truvada) once daily **PLUS** Raltegravir (Isentress) 400 mg twice daily *or* Dolutegravir (Tivicay) 50 mg daily. The alternative regimen is: Tenofovir disoproxil 300 mg/emtricitabine 200 mg once daily **PLUS** Darunavir (Prezista) 800 mg *and* Ritonavir (Norvir) 100 mg once daily. 5. For GI side-effects of medication, treat per *Nausea and Vomiting* protocol. 6. Maintain hydration and nutrition status.

Disposition: *Urgent* evacuation if a significant exposure occurs and highly active antiretroviral therapy (HAART) is not available. *Routine* evacuation if HAART is available and Rapid HIV Test is positive. Consult unit medical officer to determine the need for, and the priority of evacuation, if high-risk exposure has occurred and a Rapid HIV Test is negative

Special Considerations: 1. Initiation of the HAART should ideally occur within 2 hours of exposure, but still has some effect up to 72 hours after exposure. 2. Antiretrovirals have a significant side-effect profile, including nausea, vomiting, and diarrhea. 3. Obtain a sample of the source's blood for HIV and hepatitis testing, if possible. 4. Use of a commercially available Rapid HIV Test Kit that uses either an oral specimen or whole blood is recommended for source testing to determine if HAART therapy should be initiated. This should occur within 1-2 hours. The test requires 20-40 minutes to obtain results.

POST-EXPOSURE PROPHYLAXIS HOTLINE: CALL 1-888-448-4911 24/7 WITH ANY QUESTIONS

INGROWN TOENAIL

Definition: Ingrown toenail with inflammatory response.

S/S: Pain, edema, erythema and hyperkeratosis at lateral nail fold; pressure over the nail margins increases the pain; inflammatory or infectious responses are generally localized.

MGMT: Initial management is prevention. Appropriate nail hygiene is important. Toenails should be cut straight across, and the corners should not be rounded off. For mild ingrown toenail initial management should be conservative. The use of topical antibiotics or drainage of paronychia is appropriate if present. Conservative management is initiated with once to twice daily warm water soaks with mild traction being applied to the ingrown nail area. Elevation of the nail with a cotton tip applicator, dental floss or other instrument to pry the nail out of the skin is appropriate. If forceps and appropriate monitoring is available a small piece of gauze or cotton can be placed under the ingrown nail and removed and replaced daily to allow the nail to grow.

Partial or complete nail removal is typically indicated in chronic inflammation / infection, with severe pain of both medial and lateral nail folds, especially if the condition has lasted one month or greater. 1. Partial toenail removal: Clean the site with soap, water, and betadine; Perform a digital block at the base of the toe using lidocaine 1%; Apply constricting band to base of toe; Remove the lateral quarter of the nail toward the cuticle (or whole nail), using a sharp scissors with upward pressure; Bluntly dissect the nail from the underlying matrix with a flat object, elevate the nail and grasp it with a hemostat or forceps, removing the piece; Clean the nail grooves to remove any debris; Remove constricting band; Control bleeding with direct pressure and dry the underlying nail bed. 2. Apply Mupirocin 2% ointment to exposed nail bed. 3. Dress with a non-adherent dressing and dry bandage. 4. Instruct the patient to wash the area daily. 5. Recheck wound and change dressing daily. 6. Instruct patient to wear less constricting shoes and to trim their nails straight across. Optimal care is to limit walking and marching for 3 – 5 days. 7. Treat per *Pain Management* protocol. 7. Systemic antibiotics are typically not needed in these procedures; however, if an infection is suspected (increasing pain, redness, and swelling), then treat as per *Cellulitis* protocol.

Disposition: Evacuation is usually not required if the condition responds to therapy. The nail bed may have serous drainage for several weeks, but will usually heal within 2 – 4 weeks.

Special Considerations: 1. Consider toenail removal only if close follow-up is possible. 2. Local anesthetic with epinephrine for a digital block is still controversial although medically acceptable.

INSOMNIA

Definition: Primary insomnia is sleeplessness not caused by another sleep, medical, psychiatric disorder, medications, or other substances. Secondary insomnia is a result of one of the above causes. Common in deployed setting with changes of >4 time zones.

S/S: Perceived reduction of sleep time; difficulty initiating sleep on schedule; daytime sleepiness or tiredness; difficulty concentrating; anxiety; moodiness.

MGMT: 1. Practice consistent sleep hygiene of a sleep-wake schedule in a cool, dark, quiet environment (if possible). The CBT-I app should be used/offered as initial therapy. Cognitive behavioral therapy for insomnia is the first line and mainstay of treatment. 2. Reduce intake of stimulants, especially caffeine or energy drinks, and avoid heavy late night meals or high-calorie snacks before bedtime. Also avoid working out 2-3 hours before bedtime. 3. Encourage a 30-minute "wind down" time before attempted sleep and decreased electronic screen stimulation for 2 hours prior to bed (TV, cell phones, tablets etc.). 4. The use of first generation anti-histamines can be used if initiation of sleep is the biggest complaint. Dosing consists of 25-50mg. Consider Melatonin 3 mg PO approximately 30-120 minutes before bedtime **OR** in consultation with a Medical Provider, Zolpidem 5-10 mg PO at bedtime or Eszopiclone 2mg immediately at bedtime. Do not use these agents for longer than 2 weeks, abuse potential and side effect profile are high. Any choice of pharmacotherapy should not be used for more than two weeks.

Disposition: Evacuation not required unless individual's performance becomes a risk to mission, self or others.

Special Considerations: 1. Ensure differential diagnosis from sleep apnea, psychiatric or behavioral disorders and other medical reasons. 2. The body's circadian rhythm generally takes 1 day per time zone traveled to adjust to the new time zone or activity schedule. 3. Sleep management medications are intended to assist in adjustment of sleep schedule and not as a convenience during long travel.

JOINT INFECTION

Definition: Bacterial joint infection, infected bursitis, septic arthritis, septic joint; may result from penetrating trauma (such as animal bites or shrapnel).

S/S: History of adjacent penetrating trauma or infection; single red, swollen joint; fever; pain with axial load; inability to straighten/flex joint.

MGMT: 1. IMMOBILIZE THE JOINT. 2. Gain IV access. 3. For Septic Joint: Ceftriaxone 2 gm IV / IM bid **OR** Ertapenem 1 gm IV / IM qd; For Septic Bursitis: Treat per *Cellulitis* protocol with Clindamycin. 3. Treat per *Pain Management* protocol.

Disposition: *Priority* evacuation

Special Considerations: 1. May result from penetrating trauma (especially animal or human bites), gonorrhea, or iatrogenic causes (i.e. attempted aspiration of joint effusion). 2. Consider also an acute joint effusion due to blunt trauma or overuse (usually less red and no fever).

LACERATION

Definition: Laceration

S/S: Simple uncomplicated laceration of skin without involvement of deeper structures.

MGMT: 1: Irrigate and clean wound thoroughly. 2. Prepare area in sterile fashion. 3. Provide local anesthesia with 1% Lidocaine with or without epinephrine depending on site. 4. Close with absorbable suture, non-absorbable suture, dermabond, or steri-strips as dependent on depth of wound. 5. If dirty wound or environment, antibiotics should be considered. 6. Check tetanus status and treat as needed; do not suture if wound is >12 h old (>24 h on face), or if puncture/bite wound. 7. Non-absorbable sutures should be removed in 7-10 days. Most animal bites should not be closed with suture, consult a provider on when to close lacerations from animal bites. After sutures, place a dressing with antibiotic cream and do not soak in water while sutures are in place, keep dry for 24-48 hrs.

Disposition: Evacuation usually not required.

LOSS OF CONSCIOUSNESS (WITHOUT SEIZURES) / SYNCOPE

Definition: The most common cause of loss of consciousness in healthy adults is orthostatic hypotension (associated with sudden standing) or vasovagal syncope (associated with sudden adverse stimulus – injections are a common cause).

S/S: Unconsciousness

MGMT: 1. If no respirations or pulse, follow BLS guidelines. If associated with trauma (blast, fall, MVA, etc...) in last 14d, then manage per mTBI protocol. 2. Management of orthostatic hypotension and vasovagal syncope is accomplished by placing the patient in a supine position, ensuring the airway is open. Patients experiencing these two disorders should regain consciousness within a few seconds. If they don't, consider other etiologies and proceed to the steps below. 3. Place either 1 tube oral glucose gel or contents of one packet of sugar in buccal mucosal region (DO NOT use oral glucose if patient remains unconscious). 4. Gain IV access. 5. Naloxone 2mg IV / IM. Repeat q 2 – 3 min prn to max dose of 10mg. 6. If no response treat per appropriate Protocol per Special Considerations. 7. Pulse oximetry monitoring. 8. Oxygen if available.

Disposition: *Urgent* evacuation, unless loss of consciousness clearly due to orthostatic hypotension or vasovagal hypotension. The evacuation package should include personnel certified in Advanced Cardiac Life Support (ACLS), with equipment, supplies and medications necessary for ACLS care.

Special Considerations: Also consider hypoglycemia, anaphylactic reaction, medication, recreational drug use, head trauma, hyperthermia, hypothermia, myocardial infarction, lightning strikes, and intracranial bleeding. Obtain ECG if able in all undifferentiated syncope patients.

MALARIA

Definition: Protozoan infection transmitted by the female Anopheles mosquito; prevention through personal preventive measures is the key (anti-malarial meds, DEET, permethrin, bed nets, and minimized skin exposure).

S/S: Hx of travel to malaria-endemic area; non-compliance with anti-malarial medications and/or personal preventative measures. Prodrome of malaise, fatigue, and myalgia may precede febrile paroxysm by several days; paroxysm characterized by abrupt onset of fever, chills, rigors, profuse sweats, HA, backache, myalgia, abdominal pain, nausea, vomiting, diarrhea (may be watery and profuse) in *P. Falciparum*; intermittent or continuous fever in *P. Falciparum* malaria; classic "periodicity" is usually absent. Profuse sweating between febrile paroxysms; tachycardia, orthostatic hypotension, tender hepatomegaly, and delirium (cerebral malaria).

MGMT: If available, test with rapid assay test (BinaxNow NSN 6550-08-133-2341) or blood smear or if limited lab capability, CBC looking for anemia and low platelets. If unavailable and malaria is suspected, treat empirically. Can use Acetaminophen 1000mg q 6 hrs prn for fever. Do not use same treatment as was used for prophylaxis. If any treatments are started medics must contact a medical officer.

1. Malarone (atovaquone 250mg/proguanil 100mg) 4 tabs po qd x 3 consecutive days with food or milk **OR** 2. Coartem(artemether 20mg/lumefantrine 120mg) one tab initial dose, 8 hrs later repeat single dose, then one dose po bid for following 2 days with food or milk **OR** 3. Quinine sulfate 542 mg base po tid for 3-7 days PLUS Doxycycline 100mg po bid for 7 days **AND if known Chloroquine-resistant use:** option 1. or 3. and **ADD** Primaquine phosphate 30 mg (can cause hemolytic anemia in G6PD deficiency) base po qd x 14days as well.

Disposition: *Urgent* treatment and evacuation for complicated malaria (cerebral/Altered Mental Status, pulmonary changes with fever, or abnormal vital signs) these indicate a medical emergency. *Priority* evacuation for uncomplicated cases (normal vital signs, normal mental status, no nausea and vomiting, no cough/ shortness of breath).

Special Considerations: 1. Malaria **MUST** be considered in all febrile patients currently in or recently returned in, a malarious area. 2. It is not uncommon for malaria to present like pneumonia or gastroenteritis (with vomiting and diarrhea). 3. It is appropriate to treat suspected malaria cases empirically if diagnostic test (blood smears or rapid test) are not available. 4. However, the BinaxNow rapid Diagnostic test is now FDA approved and should be used, if available, to guide treatment selection. 5. The use of chemoprophylaxis does not rule out malaria. 6. Consider bacterial meningitis in evaluating the patient- treat for both disorders if meningitis is suspected. 7. Patients who cannot tolerate PO meds **MUST** be evacuated.

MENINGITIS

Definition: Inflammation of the meninges and spinal cord by bacterial, viral, or fungal agents.

S/S: Classic features include: severe headache, high fever, pain with any neck movement (particularly forward flexion), altered mental status; may also include: photophobia, nausea and vomiting, malaise, seizures; positive Brudzinski (pain on head and neck flexion, causing hips/knees to flex) and Kernig's (neck pain with hip flexion and knee extension) signs. May have petechiae in meningococemia (mask and gown PPE if suspected)

MGMT: 1. If meningitis is suspected, treatment should be initiated immediately. 2. Gain IV access. 3. Dexamethasone 10 mg IV / IM q 6 hr. 4. Ceftriaxone 2 gm IV q 12 hr (IM route possible alternative but prefer IV route). 5. Treat per *Pain Management* protocol. 6. Treat per *Nausea and Vomiting* protocol. 7. If seizures occur, treat per *Seizure* protocol. 8. For prophylaxis of close contacts: Ciprofloxacin 500 mg PO single-dose **OR** Rifampin 600mg PO bid for 2 days **OR** Ceftriaxone 250 mg IM once.

Disposition: Urgent evacuation.

Special Considerations: 1. May be bacterial, viral, or fungal. The bacterial type may cause death in hours, even in previously healthy young adults, if not treated aggressively with appropriate antibiotics. 2. Consider malaria as a differential diagnosis. Treat for both if malaria cannot be ruled out.

MOTION SICKNESS & PREVENTION

Definition: Not a true sickness, but a normal response to a situation in which sensory conflict about body motion exists among visual receptors, vestibular receptors, and body proprioceptors. Referred to as air sickness, car sickness, sea sickness, and physiologic vertigo.

S/S: Nausea; vomiting; diaphoresis; pallor; hypersalivation; yawning; hyperventilation; anxiety; panic; malaise; fatigue; weakness; confusion; dizziness.

MGMT: PREVENTION: 1. Meclizine 25 mg PO taken 30-60 min before travel and bid **OR** 1 X Scopolamine Transdermal Patch 1.5 mg behind ear up to 4h prior to travel. 2. If possible, sit in middle of plane/boat or fix vision on horizon while avoiding fixation on moving objects. 3. Minimize food intake before travel and increase airflow around face.

MANAGEMENT: 1. Manage as per *Nausea and Vomiting* protocol. 2. For severe responses or vertigo, consider Midazolam 1-2 mg IV q6-12h.

Disposition: Evacuation not required unless individual's performance becomes a risk to mission, self or others. Consider routine evacuation or complete re-evaluation if S/S do not alleviate <24h after last motion travel.

Special Considerations: 1. Ensure differential diagnosis from altitude illness, gastroenteritis, central neurologic cause or stroke (evaluate and treat per ACLS guidelines), and toxin exposure. 2. All above medications may cause drowsiness and should be considered for mission impacts.

NAUSEA AND VOMITING

Definition: Nausea and vomiting usually as a result of underlying medical condition and managed in conjunction with other protocol.

S/S: Nausea and Vomiting

MGMT: 1. Ondansetron 4 – 8 mg IV/IM/SL or 8 mg PO q4h prn **OR** Promethazine 25 mg IV/IM/PO q6h prn **OR** Diphenhydramine 25 – 50 mg IV/IM/PO q6h prn. 2. Treat per *Dehydration* protocol. 3. Use in conjunction with appropriate protocols.

Disposition: Evacuate per Protocol for underlying condition.

Special Considerations: 1. Avoid rapid IV administration of promethazine. 2. **DO NOT** give subcutaneous promethazine. 3. Diphenhydramine and promethazine may cause drowsiness therefore not recommended during combat operations or training.

OTITIS EXTERNA (OUTER EAR INFECTION OR SWIMMER'S EAR)

Definition: Bacterial or fungal infection of external ear canal, "swimmer's ear".

S/S: Ear pain and pain with passive ear movement, tragus swelling, erythema, pruritis in area; possible exudate and erythema in ear canal, decreased auditory acuity, sensation of fullness and moisture in ear.

MGMT: 1. If external canal exudate is present, Ofloxacin Otic 0.3% 10 drops in affected ear daily for 7-10 days **OR** Gatifloxacin Ophthalmic 0.3% 5 drops tid – qid for 7-10 days (for both - administer while awake and laying on unaffected side for at least 5 minutes); ophthalmic used to minimize meds carried. 2. Place sterile dry dressing wick into ear canal to keep canal open and allows meds to reach inner canal with canal edema. 3. Acetaminophen 1000mg PO q6h prn pain, 4. No internal hearing protection until resolution. 5. If no response or worsens, treat with Ciprofloxacin 750 mg PO bid and urgent evacuation (concern for malignant otitis externa).

Disposition: For uncomplicated cases, no evacuation is necessary. *Urgent* evacuation for complicated cases not responding to therapy or if condition worsens despite 12-24h of treatment with ciprofloxacin.

OTITIS MEDIA (MIDDLE EAR INFECTION)

Definition: Eustachian tube dysfunction, viral infection, or bacterial infection of middle ear.

S/S: Ear pain, +/- fever, decreased hearing, sensation of ear fullness; erythema and bulging of TM are hallmark signs but loss of landmarks typically seen in adults, increased pressure may cause TM rupture and discharge; often noted with accompanying URI symptoms, recent air travel, or recent ascent to altitude.

MGMT: 1. Acetaminophen 1000mg PO q6h **AND/OR** Ibuprofen 800mg PO tid prn pain **AND** Pseudoephedrine 60 mg qid. 2. Oxymetazoline nasal spray 2 squirts per nostril bid (max 3 days). 3. If grossly apparent, or no resolution in 1-2 d, or bacterial, then add antibiotics: Amoxicillin/Clavulanate Acid 875/125 mg PO bid X 10d **OR** Azithromycin 500 mg PO initially followed by 250 mg PO qd x 4 days **OR** Ceftriaxone 250 mg IM single-dose.

Disposition: For uncomplicated cases, no evacuation is necessary. *Routine* evacuation for complicated cases not responding to therapy.

Special Considerations: 1. Increased pressure in the middle ear may cause intense pain and may result in rupture of the tympanic membrane (characterized by sudden decrease in pain and drainage from ear canal). 2. If water immersion is anticipated, use ear plugs to prevent cold water entry which will cause vertigo.

PHARYNGITIS (ORAL PHARYNGEAL INFECTIONS INCLUDING VIRAL, STREP, EPIGLOTTITIS, PERITONSILLAR ABSCESS, MONONUCLEOSIS)

Definition: Inflammation of the fauces and pharynx leading to sore throat or discomfort swallowing and/or talking due to multiple etiologies. Most common causes in young healthy patients include viral URIs, Group A Beta Hemolytic Strep (GABHS) pharyngitis, odontogenic (dental origin), cutaneous sources or post-injury (wound or fracture) infections.

S/S: GABHS Pharyngitis: Pain, fever, malaise, absence of cough, odynophagia, tonsillar exudates, tender cervical adenopathy.
Peritonsillar Abscess: Pain, possibly unilateral sore throat, fever, malaise, trismus, odynophagia, muffled voice (hot potato voice), unilateral tonsillar enlargement, unilateral uvula deviation to unaffected side.
Epiglottitis: Sore throat, odynophagia, fever, muffled voice, drooling, stridor, hoarseness, dyspnea (less common in adults), tripod/sniffing position, oral cavity/oropharynx normal in most patients, pooled secretions, laryngotracheal complex tender to palpation (particularly in the hyoid region).
Mononucleosis: triad of fever/tonsillar pharyngitis/lymphadenopathy; fatigue and possibly LUQ pain to splenomegaly (seen in 50-60% of patients).
Viral (Non-GABHS): S/S of URTI with no red flags of other etiologies.

MGMT:

GABHS Pharyngitis: 1. Evaluate and treat IAW CENTOR Criteria (Exudate on Tonsils, Fever, No Cough, Anterior Cervical Lymphadenopathy). 2. Treat empirically for 3 or greater S/S CENTOR criteria with Benzathine-Penicillin-G 1.2 million units IM once (if available) **OR** Penicillin 500mg PO qid for 10 days. If 2 or less S/S CENTOR criteria, then treat symptomatically per *non-GABHS management*.

PERITONSILLAR ABSCESS: 1. If potential for airway compromise, *Urgent* evacuation for surgical intervention. 2. Needle aspiration IF TRAINED with priority evacuation. If not trained, and no airway compromise, then *Priority* evacuation. Continue to treat symptomatically and with Clindamycin 450mg PO tid **OR** Amoxicillin/Clavulanate 875mg bid for 10 days.

EPIGLOTTITIS: 1. Manage airway and breathing first IAW *Airway Management* protocol (avoid airway manipulation if possible). 2. Place patient in position of comfort. 3. Monitor pulse oximetry. 4. Oxygen prn if possible. 5. Gain IV access. 6. Ceftriaxone 1 gm IV/IM qd for 7 days **AND** Clindamycin 600 mg IV q6h **OR** Clindamycin 300-450 mg PO q6h X 7d. 7. Treat per *Pain Management* protocol. 8. Consider Dexamethasone 10mg IV for any airway involvement.

MONONUCLEOSIS: 1. Treat per URI protocol. 2. Profile for no high-impact physical training, sports, jumping/FRIES X 6 wks if able to confirm no splenomegaly on ultrasound to prevent splenic rupture; No corticosteroids.

Viral (Non-GABHS): *Treat per Upper Respiratory Tract Infection.*

Disposition: *Urgent* evacuation if any airway compromise is present. *Routine* evacuation if no airway compromise and the infection is not widespread.

Special Considerations: 1. These infections may progress rapidly from minor to airway/life-threatening.

PNEUMONIA

Definition: Acute lung (pulmonary parenchyma) infection due to virus, mycoplasma, or other bacteria

S/S: Fever >100.4, chills, productive cough (dark yellow, green, red tinged), chest pain with breathing (pleuritic), malaise, wheezes, rhonchi and/or rales, decreased breath sounds (may be absent over affected lung), dyspnea, tachypnea, shortness of breath, tachycardia, possible decrease in pulse oximetry, egophony, bronchophony and tactile fremitus.

MGMT: 1. Acetaminophen 1000mg PO q6h prn pain/fever. 2. Doxycycline 100mg PO bid x 10 d **OR** Azithromycin 500mg PO day 1 then 250mg PO days 2-5 **OR** Moxifloxacin 400mg PO daily x 5d; if unable to tolerate PO or severe, start with Ceftriaxone 2gm IM/IV q12h **OR** Ertapenem 1g IV/IM daily, then oral antibiotic regimen. 3. Albuterol MDI 2 puffs qid prn wheezing, 4. Increase PO hydration. 5. Pulse oximetry, 6. Oxygen if indicated, 7. If at altitude > 8000 ft, descend 1,500 – 3,000 feet; differential diagnosis should include HAPE, PE, and pneumothorax. Ensure smoking cessation and enforce hydration. Consider throat lozenges for accompanying pharyngitis.

Disposition: *Urgent* evacuation for severe dyspnea or hypoxia. *Observation or Routine evacuation* as necessary.

Special Considerations: Consider high altitude pulmonary edema (HAPE) at high altitudes. Consider pulmonary embolism (PE) and pneumothorax (fever and productive cough are atypical for these).

PULMONARY EMBOLISM (PE)

Definition: Usually occurs when leg DVT dislodges and enters pulmonary arterial circulation.

S/S: Acute onset of dyspnea, tachypnea, tachycardia, localized chest pain, anxiety, diaphoresis (sweating), decreased oxygen saturation, full breath sounds with no wheezing, no prominent cough, and low-grade fever; usually preceded by DVT with lower extremity pain, swelling, and tenderness with history of trauma, air travel, or long periods in sitting positions.

MGMT: Use a risk stratification tool such as PERC or Wells. PERC negative if age<50, HR<100, SpO₂>95%, no leg swelling, no hemoptysis, no recent surgery/trauma, no prior PE/DVT, and no hormone use (testosterone or birth control) 1. Monitor with pulse oximetry and provide oxygen (if available), 2. Aspirin 325mg chew 2 tabs, 3. Treat per *Pain Management* protocol. 4. Consider Myocardial Infarction and treat as per *Chest Pain* protocol, 5. If at altitude > 8,000ft, descend 1500–3000 ft as per *HAPE* protocol.

Disposition: *Urgent* evacuation

RABIES POST-EXPOSURE PROPHYLAXIS

Description: A RNA virus transmitted through the saliva of an infected animal by biting, licking of an abrasion/wound, or contact with mucosa.

Hx: Hx of being bitten/licked by potentially infected dogs, bats, raccoons, coyotes, foxes, skunks, cats, horses, cows, sheep or around aerosolized excrements of bats.

S/S: Incubation period: Incubation in humans typically 4 days-3 months. Period can be shorter if bitten in the face or bitten by an animal with a high viral count in its saliva. PT will have intense pruritis, pain, paresthesia at the bite sight, malaise, fatigue, HA, fever, anorexia, apprehension, anxiety, insomnia, depression. Classical rabies patients will progress into coma ending with death.

MGMT: 1. If suspected bite from infected animal. Evacuate at earliest opportunity for vaccine but absolutely within 48 hours. 2. Initially debride, vigorously clean, and copiously irrigate the wound using iodine solution which will increase the efficacy (vaccine failures are associated with poor wound care). 3. Give Tetanus booster 4. IF PRE- IMMUNIZED, Purified Chick Embryo Cell (PCEC) vaccination 2 doses 1.0cc IM day 0 and 3. IF NOT PRE-IMMUNIZED, inject Human Rabies Immunoglobulin around the site and remaining (<50%, not able to be injected around wound) Deep IM distant from vaccine site. **Also**, 4 doses of PCEC IM in deltoid Day 0, 3,7,14.

Special Considerations: Rabies is a universally fatal disease. Rabies virus can live dormant in bat feces; so exercise caution when going into caves. Bat bites often are unnoticed. They may only manifest by small abrasions with prolonged bleeding. If there is a suspected bat bite or PT awakens with bat in room; consider evacuation for vaccine and HRIG.

RECTAL BLEEDING

Definition: Bleeding per rectum.

S/S: Bright red blood per rectum. Anal pain with defecation usually indicates hemorrhoids or anal fissures. Significant bleeding can result in hypotension. Red flags include dark/tarry stools (melena), abdominal pain, postural hypotension, fever, weight loss.

MGMT: Obtain vitals. If hemodynamically stable, perform rectal exam in an attempt to identify external source of bleeding. If hemorrhoid or anal fissure is identified as source of bleeding, treat conservatively with increased fiber intake and topical creams. If hemodynamically unstable, continue to monitor, volume resuscitate as needed, and evacuate to higher care.

Disposition: *Urgent* evacuation if hemodynamically unstable or there is persistent significant bleeding. Priority evacuation if red flags are present.

Special Considerations: Certain medications (iron supplements, Bismuth subsalicylate [Pepto-Bismol]) can cause dark stools that may be mistaken for melena.

RHABDOMYOLYSIS

Definition: Breakdown or necrosis of skeletal muscle cells that release cellular contents into the circulation. Typical causes: Limb ischemia, carbon monoxide poisoning, electrical or thermal burns, blunt trauma or crush injury, snake Bite, hyperthermia, hypothermia, and physical exertion.

S/S: Acute muscle pain (myalgias); muscle weakness; fever; malaise; nausea or vomiting; tea-colored urine; oliguria/anuria; dipstick positive for blood, but no intact RBC on a spun specimen (due to myoglobin in urine).

MGMT: Aggressive hydration is the cornerstone of treatment. 1. Crystalloid solution 1-2 L bolus IV/IO followed by 500 ml - 1 L per hour. Avoid Ringer's lactate due to the potassium content. *Titrate fluids to achieve target urine output of >200 ml/hour.* 2. Monitor intake/output hourly. 3. If unable to monitor due to clinical condition, insert Foley catheter to facilitate measuring urine output. 4. Reassess vital signs and mental status frequently. Utilize cardiac monitoring if available.

Potential Problems / Complications: A. Monitor for signs and symptoms of hyperkalemia (cardiac dysrhythmia): administer 1 gm calcium and 40 mEq sodium bicarbonate (1 ampule) IV/IO. B. Persistent oliguria despite adequate fluid resuscitation. C. Avoid loop diuretics such as furosemide, which may increase myoglobin precipitation in kidneys and provoke acute renal failure. D. Compartment syndrome: see Compartment Syndrome protocol Protocols

Disposition: *Priority* evacuation

SEPSIS / SEPTIC SHOCK

Definition: Severe life-threatening condition resulting from the presence of harmful microorganisms in the blood or other tissues and the body's response to their presence, potentially leading to the malfunctioning of various organs, shock, and death.

S/S: Hypotension; fever; tachycardia; altered mental status; dyspnea

MGMT: Do not attempt to treat without contacting a Medical Officer. 1. Obtain IV/ IO access. 2. Ertapenem 1 gm IV / IO qd **OR** Ceftriaxone 2 gm IV / IO. 3. If patient is hypotensive, give 1 liter crystalloid solution fluid bolus. Consider additional fluids if still hypotensive, then an additional liter titrated to maintain systolic blood pressure >90mmHg or palpable radial pulse. 4. Maintain aggressive fluid management, Epinephrine 10mcg in large IV q5-15 min if persistent hypotension despite >2L IVF boluses. Initiate evacuation. 5. Monitor for decreased mental status and be prepared to manage airway.

Disposition: *Urgent* evacuation

Special Considerations: 1. Ensure complete medical history and documentation of any preceding events are sent to Medical provider.

SMOKE INHALATION

Definition: Common after closed space exposure to fire; consider airway burns, carbon monoxide poisoning, other toxin inhalation, and need for hyperbaric oxygen.

S/S: History of smoke exposure; burns (singled nares, facial burns); coughing; stridor; +/- carbaceous sputum; respiratory distress (may be delayed in onset).

MGMT: 1. Remove from environmental exposure and allow patient to rest. 2. Administer oxygen if available. 3. Refer to Airway Management Protocol and consider the use of early cricothyroidotomy if airway burns/ edema or singled nasal hair, facial burns are present/ suspected. 4. Albuterol by metered dose inhaler 2 – 4 puffs q1h or nebulizer if available. 5. Dexamethasone 10 mg IV/IM qd. 6. Patient exertion will exacerbate symptoms and should be avoided.

Disposition: *Urgent* evacuation for respiratory distress, suspected inhalation burns. *Priority* evacuation if not in distress but significant inhalation suspected.

Special Considerations: 1. Consider possible carbon monoxide (CO) poisoning and need for hyperbaric oxygen in all significant cases of smoke inhalation. 2. Normal oxygen saturation by pulse oximetry DOES NOT rule out the possibility of CO poisoning. 3. Consider Cyanide poisoning or co-existing trauma in hypotensive burn patient.

SPONTANEOUS PNEUMOTHORAX

Definition: Acute onset of pneumothorax usually without obvious or known chest trauma.

S/S: Spontaneous unilateral chest pain; Dyspnea – typically mild; No wheezing; Cough; Decreased or absent breath sounds on affected side

MGMT: 1. Pulse oximetry monitoring. 2. Oxygen if available (use oxygen for all suspected spontaneous pneumothoraces). 3. **Consider needle decompression for suspected tension pneumothorax.** 4. If needle decompression allows for patient improvement, followed by worsening of condition, consider repeat needle decompression. 5. Consider tube thoracostomy if recurrence of respiratory distress after 2 successful needle decompressions **OR** Evacuation time > 1 hr **OR** Patient requires positive pressure ventilation. 6. If at altitude, descend as far as tactically feasible. 7. If evacuation will occur in an unpressurized aircraft, consider decompression for high altitude evacuation and recommend lowest tactically feasible altitude. 8. Treat per *Pain Management Protocol*.

Disposition: *Urgent* evacuation for significant respiratory distress despite therapy. *Priority* evacuation for patients whose respiratory status is stable.

Special Considerations: 1. Consider also: anaphylaxis, pulmonary embolism, high altitude pulmonary edema (HAPE), asthma, myocardial infarction and pneumonia. 2. More common in tall, thin individuals and smokers.

SUBUNGAL HEMATOMA

Definition: Collection of blood under the nail; typically occurs after trauma to fingernail or toenail.

S/S: Pain and purplish-black discoloration under nail.

MGMT: DO NOT DRAIN IF NO PAIN or if suspected underlying fracture. 1. Decompress the nail with a large gauge needle or electrocautery by rotating needle through the nail directly over the discolored area until the underlying blood has been released and the pressure is relieved. Make sure that it is introduced into the affected nail with a gentle but sustained rotating motion. 2. Gentle pressure on the affected nail and absorbing/wicking with alcohol swabs may help to evacuate more blood. 3. Treat per *Pain Management* protocol. 4. If a fracture is suspected, tape the injured finger or toe to an adjacent digit. 5. If fracture is suspected in a setting of a subungual hematoma, give Moxifloxacin 400 mg PO qd for 7 days.

Disposition: Evacuation should not be required for this injury if the subungual hematoma is successfully treated and healing does not hinder mission performance.

TESTICULAR PAIN

Definition: Testicular pain due to torsion, epididymitis, orchitis, STDs, hernias, masses, and trauma.

S/S: Testicular Torsion: Sudden onset testicular pain; usually associated with activity; associated testicular swelling; abnormal position of the affected testicle; symptoms may be increased by testicular elevation; usually associated with pain induced nausea and vomiting;

Loss of cremasteric reflex is the best diagnostic indicator for testicular torsion.

Epididymitis: Gradual onset of worsening pain; may have fever and/or dysuria; can also be traumatic; symptoms may be relieved with elevation; significant swelling may be present.

MGMT: 1. If pain is sudden onset and the testicle is lying abnormally in the scrotum, an attempt to manual detorse the testicle is warranted. A single attempt to rotate the testicle outward (like opening the pages of a book) should be made. If pain increases, 1 attempt to rotate the opposite direction should be made. Successful detorsion will result in relief of pain. 2. Gradual onset pain with a normal lying testicle should be treated per *Urinary Tract Infection* protocol. 3. Treat pain per *Pain Management* protocol. 4. Treat per *Nausea and Vomiting* protocol.

Treat Epididymitis with sexually transmitted infection treatment. 1. Ceftriaxone 250mg IM x1 and Azithromycin 1gm PO x1.

Disposition: *Urgent* evacuation for testicular torsion. For other causes of testicular pain, treat cause and consider evacuation if symptoms persist more than 3 days.

Special Considerations: 1. The primary concern in testicular pain is differentiating testicular torsion from other causes of testicular pain. 2. Testicular torsion is a medical emergency requiring urgent correction to prevent loss of the affected testicle. 3. Other common causes of testicular pain include epididymitis and orchitis, infections commonly caused by STDs, as well as hernias and testicular masses. 4. Consider testicular cancer and further evaluation in cases with persistent mass.

UPPER RESPIRATORY INFECTION / COMMON COLD

Definition: Inflammation of nasal passages due to a respiratory virus

S/S: Nasal Congestion; sneezing; post nasal drainage; sore throat; cough; hoarseness; malaise; headache; low-grade fever; bodyache; fatigue

MGMT: 1. Increase PO hydration. 2. Acetaminophen 1000mg PO q6h AND/OR Ibuprofen 800mg PO q8h. 3. Treat symptomatically with Pseudophedrine 60 mg PO q6h **OR** Fexofenadine 60mg/Pseudophedrine 120mg PO bid **OR** Loratadine 10mg/Pseudophedrine 120mg PO qd. 4. Consider Oxymetazoline 2-3 sprays each nostril bid (not to exceed 3 days). Lozenges for sore throat.

Disposition: Evacuation usually not required. Monitor for worsening conditions.

URINARY TRACT INFECTION

Definition: Infection of urinary tract; more common in females, tactical setting, dehydration, kidney stones.

S/S: Dysuria; Increased urinary urgency and frequency; cloudy, malodorous, or dark urine may be present; suprapubic discomfort; normally no CVAT/back/flank pain; normally no fever, hx of STD exposure.

MGMT: 1. If <35y/o treat for sexually-transmitted infection, Ceftriaxone 250mg IV/IM x1 **AND** Azithromycin 1 gm PO x1. 2. For others, Cephalexin 500 mg PO qid X 7-10d **OR** Trimethoprim-Sulfamethoxazole 1 PO bid for 7-10 days in males (bid for 5-7d or 3-5d respectively in females). 3. Treat per *Pain Management* protocol. 4. If fever, back pain, flank pain, and/ or costovertebral angle tenderness develop, suspect kidney infection and treat per *Flank Pain* protocol. 5. Encourage PO hydration.

Disposition: Usually responds to therapy and evacuation not required if it does. *Routine* evacuation for worsening signs and symptoms. *Priority* evacuation for pyelonephritis (See *Flank Pain Protocol*).

Special Considerations: 1. More common after instrumentation, in females, or in tactical settings with dehydration and/or kidney stones. 2. Symptoms may be confused with a sexually transmitted disease (STD).

Notes:



Notes:



SECTION FOUR

**RANGER MEDIC
PHARMACOLOGY
&
FORMULARY**



XX. LEVEL 1 - PROFICIENT AND ALWAYS CARRIED

Level 1 pharmaceuticals designated as “Proficient and Always Carried” are those drugs that a Ranger Medic carries on virtually all assault missions. A Ranger Medic is expected to know the Class, Dose, Indications, Significant Contraindications, Significant Side Effects, Mission Impacts, and K9 dosages of these medications at all times.

This category is within the expected knowledge base for a Ranger Medic to be considered Basic Mission Qualified (BMQ). A medic must demonstrate proficiency in these medications through the Ranger Medic Assessment & Validation (RMAV) to be considered BMQ.

Level 1 - Proficient and Always Carried drugs are designated by bolded lines.

XX. LEVEL 2 – PROFICIENT

Level 2 pharmaceuticals designated as “Proficient” are those drugs that a Ranger Medic administers as directed by standing Ranger Protocols. A FMQ Ranger Medic is expected to know the Class, Dose, Indications, Significant Contraindications, Significant Side Effects, Mission Impacts, and K9 dosages of these medications at all times.

This category is the within the expected knowledge base for a Ranger Medic to be considered Full Mission Qualified (FMQ). A medic must demonstrate proficiency in these medications through the Ranger Medic Assessment & Validation (RMAV) to be considered FMQ.

Level 2 - Proficient drugs are designated by solid lines.

XX. LEVEL 3 – FAMILIAR

Pharmaceuticals designated as “Familiar” are those drugs that a Ranger Medic administers as directed by specific protocols or require familiarization for contingency health management. A Ranger Medic is expected to be familiar the Class, Dose, Indications, Contraindications, Side Effects, Mission Impacts, and K9 dosages of these medications. The Ranger Medic Handbook is a reference for the rare use of these medications.

This category is the within the familiarization expectation for a Ranger Medic to be considered Full Mission Qualified Plus (FMQ+). A medic must demonstrate familiarization with these medications through the Ranger Medic Assessment & Validation (RMAV) to be considered FMQ+.

Level 3 - Familiarization drugs are designated by hyphenated lines and the drug title is not shaded.

XX. MISSION IMPACTS

Certain drugs in all categories have very specific mission impacts. Some are directly related to mission performance while others serve as a warning for potential mission impacts.

Specific drugs are categorized as “grounding” for any aviation personnel or for Rangers to conduct in-flight operations. Aviation grounding status also is grounding status for Rangers performing military free-fall operations. REMINDER: Any flight or MFF personnel grounded due to medication use or a medical condition MUST be cleared by a flight surgeon or an aeromedical physician assistant before returning to flight/MFF status.

Mission Impact drugs are designated by the helicopter/warning symbol.



This list of pharmaceuticals is as of the current publication date of the Ranger Medic Handbook. Rangers Medics will adhere to current list as it is updated.

RULES OF DRUG ADMINISTRATION

Unless specifically noted, the drug dosages listed are for an adult.

ALWAYS DETERMINE IF THE PATIENT HAS ANY ALLERGIES TO MEDICATIONS BEFORE ADMINISTRATION

Reversals: For opioids, always have nalaxone ready to administer. For benzodiazapines, always have flumazenil ready to administer.

Antibiotics: If allergic to one class of medications, use alternate class of medications (Cephalosporins/Penicillins, Tetracyclines, Quinolones, Macrolides).

| | |
|------------------|---|
| RIGHT PATIENT | CHECK FOR CONTRAINDICATIONS |
| RIGHT INDICATION | CHECK FOR POTENTIAL INTERACTIONS |
| RIGHT DRUG | BE PREPARED FOR POTENTIAL SIDE EFFECTS |
| RIGHT DOSE | UNDERSTAND THE PHARMACOKINETICS OF YOUR ACTIONS |
| RIGHT ROUTE | |
| RIGHT TIME | |

DOCUMENTATION: Document on casualty card or SF600 all drugs administered (type, dose, route) to include outcomes or reactions.

SAFETY IN PREGNANCY

Pregnancy Category A- Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).

Pregnancy Category B- Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Pregnancy Category C- Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Pregnancy Category D- There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Pregnancy Category X- Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.

IV FLUID RATES IN DROPS PER MINUTE

| | | | | | | | | | |
|---------------|-----------|-----------|-----------|------------|------------|------------|------------|------------|------------|
| ml/HR | 50 | 75 | 80 | 100 | 125 | 150 | 175 | 200 | 250 |
| 10GTT- | 8 | 13 | 13 | 17 | 21 | 25 | 29 | 33 | 42 |
| 15GTT- | 12 | 19 | 20 | 25 | 31 | 37 | 44 | 50 | 62 |
| 60GTT- | 50 | 75 | 80 | 100 | 125 | 150 | 175 | 200 | 250 |

ACETAMINOPHEN (TYLENOL)

Class: CNS agent – non-narcotic, analgesic, antipyretic

Action: Analgesia action possibly through peripheral nervous system; fever reduction through direct action on hypothalamus heat-regulating center resulting in peripheral vasodilation, sweating, and dissipation of heat; has minimal effect on platelet aggregation, bleeding time, and gastric bleeding

DOSE: 325–975 mg PO q6h (max: 4 g/d)

ONSET/PEAK/DURATION: Onset Varies / Peak 1-3 hours / Duration 3-4 hours

Indications: For mild to moderate pain management, headache, fever reduction

Contraindications: Acetaminophen hypersensitivity; use with alcohol; pregnancy category B

Adverse/Side Effects: Negligible with recommended dose; rash; acute poisoning: anorexia, nausea, vomiting, dizziness, lethargy, diaphoresis, chills, epigastric or abdominal pain, diarrhea; hepatotoxicity: elevation of liver function tests; hypoglycemia, hepatic coma, acute renal failure; chronic ingestion: neutropenia, pancytopenia, leukopenia, thrombocytopenic purpura, renal damage

Interactions: Cholestyramine may decrease absorption; barbiturates, carbamazepine, phenytoin, rifampin, and excessive alcohol use may increase potential for hepatotoxicity

Mission Impact: None to minimal mission impact

K-9 Dosage: DO NOT GIVE

ACETAZOLAMIDE (DIAMOX)

Class: CNS Agent – carbonic anhydrase inhibitor; diuretic, anticonvulsant

Action: Diuretic effect due to inhibition of carbonic anhydrase activity in proximal renal tubule, preventing formation of carbonic acid; anticonvulsant action effect thought to involve inhibition of CNS carbonic anhydrase, retarding abnormal paroxysmal discharge from CNS neurons, decreases production of aqueous humor

DOSE: *Altitude Illness:* Prevention: PO 125 mg BID; begin the day before the ascent, may discontinue if staying at same altitude for 2-3 days or if descending. Treatment: PO 250 mg BID, **note:** With high altitude cerebral edema, dexamethasone is the primary treatment; however, acetazolamide may be used adjunctively with the same treatment dose

Indications: For acute high-altitude sickness, seizures, drug-induced edema, and for CHF edema

Contraindications: Sulfonamide and thiazide hypersensitivity; marked renal and hepatic dysfunction; adrenocortical insufficiency; hyponatremia, hypokalemia, hyperchloremic acidosis; pregnancy category C

Adverse/Side Effects: Paresthesias, sedation, malaise, disorientation, depression, fatigue, muscle weakness, flaccid paralysis; anorexia, nausea, vomiting, weight loss, dry mouth, thirst, diarrhea; agranulocytosis, bone marrow depression, hemolytic anemia, aplastic anemia, leukopenia, pancytopenia; hyperglycemia; hyperuricemia; increased calcium, potassium, magnesium, sodium excretion; gout exacerbation, dysuria, glycosuria, urinary frequency, polyuria, hematuria, crystalluria; metabolic acidosis; hepatic dysfunction

Interactions: Renal excretion of amphetamines, ephedrine, flecainide, quinidine, procainamide, TCAs may be decreased, thereby enhancing or prolonging their effects; renal excretion of lithium and phenobarbital is increased; amphotericin B and corticosteroids may accelerate potassium loss; increased risk for salicylate and digitalis toxicity

Mission Impact: **GROUNDING** medication for personnel on flight status

K-9 Dosage: Give only if indicated/directed for human use. 250mg q12h beginning 24h prior to ascent OR 500mg q24h.



ACETYLSALICYLIC ACID (ASPIRIN)

Class: NSAID; salicylate; anti-inflammatory, analgesic, antipyretic

Action: Inhibits prostaglandin synthesis involved in the production of inflammation, pain, and fever; enhances antigen removal and reduces spread of inflammation; peripheral analgesic action with limited CNS action in the hypothalamus; antipyretic by indirect centrally mediated peripheral vasodilation and sweating; powerfully inhibits platelet aggregation and ability of blood to clot; high levels can impair hepatic synthesis of blood coagulation factors VII, IX, and X, possibly by inhibiting action of vitamin K

DOSE: 325-650 mg PO/PR q4-6h (max: 4 g/d); MI prophylaxis PO 80-325 mg/d (chewable or non-enteric coated)

Indications: For mild to moderate pain management, fever reduction, and to decrease inflammation; also used for acute rheumatic fever, Systemic Lupus, rheumatoid arthritis, osteoarthritis, bursitis, calcific tendonitis, to reduce recurrence of TIA and risk of stroke, as prophylaxis and to prevent recurrence of MI

Contraindications: Salicylate and NSAID hypersensitivity; patients with "aspirin triad" (aspirin sensitivity, nasal polyps, asthma); chronic rhinitis or urticaria; GI ulcer, bleeding; hypoprothrombinemia, vitamin K deficiency, hemophilia, bleeding disorders; CHF; pregnancy category D; do NOT use in children or teenagers with viral illnesses due to link with Reye's syndrome

Adverse/Side Effects: Rash, urticaria, easy bruising, petechiae, bronchospasm, laryngeal edema, confusion, dizziness, drowsiness; tinnitus, hearing loss; nausea, vomiting, diarrhea, anorexia, heartburn, stomach pain, GI bleeding, ulceration; thrombocytopenia, hemolytic anemia, prolonged bleeding time

Interactions: Aminosalicylic acid and carbonic anhydrase inhibitors increase risk of toxicity; ammonium chloride, acidifying agents decrease renal elimination and increase toxicity; oral hypoglycemic agents increase hypoglycemic activity; corticosteroids increase ulcer potential; methotrexate toxicity is increased; anticoagulants and herbals (feverfew, garlic, ginger, ginkgo) increase bleeding potential

Mission Impact: Use of Aspirin is to be minimized in the deployed and combat environment due to known coagulopathy issues.

K-9 Dosage: Only Buffered Aspirin 10-25mg/kg PO q8-12h

ALBUTEROL (PROVENTIL)

Class: Autonomic nervous system agent – sympathomimetic, beta-adrenergic agonist, bronchodilator

Action: Acts more prominently on beta₂ receptors (particularly smooth muscles of bronchi, uterus, and vascular supply to skeletal muscles) than on beta₁ (heart) receptors; minimal or no effect on alpha-adrenergic receptors; inhibits histamine release by mast cells; produces bronchodilation, by relaxing smooth muscles of bronchial tree which decreases airway resistance, facilitates mucus drainage, and increases vital capacity

DOSE: MDI 2 puffs q4-6h prn; NEB 0.5 mL of 0.5% soln (2.5 mg) in 5 mL NS nebulized tid-qid

Indications: For prevention of exercise-induced bronchospasm, or relief of bronchospasm associated with acute or chronic asthma, bronchitis, or other reversible obstructive airway disease; also used 20-30 minutes before inhaled steroids to allow for deeper penetration of the steroids into the lungs

Contraindications: Pregnancy category C

Adverse/Side Effects: Hypersensitivity reaction, tremor, anxiety, nervousness, restlessness, convulsions, weakness, headache, hallucinations; palpitation, hyper- or hypotension, bradycardia, reflex tachycardia; blurred vision, dilated pupils; nausea, vomiting; muscle cramps, hoarseness

Interactions: Additive effect with epinephrine and other sympathomimetic bronchodilators; MAOIs and TCAs potentiate action on vascular system; beta-adrenergic blockers antagonize effects

Mission Impact: **GROUNDING** medication for personnel on flight status



AMOXICILLIN/CLAVULANATE (AUGMENTIN)

Class: Antimicrobial – antibiotic, aminopenicillin β -lactamase inhibitor

Action: Interferes with cell wall replication in certain organisms through osmotic instability and β -lactamase inhibitor

DOSE: PO immediate release: 500 mg q8-12hrs or 875 mg BID; PO extended release: 2,000 mg BID

Indications: Lower respiratory tract infections, otitis media, sinusitis, skin and skin structure infections, urinary tract infections, animal bites (dog)

Contraindications: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions can occur in individuals with history of penicillin hypersensitivity; do not use in patients with a history of liver failure; Pregnancy Category B

Adverse/Side Effects: Diarrhea/loose stools, nausea, skin rashes and urticaria, vomiting, vaginitis, hypersensitivity reactions, hepatic dysfunction, blood and lymphatic dysfunction (likely hypersensitivity-related)

Interactions: May increase effect anticoagulants, decrease effectiveness of oral contraceptives.

Mission Impact: **GROUNDING** for personnel on flight status

K-9 Dosage: 10-20mg/kg PO BID for 5-7d



ATAVAQUONE-PROGUANIL (MALARONE)

Class: Antimicrobial; antimalarial

DOSE: Prophylaxis: 250 mg/100 mg qd; start 1 to 2 days prior to entering a malaria-endemic area, continue throughout the stay and for 7 days after returning; Treatment: 1,000 mg/400 mg qd x 3 days

Indications: Prophylaxis and treatment of *Plasmodium falciparum malaria*

Contraindications: Hypersensitivity to atovaquone or proguanil, Renal impairment, Pregnancy Category C

Adverse/Side Effects: Headache, abdominal pain, nausea/vomiting/diarrhea, dizziness, cough (pediatrics), liver transaminase elevations, possible association with seizures and psychotic events (e.g. hallucinations), cutaneous reactions, including photosensitivity, erythema multiforme and Stevens-Johnson Syndrome

Mission Impact: None

ATROPINE SULFATE

Class: CNS Agent - anticholinergic parasympatholytic, antidysrhythmic, antimuscarinic belladonna alkaloid

Action: Blocks acetylcholine at parasympathetic neuroeffector sites; increases cardiac output and heart rate by blocking vagal stimulation in heart; dries secretions by blocking vagus.

DOSE: Organophosphate Poisoning (CBRN Nerve Agent): 1-6 mg IV/IM q3-5m PRN x 2-12hrs. Bradycardia: 0.5 mg IV/IM q3-5m (max 3 mg) .

Indications: Bradycardia, organophosphate poisoning, reversal of anticholinesterase agents, and decreasing secretions before surgery

Contraindications: Hypersensitivity to belladonna alkaloids, glaucoma, GI obstructions, ulcerative colitis, tachycardia/tachydysrhythmias, asthma, acute hemorrhage, myocardial ischemia

Adverse/Side Effects: Headache, dizziness, involuntary movements, confusion, psychosis, anxiety, drowsiness, insomnia, hypotension, blurred vision, photophobia, pupil dilation, dry mouth, nausea, vomiting, constipation, abdominal distention, rash, urticaria, dry skin, urine retention.

Interactions: increase anticholinergic effects of tricyclics, decreased absorption with ketoconazole, decreased effect of atropine with antacids.

AZITHROMYCIN (ZITHROMYCIN)

Class: Antimicrobial – antibiotic; macrolide

Action: Reversibly binds to 50S ribosomal subunit of susceptible organisms inhibiting protein synthesis; effective against mild to moderate infections caused by pyogenic streptococci, *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Mycobacterium avium-intracellulare*, and *Staphylococcus aureus*

DOSE: Pneumonia: 500 mg PO on day 1, then 250 mg qd x 4 days; 500 mg PO qd x 3 days; or suspension 2 g single dose. STI (gonococcal): 1 g PO x1 in adjunct with ceftriaxone.

Indications: For pneumonia, lower respiratory tract infections, pharyngitis, tonsillitis, gonorrhea, nongonococcal urethritis, skin infections, otitis media, and acute bacterial sinusitis

Contraindications: Macrolide hypersensitivity; pregnancy category B

Adverse/Side Effects: Headache, dizziness; nausea, vomiting, diarrhea, abdominal pain; hepatotoxicity

Interactions: Antacids may decrease peak level; may increase toxicity of ergotamine; food will decrease the amount of azithromycin absorbed by 50%

Mission Impact: **GROUNDING** medication for personnel on flight status



BACITRACIN

Class: Antimicrobial – antibiotic

Action: Polypeptide derived from *Bacillus subtilis* culture; bactericidal/bacteriostatic that appears to inhibit cell wall synthesis; activity similar to penicillin; active against many gram-positives including *Streptococci*, *Staphylococci*, *Pneumococci*, *Corynebacteria*, *Clostridia*, *Neisseria*, *Gonococci*, *Meningococci*, *Haemophilus influenzae*, and *Treponema pallidum*; ineffective against most other gram-negatives

DOSE: Topical ointment to AAA bid-tid, clean affected area prior to application

Indications: For topical treatment of superficial skin infections

Contraindications: Atopic individuals; pregnancy category C

Adverse/Side Effects: Bacitracin hypersensitivity (erythema, anaphylaxis)

Interactions: No clinically significant interactions established when given topically

BENZATHINE-PENICILLIN-G (BICILLIN)

Class: Antimicrobial – Anti-infective, beta-lactam antibiotic, natural (1st generation) penicillin; must be cold stored

Action: Acid-stable, penicillinase-sensitive, long-acting form of penicillin G; absorbed slowly due to extremely low water solubility; produces lower blood concentrations of penicillin G but has longer duration. Effective against many strains of *Staphylococcus aureus*, gram-positive cocci and gram-negative cocci. Also effective against gram-positive and gram-negative bacilli.

DOSE: 1.2 million units IM single dose

Indications: Group A streptococcal pharyngitis; infections susceptible to Penicillin G such as streptococcal, pneumococcal, and staphylococcal.

Contraindications: Hypersensitivity to penicillins or cephalosporins; lactation; Pregnancy Category B.

Adverse/Side Effects: Local pain, tenderness, and fever associated with IM injection; chills, fever, wheezing, anaphylaxis, neuropathy, nephrotoxicity, pruritis, and urticaria.

Interactions: May decrease efficacy of oral contraceptives



BENZONATATE (TESSALON PERLES)

Class: Nonnarcotic antitussive

Action: Produces local anesthetic effect of stretch receptors on vagal afferent fibers in the respiratory passages, lungs and pleura

Dose: 100-200 mg PO 3 time a day as needed (max single dose: 200mg; max dose: 600mg per day)

Indications: Relief of cough

Contraindications: Hypersensitivity; pregnancy category C

Side Effects: chest numbness, chills, confusion, dizziness, headache, hallucination, sedation, pruritus, rash, constipation, nausea, congestion.

Interactions: None

Mission Impact: None

BISACODYL (DULCOLAX)

Class: Laxative, stimulant, diphenylmethane

Action: Direct action on the intestine by increasing motor activity.

DOSE: 5–15 mg PO. Swallow the tablets whole with a full glass of water or juice. Do not crush or chew the tablets. The tablets should work within 6–10 hrs.

Indications: Used to treat constipation or to clean out the intestinal tract before bowel examinations or bowel surgery.

Contraindications: Ileus, intestinal obstruction, acute surgical abdominal conditions like acute appendicitis, acute inflammatory bowel diseases, severe dehydration, known hypersensitivity to substances of the triarylmethane group

Adverse/Side Effects: Rarely, abdominal discomfort and diarrhea have been reported.

Interactions: Dairy products, anacids, H2 blockers, PPIs, Tablets have a special coating and therefore should not be taken together with milk or antacids

BUPIVACAINE (MARCAINE)

Class: Local Anesthetic

Action: Decreases the neuronal membrane's permeability to sodium ions, this results in inhibition of depolarization, blocking conduction.

DOSE: 0.25% infiltrated locally; (max: 400 mg/day of bupivacaine) **note:** aspirate before every injection.

ONSET/PEAK/DURATION: Onset is fast / Peak 30-45 minutes / Duration 2-8 hours; **Note:** epinephrine reduces the rate of absorption and peak plasma concentration of bupivacaine

Indications: Local or regional anesthesia; diagnostic and therapeutic procedures.

Contraindications: Hypersensitivity to bupivacaine hydrochloride; amide-type local anesthetics; **note:** do not use as intravenous regional anesthesia, may cause cardiac arrest and death.

Adverse/Side Effects: Most effects are dose related, often due to accelerated absorption. Bradycardia; cardiac arrest; heart block; hypotension; palpitations; ventricular arrhythmias; anxiety; dizziness; restlessness; nausea; vomiting; hypersensitivity reaction; weakness; blurred vision; miosis; tinnitus; apnea

Interactions: Blood pressure lowering medications may be enhanced; enhances other local anesthetic effects.

Mission Impact: **GROUNDING** medication for personnel on flight status.



CEFAZOLIN SODIUM (ANCEF)

Class: Antimicrobial – 1st generation cephalosporin

Action: Inhibits susceptible bacterial cell wall synthesis rendering cell wall osmotically unstable. Activity against gram-negative organisms is limited.

DOSE: 1-2g IM/IV q8h (max 12g/d)

Indications: Open bone fractures or joint disruptions as pre-surgical prophylaxis.

Contraindications: Hypersensitivity to any cephalosporin and related antibiotics; lactation; Pregnancy Category B.

Adverse/Side Effects: Anaphylaxis, fever, diarrhea, anorexia, abdominal cramps, maculopapular rash, urticaria.

Interactions: Minimal pre-hospital interactions

Mission Impact: **GROUNDING** medication for personnel on flight status

K-9 Dosage: 0.5-1gram (25mg/kg) IV daily; give over 5m.



CEFTRIAXONE (ROCEPHIN)

Class: Antimicrobial – antibiotic; third-generation cephalosporin

Action: Preferentially binds to penicillin-binding proteins (PBP) and inhibits bacterial cell wall synthesis; effective against most *Enterobacteriaceae*, gram-positive aerobic cocci, *Neisseria meningitides* and *gonorrhoeae*; some effect against *Treponema pallidum*

DOSE: For moderate to severe infections, 1–2 g IV/IM q12–24h (max: 4 g/d); for meningitis, 2 g IV/IM q12h; for uncomplicated gonorrhea 250 mg IM x 1; dilute in 1% lidocaine for IM

Indications: For infections of the middle ear, lower respiratory tract, skin and skin structures, bones and joints, meningitis, intra-abdominal, urogenital tract, pelvis, septicemia; used for surgical prophylaxis

Contraindications: Cephalosporin hypersensitivity; pregnancy category B

Adverse/Side Effects: Pruritus, fever, chills, pain, induration at IM site; phlebitis at IV site; diarrhea, abdominal cramps, pseudomembranous colitis, biliary sludge

Interactions: Probenecid decreases renal elimination; alcohol produces disulfiram reaction

Mission Impact: **GROUNDING** medication for personnel on flight status

K-9 Dosage: 1gram IV/IM qd



CETRIZINE (ZYRTEC)

Class: ENT agent – H₁-receptor antagonist; non-sedating antihistamine

Action: Potent H₁-receptor antagonist and antihistamine; low lipophilicity and H₁-receptor selectivity and thus no significant anticholinergic or CNS activity; reduces local and systemic effects of histamine release

DOSE: 5–10mg PO qd

Indications: Seasonal and perennial allergic rhinitis and chronic idiopathic urticaria

Contraindications: H₁-receptor antihistamine hypersensitivity; pregnancy category B

Adverse/Side Effects: Constipation, diarrhea, dry mouth; drowsiness, sedation, headache, depression

Interactions: Theophylline may decrease clearance leading to toxicity; do not use in combination with OTC antihistamines

Mission Impact: **GROUNDING** medication for personnel on flight status



CIMETIDINE (TAGAMET)

Class: GI agent – antisecretory H₂-receptor antagonist

Action: Antihistamine with high selectivity for reversible competitive inhibition of histamine H₂-receptors on parietal cells of the stomach (minimal effect on H₁-receptors) and thus decreases gastric acid secretion, raises the pH of the stomach, and indirectly reduces pepsin secretion

DOSE: Oral: 300mg QID or 800mg at bedtime or 400 mg BID for up to 8 weeks

Indications: For treatment of duodenal/gastric ulcer, prevention of ulcer recurrence, gastroesophageal reflux, chronic urticaria, acetaminophen toxicity

Contraindications: H₂ receptor antagonists hypersensitivity; pregnancy category B

Adverse/Side Effects: Fever; cardiac arrhythmias and cardiac arrest after rapid IV bolus; diarrhea, constipation, abdominal discomfort; increased prothrombin time; neutropenia, thrombocytopenia, aplastic anemia; hypospermia; exacerbation of preexisting arthritis; drowsiness, dizziness, light-headedness, depression, headache, reversible confusion states, paranoid psychosis; rash, Stevens-Johnson syndrome, reversible alopecia; gynecomastia, galactorrhea, reversible impotence

Interactions: Decreases hepatic metabolism of warfarin, phenobarbital, phenytoin, diazepam, propranolol, lidocaine, theophylline, thus increasing their activity and toxicity; antacids may decrease absorption

CIPROFOXACIN (CIPRO)

Class: Antimicrobial – antibiotic; quinolone

Action: Synthetic broad spectrum bactericidal agent; inhibits DNA-gyrase, an enzyme necessary for bacterial DNA replication, transcription, repair, recombination, and transposition; effective against many gram-positive and gram-negative organisms including *Citrobacter diversus*, *Enterobacter cloacae*, *Enterobacter aerogenes*, *Escherichia coli*, *Haemophilus influenzae*, *Klebsiella pneumoniae*, *Neisseria gonorrhoeae*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Serratia marcescens*, *Staphylococcus aureus*, *Streptococcus pyogenes*, *Shigella*, and *Salmonella*; less active against gram-positive than gram-negative bacteria, although active against many gram-positive aerobic bacteria, including penicillinase-producing, non-penicillinase-producing, and methicillin-resistant *Staphylococci*; however, many strains of *Streptococci* are relatively resistant; inactive against most anaerobic bacteria; resistant to some strains of methicillin-resistant *Staphylococcus aureus* (MRSA)

DOSE: 250-750 mg PO bid or 200-400 mg IV q8-12h **Note: Not first line treatment**

Indications: For infections of the lower respiratory tract, skin and skin structures, bone and joints, GI tract, urinary tract, prostate; also used for nosocomial pneumonia, acute sinusitis, and post-exposure prophylaxis for anthrax

Contraindications: Quinolone hypersensitivity; syphilis, viral infection; tendon inflammation or tendon pain; pregnancy category C

Adverse/Side Effects: Nausea, vomiting, diarrhea, cramps, gas, pseudomembranous colitis; tendon rupture; headache, vertigo, malaise, peripheral neuropathy, seizures

Interactions: May increase theophylline levels; antacids, sulcralfate, iron decrease absorption; may increase PT for patients on warfarin; may cause false positive on opiate screening tests

Mission Impact: **GROUNDING** medication for personnel on flight status.

K-9 Dosage: DO NOT GIVE



CLINDAMYCIN (CLEOCIN)

Class: Antimicrobial – antibiotic

Action: Suppresses protein synthesis by binding to 50 S subunits of bacterial ribosomes; effective against strains of anaerobic streptococci, *Bacteroides* (especially *B. fragilis*), *Fusobacterium*, *Actinomyces israelii*, *Peptococcus*, *Clostridium sp*, and aerobic gram-positive cocci, including *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Streptococci* (except *S. faecalis*), and *Pneumococci*

DOSE: 600 to 1,800 mg/day in 2 to 4 divided doses; up to 2,400 mg/day in 4 divided doses may be given for severe infections. Cleocin T: topically AAA BID

Indications: For moderate to severe infections; topical applications used in treatment of acne vulgaris

Contraindications: Clindamycin or lincomycin hypersensitivity; history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis; pregnancy category B

Adverse/Side Effects: Fever, serum sickness, sensitization, swelling of face, generalized myalgia, superinfections, proctitis, pain, induration, sterile abscess; thrombophlebitis; hypotension, cardiac arrest (rapid IV); diarrhea, abdominal pain, flatulence, bloating, nausea, vomiting, pseudomembranous colitis; esophageal irritation, loss of taste, medicinal taste (high IV doses), jaundice, abnormal liver function tests; leukopenia, eosinophilia, agranulocytosis, thrombocytopenia; skin rashes, urticaria, pruritus, dryness, contact dermatitis, gram-negative folliculitis, irritation, oily skin

Interactions: Chloramphenicol and erythromycin are possibly antagonistic; neuromuscular blocking action enhanced by neuromuscular blocking agents (atracurium, tubocurarine, pancuronium)

Mission Impact: **GROUNDING** medication for personnel on flight status.

K-9 Dosage: **DO NOT GIVE**



CYCLOBENZAPRINE (FLEXERIL)

Class: Autonomic nervous system agent – central acting; skeletal muscle relaxant

Action: Structurally and pharmacologically related to TCAs; relieves skeletal muscle spasm of local origin without interfering with muscle function; believed to act primarily within CNS at brain stem with some action at spinal cord level; depresses tonic somatic motor activity, although both gamma and alpha motor neurons are affected; increases circulating norepinephrine by blocking synaptic reuptake, thus producing antidepressant effect; has sedative effect and potent central and peripheral anticholinergic activity

DOSE: 5–10 mg PO tid prn muscle spasm (max: 60 mg/d); do not use longer than 2-3 wks

Indications: As adjunct to rest and physical therapy for short-term relief of muscle spasm associated with acute musculoskeletal conditions

Contraindications: Recovery phase of MI; cardiac arrhythmias, heart block or conduction disturbances; CHF, hyperthyroidism; pregnancy category B

Adverse/Side Effects: Tongue and face edema, sweating, myalgia, hepatitis, alopecia; toxic potential of TCAs; tachycardia, syncope, palpitation, vasodilation, chest pain, orthostatic hypotension, dyspnea; arrhythmias; dry mouth, indigestion, unpleasant taste, coated or discolored tongue, vomiting, anorexia, abdominal pain, flatulence, diarrhea, paralytic ileus; drowsiness, dizziness, weakness, fatigue, asthenia, paresthesias, tremors, muscle twitching, insomnia, euphoria, disorientation, mania, ataxia; pruritus, urticaria, rash; increased or decreased libido, impotence

Interactions: Alcohol, barbiturates, other CNS depressants enhance CNS depression; potentiates anticholinergic effect of phenothiazine and other anticholinergics; MAOIs may precipitate hypertensive crisis

Mission Impact: **GROUNDING**, Causes drowsiness in most people.

K-9 Dosage: **DO NOT GIVE**



DEXAMETHASONE (DECADRON)

Class: Hormones and synthetic substitutes – steroid; adrenocorticoid; glucocorticoid

Action: Long-acting synthetic adrenocorticoid with intense glucocorticoid activity and minimal mineralocorticoid activity; Antiinflammatory and immunosuppression properties; prevents accumulation of inflammatory cells at sites of infection; inhibits phagocytosis, lysosomal enzyme release, and synthesis of selected chemical mediators of inflammation; reduces capillary dilation and permeability

DOSE: 0.25–4 mg PO bid-qid; 8–12 mg IM/IV q1–3wks. AMS: 4 mg qid; HACE: Initial: 8 mg as a single dose; Maintenance: 4 mg PO qid until symptoms resolve

ONSET/PEAK/DURATION: Onset hours / Peak in 8-12 hours / Duration 72 hours

Indications: For inflammatory conditions, allergic states, and cerebral edema

Contraindications: Systemic fungal infection, acute infections, tuberculosis, vaccinia, varicella, live virus vaccines (to patient, family members), amebiasis; pregnancy category C

Adverse/Side Effects: Euphoria, insomnia, convulsions, increased ICP, vertigo, headache, psychic disturbances; CHF, hypertension, edema; hyperglycemia; cushingoid state; hirsutism; cataracts, increased IOP, glaucoma, exophthalmos; peptic ulcer or perforation, abdominal distension, nausea, increased appetite, heartburn, dyspepsia, pancreatitis, bowel perforation, oral candidiasis; muscle weakness, loss of muscle mass, vertebral compression fracture, pathologic fracture of long bones, tendon rupture; acne, impaired wound healing, petechiae, ecchymoses, diaphoresis, dermatitis, hypo- or hyperpigmentation, skin atrophy

Interactions: May inhibit antibody response to vaccines and toxoids

Mission Impact: **GROUNDING** medication for personnel on flight status.

K-9 Dosage: 3-4mg (0.5mg/kg) IV/IM



DEXTROSE (D50)

Class: Endocrine agent – caloric, monosaccharide

Action: Needed for adequate utilization of amino acids, decreases protein and nitrogen loss, and prevents ketosis

DOSE: 0.5-1 g/kg (1-2 ml/kg) up to 25 g (50 mL) of 50% solution IV; if tolerating PO, provide glucose tabs

Indications: For treatment of hypoglycemic episode

Contraindications: Hyperglycemia, delirium tremens, cranial or spinal hemorrhage, CHF

Adverse/Side Effects: Confusion, loss of consciousness, dizziness; hypertension, CHF, pulmonary edema; glycosuria, osmotic diuresis; hyperglycemia, rebound hypoglycemia; chills, flushing, rash, urticaria

Interactions: No clinically significant interactions established

DIAZEPAM (VALIUM) ++CONTROLLED MEDICATION IV++

Class: CNS agent – benzodiazepine; anticonvulsant; anxiolytic

Action: Anticonvulsant and antianxiety psychotherapeutic drug with action at both limbic and subcortical levels of CNS; increases total sleep time, but shortens REM and stage 4 sleep

DOSE: 5-10 mg slow IV push, repeat in 3-4h; 2-10 mg PO tid-qid

ONSET/PEAK/DURATION: Onset / Peak / Duration 2-4 hours

Indications: For anxiety, seizures, skeletal muscle spasm relief; also used as an amnesic, for treatment of restless leg syndrome, acute alcohol withdrawal, and is the drug of choice for status epilepticus

Contraindications: Shock, coma, alcohol intoxication, depressed vital signs; acute narrow-angle glaucoma, untreated open-angle glaucoma; MAOIs; pregnancy category D

Adverse/Side Effects: Throat and chest pain; drowsiness, fatigue, ataxia, confusion, paradoxical rage, dizziness, vertigo, amnesia, vivid dreams, headache, slurred speech, tremor; EEG changes, tardive dyskinesia; hypotension, tachycardia, edema, cardiovascular collapse; blurred vision, diplopia, nystagmus; xerostomia, nausea, constipation, hepatic dysfunction; incontinence, urinary retention, gynecomastia (prolonged use); hiccups, coughing, laryngospasm; venous thrombosis, phlebitis

Interactions: Alcohol, CNS depressants, anticonvulsants, and herbals potentiate CNS depression; cimetidine increases levels and toxicity; may decrease effects of levodopa; may increase phenytoin levels; smoking decreases sedative and antianxiety effects

Mission Impact: Drowsiness. **GROUNDING** medication for personnel on flight status.

K-9 Dosage: For seizures, 15-30mg (0.5-1mg/kg) IV or 30-60mg (1-2mg/kg) rectally q4h. For sedation combined with opioid, 7.5mg (0.25mg/kg) IV/IM q4h.



DIPHENHYDRAMINE (BENADRYL)

Class: ENT agent – H1 blocker; Antihistamine

Action: H1-receptor antagonist and antihistamine as it competes for H1 receptor sites on effector cells; significant central anticholinergic activity as it prolongs action of dopamine by inhibiting its uptake and storage thus decreasing Parkinsonism and drug-induced extrapyramidal symptoms

DOSE: 25-50mg IV/IM/PO q4-6h

ONSET/PEAK/DURATION: IV – Onset Immediate / Peak in 1-3 hours / Duration 6-8 hours
IM – Onset 30 min / Peak 1-3 hours / Duration 6-8 hours
PO – Onset 15-60 min / Peak in 1-3 hours / Duration 6-8 hours

Indications: For allergic conditions; treatment or prevention of motion sickness or vertigo; blood or plasma reactions; treatment of Parkinsonism and drug-induced extrapyramidal reactions; also used with epinephrine for anaphylaxis; may be used as a cough suppressant, a sedative-hypnotic or for intractable insomnia.

Contraindications: Antihistamine hypersensitivity; lower respiratory tract symptoms; asthma; narrow-angle glaucoma; prostatic hypertrophy; bladder neck obstruction; GI obstruction; pregnancy category C. Avoid with nursing mothers.

Adverse/Side Effects: Drowsiness, dizziness, headache, fatigue, disturbed coordination, tingling, heaviness and weakness of hands, tremors, euphoria, nervousness, restlessness, insomnia, confusion, excitement, fever, palpitation, tachycardia, hypo- or hypertension, cardiovascular collapse, tinnitus, vertigo, dry nose/mouth, nasal stuffiness, blurred vision, diplopia, photosensitivity, dry eyes, nausea, epigastric distress, anorexia, vomiting, constipation, diarrhea, urinary frequency or retention, dysuria, thickened bronchial secretions, wheezing, chest tightness.

Interactions: Alcohol, other CNS depressants, and MAOIs compound CNS depression.

Mission Impact: **GROUNDING**, Sedative effects on patient should be considered in tactical situation.

K-9 Dosage: 50mg IM/SQ/PO. Impacts sense of smell.



DOCUSATE (COLACE)

Class: GI agent – stool softener

Action: Anionic surface-active agent with emulsifying and wetting properties; detergent action lowers surface tension, permitting water and fats to penetrate and soften stools for easier passage

DOSE: 50–500 mg/day PO divided qd-qid

Indications: For treatment of constipation associated with hard and dry stools, also used prophylactically in patients taking narcotics or patients who should avoid straining during defecation

Contraindications: Atonic constipation, nausea, vomiting, abdominal pain, fecal impaction, structural anomalies of colon and rectum, intestinal obstruction or perforation; patients on sodium restriction or with renal dysfunction; concomitant use of mineral oil; pregnancy category C

Adverse/Side Effects: Mild abdominal cramps, diarrhea, nausea, bitter taste; rash

Interactions: Increases systemic absorption of mineral oil

DOXYCYCLINE

Class: Antimicrobial – antibiotic; tetracycline

Action: Semisynthetic broad-spectrum antibiotic derived from oxytetracycline, but more completely absorbed with effective blood levels maintained for longer periods and excreted more slowly than most other tetracyclines, thus it requires smaller and less frequent dosing; primarily bacteriostatic in effect

DOSE: As antimalarial, 100 mg PO qd starting 1-2 days prior to 4 wks after exposure; as antimicrobial, 100 mg PO q12h on day 1, then 100 mg qd; for travelers' diarrhea, 100 PO QD during risk period; for gonorrhea, 200 mg PO immediately, followed by 100 mg bid x 3 d; for syphilis 100 mg PO tid x 10 d; for acne, 100 mg PO qd-bid

Indications: For suppression and chemoprophylaxis of chloroquine-resistant malaria, short-term prophylaxis and treatment of travelers' diarrhea caused by enterotoxigenic strains of *Escherichia coli*, Chlamydial and mycoplasmal infections, gonorrhea, syphilis in penicillin-allergic patients, rickettsial diseases, acute exacerbations of chronic bronchitis, and treatment of acne

Contraindications: Tetracycline hypersensitivity; use during period of tooth development including last half of pregnancy causes permanent yellow discoloration of teeth, enamel hypoplasia, and retardation of bone growth, pregnancy category D

Adverse/Side Effects: Interference with color vision; anorexia, nausea, vomiting, diarrhea, enterocolitis; esophageal irritation; rashes, photosensitivity reaction; superinfections

Interactions: Antacids, iron preparation, calcium, magnesium, zinc, kaolin-pectin, sodium bicarbonate can significantly decrease absorption; effects of both doxycycline and desmopressin antagonized; increases digoxin absorption and risk of toxicity; methoxyflurane increases risk of renal failure. **Antacids (Pepto Bismol, Kaopectate, Mylanta) can significantly decrease the absorption effects of Doxycycline.**

EPINEPHRINE (INCLUDING EPI-PEN)

Class: Autonomic nervous system agent – natural and synthetic catecholamine; alpha- and beta-adrenergic agonist; bronchodilator

Action: Sympathomimetic that acts directly on both alpha and beta receptors; the most potent activator of alpha receptors; strengthens myocardial contraction; increases systolic but may decrease diastolic blood pressure; increases cardiac rate and output; constricts bronchial arterioles and inhibits histamine release, thus reducing congestion and edema and increasing tidal volume and vital capacity

DOSE: Anaphylaxis: 0.3–0.5 mg IM q10–15min (1:1000 soln = 1mg/1ml)
ACLS: 1mg IV/IO q3-5 minutes for cardiac arrest

ONSET/PEAK/DURATION: IV/IM – Onset Rapid / Duration 1-2 minutes

Indications: For hypersensitivity and anaphylactic reactions, acute asthma attack, bronchospasm, mucosal congestion, syncope due to heart block or carotid sinus hypersensitivity, and to restore cardiac rhythm in cardiac arrest; prolong action and delay absorption of anesthetics; control superficial bleeding

Contraindications: Sympathomimetic amine hypersensitivity; narrow-angle glaucoma; hemorrhagic, traumatic, or cardiogenic shock; cardiac dilatation, cerebral arteriosclerosis, coronary insufficiency, arrhythmias, organic heart or brain disease; do NOT use with local anesthesia of fingers, toes, ears, nose, genitalia; pregnancy category C

Adverse/Side Effects: Nervousness, restlessness, sleeplessness, fear, anxiety, tremors, headache, CVA, weakness, dizziness, syncope, pallor, sweating, dyspnea; nausea, vomiting; precordial pain, palpitations, hypertension, MI, tachyarrhythmias; bronchial and pulmonary edema; urinary retention; tissue necrosis; metabolic acidoses; altered state of perception and thought, psychosis

Interactions: May increase hypotension in circulatory collapse; additive toxicities with other medications

Mission Impact: **GROUNDING** medication for personnel on flight status



ERTAPENEM (INVANZ)

Class: Antimicrobial – antibiotic, carbapenem, beta-lactam

Action: Broad-spectrum antibiotic that inhibits cell wall synthesis of gram-positive and gram-negative bacteria by its strong affinity for bacterial cell wall penicillin-binding proteins (PBPs); highly resistant to most bacterial beta-lactamases; effective against most *Enterobacteriaceae*, *Pseudomonas aeruginosa*, and *Acinetobacter spp*; poorly effective against *Enterococci*, particularly vancomycin-resistant strains

DOSE: 1 gram IV/IM q24h (For IV reconstitute with 10mL NS; for IM 3.2mL 1.0% lidocaine without epinephrine)

Indications: For complicated infections of abdomen, pelvis, urinary tract, and skin; also used for community-acquired pneumonia

Contraindications: Carbapenem, beta-lactam, or amide-type local anesthetic (ie. Lidocaine) hypersensitivity; pregnancy category B

Adverse/Side Effects: Injection site phlebitis or thrombosis; asthenia, fatigue, death, fever, leg pain, anxiety, altered mental status, dizziness, headache, insomnia; chest pain, hypo- or hypertension, tachycardia, edema; abdominal pain, diarrhea, acid reflux, constipation, dyspepsia, nausea, vomiting, increased LFTs; cough, dyspnea, pharyngitis, rales, rhonchi, respiratory distress; erythema, pruritus, rash

Interactions: Probenecid decreases renal excretion

Mission Impact: **GROUNDING** medication for personnel on flight status



ERYTHROMYCIN OPHTHALMIC OINTMENT

Class: Macrolide antibiotic

DOSE: One half inch ribbon of ointment q 3-4 hrs or 2-6 times a day.

Indications: For superficial ocular infections of the cornea and conjunctiva

Contraindications: Hypersensitivity, Astemizole, Cisapride, Pimozide, Terfenadine therapy

Adverse/Side Effects: Minor ocular irritations and redness

Interactions: Terfenadine, Atorvastatin, Lovastatin, Pravastatin, Simvastatin, Carbamazepine, Digoxin, Diltiazem, Midazolam, Oral contraceptives, ototoxic drugs, Penicillins, Warfarin

Mission Impact: Blurred vision

ESZOPICLONE (LUNESTA) ++CONTROLLED SUBSTANCE IV++

Class: Sedative-Hypnotic

Action: May potentiate effects of inhibitory neurotransmitter gamma-aminobutyric acid (GABA) by binding close to or with benzodiazepine receptors.

DOSE: 2 mg up to 3mg immediately at bedtime. Maintenance dose 3mg.

Indications: Insomnia

Contraindications: Hypersensitivity

Adverse/Side Effects: Agitation, anxiety, confusion, depression, dizziness, hallucinations, HA, nervousness, neuralgia, unusual dreams, chest pn, peripheral edema, dry mouth, gynecomastia, diarrhea, indigestion, hepatitis, nausea, vomiting, decreased libido, dysmenorrhea, UTI, asthma, respiratory tract infection, pruritus, rash, or heat stroke.

Interactions: Clarithromycin, Ketoconazole, Intraconazole, Rifampin, and alcohol.

Mission Impact: Grogginess. Puts patient at higher risk for heat injury. **GROUNDING** medication for personnel on flight status



FENTANYL ++CONTROLLED SUBSTANCE II++

Class: CNS agent - potent narcotic (opiate) agonist

Action: Action similar to morphine with more rapid and less prolonged analgesia and sedation, but less emetic effect

DOSE: 1600 mcg/d; lozenge on a stick to be placed in mouth between cheek and lower gum and sucked, not chewed (have opioid antagonist [naloxone] immediately available!) IV: For severe pain 50-100 mcg IV/IM q1-2 hrs PRN.

ONSET/PEAK/DURATION: TD: Onset 15 min; peak 20-40 min; duration 2-3 hours. IV: Onset immediate; peak 30-60 min; duration 2-4 hours

Indications: For moderate to severe pain management

Contraindications: MAOIs; myasthenia gravis; pregnancy category C

Adverse/Side Effects: Sedation, euphoria, dizziness, diaphoresis, delirium, convulsions; bradycardia, hypotension, circulatory depression, cardiac arrest; miosis, blurred vision; nausea, vomiting, constipation, ileus; muscle and thoracic muscle rigidity; urinary retention, rash; laryngospasm, bronchoconstriction, respiratory depression or arrest

Interactions: Alcohol and other CNS depressants potentiate effects; MAOIs may precipitate hypertensive crisis

Mission Impact: **GROUNDING** medication for personnel on flight status



FEXOFENADINE (ALLEGRA)

Class: ENT agent – H₁-receptor antagonist; non-sedating antihistamine

Action: Competitively antagonizes histamine at the H₁-receptor site; does not bind with histamine to inactivate it; not associated with anticholinergic or sedative properties; inhibits antigen-induced bronchospasm and histamine release from mast cells

DOSE: 60 mg PO bid or 180 mg PO qd

Indications: For symptom relief from seasonal allergic rhinitis (nasal congestion and sneezing; watery or red eyes; itching nose, palate, or eyes) and chronic urticaria

Contraindications: Fexofenadine hypersensitivity; pregnancy category C

Adverse/Side Effects: Headache, drowsiness, fatigue; nausea, dyspepsia, throat irritation

Interactions: No clinically significant interactions established

FLUCONAZOLE (DIFLUCAN)

Class: Antifungal

Action: Damages fungal cells by interfering with a cytochrome P-450 enzyme needed in cell membrane synthesis.

DOSE: Skin infection: 150mg, 1 pill per week x 4 weeks. Oropharyngeal candidiasis: The recommended dosage of fluconazole for oropharyngeal candidiasis is 200mg on the first day, followed by 100mg once daily. Clinical evidence of oropharyngeal candidiasis generally resolves within several days, but treatment should be continued for at least 2 weeks to decrease the likelihood of relapse. Vaginal candidiasis: The recommended dosage of fluconazole for vaginal candidiasis is 150mg as a single oral dose.

Indications: Vaginal candidiasis (vaginal yeast infections due to *Candida*), Oropharyngeal and esophageal candidiasis, Fungal skin infections

Contraindications: Hypersensitivity to fluconazole, Pregnancy Category C

Adverse/Side Effects: Exfoliative skin disorders including Stevens-Johnson Syndrome and toxic epidermal necrosis.

Interactions: Erythromycin; heart medications

Mission Impact: Aviation personnel are grounded for the initial 24 hours of antifungal therapy and until the medical condition no longer interferes with safely performing aviation duties and the patient is free of side-effects.



FLUTICASONE (FLONASE)

Class: Anti-inflammatory corticosteroid; skin and mucous membrane agent

Action: Inhibits cells involved in the inflammatory response of asthma (mast cells, eosinophils, basophils and lymphocytes). Also inhibits secretion of chemical mediators such as histamines.

DOSE: 1 spray in each nostril BID **OR** 2 sprays in each nostril daily

Indications: for management of nasal symptoms of seasonal and perennial allergic and non-allergic rhinitis in adults and children >4y/o

Contraindications: Hypersensitivity, Pregnancy Category C

Adverse/Side Effects: Irritation of nasal mucous membranes, blood in nasal mucous, runny nose, abdominal pain, diarrhea, dizziness, flu-like symptoms.

Interactions: Drugs with immunosuppressive properties, other steroid drugs, suspected chicken pox or measles, antiviral drugs.

GATAFLOXACIN OPHTHALMIC (ZYMAR)

Class: Antimicrobial – antibiotic, Ocular fluoroquinolone

DOSE: Days 1 and 2: instill 1 drop in affected eye(s) every 2 hrs while awake, up to 8 times/day. Days 3 to 7: Instill 1 drop in affected eye(s) up to 4 times/day while awake. To instill in eye, tilt head back, place medication in conjunctival sac and close eye(s). Apply light finger pressure on lacrimal sac for 1 minute following instillation. To avoid bottle contamination, do not touch tip of container to any surface. Replace cap after use.

Indications: Eye infections

Contraindications: Hypersensitivity to any component of product, Pregnancy Category C

Adverse/Side Effects: Upon instillation, may cause temporary blurring of vision or stinging. If stinging, burning, or itching becomes pronounced, or redness, irritation, swelling, decreasing vision, or pain persists or worsens, discontinue and consider alternative therapy. Lid margin crusting, white crystalline precipitates and foreign body sensation in the eye have been reported. Bad/bitter taste in mouth, Nausea, Discontinue at first sign of skin rash or other allergic reaction, Corneal staining, Tearing and photophobia.

Interactions: Insert Definition

Mission Impact: Aviation personnel are grounded for the initial 24 hours of antibiotic therapy and until the medical condition no longer interferes with safely performing aviation duties and the patient is free of side-effects.



GUAIFENESIN

Class: ENT agent – antitussive, expectorant

Action: Enhances reflex outflow of respiratory tract fluids by irritation of gastric mucosa; aids in expectoration by reducing adhesiveness and surface tension of secretions

DOSE: 100–400 mg PO q4h or 600-1200 mg XR PO q12h (max: 2.4 g/d)

Indications: Relief of dry, nonproductive coughs associated with colds and bronchitis

Contraindications: Guaifenesin hypersensitivity; pregnancy category C

Adverse/Side Effects: Low incidence of nausea; drowsiness

Interactions: By inhibiting platelet function, may increase risk of bleeding in patients receiving heparin

HYDROCORTISONE

Class: Skin and mucous membrane agent – synthetic hormone; adrenal corticosteroid, glucocorticoid, mineralocorticoid, antiinflammatory

Action: Stabilizes leukocyte lysosomal membranes, inhibits phagocytosis and release of allergic substances, suppresses fibroblast formation and collagen deposition

DOSE: Topically AAA qd-qid

Indications: To reduce inflammation in various skin conditions

Contraindications: Steroid hypersensitivity, viral or bacterial diseases of skin; varicella or vaccinia on surfaces with compromised circulation; pregnancy category C

Adverse/Side Effects: Anaphylactoid reaction; aggravation or masking of infections; skin thinning and atrophy, acne, impaired wound healing; petechiae, ecchymosis, easy bruising; hypopigmentation or hyperpigmentation, hirsutism, acneiform eruptions, subcutaneous fat atrophy; allergic dermatitis, urticaria, angioneurotic edema, increased sweating

Interactions: Estrogens potentiate effects; immune response to vaccines may be decreased

HYDROMORPHONE (DILAUDID) ++CONTROLLED SUBSTANCE II++

Class: CNS agent – narcotic (opiate) agonist; analgesic

Action: Semisynthetic derivative structurally similar to morphine with 8–10 times more potent analgesic effect, more rapid onset, shorter duration of action, less hypnotic effect, and less tendency to produce nausea and vomiting; also has antitussive properties

DOSE: 1mg IV; 1–2 mg IM q4–6h prn

ONSET/PEAK/DURATION: IV – Onset in 10-15 minutes / Peak in 15-30 minutes / Duration 2-3 hours
IM – Onset in 15 minutes / Peak in 30-60 minutes / Duration 4-5 hours

Indications: For moderate to severe pain management, and control of persistent nonproductive cough

Contraindications: Opiate hypersensitivity; acute bronchial asthma, COPD, decreased respiratory reserve, severe respiratory depression, opiate-naïve patients; pregnancy category C

Adverse/Side Effects: Nausea, vomiting, constipation; euphoria, dizziness, sedation, drowsiness; hypotension, bradycardia, tachycardia; respiratory depression; blurred vision

Interactions: Alcohol and other CNS depressants compound sedation and CNS depression; herbal (St. John's wort) may increase sedation

Mission Impact: **GROUNDING** medication for personnel on flight status

K-9 Dosage: 3-6mg (0.1-0.2mg/kg) IV/IM q2-4h using lower dose if IV



IBUPROFEN (MOTRIN, ADVIL)

Class: NSAID (non-selective cox-1); anti-inflammatory, analgesic, antipyretic

Action: Propionic acid inhibitor prototype that blocks prostaglandin synthesis, modulates T-cell function, inhibits inflammatory cell chemotaxis, decreases release of superoxide radicals or increases scavenging of these compounds at inflammatory sites, inhibits platelet aggregation and prolongs bleeding time

DOSE: 400–800 mg PO tid-qid (max: 3200 mg/d)

Indications: For mild to moderate pain management, symptomatic relief of arthritis, and to reduce fever

Contraindications: NSAID or aspirin induced urticaria, severe rhinitis, bronchospasm, angioedema, nasal polyps; active peptic ulcer, bleeding abnormalities; pregnancy category B

Adverse/Side Effects: Headache, dizziness, light-headedness, anxiety, emotional lability, fatigue, malaise, drowsiness, anxiety, confusion, depression, aseptic meningitis; hypertension, palpitation, CHF; peripheral edema; amblyopia (blurred vision, decreased visual acuity, scotomas, changes in color vision); nystagmus, visual-field defects; tinnitus, impaired hearing; dry mouth, gingival ulcerations, dyspepsia, heartburn, nausea, vomiting, anorexia, diarrhea, constipation, bloating, flatulence, epigastric or abdominal discomfort or pain, GI ulceration, occult blood loss; thrombocytopenia, neutropenia, hemolytic or aplastic anemia, leukopenia; decreased Hgb/Hct; acute renal failure, polyuria, azotemia, cystitis, hematuria, nephrotoxicity, decreased creatinine clearance; maculopapular and vesicobullous skin eruptions, erythema multiforme, pruritus, acne; fluid retention with edema, Stevens-Johnson syndrome, toxic hepatitis, hypersensitivity reactions, anaphylaxis, bronchospasm, serum sickness, SLE, angioedema

Interactions: Oral anticoagulants and heparin may prolong bleeding time; may increase lithium and methotrexate toxicity; herbals (feverfew, garlic, ginger, ginkgo) may increase risk of bleeding; do not take aspirin concurrently; concurrent alcohol use may increase risk of GI ulceration and bleeding tendencies.

KETOCONAZOLE

Class: Antimicrobial – Antifungal Agent, Imidazole Derivative

Action: Alters the permeability of the cell wall by blocking fungal cytochrome P450; inhibits biosynthesis of triglycerides and phospholipids by fungi; inhibits several fungal enzymes that results in a build-up of toxic concentrations of hydrogen peroxide.

DOSE: Oral: 200 mg once daily; may increase to 400 mg once daily if response is insufficient. Continue until active fungal infection is resolved; some infections may require a treatment duration of up to 6 months; **Tinea corporis, tinea cruris, tinea pedis:** Topical: Cream: Apply to the affected and immediate surrounding area once daily for Tinea corporis, cruris: 2 weeks; tinea pedis: 6 weeks; **Seborrheic dermatitis:** Topical cream apply to the affected area twice daily for 4 weeks or until clinical response is noted. Foam apply to affected area twice daily for 4 weeks. Gel apply to the affected area once daily for 2 weeks. Shampoo 2%: Apply 5 to 10 mL to wet scalp, lather, leave on 3 to 5 minutes, and rinse; apply twice weekly for 2 to 4 weeks.

Indications: **Topical** - Treatment of tinea corporis (ringworm), tinea cruris (jock itch), and tinea pedis (athlete's foot) caused by *Trichophyton rubrum*, treatment of seborrheic dermatitis. **Systemic** – Treatment of susceptible fungal infections in patients who have failed or who are intolerant to other antifungal therapies.

Contraindications: Not indicated for the treatment of onychomycosis, cutaneous dermatophyte infections, or Candida infections; ketoconazole hypersensitivity; alcoholism, fungal meningitis; ocular administration; administration of the following drugs with ketoconazole is contraindicated: dofetilide, quinidine, pimozide, cisapride, methadone, disopyramide, dronedarone, and ranolazine. Ketoconazole can cause elevated plasma concentrations of these drugs and may prolong QT intervals, sometimes resulting in life-threatening ventricular dysrhythmias, such as torsades de pointes; administration with benzodiazepines; pregnancy category C.

Adverse/Side Effects: Orthostatic hypotension, peripheral edema, fatigue, insomnia, malaise, nervousness, paresthesia, erythema, urticarial, anaphylactoid reaction.

Interactions: Topical treatment has no known drug interactions. Systemic treatment coadministration with midazolam, triazolam, and alprazolam may result in elevated plasma concentrations of the benzodiazepines, leading to prolonged hypnotic and sedative effects. There are many other drug interactions that require you to consult with a provider and pharmacology resources prior to administration.

Notes: **Systemic** - Hepatic function tests (baseline), including weekly ALT for the duration of treatment; calcium and phosphorous (periodically with long-term use); adrenal function as clinically necessary. Use ketoconazole only when other effective antifungal therapy is not available or tolerated and the potential benefits are considered to outweigh the potential risks.

KETAMINE ++CONTROLLED SUBSTANCE III++

Class: Dissociative

Action: Produces a cataleptic-like state causing dissociation from the surrounding environment by direct action on the cortex and limbic system. Ketamine is a noncompetitive NMDA receptor antagonist that blocks glutamate. Smaller doses produce analgesia, and modulate central sensitization, hyperalgesia and opioid tolerance. Reduces polysynaptic spinal reflexes.

DOSE:

Sedation: 1-1.5mg/kg slow IV push titrate to effect, followed by ½ induction dose PRN q10-20 min. 4-5mg/kg IM, repeat doses q30min prn for maintenance. Do not administer faster as this may result in respiratory depression/apnea.

Pain: 0.1-0.3mg/kg slow IV push over 30s-1min. IM/IN = 0.2-0.6mg/kg.

Avoid: 0.3-0.8mg/kg IV due to adverse effects

ONSET/PEAK/DURATION: IV – Onset in 30 seconds / Duration 5-10 minutes
IM – Onset in 3-4 minutes / Duration 12-25 minutes
IN – Onset in 5-10 minutes / Duration 12-25 minutes

Indications: General sedative and analgesic; Anesthetic agent for procedures

Contraindications: Hypersensitivity to ketamine, cardiovascular disease

Adverse/Side Effects: Hypertension, Respiratory Depression, Emergence Reactions (delirium, hallucinations, confusion)

Interactions: Effects of ketamine are increased when combined with other analgesics or muscle relaxants

Mission Impact: **GROUNDING** medication for personnel on flight status

K-9 Dosage: 100-150mg (5mg/kg) IV/IM (best given in conjunction with midazolam 2-10 mg for profound sedation)



KETOROLAC (TORADOL)

Class: NSAID; anti-inflammatory, analgesic, antipyretic

Action: Inhibits COX-1 and 2 enzymes, resulting in decreased formation of prostaglandin precursors

DOSE: **IM** - 30 mg as a single dose or 15-30 mg q6h; **IV** – 15 mg slow IV push as a single dose or 15 mg q6h (maximum: 120 mg/day)

ONSET/PEAK/DURATION: IV/IM – Onset in 30-60 minutes / Peak in 1-2 hours / Duration 4-6 hours

Indications: For short term moderate pain management

Contraindications: Ketorolac hypersensitivity; nasal polyps; angioedema or bronchospastic reaction to aspirin or other NSAIDs; severe renal impairment or renal failure due to volume depletion; patients with risk of bleeding; active peptic ulcer disease; pre- or intraoperatively; pregnancy category B

Adverse/Side Effects: Drowsiness, dizziness, headache; nausea, dyspepsia, GI pain, **hemorrhage**; edema, sweating

Interactions: May increase methotrexate and lithium levels and toxicity; herbals (feverfew, garlic, ginger, ginkgo) increase bleeding potential.

LACTATED RINGERS (LR)

Class: Plasma volume expander – crystalloid; isotonic salt solution

Action: Each liter contains 6.0 g Sodium Chloride (Na⁺ 130 mEq/L, Cl⁻ 109 mEq/L) and other electrolytes (K⁺ 4 mEq/L, Ca⁺⁺ 3 mEq/L, Lactate 28 mEq/L, and 9 kcal/L); pH 6.4; remains in the intravascular space for only a very limited time as it diffuses rapidly throughout the extracellular space

DOSE: 500–1000 mL IV

Indications: For fluid replacement and plasma volume expansion and for adjunctive treatment of shock and hypovolemic states caused by hemorrhage, burns, surgery, sepsis, trauma, dehydration, or illness; also used for irrigation

Contraindications: CHF; do not use with blood or blood products

Adverse/Side Effects: Fluid overload, CHF, edema, electrolyte imbalance, hypertension

Interactions: Calcium in LR can bind to other drugs and reduce efficacy, also has potential for creating emboli if given with blood or blood products.

K-9 Dosage: Bolus of 1L over 30m, then reassess VS; repeat if no response. Do not exceed 2L in 1h.

LEVETIRACETAM

Class: Antiepileptic

Action: Unknown

DOSE: 1000–4000 mg IV; 1000mg IV for seizure prevention; 4000mg for seizure treatment

Indications: For seizure prevention in moderate to severe TBI and treatment of active seizures

Contraindications: Hypersensitivity to drug

Adverse/Side Effects: The most common adverse effects of levetiracetam treatment include CNS effects such as somnolence, decreased energy, headache, dizziness, mood swings and coordination difficulties.

Interactions: No significant pharmacokinetic interactions

LEVOFLOXACIN

Class: Antimicrobial – antibiotic; fluoroquinolone ***NOT A FIRST LINE TREATMENT OPTION***

Action: Broad-spectrum antibiotic that inhibits DNA bacterial topoisomerase II, an enzyme required for DNA replication, transcription, repair, and recombination; prevents replication of certain bacteria resistant to beta-lactam antibiotic

DOSE: Community-acquired Pneumonia- 750 mg/d PO/IV x7 days; Skin Infection- 750mg/d x5-14 days; Rhinosinusitis (bacterial)- 500mg/d x5-7days; for chronic bacterial prostatitis: 500 mg PO qd x 28 d; for UTIs: 500-750 mg PO qd x 7 d

Indications: For treatment of maxillary sinusitis, acute exacerbations of bacterial bronchitis, community-acquired pneumonia, uncomplicated skin/skin structure infections, UTI, acute pyelonephritis; chronic bacterial prostatitis; bacterial conjunctivitis

Contraindications: Quinolone hypersensitivity; hypokalemia; tendon pain; syphilis; viral infections; phototoxicity; pregnancy category C

Adverse/Side Effects: **Prolonged QT syndrome, Tendon rupture,** headache, insomnia, dizziness; nausea, diarrhea, constipation, vomiting, abdominal pain, dyspepsia; rash, pruritus; decreased vision, foreign body sensation, transient ocular burning, ocular pain, photophobia; chest or back pain, fever, pharyngitis

Interactions: Magnesium or aluminum-containing antacids, sucralfate, iron, and zinc may decrease absorption; NSAIDs may increase risk of CNS reactions including seizures; may cause hyper- or hypoglycemia in patients on oral hypoglycemic agents; may cause false positive on opiate screening tests; avoid exposure to excess sunlight or artificial UV light; avoid NSAIDs while taking levofloxacin

Mission Impact: **GROUNDING** medication for personnel on flight status



LIDOCAINE

Class: Amide-type local anesthetic; cardiovascular agent; class IB antiarrhythmic

Action: Anesthetic effect similar to procaine; class IB antiarrhythmic action by suppressing automaticity in the His-Purkinje system and by elevating the electrical stimulation threshold of ventricles during diastole

DOSE: For local anesthesia, infiltrate 0.5%–2% injection with and without epinephrine; Max dose - 4.5mg/kg/dose (w/o epinephrine); 7 mg/kg (w/ epinephrine)

ONSET/PEAK/DURATION: Procedural local injection – Onset 1-3 minutes / Duration 10 minutes; dosing w/EPI – Onset 1-3 minutes / Duration infiltration~2 hours, nerve block ~3-3.5 hours.

Indications: For surface, infiltration, and nerve block anesthesia; also used for rapid control of ventricular arrhythmias

Contraindications: Amide-type local anesthetic hypersensitivity; systemic injection in presence of severe trauma or sepsis, blood dyscrasias, supraventricular arrhythmias, untreated sinus bradycardia, severe degrees of sinoatrial, atrioventricular, and intraventricular heart block; pregnancy category B

Adverse/Side Effects: Drowsiness, dizziness, light-headedness, restlessness, confusion, disorientation, irritability, apprehension, euphoria, wild excitement, numbness of lips or tongue, hot and cold paresthesia, chest heaviness, difficulty speaking, difficulty breathing or swallowing, muscular twitching, tremors, psychosis; convulsions, respiratory depression and arrest, hypotension, bradycardia, conduction disorders, heart block, cardiovascular collapse, and cardiac arrest in high doses; tinnitus, decreased hearing; blurred or double vision, impaired color perception; local erythema and edema; anorexia, nausea, vomiting; excessive perspiration, thrombophlebitis; urticaria, rash, edema, anaphylactoid reaction

Interactions: Barbiturates decrease activity; cimetidine, beta blockers, quinidine increase effects; phenytoin increases cardiac depressant effects; procainamide compounds neurologic and cardiac effects

Mission Impact: **GROUNDING** medication for personnel on flight status



LOPERAMIDE (IMODIUM)

Class: GI agent – antidiarrheal ***DO NOT ALLOW OPEN ACCESS***

Action: Synthetic piperidine derivative that inhibits GI peristaltic activity by direct action on circular and longitudinal intestinal muscles; prolongs intestinal content transit time, increases consistency of stools, and reduces fluid and electrolyte loss

DOSE: 4 mg PO, followed by 2 mg after each unformed stool (max: 16 mg/d)

Indications: For acute nonspecific diarrhea, chronic diarrhea associated with inflammatory bowel disease

Contraindications: Conditions in which constipation should be avoided, severe colitis, acute diarrhea caused by broad-spectrum antibiotics (pseudomembranous colitis) or from organisms that penetrate the intestinal mucosa (toxigenic *Escherichia coli*, *Salmonella*, or *Shigella*); pregnancy category B

Adverse/Side Effects: Rash; fever; drowsiness, fatigue, dizziness, CNS depression with overdose; abdominal distension, discomfort or pain, bloating, constipation, nausea, vomiting, anorexia, dry mouth; toxic megacolon in patients with ulcerative colitis

Interactions: Caution when dosing in conjunction w/ prolonging QTc medications.

Mission Impact: **GROUNDING** medication for personnel on flight status



LORATADINE

Class: ENT agent – H₁-receptor antagonist – non-sedating antihistamine

Action: Long-acting histamine antagonist with selective peripheral H₁-receptor sites that blocks histamine release; disrupts capillary permeability, edema formation, and constriction of respiratory, GI, and vascular smooth muscle

DOSE: 10 mg PO daily, take on an empty stomach

Indications: Symptom relief from seasonal allergic rhinitis; idiopathic chronic urticaria

Contraindications: Loratadine hypersensitivity; pregnancy category B

Adverse/Side Effects: Dizziness, dry mouth, fatigue, headache, somnolence, altered salivation and lacrimation, thirst, flushing, anxiety, depression, impaired concentration; hypo- or hypertension, palpitations, syncope, tachycardia; nausea, vomiting, flatulence, abdominal distress, constipation, diarrhea, weight gain, dyspepsia; arthralgia, myalgia; blurred vision, earache, eye pain, tinnitus; rash, pruritus, photosensitivity

Interactions: No clinically significant interactions established

MAALOX (ALUMINUM HYDROXIDE, MAGNESIUM HYDROXIDE)

Class: Antacid

Action: Neutralizes gastric acid, increases gastric pH.

DOSE: Oral liquid 200mg/200mg per 5ml; 10-20ml every 6 hours as needed; max: 80ml per 24 hours.

Indications: Relief of indigestion, heartburn, and GI upset.

Contraindications: Hypersensitivity, renal impairment pregnancy category C.

Adverse/Side Effects: Abdominal cramps, constipation, fecal impaction, nausea, vomiting

Interactions: May decrease efficacy of most oral medications by inhibiting gastric absorption unless separated by 2 or more hours.

Mission Impact: None

MECLIZINE (ANTIVERT)

Class: H1-Receptor antagonist; antihistamine, anti-vertigo agent

Action: Long-acting piperazine antihistamine with marked effect in blocking histamine-induced vasopressive response, but only slight anticholinergic action; marked depressant action on labyrinthine excitability and on conduction in vestibular-cerebellar pathways; exhibits CNS depression, antispasmodic, antiemetic, and local anesthetic activity

DOSE: For motion sickness, 25–50 mg PO 1 h before travel, may repeat q24h prn for duration of journey; for vertigo, 25–100 mg/d PO in divided doses

Indications: For management of nausea, vomiting, and dizziness associated with motion sickness and vertigo associated with diseases affecting the vestibular system

Contraindications: Hypersensitivity to meclizine; pregnancy category B

Adverse/Side Effects: Drowsiness; dry mouth; blurred vision; fatigue

Interactions: Alcohol and CNS depressants may potentiate sedative effects; do not drive or engage in potentially hazardous activities until response to drug is known.

Mission Impact: **GROUNDING** medication for personnel on flight status



MELATONIN

Class: Hormone produced by the pineal glands involved in mammalian circadian rhythms.

DOSE: 0.3 mg-3 mg for short periods of time (no longer than two weeks). Do not exceed 3mg due to paroxysmal hyperstimulation from elevated melatonin levels.

Indications: Insomnia and sleep disturbances

Contraindications: Hypersensitivity

Adverse/Side Effects: Stomach discomfort, morning grogginess, daytime "hangover", feeling of a heavy head, depression, HA, lethargy, amnesia, increased seizure activity, suppression of male libido, hypothermia, retinal damage, and gynecomastia

Interactions: ASA, NSAIDS, Benzodiazepines, Beta Blockers, Corticosteroids, Alcohol

Mission Impact: **GROUNDING** medication for personnel on flight status



MELOXICAM (MOBIC)

Class: NSAID; COX2 Inhibitor, anti-inflammatory, analgesic, antipyretic

Action: Inhibits cyclooxygenase

DOSE: 7.5–15 mg PO daily

Indications: For mild to moderate pain management, osteoarthritis, rheumatoid arthritis

Contraindications: NSAID or salicylate hypersensitivity; rhinitis, urticaria, angioedema, asthma; severe renal or hepatic disease; pregnancy category C (1st/2nd trimester) and category D (3rd trimester)

Adverse/Side Effects: Edema, flu-like syndrome, pain; abdominal pain, diarrhea, dyspepsia, flatulence, nausea, constipation, ulceration, GI bleed; anemia; arthralgia; dizziness, headache, insomnia; pharyngitis, upper respiratory tract infection, cough; rash, pruritus; urinary frequency, UTI

Interactions: May decrease effect of ACE inhibitors and diuretics; may increase lithium levels and toxicity; aspirin may increase GI bleed risk; warfarin and herbals (feverfew, garlic, ginger, ginkgo) may increase bleeding.

METHOCARBOMOL (ROBAXIN)

Class: Somatic nervous system agent – central-acting, skeletal muscle relaxant

Action: Causes skeletal muscle relaxation by general CNS depression

DOSE: 500mg up to 1.5 g PO qid x 2-3 d. 500mg recommended starting dose

Indications: For management of discomfort associated with acute musculoskeletal disorders as adjunct to physical therapy and other measures

Contraindications: Comatose; CNS depression; acidosis, kidney dysfunction; pregnancy category C s

Adverse/Side Effects: Fever, anaphylactic reaction, flushing, syncope, convulsions; urticaria, pruritus, rash, thrombophlebitis, pain, sloughing; conjunctivitis, blurred vision, nasal congestion; drowsiness, dizziness, light-headedness, headache; hypotension, bradycardia; nausea, metallic taste

Interactions: Alcohol and other CNS depressants enhance CNS depression.

Mission Impact: **GROUNDING** medication for personnel on flight status.



METHYLPREDNISOLONE (SOLU-MEDROL)

Class: Hormones and synthetic substitutes – adrenal corticosteroid, glucocorticoid, antiinflammatory

Action: Intermediate-acting synthetic steroid with less sodium and water retention effects than hydrocortisone; inhibits phagocytosis and release of allergic substances; modifies immune response to various stimuli; antiinflammatory and immunosuppressive

DOSE: 125mg IV q6h or 150mg IM q6h

Indications: For management of acute and chronic inflammatory diseases, control of severe acute and chronic allergic processes, acute bronchial asthma.

Contraindications: Systemic fungal infections; pregnancy category C

Adverse/Side Effects: Euphoria, headache, insomnia, confusion, psychosis; CHF, edema, nausea, vomiting, peptic ulcer; muscle weakness, delayed wound healing, muscle wasting, osteoporosis, aseptic necrosis of bone, spontaneous fractures; cushingoid features, growth suppression in children, carbohydrate intolerance, hyperglycemia; cataracts; leukocytosis; hypokalemia

Interactions: Amphotericin B, furosemide, thiazide diuretics increase potassium loss; may enhance virus replication or increase attenuated virus vaccine adverse effects; isoniazid, phenytoin, phenobarbital, rifampin increase metabolism and decrease effectiveness.

METRONIDAZOLE (FLAGYL)

Class: Antimicrobial – antibiotic, antitrichomonal, amebicide

Action: Synthetic compound with direct trichomonocidal, amebicidal, and antibacterial activity (anaerobic bacteria and some gram-negative bacteria); effective against *Trichomonas vaginalis*, *Entamoeba histolytica*, *Giardia lamblia*, obligate anaerobic bacteria, gram-negative anaerobic bacilli, and *Clostridia*; microaerophilic *Streptococci* and most aerobic bacteria are resistant

DOSE: For giardia 250 mg PO tid x 5-7 d; for amebiasis (dysentery) 500–750 mg PO tid x7-10days; for pseudomembranous colitis, 250–500 mg PO tid-qid; for trichomoniasis, 2 g PO once or 500 mg PO twice daily for 7 days; for bite wound (animal/human)- 500mg q8hrs x 3-5 days; for bacterial vaginosis 500 mg PO twice daily for 7 days

Indications: For giardiasis, trichomoniasis, amebiasis, and amebic liver abscess; topical for rosacea

Contraindications: Blood dyscrasias; active CNS disease; pregnancy category B

Adverse/Side Effects: hypersensitivity (rash, urticaria, pruritus, flushing), fever, fleeting joint pains, *Candida* overgrowth; vertigo, headache, ataxia, confusion, irritability, depression, restlessness, weakness, fatigue, drowsiness, insomnia, paresthesias, sensory neuropathy; nausea, vomiting, anorexia, epigastric distress, abdominal cramps, diarrhea, constipation, dry mouth, metallic or bitter taste, proctitis; polyuria, dysuria, pyuria, incontinence, cystitis, decreased libido, nasal congestion; ECG changes (flattening of T wave)

Interactions: Oral anticoagulants potentiate hypoprothrombinemia; alcohol and solutions of citalopram, ritonavir, lopinavir, and IV formulations of sulfamethoxazole, trimethoprim, nitroglycerin may elicit disulfiram reaction due to the alcohol content; disulfiram causes acute psychosis; phenobarbital increases metabolism; may increase lithium levels; fluorouracil, azathioprine may cause transient neutropenia

Mission Impact: **GROUNDING** medication for personnel on flight status.



MIDAZOLAM (VERSED) ++CONTROLLED SUBSTANCE II++

Class: CNS Agent - Benzodiazepine

Action: Binds to specific sites on GABA Type A receptors within the brain.

DOSE: 0.07–0.08mg/kg IM (Average or typical adult dose is 5mg IM). 5–10mg IM / IO for seizure control. 1mg IV slowly q 2–3 minutes to maximum adult dose of 10mg. Titrate to achieve necessary level. (The patient is somewhat somnolent, but still easily arousable.)

ONSET/PEAK/DURATION: IV – Onset in 1-5 minutes / Peak rapid / Duration 2-6 hours
IM – Onset in 5-15 minutes / Peak in 15-60 minutes / Duration 2-6 hours

Indications: Sedation in combination with analgesia to perform brief, but painful procedures, treatment of active seizures, sedation of agitated patients

Contraindications: Known sensitivity to benzodiazepines, acute narrow angle glaucoma, injectable midazolam should not be administered to adult or pediatric patients in shock or coma, or in acute alcohol intoxication with depression of vital signs, Pregnancy Category D

Adverse/Side Effects: Laryngospasm, bronchospasm, wheezing, shallow respirations, bradycardia, tachycardia, vomiting, retrograde amnesia, hallucination, confusion, blurred vision, diplopia, nystagmus, pinpoint pupils, anaphylactoid reactions, hives, rash, pruritus, yawning, lethargy, chills, weakness.

Interactions: Use with caution when other medications capable of producing central nervous system depression are used.

Mission Impact: **GROUNDING** medication for personnel on flight status.

K-9 Dosage: For sedation combined with opioid, 7.5mg (0.25mg/kg) IV/IM q4h.

NOTES: Monitor patients continuously for early signs of hypoventilation, airway obstruction, or apnea. Use with caution in patients with severe fluid or electrolyte disturbances.



MODAFINIL (PROVIGIL) ++CONTROLLED SUBSTANCE IV++

Class: CNS stimulant

DOSE: 200 mg daily. Shift work sleep disorder 200 mg 1 hr prior to start. Max dose 400 mg

Indications: Improve wakefulness in patients with narcolepsy, obstructive sleep apnea hypopnea syndrome, and shift work sleep disorder

Contraindications: Hypersensitivity

Adverse/Side Effects: Aggressiveness, agitation, anxiety, confusion, delusions, depression, hallucinations, HA, insomnia, mania, nervousness, psychosis, suicidal ideations, nausea, rash, Stevens-Johnson syndrome, anaphylaxis, or angioedema.

Interactions: Amitriptyline, Diazepam, Propranolol, Carbamazepine, Cimetidine, Clarithromycin, Erythromycin, Fluconazole, Oral contraceptives, Dexamethasone, Rifampin, Warfarin.

Mission Impact: Must be approved by medical officer and command leadership prior to administration. Individual must be screen tested in non-combat environment prior to administration during operational timeframes.

MORPHINE SULFATE (MSO4) ++CONTROLLED SUBSTANCE II++

Class: CNS agent – narcotic (opiate) agonist; analgesic

Action: Natural opium alkaloid with agonist activity as it binds with 3 types of the same receptors as endogenous opioid peptides; analgesia at supraspinal level, euphoria, respiratory depression and physical dependence; sedation and miosis; dysphoric, hallucinogenic, and cardiac stimulant effects

DOSE: 5–10 mg slow IV push, titrate to pain

ONSET/PEAK/DURATION: IV – Onset in 5-20 minutes / Peak in 20 minutes / Duration 4-5 hours
IM – Onset in 10-30 minutes / Peak in 30-60 minutes / Duration 4-5 hours

Indications: For severe acute and chronic pain management, pre-anesthesia and as adjunct to anesthesia, and for relief of dyspnea from acute left ventricular failure and pulmonary edema

Contraindications: Opiate hypersensitivity; seizures; acute bronchial asthma, chronic pulmonary disease, severe respiratory depression; chemical-irritant induced pulmonary edema; BPH; diarrhea due to poisoning until toxic material has been eliminated; following biliary tract surgery and surgical anastomosis; pancreatitis; acute ulcerative colitis; severe liver or renal insufficiency; hypothyroidism; pregnancy category B

Adverse/Side Effects: Pruritus, rash, urticaria, edema, anaphylactoid reaction; sweating, skeletal muscle flaccidity; cold, clammy skin, hypothermia; euphoria, insomnia, disorientation, visual disturbances, dysphoria, paradoxical CNS stimulation (restlessness, tremor, delirium, insomnia), convulsions; decreased cough reflex, drowsiness, dizziness, deep sleep, coma; miosis; bradycardia, palpitations, syncope; flushing of face, neck, and upper thorax; orthostatic hypotension, cardiac arrest; constipation, anorexia, dry mouth, biliary colic, nausea, vomiting, elevated LFTs; urinary retention or urgency, dysuria, oliguria, reduced libido or potency; severe respiratory depression or arrest; pulmonary edema

Interactions: CNS depressants, sedatives, barbiturates, alcohol, benzodiazepines, and TCAs potentiate CNS depressant effects; MAOIs may precipitate hypertensive crisis; phenothiazines may antagonize analgesia.

Mission Impact: **GROUNDING** medication for personnel on flight status.

K-9 Dosage: 2-3mg IV OR 10-20mg IM/SQ. Nausea/emesis and defecation common. Reverse with 1mg Naloxone IV/IM/SQ.



MOXIFLOXACIN (AVELOX)

Class: Antimicrobial – antibiotic; fluoroquinolone

Action: Broad spectrum bactericidal agent that inhibits DNA-gyrase topoisomerase II, an enzyme necessary for bacterial replication, transcription, repair and recombination; effective against gram-positive and gram-negative organisms, *Staphylococcus aureus*, *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Klebsiella pneumoniae*, *Moraxella catarrhalis*, *Chlamydia pneumoniae*, *Mycoplasma pneumoniae*, and other microbes

DOSE: 400 mg PO/IV daily x 5-10 days

Indications: For acute bacterial exacerbation of chronic bronchitis, acute sinusitis, community-acquired pneumonia, skin infections

Contraindications: Quinolone hypersensitivity; hepatic insufficiency; syphilis; arrhythmias; myocardial ischemia or infarction; hypokalemia, or those receiving Class IA or Class III antiarrhythmic drugs; pregnancy category C

Adverse/Side Effects: **Tendon rupture; QTc prolongation;** dizziness, headache, peripheral neuropathy, nausea, diarrhea, abdominal pain, vomiting, taste perversion, abnormal LFTs, dyspepsia, tendon rupture

Interactions: Iron, zinc, antacids, aluminum, magnesium, calcium, sucralfate decrease absorption; atenolol, erythromycin, antipsychotics, TCAs, quinidine, procainamide, amiodarone, may cause false positive on opiate screening tests

Mission Impact: **GROUNDING** medication for personnel on flight status.



MUPRICOCIN (BACROBAN)

Class: Antimicrobial – antibiotic; pseudomonic acid

Action: Inhibits protein synthesis by binding with bacterial transfer-RNA; effective against *Staphylococcus aureus* [including methicillin-resistant (MRSA) and beta-lactamase-producing strains], *Staphylococcus epidermidis*, *Staphylococcus saprophyticus*, and *Staphylococcus pyogenes*

DOSE: Topically apply tid-qid x 1-2 wks; re-evaluate for response after 3-5 days

Indications: For impetigo or nasal carriage due to *Staphylococcus aureus*, beta-hemolytic Streptococci, and *Streptococcus pyogenes*; superficial skin infections

Contraindications: Hypersensitivity to any of its components; pregnancy category B

Adverse/Side Effects: Headache, burning, stinging; pruritis, erythema, dry skin, tenderness, swelling, rash; nausea; local pain; rhinitis, congestion, pharyngitis

Interactions: None

Mission Impact: None

NALOXONE (NARCAN)

Class: CNS agent – narcotic (opiate) antagonist

Action: Pure opiate antagonist without agonistic (morphine-like) properties that displaces opioids at receptor sites. Acts by completing the mu, kappa, and sigma opiate receptor sites and forcing

DOSE: 0.4–2.0 mg IV, repeat q2–3min prn

ONSET/PEAK/DURATION: IV – Onset in 1-2 minutes / Peak in 5-15 minutes / Duration 45 minutes or longer
IM – Onset in 2-5 minutes / Peak in 5-15 minutes / Duration 45 minutes or longer

Indications: Narcotic overdose and reversal of effects of natural and synthetic narcotics (opiates), including respiratory depression, sedation, and hypotension; drug of choice for suspected acute opioid overdose or unknown ingestion with respiratory depression.

Contraindications: Hypersensitivity; pregnancy category B

Adverse/Side Effects: Analgesia reversal, tremors, hyperventilation, drowsiness, sweating; increased BP, tachycardia; nausea, vomiting; elevated PTT

Interactions: Reverses analgesic effects of narcotic (opiate) agonists and agonist-antagonists.

Mission Impact: **GROUNDING** medication for personnel on flight status.

K-9 Dosage: 1mg (0.02-0.04mg/kg) IV/IM



NAPHAZOLINE (NAPHCON, VASCON, CLEAR EYES)

Class: Autonomic nervous system agent – sympathomimetic, alpha-adrenergic agonist, vasoconstrictor, decongestant

Action: Stimulates alpha-adrenergic receptors in arterioles of conjunctiva and nasal mucosa to produce rapid and prolonged vasoconstriction, reducing fluid exudation and mucosal engorgement; systemic absorption may cause CNS depression rather than stimulation.

DOSE: 1-2 drops in each eye every 6 hours as needed (remove contact lenses before use if worn) **Limit use to 72 hours.**

Indications: Ocular vasoconstriction and decongestion

Contraindications: Hypersensitivity, narrow angle glaucoma, MAOIs, hyperthyroidism, diabetes mellitus, ocular trauma; pregnancy category C

Adverse/Side Effects: Keratitis, coma, hypertension, bradycardia, blurred vision, hyperglycemia, respiratory depression, tachycardia, shock like hypotension, increased intraocular pressure, irritation, drowsiness, weakness, headache, nausea, hypothermia, rebound congestion and chemical rhinitis with continued use.

Interactions: Vasoconstrictive nasal decongestants may reduce analgesic effect, TCAs and maprotiline may potentiate pressor effects.

Mission Impact: **GROUNDING** medication for personnel on flight status



NAPROXEN (NAPROSYN)

Class: NSAID; anti-inflammatory, analgesic, antipyretic

Action: Propionic acid derivative with properties similar to ibuprofen; inhibits COX 1 & 2 enzymes inhibiting prostaglandin synthesis and platelet aggregation; prolongs bleeding time

DOSE: 250–500 mg PO bid (max: 1000 mg/d)

Onset/Peak/Duration: Onset: 30-60 minutes, Peak: 2-4 hours, Duration: <12 hours

Indications: For mild to moderate pain management and symptomatic treatment of acute and chronic arthritis

Contraindications: Hypersensitivity; peptic ulcer; history of asthma, rhinitis, urticaria, bronchospasm or shock caused by aspirin or other NSAIDs; hyperkalemia; liver or renal impairment or disease, recent MI or CABG; pregnancy category B

Adverse/Side Effects: Headache, drowsiness, dizziness, lightheadedness, depression; palpitation, dyspnea, peripheral edema, CHF, tachycardia; blurred vision, tinnitus, hearing loss; anorexia, heartburn, indigestion, nausea, vomiting, thirst, GI bleeding, elevated LFTs; thrombocytopenia, leukopenia, eosinophilia, puritis, rash, ecchymosis, nephrotoxicity, increased risk of stroke or MI; pulmonary edema.

Interactions: Herbals (feverfew, garlic, ginger, ginkgo) may increase bleeding.

NITROFURANTOIN (MACROBID)

Class: Antimicrobial – Miscellaneous

Action: Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inactivate or alter bacterial ribosomal proteins leading to inhibition of protein synthesis, aerobic energy metabolism, DNA, RNA, and cell wall synthesis. Nitrofurantoin is bactericidal in urine at therapeutic doses.

DOSE: PO 100 mg BID x 5d for females, x 7d for males

Indications: Acute, recurrent, and prophylactic treatment for cystitis; chronic suppression of recurrent UTIs.

Contraindications: Hypersensitivity to drug or any component of the formulation; anuria, oliguria, or significant impairment of renal function.

Adverse/Side Effects: ECG changes, chills, confusion, depression, drowsiness, headache, malaise, numbness, paresthesia, psychotic reaction, alopecia, dermatitis, skin rash; Stevens-Johnsons syndrome; decreased hemoglobin, hepatitis; candida; weakness; amblyopia; cough; cyanosis; dyspnea; fever, hepatotoxicity.

Interactions: Minimal interactions

Mission Impact: **GROUNDING** medication for personnel on flight status.



OFLOXACIN OTIC (FLOXIN)

Class: Antimicrobial – antibiotic, fluoroquinolone

Action: broad-spectrum fluoroquinolone against gram-positive and gram-negative aerobic and anaerobic bacteria. Inhibits bacterial DNA replication and some aspects of its transcription, repair, recombination, and transposition.

DOSE: 10 gtts in affected ear(s) daily for 7d

Indications: Otitis externa in adults and pediatric patients (>6mo) due to *Escherichia coli*, *Pseudomonas aeruginosa* and *Staphylococcus aureus*.

Contraindications: Hypersensitivity to ofloxacin or other quinolone antibacterial agents; tendon pain; lactation; Pregnancy Category C.

Adverse/Side Effects: Hypersensitivity; fungal or bacterial superinfection with prolonged use, tendon inflammation/rupture; pruritis; earache; dizziness; headache; vertigo.

Interactions: Minimal pre-hospital interactions

Mission Impact: **GROUNDING** medication for personnel on flight status.



OMEPRAZOLE (PRILOSEC)

Class: GI agent – proton pump inhibitor (PPI)

Action: Antisecretory compound that is a gastric acid pump inhibitor; suppresses gastric acid secretion by inhibiting the H⁺, K⁺-ATPase enzyme system [the acid (proton H⁺) pump] in the parietal cells which relieves gastrointestinal distress and promotes ulcer healing

DOSE: 20 mg PO qd x 4–8 wk

Indications: Duodenal ulcer, Gastroesophageal reflux disease (GERD), Heartburn, and erosive esophagitis; used in conjunction with clarithromycin and metronidazole to treat duodenal ulcers associated with *Helicobacter pylori*

Contraindications: PPI hypersensitivity, pregnancy category C

Adverse/Side Effects: Headache, dizziness; rash; abdominal pain, diarrhea, nausea, vomiting, constipation; hematuria, proteinuria.

Interactions: May increase diazepam, phenytoin, and warfarin levels.

ONDASETRON (ZOFTRAN)

Class: GI agent – 5-HT₃ antagonist, antiemetic

Action: Selective serotonin (5-HT₃) receptor antagonist, acting centrally in the chemoreceptor trigger zone and peripherally on the vagal nerve terminals; serotonin is released from the wall of the small intestine, stimulates the vagal efferents through the serotonin receptors, and initiates the vomiting reflex

DOSE: 4-8 mg PO q4h prn; 4-8 mg slow IVP or IM q4h prn

ONSET/PEAK/DURATION: IV – Onset in 10-30 minutes / Duration 8 hours

Indications: Prevention of nausea and vomiting

Contraindications: Hypersensitivity to ondansetron; pregnancy category B

Adverse/Side Effects: Dizziness, light-headedness, headache, sedation; diarrhea, constipation, dry mouth, fatigue, fever, hypoxia

Interactions: Rifampin may decrease ondansetron levels; use with antimalarial drugs may cause decreased efficacy or increased blood toxicity; caution when dosing in conjunction with prolonging QTc medications

Mission Impact: **GROUNDING** medication for personnel on flight status.



OXYMETAZOLINE (AFRIN)

Class: ENT Agent - Vasoconstrictor (decongestant), sympathomimetic

Action: Sympathomimetic agent that acts directly on alpha receptors of sympathetic nervous system. No effect on beta receptors.

DOSE: Spray into each nostril 2 times, twice daily. Not to exceed three consecutive days due to rebound congestion. Do not tilt head backwards while spraying.

Indications: Epistaxis, Use as an adjunct to valsalva maneuver to clear ears and sinuses during compression and decompression, nasal congestion.

Contraindications: Severe damage to tympanic membrane/sinuses from barotrauma, lactation, Pregnancy Category C

Adverse/Side Effects: Burning, Sneezing and stinging of nasal mucosa, Rhinitis, Rebound congestion

PLASMA-LYTE A

Class: Plasma volume expander – crystalloid; isotonic salt solution

Action: Sterile, nonpyrogenic isotonic solution. Each 100 mL contains 526 mg of Sodium Chloride, USP (NaCl); 502 mg of Sodium Gluconate (C₆H₁₁NaO₇); 368 mg of Sodium Acetate Trihydrate, USP (C₂H₃NaO₂3H₂O); 37 mg of Potassium Chloride, USP (KCl); and 30 mg of Magnesium Chloride, USP (MgCl₂6H₂O).

DOSE: 500-1000 mL IV

Indications: A source of water and electrolytes or as an alkalizing agent. Plasma-Lyte A is compatible with blood or blood components

Contraindications: Known hypersensitivity of the product.

Adverse/Side Effects: Peripheral/pulmonary edema, anaphylactic reaction, and the following manifestations: Tachycardia, Palpitations, Chest pain, Chest discomfort, Dyspnea, Respiratory rate increased, Flushing, Hyperemia, Asthenia, Feeling abnormal, Piloerection, Edema peripheral, Pyrexia; infusion site reactions

Interactions: Caution is advised when administering to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids or patients with congestive heart failure

POLYETHYLENE GLYCOL (MIRALAX)

Class: Osmotic Laxative

Action: Increases water in the stool resulting in softer stool and increased frequency of bowel movements.

DOSE: 17g (1 heaping tablespoon) dissolved in 8 oz of beverage once daily as needed

Indications: Occasional Constipation

Contraindications: Hypersensitivity, bowel obstruction, renal disease

Adverse/Side Effects: Diarrhea, abdominal bloating, abdominal pain, nausea, cramping.

Mission Impact: None

PREDNISONE

Class: Systemic Corticosteroid

Action: Synthetic glucocorticoid; controls/prevents inflammation by governing the rate of protein synthesis, suppressing migration of leukocytes, reversing capillary permeability and stabilizing lysosomes.

Dose: Asthma attack or post anaphylaxis: 60mg PO per day x 4-5 days. Tapered dosing (systemic poison ivy, other anaphylactoid reactions) – 60 mg PO per day (days 1-5), 40 mg PO per day (days 6-10), 20 mg PO per day (days 11-15).

Indications: Asthma, anaphylaxis or other systemic swelling/edema

Contraindications: Hypersensitivity, systemic fungal infections, peptic ulcers, hypertension, osteoporosis, pregnancy category C.

Side Effects: bradycardia, CHF, edema, euphoria, headache, nausea, vomiting, peptic ulcer, muscle weakness, delayed wound healing, hypertension

Interactions: Barbiturates, diuretics; may inhibit antibody response to live vaccines or toxoids; may inhibit efficacy of hormonal birth control.

Mission Impact: None

PRIMAQUINE

Class: Antimicrobial - antimalarial

Action: Antiprotozoal agent which disrupts mitochondria and binds to DNA. Acts on primary exoerythrocytic forms of *Plasmodium vivax* and *Plasmodium falciparum*. Destroys late forms of *P. vivax* preventing relapse.

Dose: 30 mg PO once daily x 14 days immediately following departure from malaria-endemic areas. Screen for G6PD deficiency prior to providing as it can cause fatal hemolysis in severely G6PD deficient patients.

Indications: Interruption of transmission of malaria, prevents relapse of *P. vivax* and *P. ovale* following travel to endemic areas.

Contraindications: **G6PD deficiency**, rheumatoid arthritis, lupus, hemolytic drugs, bone marrow depression, NADH methemoglobin reductase deficiency, pregnancy category C.

Side Effects: Hematologic reactions to include acute hemolytic anemia if G6PD deficient; early hemolytic reaction symptoms include darkening of the urine, decrease in urine volume, chills, fever, precordial pain, cyanosis; leukocytosis, leukopenia, anemia, granulocytopenia, confusion, mental depression, visual accommodation disturbances, hypertension, arrhythmias.

Interactions: Increased toxicity of both quinacrine and primaquine. .

Mission Impact: None

PROMETHAZINE (PHENERGAN)

Class: GI agent – phenothiazine; antiemetic, anti-vertigo

Action: Long-acting phenothiazine derivative with prominent sedative, amnesic, antiemetic, and anti-motion-sickness actions and marked antihistamine activity; antiemetic action due to depression of CTZ in medulla; as with other antihistamines, it exerts anti-serotonin, anticholinergic, and local anesthetic action

DOSE: 12.5-25 mg PO/IM/IV q4-6h prn

ONSET/PEAK/DURATION: IV – Onset in 3-5 minutes / Duration 4-6 hours
IM – Onset in 20 minutes / Duration 4-6 hours
PO – Onset in 15-60 minutes / Duration 4-6 hours

Indications: For symptomatic relief from nausea, vomiting, motion sickness, or headache.

Contraindications: Phenothiazine hypersensitivity; narrow-angle glaucoma; stenosing peptic ulcer, BPH; bladder neck obstruction; epilepsy; bone marrow depression; comatose or severe depressed states; Reye's syndrome, encephalopathy, hepatic diseases; pregnancy category C

Adverse/Side Effects: Deep sleep, coma, convulsions, cardiorespiratory symptoms, extrapyramidal reactions, nightmares, CNS stimulation, abnormal movements; irregular respirations, respiratory depression; sedation drowsiness, confusion, dizziness, disturbed coordination, restlessness, tremors; transient mild hypo- or hypertension; anorexia, nausea, vomiting, constipation; leukopenia, agranulocytosis; blurred vision, dry mouth, nose, or throat; photosensitivity; urinary retention

Interactions: Alcohol and other CNS depressants add to CNS depression and anticholinergic effects

Mission Impact: **GROUNDING** medication for personnel on flight status.



PSEUDOPHEDRINE (SUDAFED)

Class: Autonomic nervous system agent–sympathomimetic; alpha/beta-adrenergic agonist, decongestant

Action: Sympathomimetic amine that produces decongestion of respiratory tract mucosa by stimulating the sympathetic nerve endings including alpha-, beta-1 and beta-2 receptors causing vasoconstriction; Stimulates beta-androgenic receptors causing bronchial relaxation and increasing heart rate and contractility.

DOSE: 30-60 mg PO every 4–6 hours or 120 mg XR PO every 12 hours

Onset/Peak/Duration: Onset in 30 minutes / Peak in 1-2 hours / Duration of 3-8 hours

Indications: Symptomatic relief of nasal and eustachian tube congestion, rhinitis, and sinusitis; promotes nasal sinus drainage and relief on sinus congestion

Contraindications: Sympathomimetic amine hypersensitivity; severe hypertension; coronary artery disease; MAOIs; glaucoma; hyperthyroidism; BPH; pregnancy category C

Adverse/Side Effects: Stimulation, tremulousness, difficulty voiding; arrhythmias, palpitation, tachycardia; nervousness, chest tightness, dizziness, headache, sleeplessness, numbness; anorexia, dry mouth, nausea, vomiting, diaphoresis, restlessness; heart palpitations when given with pre-workout

Interactions: Sympathomimetics and beta blockers increase pressor effects and toxicity; MAOIs may precipitate hypertensive crisis; decreases antihypertensive effects of guanethidine, methyl dopa, reserpine; avoid use with pre-workout

Note: Do not allow open access to this medication

RABEPRAZOLE (ACIPHEX)

Class: GI agent – proton pump inhibitor (PPI)

Action: Gastric PPI that specifically suppresses gastric acid secretion by inhibiting the H⁺, K⁺-ATPase enzyme system (the acid [proton H⁺] pump) in the parietal cells of the stomach; does not exhibit H₂-histamine receptor antagonist properties

DOSE: 20 mg PO qd

Indications: For healing and maintenance of erosive or ulcerative gastroesophageal reflux disease (GERD), duodenal ulcers, and hypersecretory conditions

Contraindications: PPI hypersensitivity; pregnancy category B

Adverse/Side Effects: Headache; Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme

Interactions: May decrease absorption of ketoconazole; may increase digoxin levels

RANITIDINE (ZANTAC)

Class: GI agent – antisecretory H₂-receptor antagonist

Action: Antihistamine with high selectivity for reversible competitive inhibition of histamine H₂-receptors on parietal cells of the stomach (minimal effect on H₁-receptors) and thus decreases gastric acid secretion, raises the pH of the stomach, and indirectly reduces pepsin secretion

DOSE: 75-150 mg PO bid or 150-300 mg PO qhs; 50 mg IV/IM q6–8h; Anaphylaxis – 50mg IV or 150mg PO

Indications: For treatment of duodenal/gastric ulcers and gastroesophageal reflux disease

Contraindications: Ranitidine hypersensitivity; acute porphyria; pregnancy category B

Adverse/Side Effects: Headache, malaise, dizziness, somnolence, insomnia, vertigo, mental confusion, agitation, depression, hallucinations in older adults; bradycardia (with rapid IV push); constipation, nausea, abdominal pain, diarrhea; rash; reversible decrease in WBC count, thrombocytopenia

Interactions: May reduce absorption of cefpodoxime, cefuroxime, delavirdine, ketoconazole, itraconazole; long-term therapy may lead to vitamin B₁₂ deficiency

Mission Impact: **GROUNDING** medication for personnel on flight status.



RIZATRIPTAN (MAXALT)

Class: CNS Agent – Sumatriptan; Autonomic Nervous System agent; adrenergic antagonist; serotonin 5-HT (1B/1D) receptor agonist.

Action: Selective (5HT 1B/1D) receptor agonist reverses the vasodilation of cranial blood vessels associated with migraine headache.

DOSE: 5-10 mg PO (may repeat 1 dose in 2h prn); max dose of 30mg/24h

Indications: Acute migraine headache with or without aura

Contraindications: Hypersensitivity; Coronary artery disease or CAD risk factors of hypertension, hypercholesterolemia, obesity, diabetes, smoking or strong family Hx; concurrent administration of ergotamine drugs, sumatriptan, or MAOIs; basilar or hemiplegic migraine.

Adverse/Side Effects: Asthenia; fatigue; pain; pressure sensation; paresthesias; throat pressure; warm/cold sensations; dizziness; headache; decreased mental acuity; euphoria; tremor; coronary artery vasospasm; transient myocardial ischemia; myocardial infarction; V-tachycardia; V-fibrillation; chest pain/tightness; palpitations; dry mouth; nausea; vomiting; diarrhea; dyspnea; flushing; hot flashes.

Interactions: Propranolol; dihydroergotamine; methysergide; other 5-HT₁ agonists; Gingko; Genseng; echinacea; St. John's wort.

Mission Impact: **GROUNDING** medication for personnel on flight status.



SCOPOLAMINE (TRANSDERM-SCOP)

Class: Autonomic nervous system agent – parasympatholytic; anticholinergic, antimuscarinic, antispasmodic

Action: Alkaloid of belladonna with peripheral action resembling those of atropine, but in contrast, produces CNS depression with marked sedative and tranquilizing effects for use in anesthesia; potent mydriatic and cycloplegic action inhibiting secretions of salivary, bronchial, and sweat glands with less prominent effect on heart, intestines, and bronchial muscles

DOSE: For motion sickness, 0.25–0.6 mg PO 1 h before travel or topical transdermal disc patch applied to dry surface behind ear q72h starting 12 h before travel

Indications: Prophylactic agent for motion sickness; used as mydriatic and cycloplegic in ophthalmology; preanesthetic agent to control bronchial, nasal, pharyngeal and salivary secretions; control of spasticity and drooling in paralytic and spastic states

Contraindications: Anticholinergic, belladonna, or barbiturate hypersensitivity; asthma; hepatitis; narrow angle glaucoma; GI or GU obstructive diseases; myasthenia gravis; pregnancy category C

Adverse/Side Effects: Fatigue, dizziness, drowsiness, disorientation, restlessness, hallucinations, toxic psychosis; dry mouth and throat, constipation; urinary retention; decreased heart rate; dilated pupils, photophobia, blurred vision, follicular conjunctivitis; depressed respiration; local irritation, rash

Interactions: Amantadine, antihistamines, TCAs, quinidine, disopyramide, procainamide add to anticholinergic effects; decreases levodopa effects; methotrimeprazine may precipitate extrapyramidal effects; decreases absorption and antipsychotic effects of phenothiazines

SODIUM CHLORIDE, 0.9% (NORMAL SALINE)

Class: Plasma volume expander – crystalloid; isotonic salt solution

Action: Each mL contains 9 g sodium chloride (Na^+ 154 mEq/L; Cl^- 154 mEq/L); pH 5.7; expands circulating volume by approximating sodium content of the blood; but, it remains in the intravascular space for only a very limited time as it diffuses rapidly throughout the extracellular space

DOSE: 500–1000 mL IV; 5-50 mL IV for medication dilution or as flush

Indications: For fluid replacement and plasma volume expansion when blood or plasma is not available, and for adjunctive treatment of shock and hypovolemic states caused by hemorrhage, burns, surgery, sepsis, trauma, dehydration, or heat injury; also used for dilution of medications, as IV flush agent, for saline locks, and irrigation of eyes and wounds

Contraindications: Congestive Heart Failure

Adverse/Side Effects: Fluid overload, CHF, edema, electrolyte imbalance, hyperchloremic metabolic acidosis, hypertension

Interactions: No clinically significant interactions established

SODIUM CHLORIDE, 3% (HYPERTONIC SALINE)

Class: Plasma volume expander – crystalloid; *hypertonic* salt solution.

Action: Each 100 mL of **3% Sodium Chloride Injection USP** contains: Sodium Chloride USP 3g; pH: 5.8 (4.5–7.0); calculated Osmolarity: 1030 mOsmol/liter

DOSE: 250mL IV bolus

Indications: For fluid replacement and plasma volume expansion when blood or plasma is not available, and for adjunctive treatment of shock and hypovolemic states caused by hemorrhage / trauma, hyponatremia. For TBI with GCS < 13.

Contraindications: CHF; do not use with blood or blood products, presence of normal or elevated plasma electrolyte concentrations

Adverse/Side Effects: Fluid overload, CHF, edema, electrolyte imbalance, hypertension

Interactions: None

SUMATRIPTAN (IMATREX)

Class: Antimigraine

Action: Insert action

DOSE: Tabs 25-100mg PO single dose q 2hrs. Max 300mg daily. Sub Q injection initial 6mg repeated 1-2 hrs if needed. Max 6 mg q 24hrs. If migraine symptoms return 50mg PO q 2 hrs up to 200 mg.

Indications: Relief of acute migraine headaches

Contraindications: Basilar migraine, cardiovascular disease, concurrent use of ergotamine-containing drugs, hypersensitivity, ischemic heart disease, use within 14 days of MAO inhibitors, within 24hrs of serotonin receptor agonist.

Adverse/Side Effects: Anxiety, dizziness, drowsiness, fatigue, fever, malaise, sedation, seizures, vertigo, arrhythmias, coronary artery vasospasm, chest tightness, hypertension, palpitations, abnormal vision, nasal irritation, photophobia, tongue numbness, abdominal discomfort, dysphagia, muscle cramps, myalgia, dermatitis, diaphoresis, flushing, pallor, or pruritus.

Interactions: Antidepressants, sertraline, and MAO inhibitors

Mission Impact: **GROUNDING** medication for personnel on flight status.



TERBINAFINE (LAMISIL)

Class: Antimicrobial – antibiotic; antifungals

Action: Inhibits sterol biosynthesis in fungi; ergosterol, the principal sterol in the fungal cell membrane, becomes depleted and interferes with cell membrane function, thus producing antifungicidal effect

DOSE: For tinea pedis, tinea cruris, and tinea corporis, topically AAA qd-bid x 1-7 wks; for onychomycosis, 250 mg PO qd x 6 wks for fingernails 12 wks for toenails (monitor baseline LFTs, repeat at least monthly)

Indications: For topical treatment of superficial mycoses such as interdigital tinea pedis, tinea cruris, and tinea corporis due to *Epidermophyton floccosum*, *Trichophyton mentagrophytes*, or *T. rubrum*; for oral treatment of onychomycosis due to tinea unguium

Contraindications: Terbinafine hypersensitivity; pregnancy category B; elevated LFT or known liver disease, hepatitis or mononucleosis.

Adverse/Side Effects: Pruritus, local burning, dryness, rash, vesiculation, redness, contact dermatitis at application site; headache; diarrhea, dyspepsia, abdominal pain, neutropenia; taste disturbances

Interactions: May increase theophylline levels; may decrease cyclosporine and rifampin levels

TETRACAINE OPHTH

Class: Local anesthetic

DOSE: 1 or 2 drops – 2 to 3 minutes before procedure. DO NOT DISPENSE TO PATIENT.

Indications: As a topical optic anesthetic (may aid in ocular exam to relieve blepharospasm); removal of foreign bodies

Contraindications: Not for prolonged use, Pregnancy Category C

Adverse/Side Effects: Stinging, Conjunctival redness, tearing swelling, sensitivity to light, transient eye pain, hypersensitivity reactions

Mission Impact: **GROUNDING** medication for personnel on flight status.



TRANEXAMIC ACID (TXA)

Class: Antifibrinolytic agent; synthetic lysine amino acid derivative

Action: Displaces plasminogen from surface of fibrin by binding to high-affinity lysine site of plasminogen which diminishes dissolution of hemostatic fibrin, which decreases bleeding

DOSE: Administer 2 grams of TXA IV/IO as soon as possible but not later than 3 hours after injury.

Indications: For patients anticipated to need significant blood transfusion presenting with hemorrhagic shock, one or more major amputations, penetrating torso trauma or evidence of severe bleeding.

Contraindications: Active intravascular clotting, Pregnancy Category B.

Adverse/Side Effects: Blurred vision or impaired color vision. Gastrointestinal disturbances (nausea, vomiting, diarrhea) may occur but disappear when the dosage is reduced. Transient hypotension has been observed when intravenous injection is too rapid.

Interactions: Should not be administered concomitantly with Factor IX Complex concentrates or Anti-inhibitor Coagulant concentrates, as the risk of thrombosis may be increased.

Mission Impact: Store at 25°C (77°F); excursions permitted to 15°–30°C (59°–86°F)

TRIMETHOPRIM-SULFAMETHOXAZOLE (TMP-SMZ, BACTRIM, SEPTRA)

Class: Antimicrobial – antibacterial, sulfonamide.

Action: Fixed combination of TMP and SMZ, synthetic folate antagonists and enzyme inhibitors that prevent bacterial synthesis of essential nucleic acids and proteins; effective against *Pneumocystis carinii* pneumonitis, *Shigellosis enteritis*, most strains of *Enterobacteriaceae*, *Nocardia*, *Legionella micdadei*, and *Legionella pneumophila*, and *Haemophilus ducreyi*.

DOSE: 1 tablet (DS) PO bid x10 days for cellulitis, 3-5 days for UTI.

Indications: For cellulitis, pneumonitis, enteritis, severe complicated UTIs, acute otitis media, acute episodes of chronic bronchitis, prevention of traveler's diarrhea, cholera.

Contraindications: TMP, SMZ, sulfonamide, or bisulfite hypersensitivity; group A beta-hemolytic streptococcal pharyngitis; megaloblastic anemia due to folate deficiency; use caution with severe allergy or bronchial asthma, G6PD deficiency, and sulfonamide derivative drug (acetazolamide, thiazides, tolbutamide) hypersensitivity; pregnancy category C.

Adverse/Side Effects: Rash, toxic epidermal necrolysis; nausea, vomiting, diarrhea, anorexia, hepatitis, pseudomembranous enterocolitis, stomatitis, glossitis, abdominal pain; kidney failure, oliguria, anuria, crystalluria; agranulocytosis, aplastic anemia, megaloblastic anemia, hypoprothrombinemia, thrombocytopenia; weakness, arthralgia, myalgia, photosensitivity, allergic myocarditis.

Interactions: CNS depressants, alcohol, and phenothiazines augment CNS depression; food significantly decreases extent and rate of absorption, do NOT give with or immediately after a meal.

Mission Impact: None

ZOLPIDEM (AMBIEN) ++CONTROLLED SUBSTANCE IV++

Class: CNS agent – non-benzodiazepine; anxiolytic, sedative-hypnotic

Action: Nonbenzodiazepine hypnotic that does not have muscle relaxant or anticonvulsant effects; preserves deep sleep (stages 3 and 4) at hypnotic doses

DOSE: 5–10 mg PO qhs, limited to 7–10 days

Indications: For short-term treatment of insomnia

Contraindications: Pregnancy category B

Adverse/Side Effects: Headache on awakening, drowsiness or fatigue, lethargy, drugged feeling, depression, anxiety, irritability, dizziness, double vision; doses >10 mg may be associated with anterograde amnesia or memory impairment; dyspepsia, nausea, vomiting; myalgia

Interactions: CNS depressants, alcohol, and phenothiazines augment CNS depression; food significantly decreases extent and rate of absorption, do NOT give with or immediately after a meal

Mission Impact: Drowsiness



NEW DRUGS

Class:

Action:

DOSE:

Indications:

Contraindications:

Adverse/Side Effects:

Interactions:

Mission Impact:

K-9 Dosage:

Class:

Action:

DOSE:

Indications:

Contraindications:

Adverse/Side Effects:

Interactions:

Mission Impact:

K-9 Dosage:

Class:

Action:

DOSE:

Indications:

Contraindications:

Adverse/Side Effects:

Interactions:

Mission Impact:

K-9 Dosage:

Class:

Action:

DOSE:

Indications:

Contraindications:

Adverse/Side Effects:

Interactions:

Mission Impact:

K-9 Dosage:

Class:

Action:

DOSE:

Indications:

Contraindications:

Adverse/Side Effects:

Interactions:

Mission Impact:

K-9 Dosage:

PHARMACOLOGY NOTES

PHARMACOLOGY NOTES

DRUG QUICK REFERENCE

ACETAMINOPHEN (Tylenol): 325-1000 mg PO q4-6h PRN (max: 4 g/d)

DEXAMETHASONE (Decadron): 4mg PO every 6-12 hours; 10 mg IV/IM single dose

DIPHENHYDRAMINE (Benadryl): 25-50mg IV/IM/PO q4-6h

EPINEPHRINE (1:1000): 0.3-0.5mg IM q10-15min

ERTAPENEM (Invanz): 1g IV/IM q24h

FENTANYL ORAL LOZ: 800-1600 mcg (max: 1600 mcg/d)

FENTANYL: 50-100 mcg IV/IM q 12 h PRN

HYDROMORPHONE (Dilaudid): 1mg PO/SC/IM/IV q2-4h PRN

IBUPROFEN: 800 mg PO TID

KETAMINE: 1-1.5mg/kg slow IV push until nystagmus, bump 20-25mg every 10-20 min

KETOROLAC (Toradol): 15 mg IV or 30mg IM q6h

LIDOCAINE: Infiltration 0.5%-2% injection

MELOXICAM (Mobic): 7.5-15 mg PO daily

MIDAZOLAM (Versed): 1 mg slow IV push every 2-3min to max dose of 10mg OR 5-10 mg IM for seizure control

MOXIFLOXACIN (Avelox): 400 mg PO/IV daily

NALOXONE (Narcan): 0.4-2.0 mg IV; repeat q2-3min to max of 10 mg PRN

NAPROXEN: 250-500 mg PO BID

ONDANSETRON (Zofran): 4-8 mg slow IV push or IM q4h prn OR 4-8 mg PO q4h prn

PROMETHAZINE (Phenergan): 12.5-25 mg PO/IM/IV q4-6h PRN


TRANEXAMIC ACID (TXA): 1 gm IV/IO ASAP, 2nd dose after blood transfusion

SECTION FIVE

**SPORTS MEDIC
SCOPE OF PRACTICE**



Shoulder – Traumatic & Acute Pain



R.I.C.E.

Relative rest as designated on profile

Ice compress 2-3 times daily for 20m


Compression by use of elastic bandage

Elevation of affected joint above heart during periods of rest

Arm / Elbow – Traumatic & Acute Pain



- RED FLAGS**
- History of FOOSH with pain TTP at lateral elbow or signs of dislocation
 - History of lifting/stretching and feeling a “pop” at biceps insertion
 - Deformities of forearm/elbow – indication of possible fracture
 - Neuro-Vascular compromise on exam
 - S/S of infection with or without other symptoms
 - Bites – human or animal
 - Unwillingness to move due to pain
 - Elbow/forearm edema



R.I.C.E.

Relative rest as designated on profile

Ice compress 2-3 times daily for 20m


Compression by use of elastic bandage

Elevation of affected joint above heart during periods of rest

Hand / Wrist – Traumatic & Acute Pain



- RED FLAGS**
- History of FOOSH with pain TTP at anatomical snuffbox or signs of dislocation
 - Deformities of wrist/hand – indication of possible fracture
 - Neuro-Vascular compromise on exam
 - S/S of infection with or without other symptoms
 - Bites – human or animal
 - Unwillingness to move due to pain
 - Wrist/Hand edema
 - Inability to actively flex/extend an individual digit



R.I.C.E.


Relative rest as designated on profile

Ice compress 2-3 times daily for 20m


Compression by use of elastic bandage

Elevation of affected joint above heart during periods of rest

Hip – Traumatic & Acute Pain



Leg – Traumatic & Acute Pain



R.I.C.E.


Relative rest as designated on profile

Ice compress 2-3 times daily for 20m

Compression by use of elastic bandage

Elevation of affected joint above heart for 10-15m every 2h.


Knee – Traumatic & Acute Pain



Ankle – Traumatic & Acute Pain



RED FLAGS
 Inability to bear weight immediately after injury (taking 4 steps)
 Bone tenderness at the posterior edge or tip of either malleolus
 Bone tenderness at the navicular or proximal base of 5th metatarsal
 Achilles Rupture
 (+) Simmond/Thompson Test
 Joint Infection S/S
 Deformity
 Fibular head tenderness
 Neurovascular Compromise



R.I.C.E.
Relative rest as designated on profile
Ice compress 2-3 times daily for 20m
Compression by use of elastic bandage
Elevation of affected joint above heart for 10-15m every 2h.

LATERAL ANKLE SPRAIN GRADING
1st Degree – stretched with some fibers torn
 + mild pain & swelling, able to ambulate
 + no mechanical instability
 + Localized tenderness anteriorly
2nd Degree – partial tear with significant disruption
 + moderate pain & swelling w/ecchymosis
 + pain with ambulation
 + moderate lateral ankle instability
3rd Degree –
 + severe ecchymosis & edema >4cm at fibula
 + unable to bear weight
 + severe ankle instability
 + heard “pop” with immediate pain and edema

Notes:



SECTION SIX

**MPC / CANINE
TRAUMA
&
TACTICAL MEDICAL
EMERGENCY PROTOCOLS**



Canine Patient Assessment



GENERAL GUIDELINES

Medics should only perform procedures necessary to treat life-threatening emergencies and prepare Multi-purpose Canines (MPC) for MEDEVAC. Canine patients differ slightly in anatomy, physiology and pharmacology to injured adult humans; however, the same trauma principles apply. Knowledge of these key differences will increase success of resuscitative efforts to our MPCs. Routine care of MPCs requires guidance from veterinary personnel. Veterinary care isn't always available within your AO. It's often limited to major transport hubs.

CANINE VITAL SIGNS AND NORMAL VALUES

1. Temperature: Normal Rectal Temp is 99.5 to 102.5 degrees F
 - a. May increase up to 106 degrees F after exercise/ work without deleterious effects.
 - b. An acclimated and conditioned dog should recover to a normal temperature within 10-15 minutes after exercise.
2. Pulse: Normal pulse rate varies from 60-120 bpm in conditioned dogs, and increases with exercise/excitement.
 - a. The femoral artery, or grasping the chest at the heart, are the easiest locations to feel a pulse. The femoral artery is located on the inside of a dog's rear limb at the division between the sartorius muscle and gracilis / adductor muscles. In simpler terms, it is generally just behind the femur on the inside of the hind leg. Apply light pressure and you should feel the pulse with two fingertips.
 - b. Alternate distal sites include: 1. Medially above the large foot pad on the backside of the front limb. 2. Medially two finger widths below the hock on the front/inside of the hind limb.
 - c. Variations will exist between individual dogs.
 - d. Count the number of beats for 15 seconds and then multiply by 4 to get beats per minute. Alternatively you can count for 10 seconds and multiply by 6 or count for 6 seconds and multiply by 10.
 - e. Pulses should be strong, succinct and synchronous with heart beats.
3. Respiration rate: 10-30 respirations per minute. Controlled panting is normal, meaning panting should stop with any significant stimulus (Ball, kong, treat, tug, smell of isopropyl alcohol).
4. Capillary refill time (CRT): less than 2 seconds.
5. Mucous membranes (MM): generally pink and moist. Many dogs will have pigmented membranes.
6. Skin Turgor: pinch the skin between the shoulder blades and lift up pulling out any slack. Release and the skin should immediately fall back into place if properly hydrated.
7. ETCO₂: normal 35-45 mm Hg
8. Pulse Ox: >95% SpO₂. Place the probe on the tongue or any highly vascularized, non-pigmented area (lip, vulva, prepuce, between toes, etc). Nonin finger probes only work on the tongue. Sedation with dexmedetomidine lowers SpO₂ reading on the tongue.
9. Indirect Blood Pressure (BP): >90 mm Hg Systolic, >60 mm Hg MAP, >40 mm Hg Diastolic. Use pediatric-sized non-invasive blood pressure cuffs (neonate 5, pediatric 6-8). The cuff should be tight without overlapping. Use pediatric settings on BP machine. Placement options below in order of ease.
 - a. Tail: place at the tail base (closest to body) with the artery indicator zone on the bottom side.
 - b. Front limb: place above the carpus with indicator zone on the back side.
 - c. Hind limb: place below the hock over the metatarsals with indicator zone on top of the foot and slightly off-center medially.
10. Labs: human analyzers may be used for canines.
 - a. Chemistry, HCT, and ABG parameters similar to humans.
 - b. Canine albumin values are falsely low using human analyzers, and not accurate for diagnostic purposes.
 - c. Urine output 1-2 ml/kg/hr. Urinalysis results comparable to humans.

CANINE CPR

1. If MPC is unresponsive, not breathing **AND** the tactical situation permits then begin CPR. Lay the animal on either side.
2. Hand placement can be directly over the heart (where the elbow crosses the chest above the sternum when the forearm is pulled caudally) or over the widest part of the chest.
3. 100 to 120 compressions per minute. Sustain compressions for at least 2 minutes per cycle before checking status. Compress 1/3 to 1/2 the chest width. Check status - palpate femoral pulse (Radial pulse is not easily palpable in a dog).
4. Establish airway as rapidly as possible (Intubate or tracheostomy without interrupting compressions).
5. Ventilate at 8-10 breaths per minute, Use oxygen if it's available.
6. With more help or higher level of care you can begin advanced life support procedures. ECG, ETCO₂, vascular access

Canine Trauma & Shock Management



S/S OF CANINE TRAUMA & SHOCK

S/S of Shock:

1. Pale, gray, blue MM.
2. Prolonged CRT, > 3 seconds.
3. Weak, "thready" pulses.
4. Tachycardia, >160 bpm.
5. Tachypnea, > 30 bpm (differentiate from panting).
6. Decreased consciousness.
7. Hypotension.
8. Collapse.

Advanced:

1. Loss of consciousness.
2. Dilated pupils.
3. Dyspnea.
4. Hypothermia, < 98 degrees F.
5. Mechanism: Often seen with penetrating wounds of the neck, chest, abdomen and hip.

CANINE TCCC MANAGEMENT

Canine trauma management follows the same TCCC/ MARCH principles as for humans. This section covers specific deviations and/or requirements from human protocols, which may improve survivability of MPC trauma patients. Handlers are trained in these principles and will usually be the first to initiate aid.

Safety. Injured MPCs may bite from fear and/or pain, even with decreased consciousness. Wounded MPCs must be muzzled when performing assessment and procedures unless presenting with respiratory distress. Sedation/ pain meds are authorized for MPCs not amenable to physical exam or treatment.

Care Under Fire.


Handler is okay: Handler will move himself and injured MPC to cover. Handler and/or medic perform quick head- to-toe check **assessing level of consciousness** and correcting life-threatening hemorrhage if the situation permits.

Handler Wounded: Wounded Rangers are first priority. Remove the injured MPC to cover if tactically feasible. Every handler should have members of their platoon identified and comfortable working with the MPC. This person will help maintain control of the injured MPC while another medic or ARFR provides care.

Tactical Field Care. MPC moves to CCP with other casualties. Medic triages other casualties before attending to MPC's wounds. Handlers and/or other EMT/ RFR will provide initial care until medics can divert their attention. Remove equipment and tactical vests to fully assess the chest area. Provide sedation/ pain meds (dosages on MPC Card) as needed in conscious patients to complete exams and treatments. Communicate MPC casualty status and evacuation requirements through normal C2 channels.

Tactical Evacuation. MEDEVAC per usual manner according to precedence (Urgent, Priority, Routine). However, MPCs will not precede other casualties of the same category. Handlers or trained representatives must remain with the MPC throughout transport. Always reassess the patient and all interventions after movement. Always complete a K9 Casualty Card and maintain with the patient throughout transport. Complete a casualty AAR in the normal manner and include the RVET on all communications. MPC casualty information is maintained in the Pre-Hospital Trauma Registry the same as Rangers.

Point of Injury:



M³ARCH Always try to consider what is killing the animal and treat that first. Use the Algorithm when you are not sure.

1. Muzzle: Although our dogs are generally sociable with other Rangers, any dog in pain will likely bite. These dogs bite really hard... Muzzle them first. Generally our handlers carry a medical muzzle in their lower leg pocket.

2. Massive hemorrhage: Control extremity bleeding with combat gauze and pressure bandages. CAT tourniquets are large and effectiveness can be tricky. If used, place above the stifle or elbow for injuries distal. SOF-T tourniquets are 100% useless on dogs. Pack GSWs to the neck, hip and shoulder with **combat gauze** using hemostats or Rochester-Carmalt 8" (curved) or Rochester-Pean (curved) 8" forceps. X-stat has been ineffective at staying in the GSW track of a hip and did not create tamponade or effective hemostasis in one Ranger MPC.

3. Medication (Consider) an alert injured dog may need its pain managed and sedated just to pack a wound/treat an injury, catheterize, bandage, etc. Unconscious dogs don't need sedation. In an alert dog start on M³ARCH and if necessary sedate. The following are protocols that may be used based on the medications available to Ranger Medics and Handlers in combat:


a. Alert dog with strong pulse (e.g. bleeding a little but not bleeding out, can't restrain for fractured leg splint/bandage or pad laceration or need to pack a GSW through the neck, leg or hip that only has minor bleeding, sedate a healthy dog for blood donation)

0.5 mL (0.25mg) of Dexmedetomidine
+1.5 mLs (150mg) of Ketamine
+ 1-2 mLs (2-10mg) Midazolam
Approx. 4mLs total volume in 5mL syringe, give IM. Takes 10 minutes lasts up to 40 min



b. Responds to voice commands, beginning of shock, losing consciousness has a weak pulse, is bleeding profusely in pain but won't hold still

1.5 mLs (150mg) of Ketamine
+ 1-2 mLs (2-10mg) Midazolam
Approx. 3.5mLs total volume in 5mL syringe, give IM



c. Unconscious dog, no response, barely detectable pulse

DOESN'T GET SEDATED

4. Airway: First check the airway to ensure it is clear using a finger sweep. Then determine the dog's breathing pattern, rate and if it is having difficulty to determine if interventions are necessary.

a. NPAs are not functional in MPCs.
b. Orotracheal intubation is easier than for humans. Intubation is only possible if there is loss of consciousness or significant sedation. If under cover, use a size 9 or 10 ET Tube found in the Handler's IFAK. Place the MPC in sternal recumbency with the head held out, extending the neck. Assistant grasps over the top of the muzzle. He then pinches the top lips behind the top canines with one hand and uses the other to open the lower jaw. The assistant then pulls the tongue out and downward between the lower canine teeth opening the mandible (use gauze if you can, its slippery). Medic/handler can then insert the ETT between the arytenoids similar as a person. Use an 8" curved Rochester-Pean (or Carmalt) Forceps or tongue depressor with light source to reach back to the soft palate and gently flip down the epiglottis to visualize the arytenoids.

NOTE: After the ET tube is inserted, pass a 2" roll of Elastikon or Coflex over the end of the ET tube and secure in the dog's mouth as a gag. Use 1" white athletic tape (handler's aid kit) to keep the dogs mouth shut around this temporary gag (see picture on the next page). This will give you time to remove or re-sedate the dog and prevent him from chewing through the tube if he wakes up.

c. Perform a surgical tracheostomy if upper airway is obstructed and the animal is unconscious (or properly sedated). The cricothyroid membrane is difficult to access in dogs. Make at least a 3" midline incision from a point that is 3 finger widths from the thoracic inlet (base of the neck) rostral (toward the head). Now make a midline incision through the facial layer of muscle and blunt dissect (fingers) to the trachea. Make a stab incision between tracheal rings to access the tracheal lumen. Insert the handler's 9-10 mm ETT (preferred) up to the thoracic inlet or use the standard 6mm Cric kit tube when an ETT is unavailable. Secure in place as usual.

d. Emma / ETCO₂ Monitor. (Ref Range is 35-45 mm Hg). Opioids (e.g. Fentanyl CRIs) can depress the CNS leading to a higher CO₂ reading. Pain will cause an animal to hyperventilate and decrease the CO₂ reading.

5. Respirations:

a. Remove the vest. Check both sides of the chest and neck. Thirty percent of our penetrating GSWs to the thorax communicated with a GSW to the neck.

b. In the conscious patient with an actively sucking wound - use a large vented occlusive dressings. It is difficult to get them to adhere, bigger is better. Try to cover as much surface area as possible with the occlusive dressing. Wrap the chest circumferentially with an Elastikon bandage if adherence is a problem. Be careful not to restrict breathing. Be prepared to treat a pneumothorax or hemothorax.

c. Dogs with pneumothorax and/or hemothorax often have increased resistance when bagging and may present ETCO₂ two ways when intubated: 1) they may have a low ETCO₂ reading because the volume of air crossing the sampling device (emma) is decreased from the restriction of tidal volume movement caused by the tension pneumothorax or 2) a high ETCO₂ reading when enough tidal volume is available to move but venous return to the heart is decreasing from pressure. This causes less blood to move to the lungs which increases the concentration of CO₂ that is released when it finally arrives. The wave form is normally square with the right side of the square/plateau slightly higher. Pneumothoraxes often show a short plateau wave form where the left side of the plateau is higher. Open chest lacerations/finger thoracostomies need positive pressure ventilation. Increased compliance while bagging may indicate hemopneumothorax / pneumothorax / hemothorax and the need to be decompressed.

d. Needle decompression: Place between 6th to 8th intercostal spaces cranial to the rib using a standard 14 ga. catheter. Place in highest portion of chest when laterally recumbent to remove air and lower third (near sternum) to remove fluid. Repeat needle decompression often indicates need for tube or finger thoracostomy. NOTE: 92% of dogs have a fenestrated mediastinum but bilateral decompression may be indicated clinically in a smaller percentage.

e. Chest tube: Indicated if needle decompression does not resolve pneumothorax or hemothorax is present. Place the dog in lateral recumbency with the affected side up. Pull skin cranially. If conscious, block the rib in front and the rib behind with 1-2mLs of lidocaine (about an inch proximal to your entry point). Use a 28-36 french chest tube (same as a human). Place mid-thorax between the 7th and 8th intercostal space (dogs have 13 ribs per side). Enter the chest at the highest point of the chest wall. Direct tubes in cranioventrally (toward the head and sternum) direction. Place entry point cranially over ribs to avoid vessels and nerves. Have an assistant pull the loose skin cranial before the incision is made in the 7th or 8th intercostal space to obtain a better seal.

6. Circulation: Make sure there is not major bleeding and control as necessary. Penetrating wounds to the neck that you believe communicate with the thorax (or severs major vasculature of the neck), obvious penetrating wounds to the chest, abdomen or hip are all considered significant mechanisms of injury. Treat for hemorrhagic shock if two or more clinical signs below are seen):

- Pulse >160bpm
- Loss of consciousness
- Weak femoral pulse
- HR > Systolic Blood Pressure
- Systolic BP < 90
- Tacky mucous membranes
- ETCO₂ <35mm Hg
- Estimated 400mls blood loss or more (one saturated roll of Kerlix)
- Mechanism of injury includes a penetrating wound to the neck, chest, abdomen or hip

Resuscitate until femoral pulses are palpable or systolic pressure >90 mmHg. Intravenous route is preferred; Secondary route is IO (lateral humoral head or tibial crest). Incorporate fluid therapy as needed. Resources will often limit canine blood availability to one unit which is generally with the Ranger medevac asset in theater. Encourage handlers to manage and carry that unit of blood on target OR convince the company commander to take the Battalion's Animal Care Tech. If blood products are unavailable make sure that it is asked for in line 4 of the 9-line request so other assets in theater can begin to pull blood from their walking canine blood banks before your patient arrives. Absolutely no human blood product should go to a Ranger MPC. It has contributed to the death of a Ranger MPC as recently as 2017. If no canine blood is available then bolus 500 to 700 mL of crystalloid over 20-30 minutes, reassess vitals, repeat only if no change in vitals and there is no foreseeable extraction for the MPC within the next fifteen minutes. Do not exceed 2 L in one hour. Follow fresh whole blood transfusion protocol if second dog is available. This is most practical after evacuation to higher care. Monitor for circulatory overload the same as humans.

7. Hypothermia: Dry the animal's coat as much as possible. Prevent loss of body heat using warming blankets. Use fluid warming devices if saline lock initiated. Protect against wind and elements.

AND

Head Trauma: The most common cause for head trauma / TBI may occur with blast injuries. Of the 6 blast injuries sustained so far by our MPCs, 2 died immediately and the other four did not report any issues related to head trauma and returned to duty. Suspect head trauma/TBI if the MPC is in close proximity to explosions/ blasts or other nearby Rangers are affected. Altered consciousness and pupillary function (equality and reactivity) are vital when assessing the patient.

a. Key to field management is prevention of Hypoxia (maintain SpO₂ >90, preferably >95) and Hypotension (maintain Systolic >90 mmHg). Maintain an airway and ventilate at 12-20 bpm with approximately 400-500 ml tidal volume. Do not hyperventilate.

b. Elevate the Head / body upward 30 degrees if hemodynamically stable. Keep the body and neck in a straight line by placing the patient on a board or litter and propping up the end toward the head. Do not place material directly under the head causing a bend in the neck, which may decrease venous return to the heart.

c. Levels of Consciousness: Alert, obtunded (verbal), stuporous (pain), and comatose (unconscious) is similar to AVPU. An obtunded animal should still respond to noise or touch. Stupor indicates a loss of consciousness (LOC); they respond only to noxious stimuli (pinch across the toes with fingers). Comatose dogs exhibit no response to repeated noxious stimuli.

d. Perform a full exam for other injuries, especially thoracic auscultation, and perform regularly throughout the mission. Treat subsequent injuries as needed.

e. Ruptured tympanic membranes require veterinary-specific otic cones to diagnose. The canine ear canal is extremely long and has a ninety degree bend.

f. All blast injuries and/or suspected head trauma/ TBI require follow up with a veterinarian for monitoring, thoracic radiographs and TM assessment

RAC (Only on the Stuporous or Unconscious MPC) Always try to consider what is killing the animal and treat that first. Use the Algorithm when you are not sure.

Ten of 18 combat deaths in Ranger MPCs involved penetrating wounds to the thorax making up 55% of all our KIAs. These wounds are 35% of all combat related injuries sustained by Ranger MPCs. No Ranger MPC has survived a penetrating chest wound to date. Dogs often die quickly from chest wounds because they have no functional body armor, a larger heart (dog at 7g/kg bwt so 223g vs a human at 5g/kg bwt and a 247g heart) and they are almost always shot through both sides of their chest which doubles the chance of pulmonary vessel involvement. Half of our MPC combat related deaths are because they bled out into their chests. In contrast, 4/29 MPC Combat Related injuries were to the extremities alone and none of those animals died. This deviation in protocol from M²ARCH is one attempt to save more dogs with a penetrating GSW to the thorax wound pattern. We are also awaiting the development of lighter and more flexible, thoracic body armor.


The new algorithm is only used in the stuporous or unconscious dog (both indicate LOC). **Check pulse and breathing for signs of life** before wasting resources and time on a dead animal. If the animal is apneic and pulseless - perform a bilateral finger thoracostomy in the 6th or 7th ICS, look for blood and reassess.

1. Respirations (Alive)

The goal is to identify any chest or neck (neck wounds often communicate with the chest wounds in our MPCs) wound while also paying attention to respirations during your search. **If there is no wound in the chest or neck, move back to M²ARCH.** If there is an assistant have them look for massive hemorrhage while you roll through RAC. If there is a wound in the chest, make a mental note, check for the exit wound but don't bother covering them with a chest seal in this algorithm. A thoracic wound with either progressively rapid shallow breathing or no breathing with a distended/swelling chest needs decompressed with a 14ga needle. This enters at the 6th or 7th ICS on the highest point/mid-point (of the chest). If the first NCD needle fails try once more on the opposite side of the chest and move on to airway. Place chest tubes, if necessary, only after airway and circulation have been addressed.

2. Airway

Obviously look for an airway obstruction and clear it if present or if it is possible. To date the Regiment has had one significant MPC airway obstruction, it never lost consciousness, never received a tracheotomy and survived. The idea in this algorithm is to quickly secure an airway in an apneic canine patient that has been shot in the chest. Intubation is much faster and easier in a dog than a tracheotomy. In the unconscious animal insert a 10mm ET tube using your large Rochester Curved Carmalt (or Penn) forceps (found in your chest tube kits) to flip the epiglottis down. Visualize the arytenoids with a head lamp and insert the ET tube to the level of the Thoracic inlet. If carried, place a roll of coflex or elastikon over the end of the ET tube to the back of the mouth and tape in place with athletic tape to create a bite block. If the animal wakes up this will prevent him from chewing through the tube until you can sedate him. Apply your Emma and bag when indicated. If bagging is necessary (Apneic, ETCO₂ above 50mm Hg) - be sure to pay attention to bag compliance (you don't want to push through a pneumothorax). If the animal is breathing move on to circulation. If the animal is apneic while intubated and there is resistance to bagging consider NCD or finger thoracostomies for pneumo/hemothorax. Finger thoracostomies would require bagging the apneic patient and likely require assistance in a canine patient that is breathing.



3. Circulation

By this point you have already checked a femoral pulse and know whether it is weak or not. An unconscious dog with a penetrating chest wound automatically makes the animal a candidate for hypovolemic shock and should be treated for it. IV catheterization > IO. TXA may be given (5 mLs or 500mg IV) in the flush once followed by Canine blood > Canine Fresh Frozen Plasma > Plasmalyte A or LR > 0.9% Saline. Give a unit of blood or a quarter shock dose of crystalloids (app 700mLs) and reassess. After RAC move back to MARCH.

Antibiotic Therapy for Penetrating Wounds: There is very little data on the use of Ertapenam (Invanz) in dogs. Plumb's recommended dose is 15 mg/kg IV or IM so about 450mg IV / IM (4.5 mLs once reconstituted) twice a day.

Canine Casualty Card: Medics must complete a casualty card provided by the handler or found on the unit portal under the RMED/RVET section. Send casualty assessment and AAR through appropriate channels with inclusion of the RVET and Bn Vet Tech. MPC casualties are stored in the PHTR the same as Rangers.

EVACUATE: Evacuate to a Veterinary Treatment Facility with surgical capabilities or human equivalent (CSH, FST) depending on MEDEVAC times and patient precedence. Canine casualties may be evacuated with human casualties. A medevac/casevac plan **MUST** be worked out for the dog during mission planning. Make sure either the handler or platoon medic briefs what facility will be used during the mission brief so the GFC and Medo know where to send it. There is **ALWAYS** confusion with what evacuation asset will be used and where a dog casualty will go after extracted from combat. Most commanders are not willing to risk the lives of air crewmen for a lone dog casualty on a hot LZ. This means the MPC often extracts with unit. Make sure the driver or pilot of the CASEVAC platform knows where to take dog casualties before the mission starts. Ensure the Medo relays line 4 information (e.g. canine blood!) to the receiving veterinarian. Ensure any handler not on the mission knows he needs to take a (spare) MPC to the veterinarian in case blood is needed. Finally make sure everyone has the veterinarian's contact information and calls them immediately.

1. Handlers or a trained representative should always escort MPC casualties.
2. Conscious canines are difficult to evacuate on human litters (even if strapped down). Most handlers carry canine specific litters.

Splinting/bandaging: Immobilize fractures when packaging for MEDEVAC to alleviate pain and reduce further soft tissue damage. One joint above and one joint below the fracture require stabilization to be effective.

1. This effectively limits splinting to fractures below the elbow and the stifle.
2. Use a Telfa on open wounds followed by white conforming gauze or kerlix to hold in place. Leave the center two toes exposed. Always start bandaging at the toes and wrap proximally, regardless of the fracture location.
3. Place a second layer over the holding gauze (second roll of kerlix, cast padding or cotton). Compress (do not constrict) with coflex (or vetwrap) leaving a 1/2" of the gauze exposed on each end. A final wrap around the chest or pelvis (usually with elastikon carried by the handler) will help hold in place.
4. Place a SAM splint, or equivalent devise, the entire length of the leg. Place on the lateral aspect of the limb from the toes to above the shoulder or hip joint.

CANINE FIELD BLOOD TRANSFUSION PROCEDURE

Coordination **WILL** be made with either the RVET, Battalion 68T or deployed veterinary assets to maintain at least a unit of whole blood at all times. Do not ever let a human receive dog blood. One unit of whole dog blood should be drawn every three weeks and (if a blood bank is not available) stored at 2-4°C (35.6-42.8°F). This blood will be clearly marked "K-9" and travel with the handler, 68T, designated dog blood mule or MEDEVAC asset in an approved container while MPC teams are on mission. Follow temperature recommendations for each product. It must then immediately be transferred back into the designated blood refrigerator upon RTB. Three Ranger MPCs had no drop off in performance (after a 450mL donation) when given 24 hours to recover and no crystalloid fluids to replace the loss. Each dog went through this protocol for two blood draws three weeks apart and were not affected when compared to controls. Two dogs on deployment will have no issue alternating blood donations every three weeks. One dog deployments occur and they cannot donate every three weeks for themselves. Coordinate with the RVET to have canine plasma available if no other MWDs are available for whole blood donations during single MPC deployments.

Indications for transfusion are the same as for people, i.e. hemorrhagic shock therapy. This protocol is designed for use on the battlefield using the standard collection set. However, situations may occur in which the medic must perform these procedures while assisting at veterinary or medical treatment facilities following MEDEVAC. Any healthy Military Working Dog is authorized as a donor because the risk of infectious disease is presumably low. Do not use indigenous dogs for fear of personnel safety, blood borne disease transmission and zoonotic diseases, i.e. rabies.


Dogs have 8 identified blood types. They do not have naturally occurring antibodies, and the first transfusion usually does not cause allergic reactions (the first one is "free" in an emergency) within the first three days. Meaning, there is no need to blood type or cross match the first transfusion a dog receives on the battlefield. An MPC that previously received a transfusion will be identified on his medical card. Discuss their medical requirements with the RVET prior to deployment.

Donor:

1. Shave the hair and aseptically prep the skin over the jugular furrow as much as possible.
2. Prepare the collection system.
3. Handler places the dog in a sit if trained, or lateral recumbency. Tilt the head up straightening the neck to expose the jugular vein.
4. Occlude the jugular vein by holding firm pressure at the thoracic inlet (clavicle region).
5. Insert the needle (not a catheter - they tend to coagulate) into the jugular vein (toward the head).
6. Collect the standard 450 ml (weighs 474g). To speed up the process place the bag below the collection site.
7. Hold pressure at the collection site after removing the needle until bleeding stops.
8. An IV catheter can be placed to replace volume. Give 1 L of crystalloids to replace volume, if time allows.

** Dogs have a large splenic blood reserve, and recover faster than humans after donating. Work performance does **NOT** deteriorate following donation if the animal is given 24hrs to recover. The MPC donor will usually have to be sedated. If two dogs are being used for a mission, pulling blood from a donor on the battlefield leaves you with potentially two compromised animals for at least 40 minutes. Donating in the field can only occur if the unit is stationary long enough to pull blood and/or has the personnel to carry or recover the second dog. Ensure handlers clip their dog's jugular and cephalic vein access sites every two weeks if a second dog is an option.

NOTE: When needed use dexmedetomidine, ketamine, midazolam combo dose. Reverse dexmedetomidine's effects with an equal volume of antisedan **IM** after collection if necessary. Consider the tactical situation and use your judgement when considering the sedation of a second dog.



Recipient:

1. Set up and administer in same fashion as for people.
2. Initiate an IV or IO.
3. Gather baseline vitals. (If in a controlled environment, collect a serum separator and CBC blood vial.)
4. Do not give Acetaminophen.
5. Give 50 mg Diphenhydramine IM if signs of reaction occur.
6. Administer antibiotics if aseptic collection from the donor is impossible.
7. Submit AAR to the RVET and/or Bn Vet Tech.

INJECTION & IV SITES

IM INJECTION SITES:

Use a 20-22 ga. 1 in. needle for IM and IV injections.

1. Thigh muscles: back of hind limb. Isolate the muscle belly mid-thigh and insert the needle at a 45 degree angle to avoid hitting the sciatic nerve.
2. Back muscles: inject approximately 3 finger widths cranial to the wing of the ileum in the muscle on either side of the spinous processes. Insert the needle at a 45 degree angle to avoid hitting bone.

IV SITES:


Use an 18 ga. IV catheter for MPC. Shave the area and clean before placing a catheter, if possible. Placement sites listed below in order of ease and precedence.

1. Cephalic vein: located on the front of the forelimb between the elbow and carpus (wrist).
2. Lateral Saphenous: vein on outside of the hind limb can be used if access to the cephalic vein is unsuccessful.
3. External Jugular: located in jugular furrow on either side of the trachea. Pressure must be placed at the cardiac inlet (near clavicle in people) to cause distension. Insert the catheter down away from the head. Insert blood collection needle up toward the head.

IO SITES:

Easy IO 15 mm or 25 mm (either hand or power driven) work best. They cannot be used in the sternum of a dog. Humeral head and proximal tibia are best, similar to human applications. Insert and set up the same as for humans. Placement listed below in order of best flow.

1. Humerus: Place patient in lateral recumbency and kneel with spine against your legs. Firmly grasp the front limb at the elbow to stabilize the limb. Drive the IO device into the flat, dorso-lateral surface of the humeral head (top outside surface) just behind the deltoid tuberosity (notch).
2. Tibia: Flat area on doro-medial aspect of tibia (top inside shin near the knee joint) on the hind leg.



Canine Tactical Medical Emergency Protocols

C1. CANINE HEAT INJURY

Definition: Hyperthermia as a result of heavy physical exertion and/or extended exposure to hot environments. Normal temperature range for a dog is 99.5-102.5°F, most acclimated/conditioned dogs can work up to 106°F. Dogs not affected by heat injury normalize their temperature within about 15 minutes.

S/S: Mild Heat Injury (Heat Stress): Excessive thirst, can still control panting (will stop panting when exposed to stimulus such as a ball or treat for instance), discomfort associated with physical activity (wants to hide, go lay down).

MGMT Mild Heat Injury: Remove MPC from the heat source/stop exercise, cool with fans or move to an air-conditioned area. Monitor for several hours by taking rectal temperature. Watch for progression by looking for changes in mentation, blood in the urine, petechiae, weakness, collapse, signs of shock (rapid breathing, rapid heart rate, weak pulse, pale membranes, anxiety or restlessness).

S/S: Moderate Heat Injury (Heat Exhaustion): Signs of mild heat injury are present but include weakness anxiety and **UNCONTROLLED panting** (pants through exposure to stimulus such as a ball or treat). CNS signs are **not** present. Temp is often over 106.

MGMT: Moderate Heat Injury: Remove MPC from the heat source/stop exercise, cool with fans or move to an air-conditioned area. **Wet the fur with lukewarm water.** Caution: using high pressure to hose down animals can cause stress and anxiety compounding the problem. Wet towels, bottles or low pressure hosing can be used. Ice baths and ice sheets may cool the animal too fast and can only be used if core temperature is monitored intensely. All cooling must stop at 104°F. Once the animal's body temperature is below 103°F provide supportive warming and dry the animal to prevent rebound hypothermia. Give small, frequent drinks of cool water; do not give a full bowl - vomiting may occur. If water is unavailable for soaking the fur of the animal then apply copious amounts of isopropyl alcohol on the inguinal and axillae areas. Intravenous fluid may be given to replace dehydration losses and help cool the animal. These can be found at the back of this section on the MPC card (For instance, a 70lb dog can receive 560mls/hr of LRS for two hours if he is assessed 5% dehydrated). IV fluids at room temperature will also help cool the animal. Monitor the temp frequently and discontinue cooling once achieving 104°F; rebound hypothermia may result with rapid cooling.

S/S Severe Heat Injury (Heat Stroke): Includes many of the signs of Moderate heat injury but the difference includes varying degrees of **CNS signs**. CNS signs include changes in mentation and level of consciousness (from depressed looking to coma), seizures, abnormal pupil size, blindness, head tremors and ataxia. Most temperatures are above 107°F but it has occurred as low as 105.8°F. Severe heat injuries are associated with a 50-64% mortality rate

MGMT Severe Heat Injury: Any animal considered a severe heat injury should be evacuated as an URGENT patient when feasible. Treatment in severe heat injury is the same for a moderate heat injury (remove from heat source/stop exercise, **wet the fur with lukewarm water**, etc) but may require other measures to treat shock, dehydration, protect the airway (if there is loss of consciousness), or treat seizures. Treat concurrent shock (e.g. weak femoral pulses, MAP < 60, SBP < 90) with room temperature fluid therapy (1/4 shock dose of crystalloid fluids is approximately 700mLs then reassess). Warm fluids are required after the animal's temperature drops below 103°F. Again, in the absence of shock use the MPC card and replace dehydration losses with fluid therapy (i.e. at 560mLs/hr for 2 hours if 5% dehydrated). Intubation (use a bite block) in the apneic, unconscious patient may be necessary, especially while cooling an unconscious patient down with running water. Monitor mental status closely and initiate the seizure protocol (10mg of Midazolam or Diazepam IV, IO or intranasal as needed) if necessary. Discontinue cooling at 104°F. Begin drying and warming at 103°F. Keep Systolic BP > 90 mmHg, MAP > 65 mmHg, RR 8-10 bpm, ETCO₂ 25-60 mmHg, SpO₂ >95% with supplemental O₂. If cerebral edema is suspected 30-60g of mannitol IV over 30 minutes with 15mg of dexamethasone IV (or 900mg of methylprednisolone IV) once. If ventricular arrhythmias are recognized/present only treat them if animal is hemodynamically unstable at 1.5 to 2.3 mg/min (2 mg/kg IV bolus, then 50-75 mcg/kg/min) of Lidocaine in a CRI/syringe pump. Monitor blood glucose for hypoglycemia every 4-6 hrs if possible (normal glucose is 60-110 mg/dL). Supplement maintenance IV fluids with dextrose to 5% and with KCl at 20 mEq/L routinely to maintain normoglycemia and normokalemia (normal potassium is 3.7-5.8mmol/L). Vomiting and/or diarrhea often occurs (sometimes with gastrointestinal **bleeding**), begin famotidine at 30mg IV or PO every 12 hrs, 16mg of Ondansetron IV or PO every 12-24hrs and 1g of sucralfate PO every 8hrs. No food or water until vomiting has resolved. Antibiotic treatment may begin with Cefazolin (Ancef) 600mg IV over 5 minutes every 8 hrs OR Ertapenam 500mg IV every 12 hours if GI hemorrhage is present.

Disposition: Evacuate to Veterinary Treatment Facility for further treatment.

Special Considerations: Critical care monitoring from veterinary personnel required after initial resuscitation due to sepsis and/or DIC.

C2. CANINE GASTRIC DILATATION VOLVULUS (GDV)

Definition: GDV is an Urgent Surgical condition in which the stomach becomes distended by excessive gas (dilatation), and can then twist (volvulus) cutting off blood supply returning to the heart. All Ranger MPCs have a surgery to prevent the volvulus, however dilatation may still occur. This is an emergency condition resulting in profound shock leading to death.

S/S: Abdominal distention, non-productive vomiting/retching, abdominal pain, signs of agitation/discomfort, SHOCK, may lead to DIC.

MGMT: 1. Treat for shock first: Insert a large bore catheter in each CEPHALIC vein and start resuscitative fluid therapy. Treat to a Systolic BP above 90 mmHg; does not require hypotensive resuscitation. 2. Decompress the stomach: Usually you need to lay the dog in left lateral recumbency (with the right side up). Anatomically in GDV, the big fundus of the stomach will most often be located on the right side. Auscultate the right side (should sound like a basketball when your finger flicks or 'pings' it) and palpate for gas distention, this helps identify the optimal location for trochar placement. Make sure you insert where the ping is loudest, a dull thud may indicate the presence of the spleen. Don't insert the needle near a thud. Hold pressure underneath the stomach on the down side pushing the stomach upward against the body wall. Insert a 14 ga. 3 in. catheter two finger widths past the last rib at the highest point on the side. You must go through the abdominal wall and stomach wall, meaning it must be a quick, forceful movement. Remove the metal stylet when in the stomach, and air should escape. If not, remove the catheter and try again.

* To increase speed of air evacuation place a 60cc syringe with 3-way stopcock to the catheter to facilitate faster aspiration.

NOTE: It is common for the spleen to block access to the stomach. If blood is seen in the catheter, remove it immediately, then try again in a different location.

Disposition: Evacuate immediately to veterinary care even if stable. Surgical correction is required.

Special Considerations: MEDEVAC at a low altitude to reduce further expansion of air in the stomach. Dilatation of the stomach may recur, be prepared to decompress again.

C3. CANINE ALTITUDE SICKNESS AND PULMONARY EDEMA

To date no Ranger MPC has had a recognized issue with altitude in training or while deployed.

Definition: Hypoxia and/or pulmonary edema usually occurring at altitude above 8,000 ft. Clinical signs **uncommon** in dogs, but possibility increases with greater activity levels.

S/S: Reduced appetite, listlessness, decreased coordination, dark tongue coloration, cough, dyspnea.

MGMT: 1. Descend from altitude 2. Provide flow-by supplemental oxygen at 5 L/ min if available (place oxygen tubing near the nose and secure on the muzzle; or make an oxygen mask with a cut plastic bottle running the oxygen tubing through the bottom). 3. Administer 3- 4 mL (0.5 mg/ kg) Dexamethasone SP (4 mg/ mL) IV or IM.

Disposition: Evacuate to veterinary care if non-responsive to treatment.

Special Considerations: PROPHYLAXIS: Acetazolamide (Diamox) 250 mg every 12 hours orally beginning 24 hours prior to ascent, and continue 48 hours after reaching maximum altitude. If using 500 mg sustained release tablets, give one 500 mg tablet every 24 hours. Prophylaxis is not needed for K9s if medical providers do not prescribe medication for Rangers.

C4. CANINE SEIZURE MANAGEMENT

Definition: Emergency seizure treatment required for status epilepticus or seizures secondary to other injuries. Status epilepticus is a seizure caused by abnormal electrical activity in the brain that is unprovoked. Provoked seizures may be caused by head trauma, heat stroke, toxin ingestion, etc.

S/S: Status epilepticus is seizures lasting more than 5 minutes or 2 or more seizures occurring without recovery (return to consciousness) in between.

MGMT: 1. Gain IV access. 2. Treat underlying cause, if possible. 3. Monitor body temperature; treat hyperthermia if temperature rises above 104 degrees F. 4. Administer an anti-convulsant- Diazepam (Valium) 15-30 mg (0.5-1 mg/kg) IV or 30-60 mg (1-2 mg/kg) per rectum (2-3 min onset) **OR** Midazolam (Versed) 7.5 mg (0.25 mg/kg) IV/ IM. **Levetiracetam (Keppra)** 30-60mg/kg (600-900mg) IV for status epilepticus or acute repetitive seizures. For refractory epilepsy: regular tablets 20mg/kg (600mg - use of 750mg tab is safe) PO every 8 hrs, Extended release tablets 30mg/kg (900mg - use of 1000mg tab is safe) PO every 12 hrs.

Disposition: Evacuate to veterinary care as soon as possible. Requires critical care monitoring.

Special Considerations: Seizures may recur. Contact a vet for guidance if one is not located in your location.

C5. CANINE TOXICITIES – EXPLOSIVES, OTHERS

Training Aid/Agent Toxicosis: Our military working dogs are exposed to certain small quantities of explosives known as training aids and may accidentally ingest them which could lead to toxicosis in the animal.

a. Nitrate/nitroglycerin-based explosives (C4, TNT, water gel, dynamite, RDX, det cord): Clinical signs- Ingestion may result in hypersalivation, severe CNS abnormalities (ataxia, incoordination, seizures, tremors), gastrointestinal irritation (nausea, vomiting), and methemoglobinemia (signs of methemoglobinemia include: cyanosis, weakness, syncope = loss of consciousness, respiratory distress). Onset of signs usually occurs between 3-12 hours after ingestion.

b. Smokeless powder explosive Clinical signs- Ingestion may result in hypotension, CNS depression (which manifests as ataxia, depressed mentation, incoordination), and methemoglobinemia (cyanosis, weakness, syncope, respiratory distress). **Treatment-** Monitor blood pressure and fluid resuscitate as needed. Close monitoring of CBC's necessary for potential methemoglobinemia.

c. Potassium and sodium chlorate explosives Ingestion may also result in methemoglobinemia (cyanosis, weakness, syncope, and respiratory distress), CNS abnormalities (ataxia, incoordination, and depressed mentation), gastrointestinal irritation (nausea, vomiting, abdominal cramping and pain, **hemorrhagic diarrhea** with **melena or hematochezia**), hematuria, hemoglobinuria, and renal and liver failure.

Treatment of Training Aid Toxicosis

a. If ingestion occurred \leq 4 hours before presentation and the MWD is conscious and has normal CNS responses, induce vomiting.

1. Apomorphine is first choice. ¼ (6mg) tablet in the conjunctival sac or 0.03mg/kg IV.

2. Hydromorphone is second choice 3mg IM

3. 3% Hydrogen Peroxide (household formula is 3%) Maximum of 30mLs can be given orally as the last option. This method will create esophageal erosion.

4. Don't try to make an MPC gag manually

b. If ingestion occurred $>$ 4 hours before presentation, or if the dog has abnormal mentation or is unconscious or seizing, do not induce vomiting.

1. 45g of Activated charcoal with sorbitol as an initial dose. Sorbitol is a laxative. This is about 30mLs of Toxiban (w/sorbitol). May require sedation with cuffed ET tube, orogastric intubation and a funnel to get the slurry in.

2. A second dose 4-6 hours later without sorbitol

3. If seizures are present give 10mg of Midazolam IV or IN or 10mg of Diazepam IV, IN or per rectum. Alternatively 600-900mg of Levetiracetam (Keppra) IV can be given.

4. If methemoglobinemia is present (blue tinge to unpigmented skin, brown blood, brown urine, tachypnea, tachycardia, lethargy, recumbence) 30-60mg of methylene blue (MB) 1% (3-6mLs) can be given as a slow bolus IV. If respiratory distress persists then repeat dose once or twice. MB will cause a Heinz body anemia so CBC must be monitored every 8 hrs if used.

Rat Poison: Is a vitamin K antagonist so it interferes with the production of coagulation proteins. This eventually inhibits hemostasis. **Clinical signs-** Some form of hemorrhage is often seen such as bruising of skin and mucous membranes, especially the axillae and inguinal regions. Blood may be seen in the urine or coming from the nose. It can also cause weakness, a painful abdomen, pale mucus membranes, coughing, wheezing and (rarely) petechiae. Dyspnea can occur from intrathoracic or intrapulmonary bleeding. Collapse is possible if pericardial hemorrhage occurs. Pale mucous membranes will occur if anemia is severe.

Treatment- 1.5 to 2.5 mg/kg (45-75mg) of Vitamin K₁ (Phytonadione) supplementation BID PO in a fatty meal for up to four weeks may be required. Supplied as 25-50mg tablets or 10mg/mL injection which must be given IM or SC. Have a veterinarian check PT time 72 hrs after last dose to know when to stop. Canine FFP or whole blood may be required to replace clotting factors and/or RBCs.

Anti-freeze: Minimum lethal dose of undiluted ethylene glycol (what makes up most antifreeze) in an MPC is about 132mLs. **Clinical signs-** within an hour of exposure vomiting, polydipsia, polyuria, and neurologic signs such as ataxia, stupor and knuckling can occur. Oliguric (abnormally small amounts of urine) Renal failure occurs between 36-72 hrs. These animals are lethargic, dehydrated, vomit, can have diarrhea, salivate excessively, sometimes have oral ulcers, breathe fast, can seizure or present in a coma.

Treatment- Generally requires veterinary care facility. If unavailable: Induce vomiting if within 2 hrs of ingestion. Activated charcoal is ineffective. If the animal is still producing urine and not already oliguric or anuric then 4-Methylpyrazole (fomepizole - costs \$1000) can be given IV at 20mg/kg (600mg) initially then 15mg/kg (940mg) 12 hrs, 24hrs and 36hrs later to block metabolism of ethylene glycol by alcohol dehydrogenase. 5.5mL/kg (165 mLs) of 20% ethanol (e.g 40 proof everclear) in IV fluids can be given over 6 hrs for five treatments and then over 8hrs for four more treatments. It competitively inhibits ethylene glycol from getting broken down by the enzyme (alcohol dehydrogenase). The metabolites are the problem. Metabolic acidosis likely needs monitored and treated with NaHCO_3 in fluids. Use $0.3 - (0.5 \times 30\text{kg}) \times (24 - \text{plasma HCO}_3)$ gives you the mEq of bicarbonate to administer. Give half this dose IV slowly and monitor plasma bicarbonate every 4hrs. Fluid therapy to replace dehydration (% dehydrated x Bwt in kgs x 0.6, so 5% dehydrated x 30kg x 0.6 = 0.9L) can be administered over 2-4 hrs while simultaneously monitoring urine output (normal urine output is 30-60mLs/hr). If urine output is less than 15mLs/hr the MPC is oliguric. Oliguria and anuria in dogs with ethylene glycol toxicity have a poor prognosis. Anuric animals should only have small amounts of fluid given to replace losses from respiration, defecation etc. If the animal is not Anuric continue kidney diuresis at maintenance rates of 60mL/kg/day (75mLs/hr) with LR or plasmalyte, continuing to monitor urine output.

C6. CANINE CBRNE

Triage: Take care of yourself and other Rangers 1st. Move affected Soldiers 1st. Use the following guide when manpower can be spared for a MPC.

M¹A²R²C²H² In a CBRNE environment terminate the exposure first. Move out of the contaminated area. Dogs do not have masks so inhalation is a major concern. Consider what is killing the animal and treat that first. Use the Algorithm when not sure.

M¹ove the MPC out of the affected area (terminate the exposure). **M²uzzle** the MPC. **M³assive** hemorrhage (treat). **M⁴edicare** (consider sedation and pain medication, again – not needed if there is a loss of consciousness).

A¹ntidote (which antidotes depend on the signs, symptoms and knowledge of the agent(s) being used against you via M8 paper or JCAD reading) **A²irway** (check that it is clear – choking agents need intubated early on).

R¹apid Decontamination There is not really a spot decon for the dog. A full decontamination can occur while awaiting evacuation to the decontamination site. Full decontamination should occur again at the designated decon site – see at the end of this section. **R²espirations** If there is no physical wound, wheezing or coughing could be a choking agent or nerve agent; hypoventilation could be from an opioid agent; apnea or dyspnea could be from cyanide; tracheal/pulmonary rales (clicking) could be from mustard exposure.

C¹irculation treat hypovolemia as before **C²ountermeasures** (oxygen, ventilation support and albuterol may be required for Lewisite/Mustard or choking agents).

H¹ypothermia and **H²ead Trauma:** Same as before.

Nerve agent signs: **DUMBBELLSS** (Diaphoresis is sweating – dogs don't sweat!, **Urination**, **Miosis** –pinpoint pupils, **Bronchospasm** – tightness of chest cannot be conveyed to you by the dog but you may hear wheezing when auscultating the chest, **Bronchorrhea** –excess watery discharge from lungs leads to productive cough, **Bradycardia** (Normal dog 70-120bpm) **Emesis** –vomiting, **Lacrimation**, **Loose stool**, **Salivation**, **Spasms/Seizures**. Remember that miosis is not an early sign if it is absorbed dermally.

Miosis of R eye.
Nerve agent would
cause miosis in both



Example of a
Seizure in a
Dog

Nerve agent Tx: You have minutes to hours depending on what agent, where the animal absorbs it (inhaled vs absorbed) and how much was absorbed.

Antidote: Mild signs 1-2 ATNAAs (2.1 - 4.2mg atropine and 600 to 1200mg pralidoxime chloride), 1 CANA (10mg diazepam), **Severe signs** (ie Respiratory coughing and seizing) give 3-4 ATNAAs (6.3 - 8.4mg atropine and 1800 - 2400mg pralidoxime chloride), 2 CANAs (20mg Diazepam). Scopalamine at 0.03mg/kg (about 0.9mg for an MPC) PO every 12-24hrs can be used as an alternative to atropine. Scopalamine acts as an antimuscarinic like atropine but may have better CNS effects.

Decontaminate: 4% chlorhexidine and water (process described at the end of this section). Don't use RSDL, it may react when bound with a chemical agent to bleach if bleach is used at the decontamination site. RSDL also only works in short haired areas or the hairless areas of the abdomen of a dog.

Treat to ease of breathing or cessation of secretions (do not worry about fixing miosis or muscle fasciculation initially, this response is usually delayed sometimes by months!)

Long term Atropine (0.4mg/ml) x50 ml in 250 ml NaCl (20mg/300ml). Drip rate is 300mls/hr. When the pupils finally begin to dilate and/or heart rate normalizes reduce drip rate to 30-60mLs/hr and continue to monitor.

Prevention: No mask. Pyridostigmine bromide 0.5 mg/kg (15mg) PO q 8hrs (half the human dose).

BZ agent signs: Almost the opposite of nerve agent. BZ agent will cause Mydriasis (dilated pupils), dry mucus membranes, tachycardia, hyperthermia, hypertension, warm skin and seizures are possible.

BZ agent Tx: Physostigmine at 0.025-0.5mg/kg (7-15mg) given slowly IV or IM. Do NOT sedate patient. Remove from the exposure.

Decontaminate Route of absorption is by inhalation only, removing from the source is all that is necessary.

Blister Agent signs: Can be immediately painful (Lewisite) or delayed (Sulfur mustard). In dogs the hair stands up (piloerection). Blisters do NOT occur. The skin becomes moist and hyperemic instead. Sloughing can occur later. **Lewisite**-immediate pain, restlessness vomiting, bloody diarrhea, shock, weakness, anemia, pulmonary edema, blepharospasm (squinting). **HD and HN (Mustard)** –asymptomatic latent period for a few hours then: Skin redness/ulcers, Respiratory- cough, nasal discharge, difficult breathing, tracheal and pulmonary rales (clicking), GI- oral ulceration, abdominal pain, vomiting, bloody diarrhea, Systemic- excitation, salivation, bradycardia, decreased WBC and platelet count, shock.

Blister Agent (Lewisite) Tx: Dimercaperol (BAL) 2.5-5mg/kg given IM every 4 hours for 2 days, Topical BAL ointment as needed. Use a chelating agent: 1) CaEDTA at 1% (10mg/mL) in 5% Dextrose at 27.5 mg/kg q 6hrs for 2 to 5 days or 2) Sodium Thiosulfate at 150mg/kg (4.5g). Adding 18mLs of 25% (250mg/mL) Na Thiosulfate into 250mLs of NaCl and bolus that over 10 min gives the patient 4.5g.

Blister Agent (Lewisite and Sulfur Mustard) Tx: Provide topical ocular analgesia, early intubation and use of ventilator/PEEP and CPAP machine. Albuterol at 0.05mg/kg PO, antiemetic and antibiotics when secondary lung infections occur. Control of bronchospasm may require more than just albuterol, if steroid is used be aware that secondary lung infection risk is increased. Dexamethasone (0.025mg/kg every 24 hrs PO so about a 0.5mg to 1mg tablet) or prednisolone (1mg/kg every 12 hrs for up to a week PO then 0.5mg/kg for another week)

Decontaminate: RAPID Decon (within 2 minutes) is vital! **4% chlorhexidine** (process described at the end of this section). Do not use RSDL, it may react when bound with a chemical agent to bleach if bleach is used at the decontamination site. RSDL also only works in short haired areas or the hairless areas of the abdomen of a dog. Flush the eyes with large amounts of water. Eye ointment for pain control only after thorough decon and examination. Steroid/antibiotic combination eye ointment works best for saving the eye.

Cyanide signs: Generally not used as a munition due to insufficient amounts delivered and the nature of the chemical. Exposure more likely through ingestion poisoning or possibly by inhalation within enclosed spaces (tunnels/gas chambers). **Inhalation:** effects begin within 15 seconds, death within 6-8 minutes of a lethal dose. **Ingestion:** Upset stomach for 7 minutes followed by increased depth and rate of breathing. Within 15 minutes the animal will likely lose consciousness. Convulsions/seizures, apnea then the heart stops within 30 minutes. The loss of consciousness and seizures shortly after inhalation is similar to nerve agent inhalation however, the cyanide casualty is not cyanotic (blue), pupil size is normal or dilated, and there are no secretions and no muscle fasciculation.

Cyanide Tx: Hydroxycobalamin (vitamin B12a) complexes with cyanide to form cyanocobalamin (vitamin B12). Requires IV access. 150mg/kg (4500mg or 1 cyanokit). It must be reconstituted/shaken for 30 seconds. More effective when combined with Sodium thiosulfate 12.5g IV over 30 min. Second treatment option requires a 2 step process: 1) Amyl nitrite (crush an ampule and find a way to get the dog to inhale) or Sodium Nitrite at 300mg IV or IO over 5-10 minutes. These agents create a methemoglobinemia. The ferric ion (Fe³⁺) in methemoglobin has a higher affinity for cyanide than the cytochrome oxidase molecule in the mitochondria. 2) Sodium Thiosulfate (12.5g over 30 min) which is a sulfur donor. The sulfur is used as a substrate to eventually convert cyanide to thiocyanate. Remember, the antidotes have to be given slowly, nitrite can cause hypotension and too much will overproduce methemoglobin causing a decrease in oxygen carrying capability. Administration of 100% O₂ is significantly helpful despite the fact that the poison prevents the use of oxygen in cellular respiration. Mechanical ventilation may be needed, circulatory support with crystalloid fluid administration, vasopressors if fluid administration doesn't correct hypovolemia. Dopamine at 10mcg/kg/min is probably ideal as it is a less potent inotrope than epinephrine or dobutamine and less vasoconstricting than norepinephrine.

Decontamination of Cyanide: Self-protection and then remove animal from the exposure source to fresh air. Dermal absorption does not occur and the substance is highly volatile. Decontamination is generally unnecessary unless liquid contamination has occurred to the coat. If this occurs, wash with water alone or water and soap.

Opiate toxicity signs: May occur if the animal is exposed to heroin or fentanyl/carfentanyl when clearing a building that turns out to be a drug facility or has a drug cache. Could be a weaponized agent someday. Occurs within 1-2 minutes by inhalation, 1-2 hours by ingestion. Altered mental status, animal may look dizzy or lethargic and end up in a coma, hypersalivation, hyperthermia, ataxia, bradycardia (normal HR 70-120), hypotension (normal SBP >90mmHg, MAP>65mmHg), hypoventilation, neck rigidity and seizures.

Opiate Toxicity Tx: Naloxone is a pure opiate antagonist. It reverses most of the effects of high dose opiate administration to include respiratory and CNS depression. Dose in dogs is 0.04mg/kg to 0.1 mg/kg (or about 1.2mgs to 3mg for an MPC) IV, IN (atomizer), IM, SQ recommendation is to give a ¼ of the max dose and repeat every three minutes until desired affect is achieved (half life is about an hour in humans). Naltrexon 2-5mg/kg (60-150mg for an MPC) PO every 24 hrs may be used when injectable naloxone is not available. Nalmefene 0.03 mg/kg (0.9mg) IV has a much longer plasma half-life (11hrs) than naloxone. Is no longer available in the United States. It is/was used as an opiate reversing agent and to manage human alcohol dependence and addictive behaviors.

Choking Agent signs: Ammonia, Chlorine, Phosgene, HC Smoke, PFIB (Perfluoroisobutylene), Nitrogen oxide and Phosgene. Ammonia (as well as sulfur mustard) work on the central airways and burn the tissue. This can cause laryngospasm and eventual collapse. Sulfur mustard will block airways when pseudomembranes slough off within the airway. The others are all peripheral acting agents except for chlorine which affects the patient peripherally and centrally. PFIB is released when Teflon burns (lines many military vehicles). Nitrogen oxide is released when gunpowder burns. **Central agents** tend to have immediate effects that include laryngospasm, sneezing that is painful, hoarseness to their bark, noise on exhalation, coughing and wheezing while breathing. **Peripherally acting agents:** can have a latent period of 30min to 72hrs. Major effects don't occur until hours later. If major signs show in less than 4 hrs the prognosis is lower. Shortness of breath from pulmonary edema occurs. As damage progresses, this dyspnea becomes more severe and coughing develops with a clear foamy sputum. Phosgene patients can lose as much as 1L of serum into their lungs from protein denaturation.

Choking agent Tx: Terminate the exposure. No mask for a dog so the animal must be moved from the contaminated environment. Establishing an airway in an animal that has stridor is important but may require sedation and the use of a bite block. Airway/trachea may require frequent suction with a squire to keep it clear. Ensure normovolemia and treat with crystalloid fluids if the animal seems dehydrated. 100% Oxygen if needed. Enforce rest. Reserve antibiotics for confirmed secondary infections when possible. Steroid or Albuterol therapy may be necessary for bronchospasm (Albuterol at 0.05mg/kg PO, Dexamethasone 0.025mg/kg every 24 hrs PO so about a 0.5mg to 1mg tablet or Prednisolone 1mg/kg every 12 hrs for up to a week PO then 0.5mg/kg for another week). Positive airway pressure helps oxygen delivery in the face of pulmonary edema but can decrease thoracic venous return and contribute to hypotension. Ensure blood pressure which may require fluid therapy. If a ventilator can be used, set as suggested below. Some BVMs have a PEEP setting.

| TABLE 7: MECHANICAL VENTILATOR SETTINGS & KEY PARAMETERS | | |
|--|----------------------------------|----------------------------------|
| PARAMETER | NORMAL LUNGS | ABNORMAL LUNGS |
| F _i O ₂ | 100%, then reduce to <60% | 100%, then reduce to <60% |
| Tidal Volume (V _t) | 5 – 15 mL/kg | 5 – 15 mL/kg |
| Breathing Rate (f) | 8 – 20 bpm | 8 – 20 bpm |
| Minute Ventilation (V _e) | 150 – 250 mL/kg/min | 150 – 250 mL/kg/min |
| Peak Inspiratory Psi (PIP) | 10 – 20 cmH ₂ O | 15 – 25 cmH ₂ O |
| Positive End-Expiratory Psi (PEEP) | 0 – 2 cmH ₂ O | 2 – 8 cmH ₂ O |
| Trigger Sensitivity | -2 cmH ₂ O or 2 L/min | -2 cmH ₂ O or 2 L/min |
| Inspiratory: Expiratory Ratio (I:E) | 1:2 | 1:2 |
| Inspiratory Time | ~ 1 sec | ~ 1 sec |

Decontamination of Choking agents: Not absorbed dermally, decontamination is only necessary to remove fluid, if present from the coat/skin of the animal and prevent vapor exposure from that source.

Biological agents: Among likely biowarfare agents, MWDs may be susceptible to plague (*Yersinia pestis*), tularemia, brucellosis, Q-fever, and anthrax. Dogs are believed to be less susceptible than humans to all of these diseases.

Prevention: Doxycycline (6 mg/kg or about 180mg per day). Doxycycline is generally considered efficacious against all biowarfare agents of concern, and the prophylactic dose may provide additional protection for MWDs. Ciprofloxacin (20-25mg/kg or about 600-750mg) every 12 hours may also be used.

Decontamination: Soap and water. MWD equipment should be decontaminated with 5% hypochlorite solution.

Nuclear and Radiologic Agents: Dogs exposed to nuclear weapons or radioactive material will have blast injuries, thermal and radiation injuries. Acute Radiation injuries will include those to the:

- 1) Bone marrow/hematopoietic system (0.3 and 10Gray). Survival rates decrease as the dose increases. Animals die from infection or hemorrhage (no platelets or wbcs)
- 2) GI tract (6 to greater than 10 Gray). Survival is unlikely, changes to bone marrow and GI tract are destructive and generally irreversible. Death from infection, dehydration and electrolyte imbalance generally within 2 weeks.
- 3) Neurologic and cardiovascular system (20 to greater than 50 Gray). Death from circulatory collapse and increased pressure from edema, vasculitis and meningitis inside the cranial vault. Death can occur within 3 days.

Burns will occur even without acute radiation injuries. Blistering, redness, itching and ulceration occur. Healing occurs but large doses can cause hair loss, fibrosis, increased or decreased skin pigmentation.



Management and Treatment of nuclear and radiologic injury: Remove from the source, M³ARCH for major trauma, decontaminate, then monitor airway, circulation and breathing (check blood pressure, electrolyte status and urine output for radiation injuries) IV fluids may be necessary, anti-emetics and analgesia. Long term CBC count for lymphocytes or possible transfusion of dog blood when necessary. Dose can be estimated in humans based on lymphocyte count over the first 8-12 hours after exposure (taken every 2-3 hours or after every 6 hours for the next 2 days). Treat vomiting and track time of onset for vomiting, diarrhea and itching, reddening and blistering of the skin. It may be possible to use an Andrews Lymphocyte Nomogram to extrapolate dose/prognosis from the human chart. Radioactive iodine is associated with nuclear energy, medical diagnostic and treatment procedures, and natural gas production. In a nuclear weapon detonation it is produced as a byproduct from the fission reaction of uranium. It is released in the fallout and is a hazard to those that survive the initial blast. In the body the thyroid will take up radioiodine along with normal iodine. Taking potassium iodide (KI) fills up the thyroid with normal iodine preventing the damage it would receive from radioactive iodine. For MWDs, KI should be administered within 4 hours before or after the exposure. KI is generally issued in 130mg tablets Administer half a tablet (65mgs) once a day to a MWD by mouth until told to discontinue. Evacuate when possible and safe to do so. Protect yourself and the dog from KI and other radionuclides in the fallout by remaining inside and minimizing the opening of doors and windows, turning off fans, air conditioners, and forced-air heating units that bring fresh air in from the outside Humans (and animals) should avoid fruits, vegetables, and milk from the area until shown to be free of contamination.

Interesting facts: Hiroshima was a 15KT bomb. Ninety percent of people within 500 meters of ground zero died. At one mile from the center 2/3 were casualties and 1/3 died. At 1.2 miles 1/2 were casualties and 10% died. At 2.4 miles 10% were casualties. Cumulative death rates rose dramatically in the first two weeks, with 90% of them within the first 3 weeks. Time shielding and distance from the center mattered for survival. Those in solid concrete buildings had better chances of survival than those in wooden building. Large numbers of deaths were caused by houses collapsing.

Canine chemical protective equipment:

Currently there is no issued equipment for military working dogs. Protective gear is limited to booties and eye protection (RexSpecs) if the unit purchases this itself. The outer bag from an MRE, extra butyl-rubber protective gloves or JSLIST gloves, tape or canvas over wrap may be used in place of booties. SERPACWA (skin exposure reduction paste against chemical warfare agent) may be used in non-haired areas. There is no chemical protective suit or mask for a dog at this time. Due to the inhaled risk of most chemical agents, the use of a MPC in an environment known to have been exposed to a chemical warfare agent is not recommended. Any handler team inadvertently exposed to a chemical environment may use MRE bags/gloves/booties/eye protection and SERPACWA for the animal in an attempt to mitigate contamination while evacuating.

Generalized Canine decontamination:



CBRNE contaminated animals will only be handled by individuals in MOPP 4 and may require plastic aprons to prevent the suit from getting wet. An alert MPC will need to be sedated. Immediate decontamination can occur as soon as the animal can be removed from the contaminated environment, even before evacuation. This would be done to mitigate the rapid effects of Nerve and Mustard agent when there is any delay in transport to a larger patient decontamination site. Another thorough decontamination then occurs at the patient decontamination site.

MPC Immediate decontamination: METT-TC will determine when these supplies are carried. Only one 500mL bottle of water is needed. A chlorhexidine surgical scrub brush, a small bottle of 4% chlorhexidine scrub and a microfiber towel are required. If mustard is suspected, flush the eyes with bottled water. Remove and discard the animal's vest. Four percent chlorhexidine is used and suds are generated over the entire body of the animal using the surgical scrub brush with minimal water from the 500mL bottle. It is not a bath, no rinse occurs. The suds are worked directly onto the dry hair of the rest of the animal's coat. The soft plastic teeth side of the brush does not abrade the skin and helps work the suds into the coat. RSDL is not required and may react with bleach needed later on. After 5 minutes the chlorhexidine suds are wiped off the coat with a dry microfiber towel. Remember it only requires 1.5 tsp of mustard agent (to cover 20% of the body surface area) to be lethal for a human. That amount can be absorbed in less than 2 minutes.

MPC Patient Thorough Decontamination: When the MPC patient is evacuated to the patient decontamination site, the same decontamination process will occur as accomplished during immediate decontamination. This is done to remove anything that was missed. As the animal is brought in to the warm zone two extra handlers (ideally the battalion animal technician and another dog handler) dressed in MOPP4 and plastic aprons will need to be available. Again, alert animals will be sedated to keep them from licking themselves and soaking the JSLIST suit of the decon team. One individual will hold the dog, protecting the airway while the other decontaminates the animal as described above in initial decontamination. After the chlorhexidine has set for the required five minutes, and the animal is sufficiently sedated, remove the collar, intubate if necessary, rinse off (use the 0.5% bleach water if that is all that is available) if necessary (determine via JCAD) and moved through the shuffle pit. A ½ Gallon of 5% (house hold) bleach goes in a 5 gallon bucket, then fill the bucket to the top with clean water to reach 0.5% bleach solution. Once cleared by JCAD (with or without the bleach wash) the animal is handed over the Hot Line to two other individuals in the cold zone (ideally the Regimental Veterinarian and the Regimental Animal Tech). A clean chain/biothane leash with a chain/biothane collar (from the cold side) will be applied in the cold zone. The animal will then be checked for residual agent using the Joint Chemical Agent Detector Monitor and moved to the triage and treatment area. After treatment the animal should be rinsed with plain water to remove any excess chlorhexidine or bleach to prevent a skin reaction. The contaminated handler would simultaneously proceed through the ambulatory patient decontamination area but likely be decontaminated by others. Care must be taken such that the animal, in its excitement, doesn't soak and contaminate the chemical protective suits of the handlers in the warm zone.

MPC Reference Card

| | | | | | | |
|--|--|---------------------------|--|--|---|--------------------|
| MWD Name: | CLYDE | Weight: | 70.0 lbs | 31.8 kg | | |
| Gender | MI | Date Card Created: | 27 JAN 2019 | Normal Values | | |
| Breed | Belgian Malinois | ET Tube Size: | 10mm | Temp: 99-102.5 F | | |
| DOB | 12-Jun-11 | | | Pulse: 70-120 bpm | | |
| Microchip number | | | | Anticipation/Excitement/Pain: 100-160 bpm | | |
| Permanent duty site | FT. BENN, GA | | | Exercising: Up to 300bpm (sled dogs) | | |
| Deployment status | CAT I | | | Shock: Usually 160-200bpm | | |
| Last FAVN (date and pass/fail) | JAN 2019: PASS | | | Resp: 16-30 bpm (resting) Usually panting after exercise or hot outside | | |
| Most recent vaccinations: | Rabies: 25 JAN 19 DA2PP: 25 JAN 19 Lepto: 25 JAN 19 | | | Temp | | |
| Gastropexied? | YES | | | BP: 110-160 Sps/60-90 Dia/85-120 MAP | | |
| Previous heat injury? | NONE | | | Resuscitation End Point MAP > 65 Shock | | |
| Master problem list | | | | Index: HR/SBP < 1.0 PCV: 35-45% | | |
| Diet (type and amount) | | | | TP: 6.5-8g/dL Acute blood loss often has normal PCV and low TP Lactate < 2.5mmol/L | | |
| Current medications | None | | | | | |
| Emergency Drug | Dosage | Units | MWD's dose | Units | Route | |
| Atropine (bradycardia, bronchoconstriction)-----> | 0.04 | mg/kg | 1.3 | mg | IV or IM | |
| Atropine (organophosphate, carbamate toxicity)-----> | 0.2-0.5 | mg/kg | 6.4 | mg | 1/4 dose IV, rest IM or SC | |
| Epinephrine (Hrt stopped, unresp CPR, shock from allerg rxn) | 0.01-0.02 | mg/kg | 0.3 | mg | IV, IT, IM or SC | |
| Levetiracetam/Keppra Seizures (Can use Diazepam/Midazolam) | 30mg/kg IV / 20 | mg/kg PO | 954.5 | mg IV | 636.4 mg PO q 8hr | |
| Diphenhydramine (Benadryl) Allergic Reactions-----> | 4 | mg/kg | 127.3 | mg | IM | |
| Dexamethasone SP (Allergic Reactions)-----> | 0.5 | mg/kg | 15.9 | mg | IM or SC | |
| Tranexamic Acid (TXA) (Massive Hemorrhage) | 15 | mg/kg | 477.3 | mg | IV initially, then same amt over 24hrs | |
| (Abbreviations): | IV= intravenous, IM= intramuscular, SC= subcutaneous, IT= intratracheal, PO=oral | | | | | |
| Toxin Ingestion | Dosage | Units | MWD's dose | Units | Route | Freq |
| Activated Charcoal (Toxiban) given at least an hr after emesis | 1 | mL/kg | 31.8 | mL | PO | Every 6hr |
| Emergency Fluid Considerations | L/per day | mL/per hour | | | | |
| Maintenance fluid needs (60mL/kg/day) | 1.9 | L | 79.5 | | | |
| 1/4 Shock dose IV Fluids (crystalloid - Plasmalyte, LRS, etc) | 700 | mL | - Give this as fast as possible, then re-assess heart rate, mm, pulse, etc | | | |
| Full Shock dose of IV fluids (crystalloid - Plasmalyte, LRS, etc) | 2864 | mL | | | | |
| Hetastarch dose of IV fluids | 159 | mL | Max Dose/24hr: | 636 | mL | |
| Assessing Hydration in an MWD (Diarrhea, Vomiting Heat Injury) | | | | | | |
| Mild Dehydration (5%)-----> | Decreased skin elasticity, dry mucous membranes | | | | | |
| Moderate Dehydration (7.5%)-----> | Small increase in capillary refill time, further decreased skin elasticity | | | | | |
| Severe Dehydration (10-12%)-----> | No skin elasticity, marked increase in capillary refill time (>3 seconds) | | | | | |
| Hypovolemic Shock-----> | Increased heart rate, weak pulse, increased capillary refill time, altered mentation, weakness/collapse, low body temperature, cool extremities, decreased urine production | | | | | |
| Fluid Therapy for Dehydration (Diarrhea, Vomiting Heat Injury) | ml/hr for 2 hrs (includes maint) | | | | | |
| Mild Dehydration-----> | 0.05 x kg x 0.6 | | 1.0 | L/ 2-4 hours | 556.8 mL/hr for 2hr | |
| Moderate Dehydration-----> | 0.075 x kg x 0.6 | | 1.4 | L/ 2-4 hours | 795.5 mL/hr for 2hr | |
| Severe Dehydration-----> | 0.010 x kg x 0.6 | | 1.9 | L/ 2-4 hours | 1034.1 mL/hr for 2hr | |
| Diarrhea/Nausea | Dosage | Units | MWD's dose | Units | Route | Freq |
| Metamucil-----> | | | 2.0 | Tblespn | PO | Every 12-24hr |
| Pepto-----> | | | 2.0 | Tblespn | PO | Every 4-6 hr |
| Imodium-----> | 0.1 | mg/kg | 3.2 | mg | PO | Every 12 hr |
| Ondansetron/Zofran if 2mg/mL give slowly 2-15 min. Use 16mg tabs if PO | 0.5 | mg/kg | 15.9 | mg | IV, PO q 12hrs mLs-----> | 7.954545455 |
| MWD Name: | CLYDE | Weight: | 70.0 lbs | 31.8 kg | | |
| Antibiotics | Dosage | Units | MWD's dose | Units | Route | Freq |
| Clavamox/Augmentin (Resp inf, wounds, UTIs)-----> | 13.75 | mg/kg | 437.5 | mg | PO | Every 12 hr |
| Cephalexin (wounds, skin infections)-----> | 30 | mg/kg | 954.5 | mg | PO | Every 8-12 hr |
| Metronidazole (Anaerobic inf, GI Infections/diarrhea)-----> | 25 | mg/kg | 795.5 | mg | PO | Every 12 hr |
| Enrofloxacin (Baytril) (Gr neg, peritonitis, pneumonia) | 15 | mg/kg | 477.3 | mg | PO, IV slow or SC | Every 24 hr |
| Ciprofloxacin (Gr neg spectrum, peritonitis, pneumonia)-----> | 10 | mg/kg | 318.2 | mg | PO crush tb, IV in bag | Every 24 hr |
| Ertapenem (Invanz)(combat wounds) | 15 | mg/kg | 477.3 | mg | IV, SC | Every 12 hr |
| Cefazolin (Severe GI Inf, Abdominal wounds)-----> | 20 | mg/kg | 636.4 | mg | IM, SC, IV | Every 8 hr |
| Sedation Mild (Losing consciousness, bleeding, weaker pulse, still moving but doesn't hold still & needs treated) | Dosage | Units | MWD's dose | Units | Route | mLs |
| Midazolam OR Diazepam (if 5mg/mL) | 0.3 | mg/kg | 9.5 | mg | IM, SC, IV | 1.909090909 |
| Ketamine (if 100mg/ml) | 5 | mg/kg | 159.1 | mg | IM, SC, IV | 1.590909091 |
| Sedation Deep (Alert animal, normal pulse that needs treated) | Dosage | Units | MWD's dose | Units | Route | mLs |
| Dexmedetomidine (dose range is 0.001-0.020mg/kg) | 0.008 | mg/kg | 0.3 | mg | IM, SC | 0.509090909 |
| Midazolam OR Diazepam (if 5mg/mL)-----> | 0.3 | mg/kg | 9.5 | mg | IM, SC, IV | 1.909090909 |
| Ketamine (if 100mg/ml)-----> | 5 | mg/kg | 159.1 | mg | IM, SC, IV | 1.590909091 |
| Sedation (For an Alert animal, normal pulse when no Ket/Mid av) | Dosage | Units | MWD's dose | Units | If 0.5mg/ml | Units/Route |
| Dexmedetomidine (dose range is 0.001-0.020mg/kg) | 0.013 | mg/kg | 0.4 | mg | | 0.8 mL/IM |
| Analgesia (Pain Mgmt) NO Advil (Ibuprofen) or Tylenol! | Dosage | Units | MWD's dose | Units | Route | mLs |
| 2% Lidocaine Max Dose (local/skin/nn blocks for lacs) 5 min | 5 | mg/kg | 159.1 | mg | SC, IM | 7.954545455 |
| Bupivacaine (0.5% Marcaine) Max Dose (nerve blocks) 30 min | 2 | mg/kg | 63.6 | mg | SC, IM | 12.72727273 |
| Rimadyl (Carprofen/NSAID)-----> | 2.2 | mg/kg | 70.0 | mg | PO, SC | Every 24 Hr |
| Mobic (Meloxicam/NSAID) Don't combine w/other NSAIDs--> | 0.1 | mg/kg | 3.2 | mg | PO, | Every 24 Hr |
| Hydromorphone-----> | 0.1 | mg/kg | 3.2 | mg | IV, IM | Every 2-6 Hr |
| Naloxone (Opioid overdose) | .04-.16 | mg/kg | 1.3 | mg | IV, IM, SC | 3.181818182 |
| Fentanyl 50mcg/mL Loading dose - excreating pain | 0.01 | mg/kg | 0.3 | mg | IV, IM | 6.363636364 |
| CRNA Ax in a syringe for dogs (Same mix as human) | Induction Range | | 0.05 | mL/kg | to | 0.1 mL/kg |
| Fentanyl 100mcg (2mL) + Midazolam 5mg (1mL) + Ketamine 100mg (1mL) | 0.05 - 0.1 | mL/kg, IV, IO | 1.6 | mL | | 3.2 |
| CRNA Ax in a syringe for dogs (Same mix as human) | Maintenance Dose | | | | | |
| Fentanyl 100mcg (2mL) + Midazolam 5mg (1mL) + Ketamine 100mg (1mL) | 1-2mLs as needed IV, IO (Half lives F= 45 min, M=2hr, K=1hr) | | | | | |
| To induce emesis (vomiting) | Dosage | Units | MWD's dose | Units | Route | |
| Apomorphine 6 mg tablets-----> | 0.04 | mg/kg | 1.3 | mg | Crush tbtt dissolve in H2O, place in conj sac | |
| Morphine-----> | 0.5 | mg/kg | 15.9 | mg | PO, IM | |
| Hydrogen peroxide (to induce vomiting, max two doses)-> | 1.0-2.0 | mL/kg | 30.0 | mL | PO | |
| Chemical Attacks (Save yourself first, MOPP gear then decon the MPC) | | | | | | |
| Nerve Agent Attack (Sarin, Soman Tabun, VX) | Signs: Constricted pupils, difficult breathing, secretions, rapid pant, decr HR, muscle fasciculations. Tx: 1-3 ATNAA injectors + 1 CANA injector IM. Add 1 Atropen q 3min until secretions stop breathing eases. | | | | | |
| BZ Agent Attack | Signs: Dilated pupils, incr HR, Behavioral changes, incoordination may not respond to commands Tx: Physostigmine salicylate 1-10mg IV Slow, IM Decon and DON'T SEDATE! | | | | | |
| Arsenic Blister Agent Attack (Lewisite) | Signs: Redness, edema of the skin, cough nasal disch, restlessness, bloody diarrhea, vomiting Tx: 100mg Dimercaprol IM (aka BAL) 4.5g Na Thiosulfate IV, 1.5mg Albuterol PO . | | | | | |
| Cyanide | Signs: Stops breathing, seizing coma within minutes, death in 5-10 minutes. Tx: 300mg (10mL ampule of 3%) Sodium Nitrate IV followed by 12.5g Sodium Thiosulfate IV over 30min | | | | | |

SECTION SEVEN

**MEDICAL PLANNING
&
CASUALTY COLLECTION
OPERATIONS**



Casualty Response Planning Overview

In planning and training for combat casualty management, the focus is on the possible, not the impossible. Essentially, there are three groups of casualties that will be encountered. In the first group, no matter what you do, the wounded will live. In the second group, no matter what you do, will die. In the third group, if you do the right thing, at the right time, your treatment and evacuation will make the difference between life and death, or between greater and lesser disability. The Casualty Response System is focused on this third group as there is a much greater probability of positively affecting mission and patient outcomes.

Decisions in tactical casualty management are not made by persons far removed from the event. The Casualty Response System will be a flattened organization with decentralized decision-making that empowers first responders, tactical leaders, and medical providers at all levels. As all will have direct ownership of the system, they will invest in realistic casualty management training in order to become more efficient and effective at and near the point of injury. Ultimately, this will equate to lives saved.

Medical planning in Ranger units, depend heavily on the experience and knowledge of the Ranger medical Team. ALL Tactical Medics, from the most junior to the most senior, must become skilled planners. Effective medical planning requires that the planner be well integrated into the unit's (platoon/company/battalion/regimental) mission planning staffs. Many medical issues that arise during planning are regulated, decided or solved by other members of the unit staff including the S3 (Operations), S3 (Air), S4 (Logistics), Commanders, Executive Officers, First Sergeants and Platoon Sergeants. Good working relationships and effective communications must be maintained for successful medical planning. Medical planners must be fluent in the unit's planning sequences (compressed or deliberate), and have a good understanding of the role they play therein. Medical planners must be involved as early as possible in planning sequences for ALL training exercises and real world contingencies.

The medical plan will include an overall "Casualty Response" plan in which every unit member has a role. When a casualty occurs, it is not just the medic's problem; it is a tactical problem that must be planned for and solved by the entire unit. Units will integrate a casualty response phase into all of their tactical battle drills. Unit members and leadership must be well versed in the casualty response plan. Medical personnel have a tendency to focus on providing critical patient care once they begin treating casualties, and as such may not be able to maintain sufficient situational awareness to execute the plan. The unit must be able to execute the casualty response plan around the medic while the medic treats the wounded. Battlefield distracters, wound distracters, C2 issues and shortcomings, all have an impact on both the commander's and medic's decision making during an ongoing mission.

Ranger Casualty Response Planning

The backbone of this section is based on the intricacies of a forced-entry combat operation or the execution of a special operations contingency. For Ranger and SOF units, the initial entry into combat operations is likely to be in a new theater of operations or one of extended distances to casualty care assets. As additional military forces follow-on and develop a theater, the medical support becomes much simpler to plan as there are more assets available. During combat operations in which the Ranger unit is deploying to a developed theater (such as Iraq or Afghanistan), the unit can quickly adapt to existing medical assets and resources to develop the casualty response plan.

The compressed time nature of contingency operations requires the medical planner be well versed in the unit planning methodology and the high expectations of a developed plan. Using the planning methodology outlined below for any type of exercise or deployment, the medical planner will gain better understanding and habits to execute such a plan under any circumstances. However, there is no such thing as a “usual” planning technique. Every mission regardless of timeline, assets or constraints is unique and must have a developed casualty response plan.

Pre-Deployment Requirements.

The 75th Ranger Regiment has very specific pre-deployment soldier readiness processing (SRP) requirements allowing the unit to be deployed on a compressed time sequence anywhere in the world. Prior to any deployment or assumption of RRF-1, unit medics should review the current Regimental Medical SOP (RTC 350-29) that outlines SRP requirements. Rangers will be briefed on the medical threats and preventive medicine measures that will keep them healthy in a particular area of operations. If a compressed time sequence deployment, Rangers will be briefed on critical preventive medicine measures significantly different than normal operating procedures. Also, during the pre-deployment phase is the time to conduct pre-deployment inspections of individual Rangers IFAKs, Advanced-RFR Bags, and Squad casualty evacuation equipment serviceability.

Medical Threat Assessment

The medical planner must assess all medical threats the unit may face during the operation. This assessment includes environmental health hazards as well as specific threats from enemy weapons systems. Through the medical threat assessment, the medical planner will identify preventive measures the unit can employ to minimize these threats. Once the preventive measures appropriate to the mission have been selected, medical planners must be prepared to make recommendations to unit commanders, leaders, and Rangers on how to employ them. The overall goal is to have healthy Rangers ready to perform a mission; keep them healthy during the mission; and safely bring Rangers back home.

Identify the Area of Operations (AO). The medical planner must develop a clear understanding of medical threats and assets in the countries, regions and environments where the operation will be conducted. The locations of targets, staging bases, etc. must be known in order to adequately plan for medical threats. The most important area to assess is the target area. This is the area or region in which the unit will be conducting tactical missions. The host country or staging area must also be evaluated. This is the secure region used as a base of operations. The threats here may or may not be the same as those of the target area.

Identify Medical Intelligence and Health Threats. Medical Intelligence is a key component of all training and contingency operations. Information on hazardous plants & animals, prevalent diseases,

required immunizations & chemoprophylaxis, climatology, and medical & hospital capabilities in the areas involved should be gathered. The National Center for Medical Intelligence (NCMI) is a primary source for medical intelligence. NCMI collects and disseminates information on disease occurrence, medical capabilities, health services, and environmental health hazards specific to regions around the world.

The unclassified NIPR internet address for the NCMI is <https://www.intelink.gov/ncmi/index.php>.
The classified SIPR internet address for NCMI is <http://www.afmic.dia.smil.mil>

Some other sources for medical intelligence are:

- Centers for Disease Control and Prevention (CDC)
<http://www.cdc.gov/>
- U.S. State Department Travel Warnings & Consular Information
<https://www.state.gov/travel/>
- World Health Organization (WHO) Homepage
<http://www.who.int/en/>
- U.S. Army Public Health Command (formerly known as the Army Center for Health Promotion and Preventive Medicine)
NIPR: <http://phc.amedd.army.mil/>
SIPR: <https://phc.army.smil.mil>

The medical planner must also maintain an awareness of the unit's medical readiness status. A review of immunization and health records should be conducted well before the operation begins.

The types of enemy weapons the unit may encounter, including chemical and biological weapons must also be determined. The planner will make recommendations to prevent and treat the injuries these weapons may inflict, such as the use of body armor, chemoprophylaxis, or protective masks.

MEDICAL THREAT ASSESSMENT

- NCMI SIPR/NIPR Website – Find Country / Area of Operations
 - ✦ Host Country (ISB / FSB)
 - ✦ Target Country
- Determine known health threats & risks
 - ✦ Diseases / Illnesses
 - ✦ Environmental threats (Plants, Animals, Climate, Terrain)
- Current Unit SRP Status
- Preventive Medicine Guidelines (what is required before, during, and after)
- Enemy weapons, munitions, and tactics, to include CBRN?
- How ready is the unit if it encounters diseases / illnesses?
- What preparation is needed by the unit?
- Do Rangers need special preventive medicine items issued?

Higher Headquarters Orders and Guidelines

Higher Headquarters Medical Guidelines and Requirements. The operational headquarters will often publish specific guidelines regarding casualty evacuation and hospitalization as well as preventive medicine requirements in its operations orders (OPORDs). The planner must determine if unit members will have to take medications before, during, and after the mission to prevent illnesses

such as malaria. A key question asked is, “Does the unit need to change normal procedures to meet higher headquarters mission guidelines or requirements?”

HIGHER MEDICAL GUIDELINES & REQUIREMENTS

- Chemoprophylaxis
 - ✦ Anti-Malarial Drugs
 - ✦ Other preventive measures
- Special SRP requirements
- WHO Traveler Advisory
- USSOCOM / USASOC / Theater guidelines
- Regiment / Battalion guidelines
- Do we need to change anything in the way we normally do business?

Requests for Information (RFI). Medical planners will be familiar with the processes for requesting updates to dated information about disease or environmental threats. Sources for such periodic reports and publications may lie within the chain of command, or may be external, such as international health organizations. Maps, imagery, and information on medical facilities in the staging or target areas will also be needed for planning.

REQUESTS FOR INFORMATION (RFI)

- Request updates to NCMI information
- Maps / Imagery
- Host Nation (ISB) Medical Capabilities
 - ✦ Hospitals / medical facilities
 - ✦ Nationwide medical training / competency
- Any information not covered in NCMI online resources or higher guidelines
- Submit through medical, intelligence (S2), and/or operations (S3) channels
- Ask for more information for what you need to know

Determine Medical Assets

On a given operation, the unit will be supported by its internal medical assets. External medical personnel, equipment or units may also be attached or utilized as needed. A thorough understanding of all medical assets available to the mission is crucial. This includes the proper unit designations or names, number of personnel by specialty, treatment & evacuation capabilities, logistical requirements, task organization, and command & control. It is important to ensure that all external medical assets are well connected into the unit's structure operationally, logistically, and administratively.

Evacuation Assets. There are two types of evacuation during tactical evacuation (TACEVAC) operations are Casualty Evacuation (CASEVAC) and Medical Evacuation (MEDEVAC). CASEVAC implies the use of non-medical platforms to evacuate casualties. These mission platforms are ground vehicles, watercraft, or aircraft typically used by the unit for infiltration, exfiltration, or re-supply. These vehicles do not usually have organic medical personnel or equipment onboard unless repositioned in the operational plan. These assets are more suited for routine evacuation of non-emergent casualties, but pre-staged medical personnel and equipment can facilitate the treatment and transport of the more seriously wounded. Medical planners should plan for the use of CASEVAC assets as much as possible, as these assets are often the most readily available for rapid evacuation.

Furthermore, CASEVAC assets are usually armed, and are thus better prepared to conduct evacuation while the fight with the enemy is still ongoing. MEDEVAC refers to the use of dedicated medical platforms whose primary mission is the evacuation of casualties. Most often conducted by aircraft, MEDEVAC can also be carried out using medically staffed and equipped front line ambulances (FLAs, MRAP, Stryker). MEDEVAC platforms are usually assigned to a regulated region, are not under the direct control of the tactical unit, and must be requested through operational channels in the execution sequence. Controllers in operations centers receive MEDEVAC requests and launch or divert MEDEVAC assets as required on a prioritized basis.

Unit medical planners will determine the casualty evacuation assets that will likely be needed to support the unit's mission whether by air, ground, or water. Assets should be matched to the expected needs in pre-mission planning.

DETERMINE MEDICAL ASSETS

- Organic, Attached, Air, Ground, Theater, JTF, Host Nation, ISB, FSB, etc...
- CASEVAC / MEDEVAC Support
 - ✦ How many and what type?
 - ✦ Capabilities and Limitations?
 - ✦ Hoist and high angle extraction?
 - ✦ Medical Personnel and Equipment on board? Level of Training?
- Determine nearest surgical capability
 - ✦ Where are your casualties being evacuated to?
 - ✦ What are the capabilities / limitations?
 - ✦ What is their MASCAL or overload plan for their system?
- Determine Staging Base area medical support
 - ✦ Can they provide labs, x-rays, medications, preventive medicine, etc?

Familiarization with Evacuation Assets. In pre-mission planning, there are key questions that must be answered concerning CASEVAC and MEDEVAC. How many and what type of platforms are available? What are the capabilities, limitations and restrictions of the platforms? Are air evacuation assets capable of hoist or high-angle extractions? What medical equipment is on board each platform? Who are the assigned medical personnel and to what levels are they trained?

Requesting Evacuation. MEDEVAC requests are normally transmitted using the standard NATO 9-Line MEDEVAC Request Format. The MEDEVAC request provides controllers in operations centers with the critical information needed to launch and manage MEDEVAC platforms. The standard format can be used to request any kind of evacuation asset, air, ground or waterborne. CASEVAC requests can be tailored specifically to the unit mission and operating area, but typically consist of the first 5 lines of a MEDEVAC request. This works for CASEVAC platforms since they are normally already part of the tactical operation, and the pilots/drivers have a clear understanding of the battle space through previous coordination and ongoing communications. Though the request from the tactical element on the ground is normally transmitted by radio; the request from the unit's C2 may be by other means such as e-mail, operational chat room (mIRC or TransVerse) or telephone. The unit C2 must be aware of these requirements to better streamline the evacuation request process during the execution phase.

| MEDEVAC REQUEST 9-LINE | |
|---|--|
| LINE 1: LOCATION OF UNIT | HLZ GRID (MGRS): |
| LINE 2: CALLSIGN AND FREQUENCY AT THE PZ | CALLSIGN: FREQUENCY: |
| LINE 3: NUMBER AND PRECEDENCE OF CASUALTIES | A: Number of Urgent Casualties B: Number of Priority Casualties C: Number of Routine Casualties |
| LINE 4: SPECIAL EQUIPMENT REQUIRED | A: None B: Hoist C: Extraction D: Ventilator E: Other (specify) |
| LINE 5: NUMBER OF CASUALTIES BY TYPE | L: Number of Litter Casualties A: Number of Ambulatory Casualties E: Number of Escorts |
| LINE 6: SECURITY AT PZ | N: No enemy P: Possible enemy E: Enemy in area X: Armed escort required |
| LINE 7: PZ MARKING | A: Panels B: Pyrotechnics C: Smoke (designate color) D: None E: Other (specify) |
| LINE 8: CASUALTIES BY NATIONALITY/STATUS | A: US/Coalition Military B: US/Coalition Civilian C: Non-Coalition D: Non-Coalition Civilian E: Opposing Forces/Detainee F: Child |
| LINE 9: PZ TERRAIN/OBSTACLES (CBRN CONTAMINATION IF APPLICABLE) | Brief description of significant obstacles on approach / departure headings and type of predominant terrain for the HLZ |

Additional Evacuation Request Information. Depending on how developed the theater of operations has become or the number of units being supported by a particular evacuation asset, there may be additional information requirements. Such requirements can both allow evacuation C2 better prioritize assets and can notify receiving facilities of patient conditions. After a patient is assessed, a MIST report will be transmitted in the same manner as the 9-Line medevac. The MIST report both informs the MEDEVAC crew of patient status as well as notifies the receiving facility of incoming patient requirements. The MIST report is not required to launch an evacuation asset, but is to be transmitted as soon as possible.

| MIST REPORT | |
|---|---|
| M – MECHANISM OF INJURY AND TIME OF INJURY (IF KNOWN) | Mechanism of Injury and time of injury (if known) |
| I – INJURY OR ILLNESS | Injury or Illness |
| S – SYMPTOMS AND VITAL SIGNS | A – Airway status B – Breathing rate C – Pulse rate D – Conscious/Unconscious E – Other signs |
| T – TREATMENT GIVEN | Such as Tourniquet/Time Applied Drugs administered |

Rehearsals with External Assets. The unit's leaders and tactical medics will coordinate face-to-face with external evacuation personnel prior to mission execution to assure a clear understanding of procedures by all personnel. The rule, not the exception is that live rehearsals with evacuation assets are conducted to prepare for smooth handover of casualties. Unit operators, medical teams, aid & litter teams, and C2 must practice with the evacuation platforms prior to mission execution. During the real evacuation of a wounded Ranger is not the time to learn how to position and secure a litter to the evacuation platform.

Surgical and Area Medical Support Assets. The medical treatment facilities to which combat casualties will be transported must be identified. Their capabilities and capacities (especially surgical) should also be documented. With this knowledge, planners can predict how many of what type of casualties could overwhelm a given facility, and casualty flow can be directed accordingly. Furthermore, casualties can be routed directly to facilities with greater capabilities if dictated by the severity of their injuries. For casualties with severe injuries, evacuation to a fully capable combat support hospital has been found to produce better outcomes than evacuation to a treatment facility with limited surgical and intensive care capabilities if the evacuation times are comparable.

MEDICAL TREATMENT FACILITIES

Per Allied Joint Publication-4.10(A), the following define the levels of medical treatment facilities in a theater of operations.

ROLE 1 MTF (Maritime Echelon 1) – provides primary health care, specialized first aid, triage, resuscitation and stabilization. The basic Role 1 capabilities include basic occupational and preventive medical advice to the chain of command, routine sick call and the management of minor sick and injured personnel for immediate return to duty, as well as casualty collection from the point of wounding and preparation of casualties for evacuation to the higher level MTF. *Nearly all Ranger health care capabilities are considered Role 1 unless augmented by external assets made organic to the task force. Generally, the Regiment maintains role-1 capability within the confines of tactical health care / casualty response on target and aid stations established at forward operating bases.*

ROLE 2 MTF – A Role 2 medical facility is an intermediate structure capable of receiving casualties, providing triage and stabilization for further evacuation, treatment and holding of patients until they can be returned to duty or evacuated. Role 2 minimum capability includes: Re-supply to Role 1, Evacuation from Role 1, Limited holding capacity, Personnel reinforcement to Role 1, Patient record maintenance, Tracking of evacuated patients, and Operational stress management. *Under specific conditions, Ranger units may be augmented by other units to have a Role 2 capability organic to a special operations task force.*

ROLE 2 (+) MTF (Maritime Echelon 2) – Augmented Role 2 (Role 2+) medical facilities consist of Role 2 minimum capability augmented by any or all the following: Emergency surgery, Intensive care, Essential post operative care, Blood replacement, Laboratory capability, and Basic imaging capability (e.g., radiology, ultrasound).

ROLE 3 MTF – Facilities include the capability of Role 2 extended by surgery, intensive and post-operative care, medical, dental and nursing care, and relevant diagnostics. Role 3 units can provide lower level units medical personnel replacement. Resupply of Role 2 facilities and either control of or ready access to patient evacuation assets are included within the minimum capability. In addition to beds required for the seriously ill, the holding capacity will be sufficient to allow diagnosis, treatment and holding of those patients who can receive adequate treatment and be returned to duty within the evacuation policy.

ROLE 3 (+) MTF (Maritime Echelon 3) – Augmented Role 3 (Role 3+) medical facilities include one or more of the following: Specialist surgery (neuro-surgery, maxillo-facial, burns, etc.), Advanced and specialist diagnostic capabilities (CT scan, arthroscopy, sophisticated lab tests, etc.), Major medical, dental and nursing specialties, Preventive medicine and Environmental health capability.

ROLE 4 MTF (Maritime Echelon 4) – A facility that provides definitive care of patients for whom the treatment required is longer than that dictated by the theatre evacuation policy or for whom the capability usually found at Role 3 is inadequate. This would normally include definitive care specialist surgical and medical procedures, reconstruction and rehabilitation. This care is usually highly specialized, time consuming and normally provided in the casualty's country of origin. Under very unusual circumstances, a Role 4 medical facility may be established in the Theater of Operations.

Face-to-face coordination with appropriate external medical assets is critical. The medical planner must visit the supporting medical facilities to gain an understanding of their physical layouts, unique equipment, procedures, casualty management and patient accountability. Also, unit medical personnel must know how to follow up with the unit casualties as commanders will require serial reports on their status.

Deployed troops will suffer routine illnesses and non-combat injuries that may require medical attention exceeding the tactical medic's scope of practice. Area medical support assets are those facilities that provide medical services other than combat trauma care to meet these needs. Established policies and procedures for operators' care at area medical support facilities should be conveyed to unit leaders and medical personnel.

FAMILIARIZATION WITH MEDICAL ASSETS

- Published References (Look it up!)
 - ✦ What is a CSH?
 - ✦ What is a FST/FRSS?
 - ✦ What is an ASMC?
- Can you see their layout / equipment?
- Can you conduct familiarization training as required?
- What are their capabilities and limitations?
- Can you talk to them and what can they know about you and your mission?

Special Operations and Augmentation of Surgical or Medical Support Assets. In special operations contingencies, the evacuation and receiving facilities options may be greatly different from the medical support in a developed theater. The “Golden hour” can be significantly extended in distance and time from the point of injury to an established medical or surgical facility with proper implementation of Special Operations Surgical assets. The current battlefield and future contingency operations nullify the option of calling in a MEDEVAC or quickly evacuating a casualty to a combat support hospital. The evacuation and long range care capability may need to be completely planned and coordinated using the assets organic to the special operations task force. In these cases, it is critical that these capabilities be augmented into the special operations task force when time and OPSEC allows. The intent remains to get a traumatized casualty appropriate en route care to an advanced surgical or medical capability as quickly as possible. Such contingencies will require augmentation from other units or attachments to conduct en route casualty stabilization on a designated platform or sequence of platforms until the casualty reaches a fixed facility. Augmentation capabilities requirements must be identified early in the planning process to allow adequate time for the planning and coordination. Once this medical asset is identified, it must integrate early into the planning and synchronization process. Assets will need to be pre-staged at specific locations or on evacuation platforms in order to provide the unit with the upmost capability. Unit leadership will develop a thorough understand that these special medical assets become part of the overall unit plan and execution. The unit may have to adjust combat loads in order to stage or infiltrate medical support assets as required. Ultimately, the unit commander is responsible for the allocation, synchronization, and employment of all the augmented medical resources available to complete the unit’s mission. The medical planner’s responsibility is to ensure the commander and staff is well-informed of requirements, capabilities, limitations, and employment methods of medical augmentation. Subsequently, the medical planner must provide the medical augmentation with the constraints and restrictions that they must operate within the mission. Special operations, by its very nature, tend to be a joint, interagency, and international affair. Therefore, the medical planner must widen their viewpoint to all available medical resources and capabilities within reach. Familiarization with the medical unit capabilities of other military services and international assets is imperative to mission success. Additionally, the use of host-nation medical capabilities must be factored in as an option if necessary.

Primary and Alternate Planning. As with all military operations, the unit and the medical planner will develop back-up plans. A unit should never launch on a combat mission with a single planned means of casualty evacuation. Alternatives for all possible routes of evacuation to and from the objective (e.g. -air, ground, water) should be written into the medical plan. Alternate receiving facilities should be identified in case mass casualty situations occur or conditions prohibit evacuation to primary facilities. Additionally, weather and environmental conditions can have detrimental effects on pre-planned evacuation operations that can be mitigated by a good alternate plan. As the medical planner develops the tactical medical support plan the following must be considered: Primary and alternate means of evacuation including the capabilities, limitations, distances and communications

methods; primary and alternate receiving medical treatment facility to include capabilities, limitations, bed status and mass casualty over-flow contingencies.

Tactical Medical Support Plan Development

Understand the Tactical Commander's Plan. The tactical medical planner must understand the overall scheme of maneuver of the forces arrayed on the battlefield. This understanding is gained by attending all of the operations planning meetings and ensuring that medical operations are well synchronized into the tactical plan. Tactical plans may evolve rapidly, so the medical planner must keep abreast of changes, and should participate in course of action development to determine how the various options can be supported medically.

Casualty Estimation. Medical and tactical planners should predict where casualties are likely to occur and develop casualty management and evacuation plans for all phases of the operation (infiltration, assault, clear/secure, consolidation, exploitation, defense and exfiltration). Other key elements to consider are the layout of the target and template of enemy positions as projected by intelligence and operations staffs. Understanding the commander's tactical plan will indicate how best to develop the medical support plan.

Casualties should be expected and planned for in all phases of any tactical operation from en route, infiltration, assembly, assault, actions on the objective, consolidation, defense, exfiltration, and return to base.

The casualty estimation also includes projecting possible Disease Non-Battle Injuries (DNBI). Based on known medical threats, unit activities, previous events, and individual health profiles, determine the potential non-battle injuries that may occur. DNBI can also include traumatic injuries that did not occur as a result of firefights such as parachute landing injuries or vehicle accidents. Keep in mind that some minor casualties may not come to the attention of the medic until post mission after return to base. Include in your plan a post mission screening for potential casualties who may require medical treatment.

CASUALTY ESTIMATION

- Analyze the target and the templated enemy positions
- Analyze the commander's assault plan
- Plan to take casualties during every phase of the operation (infiltration, assault, clear/secure, consolidate, defend, exfiltration).**
 - ✦ Where do you foresee taking casualties?
 - ✦ Where is it most critical for the medics to be located?
 - ✦ Do you need to task organize your medical team?
 - ✦ Where does the unit need to establish CCP's?
 - ✦ What evacuation methods need to be considered?
 - ✦ Where is the closest HLZ or AXP?
 - ✦ Where do you emplace and preposition medical assets/augmentation?
- Review Preventive Medicine issues and anticipate DNBI
 - ✦ What are the health threats?
 - ✦ What actions will prevent or decrease disease and non-battle injuries?

Issue Initial Medical Planning Guidance to Subordinates. Medical planners should constantly disseminate information to subordinate elements and junior medics. Information provided should be as comprehensive as possible consistent with operational security considerations. Planning guidance


should include the medical threat, medical assets, copies of higher OPORDs/OPLANs, and information that will assist subordinates with medical planning at their level. Guidance from above helps junior medics better prepare themselves and their equipment for tactical operations.

Determine Casualty Flow from Target to Hospitalization. The tactical medic will always have a detailed understanding of the casualty flow up to two levels above themselves, including patient regulating, casualty accountability, and hospitalization requirements. Furthermore, casualty flow is planned from the point-of-injury all the way back to admission to a Continental United States (CONUS) medical facility. However, in an established combat theater, a casualty may be admitted, treated and even released from an intermediate facility between the battlefield and CONUS.


CASUALTY FLOW CONSIDERATIONS

- Where will the unit's casualties be evacuated to?
- Will evacuation be conducted by ground or air (or water) assets to a casualty collection point?
- How will evacuation be conducted to casualty transload points?
- What are the distances and times of travel?
- Will expected casualties be able to make it that far? If not, what parts of the plan need to be adjusted?
- Who will evacuate the casualties (unit, frequency, callsigns)?
- Will medical assets be properly positioned to ensure continuity of care?

EXAMPLE 1:



EXAMPLE 2:



Determine Key Locations. Key locations for medical assets are determined based upon the casualty estimation and the commander's tactical assault plan.

DETERMINE KEY LOCATIONS

- Based on your casualty estimation and the tactical assault plan...
 - ✦ Where should the CCP be located?
 - ✦ Where should patient exchanges be located? (CEP, CCP, HLZ, AXP)
 - ✦ Where are the projected blocking positions, fighting positions, etc...?
 - ✦ Where is the CP / TOC?
 - ✦ Who is in charge of each key location?
 - ✦ Primary and Alternate Locations?
 - ✦ What are the ground movement routes?
 - ✦ Where are re-supply points (BLOC/Supply Bundles)?

Establish the Tactical Medical Support Plan. The medical support plan can be developed alongside tactical plans, but often it is difficult to lock in the medical plan until tactical planners have settled on the preferred course of action. A basic tactical medical support plan should include the following elements: 1) The distribution, task organization and tactical movement (infiltration/exfiltration) of medical elements, all synchronized with each other and the overall tactical plan; 2) The casualty flow plan from point of injury, through evacuation, to a medical treatment facility, including primary and secondary evacuation routes, method, and modes (aid & litter, air, ground, water); 3) Primary and alternate sites for CCPs, casualty evacuation locations; 4) A medical communications plan; 5) A medical re-supply plan if the operation will continue for a length of time; 6) Management plans for wounded hostile combatants and non-combatant casualties.

Air Tactical Evacuation Plan. The following information should be gathered in the formulation of a tactical air evacuation plan:

AIR CASEVAC PLAN

- What is the type of Air CASEVAC mission?
 - ✦ Dedicated – an air asset whose purpose after infiltration is casualty evacuation. It is outfitted and manned for casualty management.
 - ✦ Designated – an air asset that will be the aircraft instructed to evacuate casualties. May be equipped for casualties if requested.
 - ✦ On-Call – air assets that are held in reserve or must be launched to respond to casualty evacuation.
- May also apply to MEDEVAC covering the area.
- Aircraft type?
- Maximum casualty load?
- How are casualties to be loaded?
 - ✦ Packaging requirements: Litters, Skedcos, etc..?
 - ✦ Is the aircraft equipped with litter stanchions?
 - ✦ Loading procedures? Approach procedures?
- What medical capability is on the aircraft?
 - ✦ Flight medic or medical officer?
 - ✦ Casualty management equipment?
 - ✦ Medical resupply bundles?
 - ✦ Does the unit need to outfit the platform with medical capability?
- Request Procedures?
 - ✦ Procedures for requesting CASEVAC?
 - ✦ 9-Line MEDEVAC request versus modified format?
 - ✦ Communication requirements?
- Launch Authority?
 - ✦ Who is the launch authority for the aircraft?
 - ✦ What are the impacts on Ranger CASEVAC operations?
- Landing requirements?
 - ✦ Special HLZ considerations?
 - ✦ Special markings required?
- Special equipment required?

Ground Tactical Evacuation Plan. There are two major components of a ground tactical evacuation plan. The first is ground evacuation in the target area and the second is from the target area to higher echelon of care. The security of the ground element is a critical aspect of moving casualties within or out of the target area. The unit must ensure that a fighting element will protect the evacuation asset from enemy attack.

Ground tactical evacuation at the objective consists of moving casualties from their points of injury to casualty collection points or evacuation points. Aid & litter teams will be formed by personnel within the fighting elements. These personnel will be trained, equipped and rehearsed to conduct this mission prior to launching the tactical mission. Vehicles of opportunity such as abandoned or captured enemy vehicles on the target can be used to move casualties. For instance, in an airport/airfield seizure, the unit could use baggage carts to move casualties.

Planning for evacuation by ground from the objective to a medical facility incorporates the same kind of information as planning for air evacuation, except for questions unique to the vehicles. One critical aspect of ground evacuation, however, is whether the unit will conduct the evacuation using its own assets or call upon another unit.

GROUND CASEVAC PLAN – TWO PHASES

1. Actions required on the target.

- How should Rangers move casualties on the target to the CCP?
 - ✦ Aid & Litter Teams
 - ✦ Skedco, Litter, etc...
 - ✦ Ranger Ground Mobility (Quad, MEDSOV, GMV, RSOV, Stryker, MEV, MRAP)

2. Actions required for evacuation away from the target.

- What is the type of Ground CASEVAC mission?
 - ✦ Dedicated – a ground asset whose purpose after infiltration is casualty evacuation. It is outfitted and manned for casualty management
 - ✦ Designated – a ground asset that will be the vehicles instructed to evacuate casualties. May be equipped for casualties if requested.
 - ✦ On-Call – ground assets that are held in reserve or must be launched to respond to casualty evacuation. This may be vehicles of opportunity (tactical or captured).
- Vehicle type and maximum casualty load?
- How are casualties to be loaded?
 - ✦ Packaging requirements: Litters, Skedcos, etc..?
 - ✦ Is the vehicle equipped with a carrying configuration?
 - ✦ Loading procedures?
- What medical capability is on the vehicle?
 - ✦ Medics? Medical Officers?
 - ✦ Casualty management equipment?
- Request Procedures?
 - ✦ Procedures for requesting ground CASEVAC?
 - ✦ 9-Line MEDEVAC request versus modified format?
 - ✦ Communication requirements (Freq/Callsign)?
- Launch Authority?
 - ✦ Who is the launch authority for the vehicles?
- Link-up Requirements
 - ✦ At your CCP or an AXP?
 - ✦ Marking / signaling procedures?

QRF capabilities and integration

Medical Communications. The Tactical Medical Support Plan includes a plan for medical communications. In formulating this plan, the following should be considered:

COMMUNICATIONS REQUIREMENTS

- Do all medics have radios?
- Can a medic contact a higher care provider for guidance?
- Types of radios / COMSEC?
- Medical Command & Control Delineation
- Callsigns / Frequencies / SOI
- Evacuation request frequencies?
- Evacuation asset frequencies?
- Casualty reporting/accountability?
- Re-Supply requests

Medical Re-Supply Requirements & Methods. Medical planners must develop a thorough understanding of the unit's normal medical equipment, supplies, load plans, and pre-mission shortages. For the development of the medical support plan, determinations are made regarding the equipment and supplies that will be initially carried onto the target, and a further plan established for a

first and second echelon of re-supply. The tactical medical planners should also understand the acquisition and availability of blood products, special vaccines, antidotes, and antivenins as required.

CLASS VIII RE-SUPPLY REQUIREMENTS & METHODS

- How do you request re-supply?
- What are the re-supply methods?
 - ✦ Speedballs?
 - ✦ Drag-off bundles?
 - ✦ CDS?
- Medical packing lists? Do you need to reconfigure/repack (aidbag, pelican)?
- How do you request specific line items?

Briefs, Rehearsals and Pre-Combat Inspections

The operations order (OPORD) at all levels will include the tactical medical support plan. For forced-entry type missions in which the assault force is making an initial entry into an operational area, the medical component must be extensive and informative.

MEDICAL & CASUALTY RESPONSE OPORD BRIEFING AGENDA

- Health Threat
- Casualty Response Concept of the Operation
- Key Locations (CCPs, HLZs, AXPs, etc)
- Casualty Flow (to key locations to HLZ/AXP to MTF)
- Requesting Procedures (CASEVAC, MEDEVAC, Assistance, Re-Supply, including net/freq/callsign of supporting elements)
- Medic callsigns / frequencies
- Casualty Accountability

Rehearsals. Rehearsals familiarize unit members with the mission plan and visualize the expected action. Depending on the level and repetition of rehearsal, unit members can develop a thorough familiarity with the sequence of events that will be executed. A rehearsal should be conducted as a scripted event that lays out the operational plan in a sequence of overlapping events. Contingencies and complications can be injected to assess unit member reactions and to practice alternate plans.

Full Dress Rehearsals provide the most detailed understanding of the operation and involve all unit members executing their expected tasks flowing through the expected timeline of the event. A full dress rehearsal is a military field exercise; a training event preparing for the real event at a similar location layout. A Reduced Force Rehearsal involves only key leadership of subordinates and operational units. Terrain Model Rehearsals, also known as ROC Drills or Sandbox Drills, use miniature depictions of the operational area. Terrain model rehearsals are historically the most commonly used method for rehearsal of military operations. Map rehearsals can be used virtually anywhere using actual maps, imagery or sketches of operational areas.

A Communications Rehearsal, also known as a COMMEX, is a combination of testing communications systems as well as unit members running through the sequence of events through radio calls. For the communications equipment tests, using the same equipment, same frequencies, and same distances specified in the operational plan will provide the unit with the best insight into whether their equipment will function properly. If possible, line-of-sight obstacles such as buildings or terrain should be interposed between radios to exactly replicate conditions at the target. Casualty

response specific execution checklist calls must be integrated into the overall unit EXCHECK. Example calls may be CCP established, evacuation asset in place/on station, casualty HLZ (CEP or AXP) established, and most importantly the radio notification call for a casualty report. Contingency or deviation calls may be required for mass casualty situations, accidents/incidents involving aircraft or vehicles, and changes from primary to alternate aircraft/vehicles, key locations, evacuation assets or receiving medical facilities.

REHEARSALS

- RFR Drills
- Squad Casualty Response Drills (care under fire, TFC and evacuation)
 - ✦ Each element should rehearse alerting aid & litter team and movement of a casualty
- Aid & Litter Team Drills
 - ✦ Alert and movement
 - ✦ Evacuation equipment prep
 - ✦ Clearing / securing weapons
- Evacuation Request and Loading Procedures
- COMMEX
- Unit-wide Casualty Tracking / Accountability
- CCP Operations
 - ✦ Assembly, security & movement
 - ✦ Recon, Clear and Secure CCP Location
 - ✦ CCP markings, link-up procedures, and vehicle parking
 - ✦ Choke Point / CCP Command Post
 - ✦ Triage, treatment and management of casualties
 - ✦ Casualty Accountability & Reporting
 - ✦ Marking & Tagging
 - ✦ Equipment removal tagging/consolidation
- Review of execution checklist calls pertinent to the casualty response plan.

Pre-Combat Inspections. Every combat unit will conduct pre-combat inspections (PCIs) prior to launching on a mission. PCI are conducted from the lowest leadership levels to the highest; no individual will be exempt.

PRE-COMBAT INSPECTIONS

- Individual Rangers
 - ✦ Ranger Bleeder Kits (BCKs)
 - ✦ TQ on kit serviceable
- Squad Casualty Response Kit
 - ✦ ARFR Bag
 - ✦ Evacuation Equipment (Skedco, Litters, etc...)
 - ✦ Vehicle mounted aidbags
- RMED Individual Equipment (weapon, NVG, radio, packing list, mission specific)
- RMED Aidbags (Pack and/or reconfigure as required)
 - ✦ Select appropriate aidbag system per mission requirements
 - ✦ Ensure packing list IAW recommended Ranger Medic Standards
- Re-Supply Packages (Pack and/or reconfigure per mission requirements)
 - ✦ Reconfigure per mission specifics (ground, air, etc...)
 - ✦ Utilize speedballs, bundles, or pull-off configured as required
 - ✦ Pre-position as required with aircraft and vehicles or at staging base with BLOC and logistics teams
- Evacuation Assets (Quads, Vehicles, etc...)

Sustained Combat Operations & Time Sensitive Targets

When a unit is deployed and operating in a particular area of operations, several planning mechanisms will become more streamlined and habitual. The casualty response brief will be minimized to essential changes of information. While still covering the essential information, the brief will be tailored to a single slide within the overall OPORD or CONOP. This is especially useful in time sensitive operations in which there may be only a few hours to minutes prior to launching the assault force on the mission. It is best to maintain a single slide in which critical information is routinely updated. This allows for making specific minimal changes based on the mission at hand.

OBJ XXXXXXXXXXXX CONOP – Mission Type

OBJ GRID: XXX XX XXXXX XXXXX

Prepared BY: XXX XXXXXXXXXXXX
 Position: XXXXXXXXXXXX
 Name: XXX XXXXXXXXXXXX
 Contact: XXXXXXXXXXXX

MISSION MEDICAL PERSONNEL

CSAR ASSETS

| | Asset | Call Sign / Frequency | Locations (INFIL / EXFIL / ON OBJ) | Call Sign | Location/SAT | Alert + Time of Flight |
|---|-------|-----------------------|------------------------------------|-----------|--------------|------------------------|
| 1 | | | | P: | | XX min + XX min |
| 2 | | | | S: | | XX min + XX min |
| 3 | | | | Note: | | |

CASEVAC / MEDEVAC

| Order | Asset | Unit | Contact / Type | Call Sign / Frequency | Staging Location | Response Time (S/U + time to TGT) | Target to Primary Med Facility |
|-----------|-------|------|----------------|-----------------------|------------------|-----------------------------------|--------------------------------|
| Primary | | | | | | XX min | XX min |
| Secondary | | | | | | XX min | XX min |

Notes: _____

MEDICAL TREATMENT FACILITIES

| Order | MTF Name / Grid | Total time from Alert to MTF |
|-----------------|-----------------|------------------------------|
| Primary | | XX min |
| Secondary | | XX min |
| Head Injury MTF | | XX min |
| MWD | | XX min |

Note: Time to MTF is using primary CASEVAC/MEDEVAC

(P) MTF CAPABILITIES

| LOCATION (ROLE #) |
|-------------------|
| SVOIP: |
| DSN: |
| mIRC: |
| Grid: |
| # x OR |
| # x ICU |
| # x ICW |
| # x CT Scanner |

(S) MTF CAPABILITIES

| LOCATION (ROLE #) |
|-------------------|
| SVOIP: |
| DSN: |
| mIRC: |
| Grid: |
| # x OR |
| # x ICU |
| # x ICW |
| # x CT Scanner |

NON-TF CSAREVENT = POI → GFC REQUEST CSAR FORCES → REGIONAL TF → TF APPROVAL → CSAR LAUNCH → RECOVERY

NON-TF EVACFLOW = POI → RTO 9 LINE TO TOC / JOC → MEDO CALLS OR MIRC PRIMEDEVAC → TF MEDOPS APPROVAL → MEDEVAC LAUNCH → EVAC

Time Sensitive Targets (TST). The key to successful time sensitive target planning is maximizing coordination's prior to the unfolding events. The medical planner should have already made face-to-face or phone contact with evacuation assets, receiving hospital facilities and other unit planners. The essentials of planning TST casualty response remains consistent with normal planning except that it is done rapidly and heavily based on pre-coordinated activities. The planner must be well versed in the unit compressed planning sequence and use of appropriate computer software, communications capabilities and methods to check status of assets. As soon as the unit receives the WARNORD of an upcoming mission, the medical planner must immediately initiate their planning sequence of events. WARNORD briefs are usually conducted quickly upon receipt from the higher HQ or the unit commander. The medical planner must be considered a key leader in the unit planning sequence for TST missions. Critical pieces of information are the target location, projected HLZs, and available evacuation and treatment facility assets.

Generally, the primary means of evacuation will be CASEVAC using the mission platforms used for infiltration and exfiltration. The alternate evacuation means will mostly be using the conventional assets from their bed down locations. However, each mission must be tailored to available assets. Unless the unit is augmented, the receiving facility will be the nearest Role 2 or higher capability within range of the target. The planner must be careful in selecting the receiving MTF while considering distances, capabilities and the current status of each facility. The planner must always establish a primary, alternate and perhaps a tertiary receiving facility. Ensure you have a good understanding of which facilities should receive casualties with specific injuries such as head injuries or burns.

Once the commander has established the basic tactical CONOP, determine the casualty estimate and select appropriate locations for primary and alternate CCPs as well as evacuation HLZs/CEPs. Identify personnel designated to perform aid & litter team duties on target. Confirm the JOC/TOC Battle Captain/NCO understands the procedures for requesting external evacuation support and notification of receiving medical facilities of inbound casualties.

Develop the casualty response CONOP based on all information gathered. Modify the one-slide casualty response CONOP and ensure it is integrated into the unit CONOP. Disseminate all information to subordinate medics and unit personnel. Brief the casualty response plan in the unit brief and send the medical CONOP to higher HQ as required. When feasible and approved within OPSEC guidelines, notify receiving medical facilities and evacuation assets of the upcoming mission.

Conduct pre-combat inspections of individual Rangers, Medic aid bags, Squad ARFR kits, aid & litter team equipment, CASEVAC platform medical equipment, and re-supply packages.

Post mission, ensure that all medical supplies and equipment is refit and restocked. Conduct post-mission screening of all assault force members for unreported injuries. Follow-up with receiving facilities on status of any casualties evacuated. Provide an update to the commander on casualty status. Conduct an AAR of the mission to identify any lessons learned and/or modifications to future CONOP plans. Additionally, a casualty after-action review/report will be submitted on each Ranger/MWD casualty within 72 hours post mission.

TST Planning

- Receive WARNORD of pending TST mission
 - ✦ Confirm target location grid
 - ✦ Confirm preliminary HLZ information (or infiltration locations/methods)
 - ✦ Confirm status of task force organic medical personnel and evacuation capabilities
 - ✦ Determine any medical augmentation requirements and initiate appropriate requests
- Assess Distances and Response Times based on target location and/or HLZs (based on appropriate routes through terrain obstacles such as mountains or around enemy areas)
 - ✦ Confirm travel distance and time to the target
 - ✦ Confirm distance from target to primary, alternate, and tertiary receiving facilities
 - ✦ Confirm distance to target, response time, distance to destination and time to destination for primary, secondary and tertiary forms of evacuation. Ensure response time includes notification and spin-up time for launch of the asset.
 - ✦ Determine if specific receiving medical facilities need to be designated for specific injuries (head injuries or burns)
- Confirm readiness of receiving facilities and external evacuation assets
 - ✦ Contact primary and secondary medical receiving facilities to confirm their bed status and readiness to accept casualties.
 - ✦ Contact primary and secondary evacuation assets to confirm their readiness status.
 - ✦ Contact CSAR coverage asset and confirm readiness status and response times.
- Finalize tactical medical support plan based off of commander's tactical CONOP
 - ✦ Conduct casualty estimate on target to determine where casualties are likely to occur
 - ✦ Confirm/Assess best locations for primary and alternate CCPs on target
 - ✦ Confirm/Assess best locations for primary and alternate Evacuation HLZs/CEPs
 - ✦ Confirm/Determine personnel tasked to be aid & litter teams on target
 - ✦ Confirm JOC/TOC Battle Captain/NCO knows appropriate evacuation JOC/TOC drill for requesting external evacuation and notification of receiving facility (to include 9-Line MEDEVAC request transmission procedures)
 - ✦ Develop casualty response CONOP using the one-slide with changes as required.
- Perform Pre-Combat Inspections
 - ✦ Check individual Rangers for bleeder control kits, squad casualty response kits, and identified aid & litter team equipment
 - ✦ Check individual medic aidbags and kit
 - ✦ Check CASEVAC assets equipment and Re-Supply packages
- Post-Mission Activities
 - ✦ Restock and refit any expended medical supplies and equipment in RFR kits, medic aidbags or CASEVAC platforms.
 - ✦ Conduct AAR of mission to gather lessons learned and/or modifications to future CONOPS
 - ✦ Follow-up on casualties with receiving facilities and provide an update to the commander
 - ✦ Perform maintenance on medic equipment to include weapons, NVGs, radios, and medical equipment
 - ✦ Conduct screening of mission personnel for any injuries sustained and not previously reported to include post-blast assessments

Casualty Collection Point Operations

Casualty collection point (CCP) operations must be a well planned and rehearsed. In the planning phase, both unit leadership and members of the CCP element have critical responsibilities. In the

execution phase, the members of the CCP must act as a cohesive team with every member fulfilling his responsibilities. A CCP will never be exactly the same as it was on a previous mission. However, there are critical guidelines in the planning and execution of any CCP.

CCP SITE SELECTION

- Reasonably close to the fight
- Near templated areas of expected high casualties
- Cover and Concealment
- In building or on hardstand (exclusive CCP building limits confusion)
- Access/trafficable to evacuation routes/assets (foot, vehicle, aircraft)
- Proximity to Lines of Drift on the objective
- Adjacent to Objective Choke Points (breeches, HLZ's, etc...)
- Avoid natural or enemy choke points
- Area allowing passive security (inside the perimeter)
- Good Drainage
- Expandable if casualty load increases
- Consider placement of CCP locations near recognizable landmarks such as airfield control towers, fire stations, religious buildings, or local medical facilities.

UNIT LEADERSHIP CCP DUTIES & RESPONSIBILITIES

- ❖ **Planning Phase**
 - Evacuation Plan by phase of the operation
 - CCP locations, HLZ/AXP locations,
 - Security of CCP, Security of HLZ/AXP
 - Allocate Aid & Litter teams and carry evacuation equipment
 - Accountability / Reporting Plan
 - Distribution/Task Organization of Medical Personnel
 - Pre-Combat Inspections of Junior Medics, Squad Casualty Response Kits, and Individual Ranger BCK/RFR Tasks
 - Conduct Casualty Response Rehearsals
- ❖ **Execution Phase**
 - Establish and Secure CCP
 - Provide assistance to medics with ARFR augmentation and directing aid & litter teams
 - Gather and Distribute casualty equipment and sensitive items
 - Accountability and Reporting to Higher
 - Request Evacuation and Establish CASEVAC link-up point
 - Manage KIA remains (or as coordinated by BLOC/S4)

BATTALION-LEVEL MEDICAL PERSONNEL CCP DUTIES & RESPONSIBILITIES

❖ Planning Phase

- Provide recommendations and advise to leadership on medical support
- Recommend to the Unit Leadership & Coordinate as required:
 - CCP Locations of subordinate units by phase
 - Medical Task Organization & Distribution
 - Ground (on the target) Evacuation Plan & Assets for all targets
 - Air/Ground (off the target) Evacuation Plan & Assets for all targets
 - CCP, HLZ, and Evacuation Asset Security for all targets
- Augmentation requirements of subordinate units
- Link-in with the tactical operations center

❖ Execution Phase

- Triage, Treatment, Monitoring, and Packaging
- Delegation of Treatment
- Request Assistance from other medical or platoon assets
- Provide guidance and recommendations to leadership on casualty management

UNIT MEDICS CCP DUTIES & RESPONSIBILITIES

❖ Planning Phase

- Provide recommendations and advise to leadership on medical support
- Medical Support Planning by phase of the operation
- Casualty Response & Evacuation Plan by phase of the operation
- Recommend to the Unit Leadership & Coordinate as required:
 - CCP Locations by phase
 - Medical Task Organization & Distribution
 - Ground (on the target) Evacuation Plan & Assets
 - Air/Ground (off the target) Evacuation Plan & Assets
 - CCP, HLZ, and Evacuation Asset Security
- Pre-Combat Inspections of Junior Medics, Squad Casualty Response Kits, and Individual Ranger BCK/RFR Tasks

❖ Execution Phase

- Triage, Treatment, Monitoring, and Packaging
- Delegation of Treatment
- Request Assistance from other medical or unit assets
- Provide guidance and recommendations to leadership on casualty management & evacuation

CCP OPERATIONAL GUIDELINES

- 1SG / PSG is responsible for casualty movement and everything outside the CCP
 - Provides for CCP structure and organization (may be color coded with chemlights)
 - Maintains C2 and battlefield situational awareness
 - Controls aid & litter teams, and establishes security
 - Strips, bags, tags, organizes, and maintains casualty equipment outside of treatment area as possible
 - Ensures reallocation of equipment as required (weapons systems, etc...)
 - Accountable for tracking casualties and equipment into and out of CCP and provides reports to higher
 - Casualties move through CCP entrance / exit choke point which should be marked with an IR Chemlight

- Medical personnel are responsible for everything inside the CCP
 - Triage officer sorts and organizes casualties at choke point into appropriate treatment categories
 - Medical officers and/or medics organize medical equipment/supplies and render treatment to casualties
 - Directs ARFRs, RFRs, A&L Teams assist with treatment and packaging of casualties

- Minimal casualties should remain with original element or assist with CCP security if possible
- KIAs should remain with original element or be transported to the BLOC

- All CCP Personnel:
 - Maintain Security
 - Maintain Adequate Treatment
 - Maintain Situational Awareness
 - Maintain Organization
 - Maintain Control of Equipment & Supplies

CCP WITHIN A BUILDING GUIDELINES


- Ensure building is cleared and secured
- Enter and assess the building prior to receiving casualties
 - Use largest rooms
 - Consider litter / skedco movement (can you do it in the area?)
 - Separate rooms for treatment categories?
 - Determine location of choke point / triage
 - Minimize congestion
- Remove / re-locate furniture or obstructions
- Color-code rooms to treatment categories (mark doors, etc...)

EVACUATION GUIDELINES


- Know the Evacuation Asset
 - Medical provider on board?
 - Monitoring equipment on board?
 - How many CAX can evacuate on asset?
- Packaging requirements for asset
 - Type litters?
 - Are there stirrups? Floor-Loading?
- Determine flow of casualties to the asset
 - Large Asset (Multiple CAX)
 - Routine on first
 - Priority on next
 - Critical (Urgent) on last, so they are first off at destination
 - Small Asset
 - Critical (Urgent) and Priority evacuated first

The following diagrams are common templates for the layout and organization of casualty collection points. No template is perfect and should be reasonably modified based on the setting, terrain, and mission circumstances.


**CCP / CEP Template 1
(Adjacent to Breach)**




**CCP / CEP Template 2
(Flow Through Style)**



**CCP / CEP Template 3
(Building - Rooms)**




**CCP / CEP Template 4
(Building – Open/Hanger)**



**CCP / CEP Template 5
(Open Area / Field)**


12



6

**CCP / CEP Template 6
(U-Shaped)**

ROUTINE/Minimal/Expectant



After Action Review No mission (training or combat) is complete until an after action review (AAR) has been completed. After each operation, an assessment of its conduct from beginning to end is conducted to gather all possible lessons. Units will often need to provide detailed reports to higher headquarters about the conduct of a combat operation. The planning and execution of the unit's casualty response will often bring critical lessons learned to the forefront. Keep in mind that a lesson is not learned until the problem has been identified, the unit has solved the problem, and the solution becomes the normal way of operating in the future. The list of questions below is a basic topic list for the AAR.

AFTER ACTION REVIEW (AAR) IN TRAINING OR COMBAT

- Was the mission executed as planned?
- What went right?
- What went wrong?
- What could have been done better?
- What could be fixed by planning / preparation?
- What could be fixed by training?
- What could be fixed by equipment modification?
- Identify and record Sustains & Improves by Phase of the Operation.

Relief-in-Place Operations

Staging Base Relief-in-Place

Ranger units have been continuously deployed to combat since October of 2001. Units conduct relief-in-place operations as Ranger units deploy to and re-deploy from the area of operations. It is critical that the unit pass on everything possible that it has learned, experienced and coordinated with the incoming unit. By no means does this relinquish responsibility of the incoming unit to confirm and

conduct further coordination's. Ensure you provide a good turnover to the incoming team. Keep in mind, you will be the incoming medic on your next rotation and would expect the same.

Tactical Relief-in-Place

Ranger units may turn over a target or seized terrain to a follow-on unit. Until the incoming unit makes adjustments to its tactical plan, it is best for them to assume the positions and procedures previously conducted. The senior Ranger tactical medical provider will link up with their counterpart of the incoming unit and provide as much information as possible.

TACTICAL RELIEF-IN-PLACE

- Current primary and alternate CCPs and HLZs
- Current external evacuation assets and receiving medical facilities supporting the area and any problems encountered.
- Ensure the incoming unit understands the capabilities and limitations of supporting evacuation and medical treatment facilities.
- Where, how many and types of casualties sustained during the previous operation.
- Any health trends that the relieving unit should be aware of.
- Potential hazards to unit personnel such as contaminated water or HAZMAT.
- Turnover of detainees or EPWs should include any medical conditions noted.

SECTION EIGHT

HAZARDOUS TRAINING MEDICAL COVERAGE



HAZARDOUS TRAINING MEDICAL COVERAGE DUTIES & RESPONSIBILITIES

Senior Coverage Medic

- Plan & coordinate medical support requirements & considerations
- Identify Hospitals and evacuation routes
 - Conduct Hospital Site Survey as required
 - Conduct face-to-face with hospital ER
 - Conduct route recon from target to hospital
- Establish target medical coverage plan and casualty flow
- Brief OIC/NCOIC medical support plan
 - Clarify OIC/NCOIC responsibilities and guidance
 - Clarify Medical responsibilities and guidance
- EXECUTION Duties:
 - Patient Treatment & Monitoring on target and en route
 - Advise OIC/NCOIC as required
 - Update OIC/NCOIC/Higher HQ on condition of evacuated casualties
 - Inform unit medical officer of all casualties
- After Training Event
 - Follow-up any evacuated casualties and update C2 and Medical Director
 - Clean, Refit, Store all coverage equipment
 - Submit AAR IAW unit or event-specific requirements

OIC / NCOIC of Event

- Overall responsible for administrative coverage (including medical)
- Request / track external medical support requirements
- Ensure appropriate type and number of vehicles with assigned drivers are dedicated to medical coverage
- Ensure appropriate communications equipment is allocated to medical personnel.
- Link medical coverage plan with overall administrative coverage plan.
- EXECUTION Duties:
 - Collect casualty data and report to higher HQ
 - Request MEDEVAC
 - Identify and establish MEDEVAC HLZ

HAZARDOUS TRAINING MEDICAL COVERAGE PLANNING

Maps & Route Recon

- Request/Purchase/Acquire appropriate maps of training areas, adjacent military installations, and cities
- Conduct map and ground recon of training areas (specifically key entrance & exit points).
- Identify hospitals/fire/EMS locations

Identify Special Coverage Considerations

- Weather
- Animals
- Plants
- Terrain hazards (high angle or high altitude)

Identify Hospitals

- Primary and Alternate evacuation hospital (one should be a Level 1 Trauma Center)
- Conduct hospital site survey and face-to-face
- Determine Hospital Communications:
 - o ER Phone Line
 - o ER Ambulance Line
 - o Patient Admin Phone Line
 - o Security Line Phone Line
- Determine Routes and Directions to hospitals
- Where are special injuries evacuated?
 - o Neurosurgical
 - o Burns
 - o Trauma Centers
 - Level 1 (Neurosurgeon on staff 24 hours)
 - Level 2 (Neurosurgeon on call, but not on site 24/7)

Vehicle Requirements

- Driver:** A dedicated driver – NOT the medic covering the event. Must be familiar with training area and evacuation routes.
- Ambulance:** A dedicated, climate controlled, covered vehicle capable of carrying at least 1 litter. The vehicle must provide environmental control and adequate space for medical equipment. Mark vehicle as appropriate (ambulance symbols or lights).
 - o Optimal Vehicles:
 - Van (15PAX only)
 - Large SUV (Expedition, Tahoe, etc...)
 - FLA (M996/M997)
 - o Suboptimal Vehicles
 - Open HMMWV / GMV
 - MEDSOV (tactical operations only – not for admin coverage)
 - Small SUV (Explorer, Durango, Cherokee, etc...) or Small Van (7PAX)

Communication Requirements

- Equipment
 - o FM Radios or Installation "Brick" Radios
 - o Cell Phone
- Radio Nets & Frequencies
 - o Administrative Coverage (DZSO Net)
 - o Exercise/Target Control or Observer/Controller Nets
 - o Tactical Nets
- En route Evacuation Communications
 - o Cell Phone to notify receiving facilities
 - o Borrowed local radios
- Establish Speed Dials / Specific Channels
 - o Receiving Medical Facilities and Evacuation Assets

EQUIPMENT REQUIREMENTS

Standard Medical Equipment

- Rigid Litter
- Splint Sets
- Oxygen/Masks/BVM
- Suction, Mechanical & Manual
- Mechanical Traction Splint
- Vital Signs Monitor
- Litters
- Blankets/Hypothermia Management
- Trauma AidBag
- Pain Management

Special Equipment Considerations

- Hot Weather
 - Ice Sheets
 - Fans (battery operated)
 - Cold Packs
- Cold Weather
 - Rescue Wraps/Patient Heaters
 - IV Fluid Warmer
- Rescue
 - High-Angle Rescue Kit
 - Skedco
- Blood Products for High Risk Training

MEDICAL COVERAGE DURING TACTICAL EXERCISES

- Plan for all casualties to be evacuated to Level 1 or 2 Trauma Centers ONLY.
- If evacuation time to primary center is more than 20 minutes training is considered HIGH RISK.
- Obtain PDSS Checklist from MEDO.
- All casualties go through the tactical evacuation channels unless life, limb or eyesight is threatened. A Ranger exercise does not "go admin" unless absolutely required to save the injured Ranger.
- All patients are treated to U.S. Standard of Care and unit protocols.
- Vehicles do not enter or move on drop zones without DZSO permission and notification of the tactical C2.
- Use of white lights during night operations will be minimized to patient care.
- If possible, utilize the tactical unit's capabilities to move casualties to minimize impact on the ongoing exercise.
- Notify receiving medical facilities of incoming casualties and status.
- Keep training event OIC/NCOIC informed of patient status with routine updates
- Vehicles do not enter or move on drop zones without DZSO permission and notification of the tactical C2.
- Inform unit medical officers of casualties and status.

PRE-COVERAGE INSPECTIONS

****NO RANGER IS EXEMPT FROM PCIs****

Inspect / Inventory Medical Equipment

- Inventory IAW Hazardous Coverage Checklist
- Function check all mechanical devices and monitors
- Check battery charges

Inspect Vehicle(s)

- PMCS of Vehicle
- Fuel Level
- Dispatch or Rental Agreement
- Maps/Routes posted

Support Equipment

- Communications Equipment
- Strobe lights / Flashlights / Headlamps
- Night Vision
- GPS
- Rescue Equipment

PRE-COVERAGE REHEARSALS

- Drive routes to hospitals during daytime and nighttime. Determine/Record time from training site to hospital. Consider civilian traffic pattern interference on evacuation route.
- Brief OIC, NCOIC, OPFOR, and Role-players on medical coverage plan and actions. Specifically, CCP or MEDEVAC locations and casualty notification/evacuation request procedures.
- Conduct rehearsal of casualty movement in the exercise area and prep for evacuation.

75th Ranger Regiment Trauma Management Team

Hazardous Training Medical Coverage Checklist

| VEHICLE / AMBULANCE | | |
|--|-----------------|------------------------------------|
| CHECKLIST | INITIALS | NOTES / FINDINGS |
| Vehicle w/Dispatch (or rental agreement) | | Dispatch Date: |
| Dispatch Book (w/incident forms) | | |
| PMCS of Vehicle | | Last PMCS: |
| Fuel Level (if <1/4 tank, re-fuel) | | Fuel Level: |
| Warning Strobe Light for roof | | |
| Spot Light w/car charger | | |
| EMS Magnetic Symbols (4 sides of vehicle) | | |
| MEDICAL EQUIPMENT | | |
| <i>Account for and test all equipment before and after mission</i> | | |
| CHECKLIST | INITIALS | NOTES / FINDINGS |
| Litter w/Straps | | |
| Cervical Collar | | |
| BVM w/ O2 Tubing | | |
| O2 Set (Tank, Regulator, Non-Rebreather Mask) | | PSI Level: |
| Airway Kit | | |
| Suction, Mech (w/ battery and car charger) Function Check | | Status: |
| Suction, manual operated | | |
| Splint Set (Velcro applied) | | |
| Mechanical Traction Splint w/straps | | |
| Blankets (2 each) | | |
| Hypothermia Protection System (HPMK or Rescue Wrap) | | |
| Vital Signs Monitor w/cables, attachments, and car charger (Conduct complete function check) | | Monitor Type: Calibration Date: |
| Thermometer, Electronic w/probe and covers (min 10) | | |
| Blood Glucose Monitor w/test strips and lancets | | |
| Ice Cooler with 50/50 Ice/Water and 15 saturated sheets | | |
| Trauma Hangbag | | |
| Chemlight Set (min 3 ea of 3 colors) | | |
| MEDIC INDIVIDUAL EQUIPMENT | | |
| CHECKLIST | INITIALS | NOTES / FINDINGS |
| Trauma Pack | | |
| Ranger Medic Handbook | | |
| Narcotics & Medications Kit | | |
| Admin Head Lamp | | |
| Cell Phone w/car charger (key numbers pre-programmed) | | Phone Number: |
| Field Sick Call Kit (as directed) | | |
| Night Vision Goggles (as directed) | | |
| GPS Navigation System (as directed) | | |
| Radio (as directed) | | |
| EVACUATION SUPPORT EQUIPMENT | | |
| CHECKLIST | INITIALS | NOTES / FINDINGS |
| Trauma SF 600 (20 ea) and RGR CAX Card (20 ea) | | |
| Hazardous Training Medical Coverage Checklist (20 ea) | | |
| Map of Training Area | | |
| Hospital Directions w/Strip Map from Training Area | | |
| Hospital Site Survey with phone numbers | | |
| VS-17 Panel | | |
| Strobe Light w/battery | | |
| Evacuation Procedures Checklist | | |
| 550 cord (30ft) & Tape, 100pmh | | |

Medic Name _____ Date _____

Training Event _____ Location _____

SR Medic or Range NCOIC/OIC Name & Countersign: _____

SECTION NINE

PACKING LISTS



Kit / Aid Bag Minimum Stock

The following list is what each medic should carry at a minimum and used as a guide to pack their Kit and Aid Bag. The medic must have enough supplies to treat two multi-system trauma casualties. Items packed in the Kit provide immediate initial care to life-threatening injuries on a trauma casualty without external bags and equipment.

| Common Name | Quantity | Notes |
|---|----------|--|
| Massive Hemorrhage Control | | |
| Tourniquet | 2 | |
| Hemostatic Dressing | 2 | |
| Pressure Dressing | 2 | |
| Airway Management | | |
| Cricothyroidotomy Kit | 2 | |
| Nasopharyngeal Airway 28fr w/lubricant | 1 | |
| Bougie Device | 1 | |
| Supra-glottic Airway Device | 1 | Any device is acceptable |
| Suction, Hand-Held Manual Device | 1 | |
| ETCO2 Device | 1 | |
| Respiratory Management | | |
| 10G or 14G / 3.25" NCD | 4 | |
| Chest Seal | 4 | |
| Occlusive Dressing | 4 | Used for securing chest tube / cric |
| Bag-Valve Mask | 1 | |
| Pulse Oximetry Device | 1 | |
| Stethoscope | 1 | |
| Circulation / Fluid Resuscitation Management | | |
| Intraosseous Device | 2 | Sternal Intraosseous x 1 , EZ IO x 1 |
| IV Starter Kit | 2 | |
| NS Flush 10cc | 4 | |
| Fluid Warmer | 1 | With cartridges x 2 |
| 250cc Normal Saline | 2 | |
| Blood Collection Bag | 1 | |
| Filtered Tubing | 1 | "Y" or "Single" |
| BP Cuff Manual | 1 | |
| Sharps Shuttle | 1 | |
| Disability / Immobilization | | |
| Splint, Malleable | 2 | |
| Ace Wrap | 2 | |
| Miscellaneous | | |
| Casualty Card | 4 | |
| Marker | 2 | |
| Tape | 2 | |
| Shears | 2 | |
| Scalpels | 4 | |
| 9" pings | 1 | |
| Narcotics Box | 1 | Hydromorphone, Ketamine, Midazolam, Fentanyl Oral Lozenge |
| Medication Box | 1 | Nalaxone, Ondasetron, Ertapenem, Ketorolac, Tranexemic Acid, Levetiracetam, Diphenhydramine, Calcium, CWPP |
| 1cc syringe | 3 | |
| 3cc syringe | 3 | |
| 10cc syringe | 3 | |
| 18ga hard needle | 5 | |
| 23ga hard needle | 5 | |
| MASCAL Card | 1 | |
| Chem Lights (Red, Blue, Green) | 2ea | |
| Light Source | 2 | |
| Gloves | | |

Advanced Ranger First Responder Medical Kit Contents

The following list is what each Advanced Ranger First Responder should carry at a minimum and used as a guide to pack their medical kit.

| Common Name | Quantity | Notes |
|---|----------|--------------------------------------|
| Massive Hemorrhage Control | | |
| Tourniquet | 2 | |
| Hemostatic Dressing | 2 | |
| Pressure Dressing | 2 | |
| SAM Junctional Tourniquet | 1 | Mission Dependent |
| Airway Management | | |
| Nasopharyngeal Airway 28fr w/lubricant | 1 | |
| Supra-glottic Airway Device | 1 | King LT/iGEL |
| Respiratory Management | | |
| 10G or 14G / 3.25" NCD | 2 | |
| Vented Chest Seal | 2 | |
| Pulse Oximetry Device | 1 | |
| BVM | 1 | Mission Dependent |
| Circulation / Fluid Resuscitation Management | | |
| Intraosseous Device | 2 | Sternal Intraosseous x 1 , EZ IO x 1 |
| IV Starter Kit | 2 | |
| NS Flush 10cc | 2 | |
| Blood Collection Bag | 1 | |
| Filtered Tubing | 1 | "Y" or "Single" |
| Sharps Shuttle | 1 | |
| Disability / Immobilization | | |
| Splint, Malleable | 1 | |
| Ace Wrap | 2 | |
| Miscellaneous | | |
| Casualty Card | 2 | |
| Shears | 1 | |
| Marker | 2 | |
| 3" Tape | 1 | |
| 10cc syringe | 2 | |
| Light Source | 1 | |
| Gloves | | |

Ranger Bleeder Control Kit Contents

The bleeder control kit will be worn on the left side of the body or the lower back.

| Common Name | Quantity |
|--|----------|
| Massive Hemorrhage Control | |
| Tourniquet | 2 |
| Hemostatic Dressing | 2 |
| Pressure Dressing | 1 |
| Airway Management | |
| Nasopharyngeal Airway 28fr w/lubricant | 1 |
| Respiratory Management | |
| Vented Chest Seal | 2 |
| 10G or 14G / 3.25" NCD | 2 |
| Miscellaneous | |
| TCCC Card, DD Form 1380 | 1 |

SECTION TEN

**REFERENCES
& ABBREVIATIONS**



| | | | |
|----------|--|---------|---|
| 1SG | first sergeant | A&O X - | alert and oriented times orientation |
| 1T2X1 | AFSC pararescueman | AO | area of operations |
| 4N0X1 | AFSC aerospace medical specialist | AOR | area of responsibility |
| 5392 | navy NEC naval special warfare medic (SOCM) | AP | anteroposterior |
| 61N | army flight surgeon | ARDS | acute respiratory distress syndrome |
| 65B | army AOC physical therapist | ARF | airfield reaction force |
| 65D | army AOC physician assistant | ASA | acetylsalicylic acid (aspirin) |
| 68J | army MOS medical logistics specialist | ASAP | as soon as possible |
| 68W | army MOS health care specialist | ASMB | area support medical battalion |
| 68W-R-W1 | army MOS health care specialist – Ranger qualified-ranger unit service – special operations combat medic | ASMC | area support medical company |
| 68W-V-W1 | army MOS health care specialist – ranger school qualified – special operations combat medic | AT/NC | atraumatic, normocephalic |
| 68W-W1 | army MOS health care specialist – special operations combat medic | ATLS | advanced trauma life support |
| 68S | army MOS preventive medicine specialist | ATM | advanced trauma manager / management |
| 68T | army MOS veterinary specialist | ATP | advanced tactical practitioner |
| 68X | army MOS mental health specialist | ATT | ...at this time |
| 70B | army AOC medical service corps | AWLS | advanced wilderness life support |
| 70H | army AOC medical operations officer | AXP | ambulance exchange point |
| 70K | army AOC medical logistics officer | BALCS | body armor load carriage system |
| 8404 | navy NEC field medical service technician | BAS | battalion aid station |
| 8427 | navy NEC special amphibious reconnaissance corpsman | bid | twice a day |
| AA | assembly area | BCK | bleeder control kit |
| AAR | after action review | Bingo | out of fuel |
| AAS | acute abdominal series | BKA | below-the-knee amputation |
| ABD | abdomen | BLOC | battalion logistics operations center |
| ABG | arterial blood gas | BLS | basic life support |
| ABLS | advanced burn life support | BLUF | bottom line up front |
| Abx | antibiotics | BM | bowel movement |
| AC | before eating (ante cibium) | BMNT | before morning nautical twilight |
| A/C | aircraft | BN | battalion |
| ACE | ammunition, casualty, equipment | BP | blood pressure or blocking position |
| ACL | anterior cruciate ligament | BPM | beats per minute |
| ACLS | advanced cardiac life support | BRBPR | bright red blood per rectum |
| ACP | alternate command post | BS | bowel sounds |
| AE | aeromedical evacuation | BSI | body substance isolation |
| AECC | aeromedical evacuation control Center | BVM | bag-valve-mask |
| AELT | aeromedical evacuation liaison team | BW | biological warfare |
| AF | afebrile | Bx | biopsy |
| AFSC | air force specialty code (MOS) | c | with (cum) |
| AFSOC | air force special operations command | C | celsius or centigrade |
| AGL | above ground level | C2 | command & control |
| AKA | above-the-knee amputation | CA | civil affairs |
| ALCON | all concerned | CAD | coronary artery disease |
| ALS | advanced life support | CAM | chemical agent monitor |
| AMCIT | american citizen | CAMS | civil affairs medical sergeant |
| AMEDD | army medical department | CANA | convulsant antidote for nerve agents |
| AMS | acute mountain sickness | CARP | calculated air release point |
| | | CAT | computed axial tomography |
| | | CAT | combat application tourniquet |
| | | CAX | casualties |
| | | CBC | complete blood count |
| | | CBRN | chemical, biological, radiological, nuclear |
| | | cc | cubic centimeter |
| | | CC | chief complaint |
| | | CCP | casualty collection point |
| | | CDC | centers for disease control |
| | | CDR | commander |
| | | CENTCOM | united states central command |

| | | | |
|----------|--|---------|---|
| CEP | casualty evacuation point | DOE | dyspnea on exertion |
| CHI | closed head injury | DOW | died of wounds |
| CHOPS | chief of operations | DNBI | disease/non-battle injury |
| CJTF | combined joint task force | DNR | do not resuscitate |
| CLS | combat lifesaver | DPL | diagnostic peritoneal lavage |
| CMB | combat medical badge | DPN | drops per minute |
| CMD | command | DPT | diphtheria, pertussis, tetanus |
| CMO | civil-military operations | DSN | defense switching network |
| CNS | central nervous system | DTG | date time group DDTTTTMMYY |
| C/O | complaining of | DTR | deep tendon reflex |
| CO | commanding officer | DVT | deep venous thrombosis |
| CO | carbon monoxide | Dx | diagnosis |
| CO2 | carbon dioxide | DZ | drop zone |
| COA | course of action | EA | each |
| COB | close of business (time of day) or civilians on the battlefield | EBL | estimated blood loss |
| CONOP | concept of the operation | ECC | emergency cardiac care |
| CONUS | continental united states | ECG | electrocardiogram |
| COP | command outpost or common operating picture | EDC | estimated date of confinement |
| COTCCC | committee on tactical combat casualty care | EDRE | emergency deployment readiness Exercise |
| COTS | commercial-of-the-shelf (purchase) | EENT | early evening nautical twilight |
| CP | command post | EFMB | expert field medical badge |
| CPAP | continuous positive airway pressure | EKG | electrocardiogram |
| CPR | cardiopulmonary resuscitation or critical, priority, routine | EKIA | enemy killed in action |
| CQB | close quarters battle | EJ | external jugular |
| CQC | close quarters combat | EMG | electromyogram |
| CQM | close quarters marksmanship | EMS | emergency medical system or service |
| CR | casualty response | EMT | emergency medical technician |
| Cric | cricothyroidotomy | EMT-B | emergency medical technician-basic |
| CRTRL | casualty response training for ranger leaders | EMT-I | emergency medical technician- intermediate |
| CSAR | combat search and rescue | EMT-P | emergency medical technician- paramedic |
| CSF | cerebral spinal fluid | EOM | extraocular muscles |
| CSH | combat support hospital | EOMI | extraocular muscles intact |
| CSS | combat service support | EPW | enemy prisoner of war |
| CTA | clear to auscultation | ET | endotracheal (tube) |
| CTM | combat trauma management | ETOH | ethanol alcohol |
| CUF | care under fire | EWIA | enemy wounded in action |
| CWIED | command wired improvised explosive device | EXCHECK | execution checklist |
| CWPP | combat wound pill pack | Exfil | exfiltration |
| CXP | casualty exchange point | EXORD | execution order |
| CXR | chest x-ray | F | fahrenheit |
| DA | department of the army or direct action | FABER | flexion, abduction and external rotation |
| DACO | departure airfield control officer/operations | FARP | forward aerial refueling point |
| D/C | discontinue or discharge | FB | foreign body |
| DDx | differential diagnosis | F&D | fixed and dilated |
| DEA | drug enforcement agency | FamHx | family history |
| DHB | defense health board | F/C | fevers, chills |
| DIRLAUTH | direct liaison authorized | FDA | food and drug administration |
| DLS | dirt landing strip | FITT | frequency, intensity, time, type |
| DMO | diving medical officer | FKIA | friendly killed in action |
| DMT | diving medical technician | FMC | final manifest call or field medical card |
| DO | doctor of osteopathy | FMED | flight medic |
| DOA | dead on arrival | FOB | forward operating base |
| DOB | date of birth | FOOSH | fall on out-stretched hand |
| DOD | department of defense | FP | family practice |
| | | FRAGO | fragmentation order |
| | | FRIES | fast rope insertion/extraction system |
| | | FSB | forward staging base |

| | | | |
|--------|--|---------|---|
| FST | forward surgical team | ICW | in conjunction with... |
| FTX | field training exercise | I&D | incision and drainage |
| F/U | follow-up | ID | infectious disease |
| FUO | fever of unknown origin | IDC | see IDHC |
| FWIA | friendly wounded in action | IDHC | USN independent duty hospital corpsman |
| Fx | fracture | IDMT | independent duty medical technician (USAF) |
| g | gram(s) | IED | improvised explosive device |
| G | guage (needle) | IM | intramuscular |
| G6PD | glucose-6 phosphate dehydrogenase | IMC | initial manifest call |
| GAF | ground assault force | Infil | infiltration |
| GCS | glasgow coma scale | I&O | intake and output |
| GERD | gastroesophageal reflux disease | IO | intraosseous |
| GFC | ground force commander | IOT | in order to... |
| GI | gastrointestinal | IPPB | intermittent positive pressure Breathing |
| GPS | global positioning system | IPR | in process review |
| GRG | grid reference guide | IRF | immediate reaction force |
| GSW | gunshot wound | ISB | intermediate staging base |
| gtts | drops | ISO | in support of... |
| GU | genitourinary | IV | intravenous |
| GWOT | global war on terrorism | IVO | in vicinity of... |
| HA | headache | JOC | joint operations center |
| HACE | high altitude cerebral edema | JOMAC | judgement, orientation, mentation, abstraction, calculation |
| HAF | helicopter assault force | JVD | jugular venous distention |
| HAHO | high altitude, high opening (parachute) | JCCP | joint casualty collection point |
| HALO | high altitude, low opening (parachute) | JSOC | joint special operations command |
| HAPE | high altitude pulmonary edema | JSOM | journal of special operations medicine |
| HAZMAT | hazardous materials | JSOMTC | joint special operations medical training center |
| Hct | hematocrit | JSOTF | joint special operations task force |
| HE | high explosive | kg | kilogram |
| HEENT | head, eyes, ears, nose, throat | K | potassium |
| Hg | mercury | KIA | killed in action |
| Hgb | hemoglobin | L | left |
| HLZ | helicopter landing zone | LA | lymphadenopathy |
| HM3 | USN hospital corpsman 3 rd class (E4) | lac | laceration |
| HM2 | USN hospital corpsman 2 nd class (E5) | LASER | light amplification by stimulated emission of radiation |
| HM1 | USN hospital corpsman 1 st class (E6) | LASIK | laser-assisted in situ keratomileusis |
| HMC | USN chief hospital corpsman (E7) | LBP | low back pain |
| HMCS | USN senior chief hospital corpsman (E8) | LE | lower extremities |
| HMCM | USN master chief hospital corpsman (E9) | LIH | left inguinal hernia |
| HN | USN hospitalman (E3) or host nation | LLL | left lower lobe |
| HPI | history of present illness | LMP | last menstrual period |
| HPS | human patient simulator | LOC | loss of consciousness |
| Hr | hour | LOD | line of duty |
| HR | heart rate | LP | lumbar puncture or listening post |
| HS | bed time (hours of sleep) | LR | lactated ringers |
| HSV | herpes simplex virus | LLQ | left lower quadrant |
| HTN | hypertension | LTT | live tissue training |
| HTS | hypertonic saline | LUL | left upper lobe |
| Hx | history | LUQ | left upper quadrant |
| IAPP | inspection, auscultation, palpation, percussion | MACE | military acute concussion evaluation |
| IAW | in accordance with... | MAPCODE | Monitor, Antibiotics, Pain Control, Contact MO, Oxygen, Document, Evacuate |
| ICRC | international committee of the red cross | MARCH | massive hemorrhage, airway, respiration, circulation, head injury/hypothermia |

| | | | |
|---------|--|--------|---|
| MAST | military anti-shock trousers | OCONUS | outside continental united states |
| MASSCAL | mass casualty | OD | right eye (oculus dexter), overdose |
| MASSCAX | mass casualty | OE | otitis externa |
| MBITR | multi-band intra team radio | OEF | operation enduring freedom |
| MC | medical control | OIF | operation Iraqi freedom |
| MC | medical corps | OM | otitis media |
| MDMP | military decision making process | OND | operation new dawn (Iraq) |
| MEDLOG | medical logistics | OPA | oralpharyngeal airway |
| MEDO | medical operations officer | OPLAN | operations plan |
| MEDOPS | medical operations | OPORD | operations order |
| MEDSOV | medical special operations vehicle | OPREP | operational report |
| MES | medical equipment set | OPQRST | onset, provokes, quality, radiates, severity, time |
| MGMT | management | OPSEC | operations security |
| MI | myocardial infarction | OPSO | operations officer |
| MICH | modified individual combat helmet | OPV | oral polio vaccine |
| mmHg | millimeters of mercury | ORP | objective rally point |
| MMR | measles, mumps, rubella | OS | left eye (oculus sinister) |
| MOA | memorandum of agreement | OTSG | office of the surgeon general |
| MOI | mechanism of injury or memorandum of instruction | PA | physician assistant |
| MO | medical officer | PALS | pediatric advanced life support |
| MOS | military occupational specialty | PAX | personnel |
| MOU | memorandum of understanding | PB | patrol base |
| MOUT | military operations in urban terrain | PC | precious cargo (operational) |
| MRI | magnetic resonance imaging | PC | after eating (post cibum) |
| MROE | medical rules of engagement | PCI | pre-combat inspection |
| MTF | medical treatment facility | PCN | penicillin |
| MVA | motor vehicle accident | PDHA | pre/post deployment health assessment |
| MWD | military working dog | PDHRA | post deployment health reassessment |
| NAD | no acute distress | PDSS | pre-deployment site survey |
| NAEMT | national association of emergency medical technicians | PE | physical exam or pulmonary embolism |
| NCM | nurse case manager | PEA | pulseless electrical activity |
| NEC | naval enlisted classification (MOS) | PECC | patient evacuation control center |
| NEO | non-combatant evacuation operation | PEPP | pediatric emergencies for pre-hospital providers |
| NET | no earlier than... | PERRLA | pupils equal, round, reactive to light and accomadation |
| NGO | non-governmental organization | PFT | pulmonary function test |
| N-Hour | notification hour | PHA | periodic health assessment |
| NKA | no known allergies | P-HR | parachute hour |
| NKDA | no known drug allergies | PHTLS | pre-hospital trauma life support |
| NLT | no later than... | PHTR | pre-hospital trauma registry |
| NMA | non-medical attendant | PIR | priority intelligence requirements |
| NOK | next of kin | PJ | USAF pararescuemen |
| NPA | nasopharyngeal airway | PLF | parachute landing fall |
| NPO | nothing by mouth (nil per os) | PM | preventive medicine |
| NS | normal saline | PMCS | preventive maintenance checks & services |
| NREMT | national registry of emergency medical technicians | PMHx | past medical history |
| NSAID | nonsteroidal antiinflammatory drug | PMI | point of maximal impulse |
| NSR | normal sinus rhythm | PNOK | primary next of kin |
| NTG | nitroglycerin | PO | by mouth (per os) |
| N/V/D | nausea, vomiting, diarrhea | POC | point of contact |
| NVG | night vision goggles | POD | period of darkness |
| NWB | non-weight bearing | POI | point of injury or program of instruction |
| OB | obstetrics | POW | prisoner of war |
| OBJ | objective | PPD | purified protein derivative |
| O/C | observer/controller | PPE | personal protective equipment |
| OCO | OCONUS contingency operations | ppm | parts per million |
| OCOKA | observation and fire, concealment and cover, obstacles, key terrain, and avenues of approach | PPV | positive pressure ventilation |

| | | | |
|--------|---|---------|--|
| PR | per rectum or personnel recovery | ROC | ranger operations company |
| PRK | photorefractive keratectomy | ROE | rules of engagement |
| PRN | as often as needed (pro re nata) | ROM | range of motion |
| PSHx | past surgical history | ROS | review of systems |
| PSI | pounds per square inch | RP | rally point |
| Pt | patient | R-PA | regimental physician assistant |
| PT | physical therapist or physical training | RPSYCH | regimental psychologist |
| PTSD | post traumatic stress disorder | RR | respiratory rate |
| PUD | peptic ulcer disease | RRC | regimental reconnaissance company |
| PULHES | physical profile factors: P-physical capacity or stamina, U-upper extremities, L-lower extremities, H-hearing and ears, E-eyes, S-psychiatric | RRF-1 | ranger ready force one |
| | | RRF-2 | ranger ready force two |
| | | RRF-3 | ranger ready force three |
| | | RRR | regular rate and rhythm |
| | | RRT | regimental reconnaissance team |
| PZ | pickup zone | R&S | reconnaissance and surveillance |
| q | every (quaque) | RSM | regimental sergeant major |
| QC | quality control | RSOV | ranger special operations vehicle |
| qd | every day | RSRMED | regimental senior medic |
| qh | every hour | RSTB | regimental special troops battalion |
| q_h | every _ hours | RSURG | regimental surgeon |
| q_m | every _ minutes | RTB | return to base or ranger training brigade/battalion |
| qid | four times a day (quater in die) | | |
| qod | every other day | RTC | return to clinic |
| QRF | quick reaction force | RUL | right upper lobe |
| qt | quart | RUQ | right upper quadrant |
| qty | quantity | RVET | regimental veterinarian |
| R | right | Rx | prescription, treatment |
| RASP | ranger assessment & selection program | s | without (sine) |
| | | S1 | personnel and administration |
| RAW | ranger athlete warrior (program) | S2 | intelligence and security |
| RBC | red blood cell | S3 | operations and training |
| RCMS | ranger casualty management system | S4 | logistics and supply |
| RC | regional command | S5 | civil affairs and information operations |
| RCO | regimental commander | | |
| RCP | runway crossing point | S6 | signal and communications |
| RDA | recommended dietary allowance | S8 | force modernization, plan, R&D |
| RECC | ranger enhanced care clinic | SA | situational awareness |
| REM | rapid eye movement | SARC | USN surface amphibious reconnaissance corpsman |
| RFI | request for information | | |
| RFM | release for medical (standards) or regimental finance management | SCUBA | self-contained underwater breathing apparatus |
| | | SCRK | squad casualty response kit |
| RFR | ranger first responder | SEA | senior enlisted advisor |
| RFS | release for standards | SEM | systolic ejection murmur |
| Rh | Rhesus blood factor | SF | special forces |
| RHQ | regimental headquarters | SFG | special forces group |
| RGR | ranger | SFMS | special forces medical sergeant |
| RIH | right inguinal hernia | SITREP | situation report |
| RLL | right lower lobe | SL | sublingual |
| RLCS | ranger load carriage system | SLLS | stop, look, listen, smell (tactical) |
| RLQ | right lower quadrant | SMO | senior medical officer |
| RLTW | rangers lead the way | Sn | signs |
| RMAV | ranger medic assessment and validation | SNL | standard name line (last, first, MI, rank, SSN, unit, DOB) |
| | | | |
| RMed | ranger medic | SocHx | social history |
| RMED | regimental medical section | SOAR | special operations aviation regiment |
| RMEDFM | regimental medical force modernization | SOB | shortness of breath |
| | | SOCM | special operations combat medic |
| RMEDO | regimental medical operations officer | SOCMSSC | special operations combat medic skills sustainment course |
| RML | right middle lobe | | |
| R/O | rule out | SOF | special operations forces |
| | | SOI | signal operating instructions |

| | | | |
|---------|--|------------|--|
| SOMA | special operations medical association | USUHS | uniformed services university of health sciences |
| SOP | standard operating procedures | UTI | urinary tract infection |
| SOR | statement of requirements | UXO | unexploded ordnance |
| SP | start point | V | army special qualification identifier for ranger-parachutist |
| SQ | subcutaneous | VA | visual acuity |
| SQD | squad | VBIED | vehicle borne improvised explosive device |
| SRMED | senior ranger medic | VD | venereal disease |
| SRP | soldier readiness processing | VDO | vehicle drop off |
| SRT | surgical resuscitation team | VOIED | victim operated improvised explosive device |
| S/S | signs and symptoms | VSS | vital signs stable |
| SSN | social security number | W1 | special operations combat medic additional skill identifier |
| STANAG | standardization agreement | WALK | warrior aid & litter kit |
| STD | sexually transmitted disease | WARNORD | warning order |
| SURG | Surgeon (Battalion, Regimental, or command) | WBAT | weight bearing as tolerated |
| SURT | small unit ranger tactics | WBC | white blood cell |
| SVBIED | suicide vest borne improvised explosive device | WD | well developed |
| Sx | symptoms | WHO | world health organization |
| Tab | tablet | Winchester | out of ammunition |
| TACEVAC | tactical evacuation | WIA | wounded in action |
| TBD | to be determined | WMD | weapons of mass destruction |
| TBSA | total body surface area | WN | well nourished |
| TCCC | tactical combat casualty care | WNL | within normal limits |
| TC3 | tactical combat casualty care | WP | white phosphorus |
| TCR | trauma center rotation | W/U | wheels up (aircraft departure) |
| Td | tetanus-diphtheria toxoid | XO | executive officer |
| TF | task force | Y/O | years old |
| TFC | tactical field care | >,<,= | greater than, less than, equal |
| TGT | target | LATIN: | |
| TIC | troops in contact or toxic industrial chemical | Dominatus | mastery in |
| tid | three times a day (ter in die) | Comminus | close combat |
| TIM | toxic industrial materials | Remendium | medicine |
| TKO | to keep open | | |
| TLP | troop leading procedures | | |
| TM | tympenic membrane | | |
| TMEP | tactical medical emergency protocol | | |
| TMT | trauma management team | | |
| TNTC | to numerous to count | | |
| TOC | tactical operations center | | |
| TOD | time of death | | |
| TOT | time on target | | |
| TQ | tourniquet | | |
| tsp | teaspoon | | |
| TST | time sensitive target | | |
| TTP | tenderness to palpation or tactics, techniques & procedures | | |
| TTWB | toe-touch weight bearing | | |
| Tx | treatment | | |
| U | army special qualification identifier – ranger qualified & ranger unit service | | |
| ud | as directed (ut dictum) | | |
| UE | upper extremities | | |
| UIC | unit identification code | | |
| URI | upper respiratory tract infection | | |
| USAISR | united states army institute of surgical research | | |
| USASOC | united states army special operations command | | |
| USN | united states navy | | |
| USSOCOM | united states special operations Command | | |

MACE 2

Military Acute Concussion Evaluation



Use MACE 2 as close to time of injury as possible.

Service Member Name: _____

DoDI/EDIPI/SSN: _____ Branch of Service & Unit: _____

Date of Injury: _____ Time of Injury: _____

Examiner: _____

Date of Evaluation: _____ Time of Evaluation: _____

Purpose: MACE 2 is a multimodal tool that assists providers in the assessment and diagnosis of concussion. The scoring, coding and steps to take after completion are found at the end of the MACE 2.

Timing: MACE 2 is most effective when used as close to the time of injury as possible. The MACE 2 may be repeated to evaluate recovery.

RED FLAGS

Evaluate for red flags in patients with Glasgow Coma Scale (GCS) 13-15.

- Deteriorating level of consciousness
- Double vision
- Increased restlessness, combative or agitated behavior
- Repeat vomiting
- Results from a structural brain injury detection device (if available)
- Seizures
- Weakness or tingling in arms or legs
- Severe or worsening headache

Defer MACE 2 if any red flags are present. Immediately consult higher level of care and consider urgent evacuation according to evacuation precedence/Tactical Combat Casualty Care (TCCC).

- Negative for all red flags**
Continue MACE 2, and observe for red flags throughout evaluation.

MILITARY ACUTE CONCUSSION SCREENING

Complete this section to determine if there was an injury event AND an alteration of consciousness or memory.

1. Description of Incident**A. Record the event as described by the service member or witness.**

Use open-ended questions to get as much detail as possible.

Key questions:

- Can you tell me what you remember?
- What happened?
- Who were you last with?

B. Observable Signs

At the time of injury were any of these observable signs witnessed?

Visual clues that suggest a possible concussion include:

- Lying motionless on the ground
- Slow to get up after a direct or indirect blow to the head
- Disorientation, confusion, or an inability to respond appropriately to questions
- Blank or vacant look
- Balance difficulties, stumbling, or slow labored movements
- Facial injury after head trauma
- Negative for all observable signs

C. Record the type of event.

Check all that apply:

- | | | |
|---------------------------------------|---|--|
| <input type="checkbox"/> Blunt object | <input type="checkbox"/> Sports injury | <input type="checkbox"/> Gunshot wound |
| <input type="checkbox"/> Fall | <input type="checkbox"/> Assault | <input type="checkbox"/> Explosion/blast Estimated distance _____ |
| <input type="checkbox"/> Fragment | <input type="checkbox"/> Motor vehicle crash | <input type="checkbox"/> Other _____ |

D. Was there a blow or jolt to the head?

- Did your head hit any objects?
- Did any objects strike your head?
- Did you feel a blast wave? (A blast wave that is felt striking the body or head is considered a blow to the head.)
- Did you have a head acceleration or deceleration?

YES NO UNKNOWN

2. Alteration of Consciousness or Memory

A. Was there alteration of consciousness (AOC)?

AOC is temporary confusion or "having your bell rung."

YES NO

If yes, for how long? _____ seconds
 _____ minutes

UNKNOWN

Key questions:

- Were you dazed, confused, or did you "see stars" immediately after the event?
- Did you feel like you were in a fog, slowed down, or "something was not right"?

B. Was there loss of consciousness (LOC)?

LOC is temporarily passing out or blacking out.

YES NO

If yes, for how long? _____ seconds
 _____ minutes

UNKNOWN

Key questions:

- Did you pass out or black out?
- Is there a period of time you cannot account for?

C. Was there any post traumatic amnesia (PTA)?

PTA is a problem remembering part or all of the injury events.

YES NO

If yes, for how long? _____ seconds
 _____ minutes

UNKNOWN

Key questions:

- Is there a period of time you cannot account for?
- What is the last thing you remember before the event?
- What is the first thing you remember after the event?

D. Was the AOC, LOC or PTA witnessed?

YES NO

If yes, for how long? _____ seconds
 _____ minutes

UNKNOWN

Tips for assessment:

- Ask witness to verify AOC, LOC or PTA and estimate duration.

3. Symptoms

Common symptoms after a concussion are listed below. For this event, check all that apply.

- Headache
- Dizziness
- Memory problems
- Balance problems
- Nausea/vomiting
- Difficulty concentrating
- Irritability
- Visual disturbances
- Ringing in the ears
- Other _____
- Negative for all symptoms

4. History

A. During the past 12 months, were you diagnosed with a concussion, not counting this event?

YES NO

If yes, how many? ____

UNKNOWN

B. History of diagnosed/treated headache disorder or migraine.

YES NO

C. History of depression, anxiety, or other behavioral health concerns.

YES NO

CONCUSSION SCREENING RESULTS (Possible Concussion?)

Was there a blow or jolt to the head (1D)

AND

ANY alteration of consciousness or memory? (2A, 2B, 2C, or 2D)

YES (to both)



NO (to either or both)



POSITIVE CONCUSSION SCREEN:

1. **Continue** MACE 2.
2. Complete evaluation before prescribing rest.
3. Communicate findings to line leadership.
4. Document and code findings in electronic health record (EHR).

NEGATIVE CONCUSSION SCREEN:

1. **Stop** MACE 2.
2. Initiate 24 hour-rest period, if deployed. During rest, avoid activities that worsen symptoms. Follow up with the service member after rest period per concussion management tool (CMT).
3. Communicate findings to line leadership.
4. Document and code findings in electronic health record (EHR).

COGNITIVE EXAM

5. Orientation

Score one point for each correct response.

| Ask This Question | Incorrect | Correct |
|---|-----------|---------|
| "What month is this?" | 0 | 1 |
| "What is the date or day of the month?" | 0 | 1 |
| "What day of the week is it?" | 0 | 1 |
| "What year is it?" | 0 | 1 |
| "What time do you think it is?" | 0 | 1 |

Correct response must be within one hour of actual time.

ORIENTATION TOTAL SCORE

5

6. Immediate Memory

Choose one list (A-F below) and use that list for the remainder of the MACE 2.

Read the script for each trial and then read all five words. Circle the response for each word for each trial. Repeat the trial three times, even if the service member scores perfectly on any of the trials.

Trial 1 script: Read the script exactly as written.

- "I am going to test your memory. I will read you a list of words and when I am done, repeat back to me as many words as you can remember, in any order."

Trials 2 and 3 script: Read the script exactly as written.

- "I am going to repeat that list again. Repeat back to me as many words as you can remember, in any order, even if you said them before."

| | Trial 1 | | Trial 2 | | Trial 3 | |
|--------|-----------|---------|-----------|---------|-----------|---------|
| List A | Incorrect | Correct | Incorrect | Correct | Incorrect | Correct |
| Jacket | 0 | 1 | 0 | 1 | 0 | 1 |
| Arrow | 0 | 1 | 0 | 1 | 0 | 1 |
| Pepper | 0 | 1 | 0 | 1 | 0 | 1 |
| Cotton | 0 | 1 | 0 | 1 | 0 | 1 |
| Movie | 0 | 1 | 0 | 1 | 0 | 1 |

IMMEDIATE MEMORY TOTAL SCORE

15

Immediate Memory Alternate Word Lists

| List B | List C | List D | List E | List F |
|--------|---------|---------|----------|--------|
| Dollar | Finger | Baby | Candle | Elbow |
| Honey | Penny | Monkey | Paper | Apple |
| Mirror | Blanket | Perfume | Sugar | Carpet |
| Saddle | Lemon | Sunset | Sandwich | Saddle |
| Anchor | Insect | Iron | Wagon | Bubble |

NEUROLOGICAL EXAM

7. Speech Fluency

Normal

Abnormal

- Speech should be fluid and effortless
 - no pauses or unnatural breaks.
 - Stuttering or struggling to speak is abnormal.

8. Word Finding

Normal

Abnormal

- Assess difficulties with word finding:
 - Difficulty in coming up with the name of an object or grasping to find words is abnormal.

9. Grip Strength

Normal

Abnormal

- Assess grip strength. Grip strength should be strong and equal bilaterally.
 - Unequal or weak grip strength is abnormal.

10. Pronator Drift

Normal

Abnormal

- Direct service member to stand with eyes closed and arms extended forward, parallel to the ground with palms up. Assess for five to 10 seconds:
 - Any arm or palm drift is abnormal.

11. Single Leg Stance

Normal

Abnormal

- Remove shoes if possible. Have service member stand on one leg, arms across chest, hands touching shoulders, eyes open initially. Once service member is balanced, have them close their eyes and time for 15 seconds how long they can maintain their balance. Repeat test with opposite leg.
 - Loss of balance on either leg before eight seconds is abnormal.

NEUROLOGICAL EXAM - Continued

12. Tandem Gait

- Normal
 Abnormal

- Remove shoes if possible. Have service member take six steps one foot in front of the other, heel-to-toe, with arms at side
 - Stumbling or shifting feet is abnormal.

13. Pupil Response

- Normal
 Abnormal

- Pupils should be round, equal in size and briskly constrict to a direct, bright light.
 - Unequal pupil size, dilation or constriction delay is abnormal.

14. Eye Tracking

- Normal
 Abnormal

- Both eyes should smoothly track your finger side-to-side and up and down.
 - Unequal, irregular or delayed eye tracking is abnormal.

NEUROLOGICAL
EXAM RESULTS
(Questions 7-14)

All Normal

Any Abnormal

COGNITIVE EXAM

15. Concentration

A. Reverse Digits

Read the script and begin the trial by reading the first string of numbers in Trial 1.

Circle the response for each string.

- If correct on string length of Trial 1, proceed to the next longer string length in the same column.
- If incorrect on string length of Trial 1, move to the same string length of Trial 2.
- If incorrect on both string lengths in Trials 1 and 2, **STOP** and record score as zero for that string length. Record total score as sum of previous correct trials.

COGNITIVE EXAM - Continued

15. Concentration - Continued

A. Reverse Digits

Script: Read the script exactly as written.

- "I am going to read you a string of numbers. When I am finished, repeat them back to me backward. That is, in reverse order of how I read them to you. For example, if I said 7 - 1 - 9, then you would say 9 - 1 - 7."

| List A | | Incorrect | Correct |
|-------------|--------------------------------------|-----------|---------|
| Trial 1 | Trial 2 (if Trial 1 is incorrect) | | |
| 4-9-3 | 6-2-9 | 0 | 1 |
| 3-8-1-4 | 3-2-7-9 | 0 | 1 |
| 6-2-9-7-1 | 1-5-2-8-5 | 0 | 1 |
| 7-1-8-4-6-3 | 5-3-9-1-4-8 | 0 | 1 |

REVERSE DIGITS SCORE (16A)

| |
|---|
| 4 |
|---|

Concentration Alternate Number Lists

Note: Use the same list (A-F) that was used in Question 6.

| List B | |
|-------------|-------------|
| Trial 1 | Trial 2 |
| 5-2-6 | 4-1-5 |
| 1-7-9-5 | 4-9-6-8 |
| 4-8-5-2-7 | 6-1-8-4-3 |
| 8-3-1-9-6-4 | 7-2-7-8-5-6 |

| List C | |
|-------------|-------------|
| Trial 1 | Trial 2 |
| 1-4-2 | 6-5-8 |
| 6-8-3-1 | 3-4-8-1 |
| 4-9-1-5-3 | 6-8-2-5-1 |
| 3-7-6-5-1-9 | 9-2-6-5-1-4 |

| List D | |
|-------------|-------------|
| Trial 1 | Trial 2 |
| 7-8-2 | 9-2-6 |
| 4-1-8-3 | 9-7-2-3 |
| 1-7-9-2-6 | 4-1-7-5-2 |
| 2-6-4-8-1-7 | 8-4-1-9-3-5 |

| List E | |
|-------------|-------------|
| Trial 1 | Trial 2 |
| 3-8-2 | 5-1-8 |
| 2-7-9-3 | 2-1-6-9 |
| 4-1-8-6-9 | 9-4-1-7-5 |
| 6-9-7-3-8-2 | 4-2-7-9-3-8 |

| List F | |
|-------------|-------------|
| Trial 1 | Trial 2 |
| 2-7-1 | 4-7-9 |
| 1-6-8-3 | 3-9-2-4 |
| 2-4-7-5-8 | 8-3-9-6-4 |
| 5-8-6-2-4-9 | 3-1-7-8-2-6 |

COGNITIVE EXAM - Continued

15. Concentration - Continued

B. Months in Reverse Order

Script: Read the script exactly as written.

- “Now tell me the months of the year in reverse order. Start with the last month and go backward. So you'll say: December, November...Go ahead.”

Correct Response:

Dec – Nov – Oct – Sep – Aug – Jul –
Jun – May – Apr – Mar – Feb – Jan

| | Incorrect | Correct |
|-----------------------------|-----------|---------|
| ALL months in reverse order | 0 | 1 |

MONTHS IN REVERSE ORDER (16B)

CONCENTRATION TOTAL SCORE

Sum of scores:
15A (0-4 points) and 15B (0 or 1 point)

16. Delayed Recall

Read the script and circle the response for each word. Do NOT repeat the word list.

Note: Use the same list (A-F) that was used in Question 6.

Script: Read the script exactly as written.

- “Do you remember that list of words I read a few minutes earlier? I want you to tell me as many words from that list as you can remember. You can say them in any order.”

| List A | Incorrect | Correct |
|--------|-----------|---------|
| Jacket | 0 | 1 |
| Arrow | 0 | 1 |
| Pepper | 0 | 1 |
| Cotton | 0 | 1 |
| Movie | 0 | 1 |

DELAYED RECALL TOTAL SCORE

Delayed Recall Alternate Word Lists

| List B |
|--------|
| Dollar |
| Honey |
| Mirror |
| Saddle |
| Anchor |

| List C |
|---------|
| Finger |
| Penny |
| Blanket |
| Lemon |
| Insect |

| List D |
|---------|
| Baby |
| Monkey |
| Perfume |
| Sunset |
| Iron |

| List E |
|----------|
| Candle |
| Paper |
| Sugar |
| Sandwich |
| Wagon |

| List F |
|--------|
| Elbow |
| Apple |
| Carpet |
| Saddle |
| Bubble |

17. Vestibular/Ocular-Motor Screening (VOMS) for Concussion Instructions

VOMS Contraindication: Unstable Cervical Spine.

Consider deferring VOMS if patient is overtly symptomatic or a trained provider unavailable. VOMS should be completed before return to duty. Use comment section for any provider-observed difficulty with specific VOMS tasks.

- A. Baseline symptoms.** Record headache, dizziness, nausea and foggiess (HDNF), on zero to 10 scale prior to screening.
- B. Smooth pursuits.** Service member and examiner are seated. Hold fingertip three feet from patient. Service member focuses on fingertip target as examiner moves fingertip smoothly horizontally one and a half feet right and left of midline at rate requiring two seconds to go fully from left to right and right to left. Perform twice. Repeat in vertical direction one and a half feet above and one and a half feet below midline up and down, moving eyes two seconds fully up and two seconds down. Perform twice. Record HDNF on a zero to 10 scale.
- C. Saccades.** Service member and examiner are seated.
- 1) Horizontal saccades:** Hold two fingertips horizontally at a distance of three feet from service member, and one and a half feet left and right of midline so service member gazes 30 degrees left and right. Service member moves eyes as quickly as possible from point to point. Perform 10 times. Record HDNF on a zero to 10 scale.
 - 2) Vertical saccades:** Repeat with two fingertips vertically three feet from service member, and one and a half feet above and below midline so service member gazes 30 degrees upward and downward. Service member moves eyes as quickly as possible from point to point. Perform 10 times. Record HDNF on a zero to 10 scale.
- D. Convergence.** Service member and provider are seated facing each other. Service member focuses on font target (page 14) at arm's length and slowly brings toward tip of nose. Service member stops target when two distinct images seen or when outward deviation of eye observed. Repeat and measure three times. Record centimeters between target and tip of nose for each trial. A near point of convergence \geq five centimeters from the tip of the nose is considered abnormal. Record HDNF on a zero to 10 scale.

17. Vestibular/Ocular-Motor Screening (VOMS) for Concussion Instructions (Continued)

E. Vestibular-ocular reflex (VOR) test. Service member and examiner are seated. Examiner holds font target (page 14) in front of service member in midline at three feet, rotation speed set with metronome.

1) Horizontal VOR test: Service member rotates head horizontally focusing on target at 20 degrees to each side. Rotation = 180 beats per minute (bpm). Perform 10 times. Record: HDNF 10 seconds after test.

2) Vertical VOR test: Repeat test moving head vertically 20 degrees up and down at 180 bpm. Perform 10 times. Record HDNF 10 seconds after test.

F. Visual motion sensitivity (VMS) test. Service member stands with feet shoulder width apart, facing a busy area. Examiner stands next to and slightly behind service member. Service member outstretches arm. Focusing on their thumb, the service member rotates head, eyes and trunk as unit 80 degrees right and left. Rotation = 50 bpm. Perform five times. Record HDNF on a zero to 10 scale.

17. VOMS Score Card

| | | | | | | |
|--------------------------------|------------|---------------|----------------|-------------|----------------|---|
| Vestibular/Ocular Motor Test: | Not Tested | Headache 0-10 | Dizziness 0-10 | Nausea 0-10 | Fogginess 0-10 | Comments |
| BASELINE SYMPTOMS: | N/A | | | | | |
| Smooth Pursuits | | | | | | |
| Saccades – Horizontal | | | | | | |
| Saccades – Vertical | | | | | | |
| Convergence (Near Point) | | | | | | (Near Point in cm): Measure 1: _____ Measure 2: _____ Measure 3: _____ |
| VOR – Horizontal | | | | | | |
| VOR – Vertical | | | | | | |
| Visual Motion Sensitivity Test | | | | | | |
| Total | | | | | | |

Any score above baseline is considered abnormal

VOMS RESULTS

All Normal

Any Abnormal

MACE 2 - Military Acute Concussion Evaluation

EXAM SUMMARY

Record the data for correct MACE 2 documentation.

Cognitive Summary

Orientation Total Score - Q5

Immediate Memory Total Score (all 3 trials) - Q6

Concentration Total Score (Sections A and B) - Q15

Delayed Recall Total Score - Q16

COGNITIVE RESULTS

≤ 25 is abnormal

NEUROLOGICAL RESULTS (Q 7-14)

Abnormal (+)

Normal (-)

SYMPTOM RESULTS (Q 3)

1 or more symptoms (+)

No symptoms (-)

HISTORY RESULTS (Q 4A-4C)

Positive (+)

Negative (-)

VOMS RESULTS (Q 17)

Abnormal (+)

Normal (-)

Deferred

MACE 2 RESULTS

Positive (+)

Negative (-)

AFTER COMPLETING MACE 2:

- Document MACE 2 results in the EHR with coding instructions.
- Initiate 24-hour rest.
- Refer to concussion management tool for the management recommendations based on MACE 2 results.
- After 24-hour rest period, evaluate for initiation into the Progressive Return to Activity (PRA) following the guidance of the PRA Clinical Recommendation.

Refer to Progressive Return to Activity Clinical Tool at

dvbic.dcoe.mil/files/resources/2013_PRA_PCM_CST_FINAL.pdf

VOMS Equipment Sample 14 point font: **A**

Centimeter Ruler

0 cm

5 cm

15 cm

TBI CODING INSTRUCTIONS

Initial TBI screening code*: Z13.850

TBI coding sequence:

- 1. Primary TBI diagnostic code: S06. E L S E****
- 2. Primary symptom code**, if applicable: (e.g., H53.2 - diplopia)
- 3. Deployment status code**, if applicable:*** (e.g., Z56.82 for deployed or Z91.82 for history of military deployment)
- 4. TBI external cause of morbidity code:** (For example, Y36.290A (A- use for initial visit) for war operations involving other explosions and fragments, military personnel, initial encounter)
- Place of occurrence code, if applicable
- 6. Activity code**, if applicable
- 7. Personal History of TBI code:** if applicable Z87.820

* MACE 2

** Etiology, Location, Severity, Encounter

*** Deployment code must fall within the first four codes when applicable

For more information, see DVBIC ICD-10 Coding Guidance Tool.

References available at <https://dvvic.dcoe.mil/material/military-acute-concussion-evaluation-2-mace-2-reference-list>.

We are authorized to collect the information on this form and any supporting documentation, including social security numbers, under the Patient Protection and Affordable Care Act (Public Law No. 111-148), as amended by the Health Care and Education Reconciliation Act of 2010 (Public Law No. 111-152), and the Social Security Act.

THIS TOOL MAY BE COPIED FOR CLINICAL USE.

PUID 4901

Released: February 2012 | Revised October 2018
by Defense and Veterans Brain Injury Center.

This product is reviewed annually and is current until superseded.

Reference Charts



AVPU Responsiveness Assessment

ALERT
 VERBAL – Responds to verbal stimuli
 PAIN – Responds to painful stimuli
 UNCONSCIOUS – Does not respond to any stimuli

AMPLE Patient History

A – Allergies
 M – Medications
 P – Past Medical History
 L – Last Meal
 E – Events Associated

Glasgow Coma Scale

| | | |
|-----------------|------------------------|---|
| Eye Opening | Spontaneous | 4 |
| | To Voice | 3 |
| | To Pain | 2 |
| | None | 1 |
| ----- | | |
| Verbal Response | Oriented | 5 |
| | Confused | 4 |
| | Inappropriate Words | 3 |
| | Incomprehensible Words | 2 |
| | None | 1 |
| ----- | | |
| Motor Response | Obeys Commands | 6 |
| | Localizes Pain | 5 |
| | Withdraws (Pain) | 4 |
| | Flexion | 3 |
| | Extension | 2 |
| | None | 1 |

Document as: E ___ + V ___ + M ___ = ___

OPQRST Patient History

Chief Complaint
 O – Onset
 P – Provocation
 Q – Quality
 R – Radiation
 S – Severity
 T – Time

Neurological Assessment

Mental Status

Orientation
 Affect
 Speech (Content & Process)

Cranial Nerves

- I Olfactory (Identify an odor or distinguish between 2 odors)
- II Optic (Visual Acuity test)
- III Oculomotor (Assess 6 cardinal eye movements & pupillary reactcion)
- IV Trochlear (Assess 6 cardinal eye movements)
- V Trigeminal (Facial Sensitivity & Biting/Clinching teeth)
- VI Abducens (Eye movement looking left and right)
- VII Facial (Smile, frown, raise brows, and taste)
- VIII Vestibulocochlear (Hearing-rubbing fingers & Equilibrium)
- IX Acoustic (Gag reflex and identify tastes)
- X Vagus (Gag reflex and speech)
- XI Spinal Accessory (Head movement and shoulder shrugging)
- XII Hypoglossal (stick out tongue and move left and right)

Motor Status

Posture
 Strength in basic muscle movements
 Resistance to passive movement
 Tremors or Involuntary Movements

Sensation Status

Senses light touch
 Senses pain or pricks
 Senses temperature
 Senses vibration (tuning fork)

Coordination

Gait and Stance
 Finger to nose
 Heel to shin

Reflexes

Deep tendon reflexes (biceps, triceps, knees, ankles)
 Plantar reflexes

CONVERSION CHARTS

| Length Conversions | | Weight Conversions | |
|----------------------------|--------------------------|---------------------------|-------------------------------------|
| 1 inch = 2.54 cm | 1 mm = 0.1 cm = 0.039 in | 1 oz = 30 g | 1 g = 001 kg = 0.36 oz |
| 1 foot = 30.5 cm = 0.305 m | 1 cm = 10 mm = 0.39 in | 1 lb = 16 oz = 0.45 kg | 1 kg = 1000 g = 2.2 lbs |
| 1 yard = 0.91 m | 1 m = 100 cm = 39 in | 1 ton = 2000 lbs = 907 kg | 1 ton (metric) = 1000 kg = 2200 lbs |
| 1 mile = 1.6 km | 1 km = 100 m = 1093 yd | 1 grain = 65 mg | |


| Volume Conversions | | Conversion Formulas | |
|--------------------------------|-------------------------------|---------------------|---------------------|
| 1 fl oz = 30 ml = 30 cc | 1 cc = 0.001 liter | WEIGHT | LENGTH |
| 1 US Gal = 128 fl oz = 3785 ml | 1 ml = 1 cc = 0.34 fl oz | lb = kg X 2.2 | Inches = cm X 0.394 |
| | 1 liter = 1000 ml = 340 fl oz | kg = lb X 0.45 | cm = inches X 2.54 |

| Quick Conversions | | | | | | |
|-------------------|----|-----|---------------|-------|--------------------|------|
| <u>HEIGHT</u> | | | <u>WEIGHT</u> | | <u>TEMPERATURE</u> | |
| ft/in | in | cm | lb | kg | F | C |
| 4'8" | 56 | 142 | 40 | 18.2 | 212 | 100 |
| 4'9" | 57 | 145 | 50 | 22.7 | 108 | 42.2 |
| 4'10" | 58 | 147 | 60 | 27.3 | 107 | 41.6 |
| 4'11" | 59 | 150 | 70 | 31.8 | 106 | 41.1 |
| 5'0" | 60 | 152 | 80 | 36.4 | 105 | 40.6 |
| 5'1" | 61 | 155 | 90 | 40.9 | 104 | 40.0 |
| 5'2" | 62 | 157 | 100 | 45.5 | 103 | 39.4 |
| 5'3" | 63 | 160 | 110 | 50.0 | 102 | 38.9 |
| 5'4" | 64 | 163 | 120 | 54.5 | 101 | 38.3 |
| 5'5" | 65 | 165 | 130 | 59.1 | 100 | 37.8 |
| 5'6" | 66 | 168 | 140 | 63.6 | 99 | 37.2 |
| 5'7" | 67 | 170 | 150 | 68.2 | 98 | 36.7 |
| 5'8" | 68 | 173 | 160 | 72.7 | 98.6 | 37.0 |
| 5'9" | 69 | 175 | 170 | 77.3 | 97 | 36.1 |
| 5'10" | 70 | 178 | 180 | 81.8 | 96 | 35.6 |
| 5'11" | 71 | 180 | 190 | 86.4 | 95 | 35.0 |
| 6'0" | 72 | 183 | 200 | 90.9 | 94 | 34.4 |
| 6'1" | 73 | 185 | 210 | 95.5 | 93 | 34.0 |
| 6'2" | 74 | 188 | 225 | 102.3 | 92 | 33.3 |
| 6'3" | 75 | 191 | 250 | 113.6 | 91 | 32.8 |
| 6'4" | 76 | 193 | 275 | 125.0 | 90 | 32.1 |
| 6'5" | 77 | 196 | 300 | 136.4 | | |


| | |
|----------------------|--|
| TEMPERATURE | |
| F = (1.8) X C + 32 | |
| C = (F - 32) / (1.8) | |

| IV FLUID RATES IN DROPS PER MINUTE | | | | | | | | | |
|------------------------------------|----|----|----|-----|-----|-----|-----|-----|-----|
| ml/HR | 50 | 75 | 80 | 100 | 125 | 150 | 175 | 200 | 250 |
| 10GTT- | 8 | 13 | 13 | 17 | 21 | 25 | 29 | 33 | 42 |
| 15GTT- | 12 | 19 | 20 | 25 | 31 | 37 | 44 | 50 | 62 |
| 60GTT- | 50 | 75 | 80 | 100 | 125 | 150 | 175 | 200 | 250 |

Reference Charts



Dermatomes of Cutaneous Innervation, Anterior View
(United States Navy Dive Manual)



Dermatomes of Cutaneous Innervation, Posterior View
(United States Navy Dive Manual)

Neurological Assessment

Mental Status

- Orientation
- Affect
- Speech (Content & Process)

Cranial Nerves

- I Olfactory (Identify an odor or distinguish between 2 odors)
- II Optic (Visual Acuity test)
- III Oculomotor (Assess 6 cardinal eye movements & pupillary reaction)
- IV Trochlear (Assess 6 cardinal eye movements)
- V Trigeminal (Facial Sensitivity & Biting/Clinching teeth)
- VI Abducens (Eye movement looking left and right)
- VII Facial (Smile, frown, raise brows, and taste)
- VIII Vestibulocochlear (Hearing-rubbing fingers & Equilibrium)
- IX Acoustic (Gag reflex and identify tastes)
- X Vagus (Gag reflex and speech)
- XI Spinal Accessory (Head movement and shoulder shrugging)
- XII Hypoglossal (stick out tongue and move left and right)

Neurological Assessment

Motor Status

- Posture
- Strength in basic muscle movements
- Resistance to passive movement
- Tremors or Involuntary Movements

Sensation Status

- Senses light touch
- Senses pain or pricks
- Senses temperature
- Senses vibration (tuning fork)

Coordination

- Gait and Stance
- Finger to nose
- Heel to shin

Reflexes

- Deep tendon reflexes (biceps, triceps, knees, ankles)
- Plantar reflexes

Ketamine Drip

Ketamine drip (for sedation): Sedation loading dose first (1mg/kg IV/IO over 60 seconds).

MIX: 750mg (1.5 vials of 500mg/5mL) in 250mL of normal saline (3mg/mL solution).

Initial drip dose:

- **Best:** Using an IV pump, set to $\mu\text{g}/\text{kg}/\text{min}$ dose desired. Increase or decrease dose by 5–10 $\mu\text{g}/\text{kg}/\text{min}$ increments.
- **Better:** Using a dial flow adaptor, initial drip rate in mL/h equals the casualty's weight in kg divided by 2 (see mL/h table).
- **Minimum:** Count drip rate. Increase or decrease rate by 1–2 drips/min (very slowly) to achieve goal.

Drip adjustments: Increase or decrease drip by 0.25mg/kg/h (1 row).

| Ketamine Drip Dosing Tables | | | | | |
|---|------------------------------------|---------------------------------|------|------|------|
| Ketamine drip rate for dial flow or IV pump (starting dose highlighted) | | | | | |
| Dose | | Patient's Weight, kg | | | |
| | | 40 | 60 | 80 | 100 |
| mg/kg/h | $\mu\text{g}/\text{kg}/\text{min}$ | Infusion Rate, mL/h | | | |
| 0.5 | 8 | 7* | 10 | 13 | 17 |
| 0.75 | 13 | 10 | 15 | 20 | 25 |
| 1.0 | 17 | 13 | 20 | 27 | 33 |
| 1.25 | 21 | 17 | 25 | 34 | 42 |
| 1.5 | 25 | 20 | 30 | 40 | 50 |
| 1.75 | 29 | 24 | 35 | 47 | 59 |
| 2.0 | 33 | 27 | 40 | 53 | 67 |
| Ketamine drip count for 15 drips/mL tubing (starting dose highlighted) | | | | | |
| | | Infusion Rate, 1 drip/X seconds | | | |
| 0.5 | 8 | 1/35 | 1/24 | 1/18 | 1/9 |
| 0.75 | 13 | 1/27 | 1/18 | 1/14 | 1/8 |
| 1.0 | 17 | 1/18 | 1/12 | 1/9 | 1/7 |
| 1.25 | 21 | 1/15 | 1/10 | 1/8 | 1/6 |
| 1.5 | 25 | 1/12 | 1/8 | 1/6 | 1/5 |
| 1.75 | 29 | 1/11 | 1/7 | 1/6 | 1/5 |
| 2.0 | 33 | 1/9 | 1/6 | 1/5 | 1/4 |
| Ketamine drip count for 10 drips/mL tubing (starting dose highlighted) | | | | | |
| | | Infusion Rate, 1 drip/X seconds | | | |
| 0.5 | 8 | 1/53 | 1/36 | 1/27 | 1/14 |
| 0.75 | 13 | 1/41 | 1/27 | 1/21 | 1/12 |
| 1.0 | 17 | 1/27 | 1/18 | 1/14 | 1/11 |
| 1.25 | 21 | 1/23 | 1/15 | 1/12 | 1/9 |
| 1.5 | 25 | 1/18 | 1/12 | 1/9 | 1/8 |
| 1.75 | 29 | 1/17 | 1/11 | 1/9 | 1/8 |
| 2.0 | 33 | 1/14 | 1/9 | 1/8 | 1/6 |

ARDSNET Vent Settings

| HEIGHT | PBW | 4 ml | 5 ml | 6 ml | 7 ml | 8 ml |
|-------------|-------|------|------|------|------|------|
| 4' 0" (48) | 17.9 | 72 | 90 | 107 | 125 | 143 |
| 4' 1" (49) | 20.2 | 81 | 101 | 121 | 141 | 162 |
| 4' 2" (50) | 22.5 | 90 | 113 | 135 | 158 | 180 |
| 4' 3" (51) | 24.8 | 99 | 124 | 149 | 174 | 198 |
| 4' 4" (52) | 27.1 | 108 | 136 | 163 | 190 | 217 |
| 4' 5" (53) | 29.4 | 118 | 147 | 176 | 206 | 235 |
| 4' 6" (54) | 31.7 | 127 | 159 | 190 | 222 | 254 |
| 4' 7" (55) | 34 | 136 | 170 | 204 | 238 | 272 |
| 4' 8" (56) | 36.3 | 145 | 182 | 218 | 254 | 290 |
| 4' 9" (57) | 38.6 | 154 | 193 | 232 | 270 | 309 |
| 4' 10" (58) | 40.9 | 164 | 205 | 245 | 286 | 327 |
| 4' 11" (59) | 43.2 | 173 | 216 | 259 | 302 | 346 |
| 5' 0" (60) | 45.5 | 182 | 228 | 273 | 319 | 364 |
| 5' 1" (61) | 47.8 | 191 | 239 | 287 | 335 | 382 |
| 5' 2" (62) | 50.1 | 200 | 251 | 301 | 351 | 401 |
| 5' 3" (63) | 52.4 | 210 | 262 | 314 | 367 | 419 |
| 5' 4" (64) | 54.7 | 219 | 274 | 328 | 383 | 438 |
| 5' 5" (65) | 57 | 228 | 285 | 342 | 399 | 456 |
| 5' 6" (66) | 59.3 | 237 | 297 | 356 | 415 | 474 |
| 5' 7" (67) | 61.6 | 246 | 308 | 370 | 431 | 493 |
| 5' 8" (68) | 63.9 | 256 | 320 | 383 | 447 | 511 |
| 5' 9" (69) | 66.2 | 265 | 331 | 397 | 463 | 530 |
| 5' 10" (70) | 68.5 | 274 | 343 | 411 | 480 | 548 |
| 5' 11" (71) | 70.8 | 283 | 354 | 425 | 496 | 566 |
| 6' 0" (72) | 73.1 | 292 | 366 | 439 | 512 | 585 |
| 6' 1" (73) | 75.4 | 302 | 377 | 452 | 528 | 603 |
| 6' 2" (74) | 77.7 | 311 | 389 | 466 | 544 | 622 |
| 6' 3" (75) | 80 | 320 | 400 | 480 | 560 | 640 |
| 6' 4" (76) | 82.3 | 329 | 412 | 494 | 576 | 658 |
| 6' 5" (77) | 84.6 | 338 | 423 | 508 | 592 | 677 |
| 6' 6" (78) | 86.9 | 348 | 435 | 521 | 608 | 695 |
| 6' 7" (79) | 89.2 | 357 | 446 | 535 | 624 | 714 |
| 6' 8" (80) | 91.5 | 366 | 458 | 549 | 641 | 732 |
| 6' 9" (81) | 93.8 | 375 | 469 | 563 | 657 | 750 |
| 6' 10" (82) | 96.1 | 384 | 481 | 577 | 673 | 769 |
| 6' 11" (83) | 98.4 | 394 | 492 | 590 | 689 | 787 |
| 7' 0" (84) | 100.7 | 403 | 504 | 604 | 705 | 806 |

| HEIGHT | PBW | 4 ml | 5 ml | 6 ml | 7 ml | 8 ml |
|-------------|-------|------|------|------|------|------|
| 4' 0" (48) | 22.4 | 90 | 112 | 134 | 157 | 179 |
| 4' 1" (49) | 24.7 | 99 | 124 | 148 | 173 | 198 |
| 4' 2" (50) | 27 | 108 | 135 | 162 | 189 | 216 |
| 4' 3" (51) | 29.3 | 117 | 147 | 176 | 205 | 234 |
| 4' 4" (52) | 31.6 | 126 | 158 | 190 | 221 | 253 |
| 4' 5" (53) | 33.9 | 136 | 170 | 203 | 237 | 271 |
| 4' 6" (54) | 36.2 | 145 | 181 | 217 | 253 | 290 |
| 4' 7" (55) | 38.5 | 154 | 193 | 231 | 270 | 308 |
| 4' 8" (56) | 40.8 | 163 | 204 | 245 | 286 | 326 |
| 4' 9" (57) | 43.1 | 172 | 216 | 259 | 302 | 345 |
| 4' 10" (58) | 45.4 | 182 | 227 | 272 | 318 | 363 |
| 4' 11" (59) | 47.7 | 191 | 239 | 286 | 334 | 382 |
| 5' 0" (60) | 50 | 200 | 250 | 300 | 350 | 400 |
| 5' 1" (61) | 52.3 | 209 | 262 | 314 | 366 | 418 |
| 5' 2" (62) | 54.6 | 218 | 273 | 328 | 382 | 437 |
| 5' 3" (63) | 56.9 | 228 | 285 | 341 | 398 | 455 |
| 5' 4" (64) | 59.2 | 237 | 296 | 355 | 414 | 474 |
| 5' 5" (65) | 61.5 | 246 | 308 | 369 | 431 | 492 |
| 5' 6" (66) | 63.8 | 255 | 319 | 383 | 447 | 510 |
| 5' 7" (67) | 66.1 | 264 | 331 | 397 | 463 | 529 |
| 5' 8" (68) | 68.4 | 274 | 342 | 410 | 479 | 547 |
| 5' 9" (69) | 70.7 | 283 | 354 | 424 | 495 | 566 |
| 5' 10" (70) | 73 | 292 | 365 | 438 | 511 | 584 |
| 5' 11" (71) | 75.3 | 301 | 377 | 452 | 527 | 602 |
| 6' 0" (72) | 77.6 | 310 | 388 | 466 | 543 | 621 |
| 6' 1" (73) | 79.9 | 320 | 400 | 479 | 559 | 639 |
| 6' 2" (74) | 82.2 | 329 | 411 | 493 | 575 | 658 |
| 6' 3" (75) | 84.5 | 338 | 423 | 507 | 592 | 676 |
| 6' 4" (76) | 86.8 | 347 | 434 | 521 | 608 | 694 |
| 6' 5" (77) | 89.1 | 356 | 446 | 535 | 624 | 713 |
| 6' 6" (78) | 91.4 | 366 | 457 | 548 | 640 | 731 |
| 6' 7" (79) | 93.7 | 375 | 469 | 562 | 656 | 750 |
| 6' 8" (80) | 96 | 384 | 480 | 576 | 672 | 768 |
| 6' 9" (81) | 98.3 | 393 | 492 | 590 | 688 | 786 |
| 6' 10" (82) | 100.6 | 402 | 503 | 604 | 704 | 805 |
| 6' 11" (83) | 102.9 | 412 | 515 | 617 | 720 | 823 |
| 7' 0" (84) | 105.2 | 421 | 526 | 631 | 736 | 842 |

PBW and Tidal
Volume for Females

PBW and Tidal
Volume for Males

ARDSNET Vent Settings



NIH NHLBI ARDS Clinical Network
Mechanical Ventilation Protocol Summary

INCLUSION CRITERIA: Acute onset of

1. $PaO_2/FiO_2 \leq 300$ (corrected for altitude)
2. Bilateral (patchy, diffuse, or homogeneous) infiltrates consistent with pulmonary edema
3. No clinical evidence of left atrial hypertension

PART I: VENTILATOR SETUP AND ADJUSTMENT

1. Calculate predicted body weight (PBW)
Males = $50 + 2.3 [\text{height (inches)} - 60]$
Females = $45.5 + 2.3 [\text{height (inches)} - 60]$
2. Select any ventilator mode
3. Set ventilator settings to achieve initial $V_T = 8$ ml/kg PBW
4. Reduce V_T by 1 ml/kg at intervals ≤ 2 hours until $V_T = 6$ ml/kg PBW.
5. Set initial rate to approximate baseline minute ventilation (not > 35 bpm).
6. Adjust V_T and RR to achieve pH and plateau pressure goals below.

OXYGENATION GOAL: PaO_2 55-80 mmHg or SpO_2 88-95%
Use a minimum PEEP of 5 cm H₂O. Consider use of incremental FiO_2 /PEEP combinations such as shown below (not required) to achieve goal.

Lower PEEP/higher FiO_2

| | | | | | | | | |
|---------|-----|-----|-----|-----|-----|-----|-----|-----|
| FiO_2 | 0.3 | 0.4 | 0.4 | 0.5 | 0.5 | 0.6 | 0.7 | 0.7 |
| PEEP | 5 | 5 | 8 | 8 | 10 | 10 | 10 | 12 |

| | | | | | | |
|---------|-----|-----|-----|-----|-----|-------|
| FiO_2 | 0.7 | 0.8 | 0.9 | 0.9 | 0.9 | 1.0 |
| PEEP | 14 | 14 | 14 | 16 | 18 | 18-24 |

Higher PEEP/lower FiO_2

| | | | | | | | | |
|---------|-----|-----|-----|-----|-----|-----|-----|-----|
| FiO_2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.4 | 0.4 | 0.5 |
| PEEP | 5 | 8 | 10 | 12 | 14 | 14 | 16 | 16 |

| | | | | | | |
|---------|-----|---------|-----|-----|-----|-----|
| FiO_2 | 0.5 | 0.5-0.8 | 0.8 | 0.9 | 1.0 | 1.0 |
| PEEP | 18 | 20 | 22 | 22 | 22 | 24 |

PLATEAU PRESSURE GOAL: ≤ 30 cm H₂O

Check Pplat (0.5 second inspiratory pause), at least q 4h and after each change in PEEP or V_T .

If Pplat > 30 cm H₂O: decrease V_T by 1ml/kg steps (minimum = 4 ml/kg).

If Pplat < 25 cm H₂O and $V_T < 6$ ml/kg, increase V_T by 1 ml/kg until Pplat > 25 cm H₂O or $V_T = 6$ ml/kg.

If Pplat < 30 and breath stacking or dys-synchrony occurs: may increase V_T in 1ml/kg increments to 7 or 8 ml/kg if Pplat remains ≤ 30 cm H₂O.

ARDSNET Vent Settings

pH GOAL: 7.30-7.45

Acidosis Management: (pH < 7.30)

If pH 7.15-7.30: Increase RR until pH > 7.30 or PaCO₂ < 25 (Maximum set RR = 35).

If pH < 7.15: Increase RR to 35.

If pH remains < 7.15, V_T may be increased in 1 ml/kg steps until pH > 7.15 (Pplat target of 30 may be exceeded).
May give NaHCO₃

Alkalosis Management: (pH > 7.45) Decrease vent rate if possible.

I: E RATIO GOAL: Recommend that duration of inspiration be \leq duration of expiration.

PART II: WEANING

A. Conduct a SPONTANEOUS BREATHING TRIAL daily when:

1. FIO₂ \leq 0.40 and PEEP \leq 8.
2. PEEP and FIO₂ \leq values of previous day.
3. Patient has acceptable spontaneous breathing efforts. (May decrease vent rate by 50% for 5 minutes to detect effort.)
4. Systolic BP \geq 90 mmHg without vasopressor support.
5. No neuromuscular blocking agents or blockade.

B. SPONTANEOUS BREATHING TRIAL (SBT):

If all above criteria are met and subject has been in the study for at least 12 hours, initiate a trial of UP TO 120 minutes of spontaneous breathing with FIO₂ \leq 0.5 and PEEP \leq 5:

1. Place on T-piece, trach collar, or CPAP \leq 5 cm H₂O with PS \leq 5
2. Assess for tolerance as below for up to two hours.
 - a. SpO₂ \geq 90; and/or PaO₂ \geq 60 mmHg
 - b. Spontaneous V_T \geq 4 ml/kg PBW
 - c. RR \leq 35/min
 - d. pH \geq 7.3
 - e. No respiratory distress (distress = 2 or more)
 - HR > 120% of baseline
 - Marked accessory muscle use
 - Abdominal paradox
 - Diaphoresis
 - Marked dyspnea
3. If tolerated for at least 30 minutes, consider extubation.
4. If not tolerated resume pre-weaning settings.


Definition of UNASSISTED BREATHING (Different from the spontaneous breathing criteria as PS is not allowed)

1. Extubated with face mask, nasal prong oxygen, or room air, OR
2. T-tube breathing, OR
3. Tracheostomy mask breathing, OR
4. CPAP less than or equal to 5 cm H₂O without pressure support or IMV assistance.

Name/Unit _____

DTG: _____ ALLERGIES: _____

Friendly Unknown NBC



GSW BLAST MVA Other _____

| | | | | |
|-------|--|--|--|--|
| TIME | | | | |
| AVPU | | | | |
| PULSE | | | | |
| RESP | | | | |
| BP | | | | |

A: Intact Adjunct Cric Intubated

B: Chest Seal NeedleD ChestTube

C: TQ Hemostatic Packed PressureDrsg

FLUIDS: IV IO

NS / LR 500 1000 1500

Hexend 500 1000

Other: _____

DRUGS (Type / Dose / Route):

PAIN

ABX

OTHER

First Responder's Name _____

Prolonged Field Care Flowsheet v.2.1.1 (16 Jan 2018)

| | | | | | |
|---|--|-------|---------|-------------|----------------------------------|
| Name: | Date: | Time: | Weight: | Blood type: | EVAC Category: I D M E |
| S: | <div style="display: flex; justify-content: space-around;"> </div> | | | | |
| A: | | | | | |
| M: | | | | | |
| P: | | | | | |
| L: | | | | | |
| E: | | | | | |
| M.I.S.T. Report: MOI: _____ Stable or Unstable _____ Injuries / Illness / Problems _____ Treatments - Plans _____ | | | | | |
| TQ 1 time on: _____ TQ 2 time on: _____ TQ 3 time on: _____ TQ 4 time on: _____ TQ 1 Converted: _____ TQ 2 Converted: _____ TQ 3 Converted: _____ TQ 4 Converted: _____ TXA Dose 1 on: _____ TXA Dose 2 on: _____ | | | | | |
| Notes: _____ Teleconsult Call Script and Patient Handover Info Time: _____ This is _____, an _____ (Job Position) who I think has _____ and I need _____ Complaint: _____ Chief _____ History: _____ Brief _____ HR: _____ RR: _____ BP: _____ Temp: _____ Pulse: _____ OX: _____ UOP: _____ AVPU: _____ Exam: _____ Findings: _____ Recommendations: _____ Fluids/Meds: _____ Interventions: _____ Flags: _____ Red: _____ | | | | | |

TBI RTD Protocol

Ranger TBI Return to Duty Protocol

| Stage (24h per stage if symptom-free) | Vestibular/Ocular-Motor/Cervical Physical Activities | Cognitive/Mood/Migraine Activities | Restrictions | Stage Objective | | | | | | |
|--|--|--|---|--|--|-----------|--|---|--|---|
| 1 | <ul style="list-style-type: none"> Daily activity that does not provoke symptoms. Light leisure activity, including walking on level surfaces Low light, low noise environment | <ul style="list-style-type: none"> Rest with minimal limited cognitive activity Light reading TV limited to 1-2 hours a day | <ul style="list-style-type: none"> No work (stay home) No alcohol No exercise, video games, studying, or driving Any activity that worsens or causes symptoms | Rest, limit activity to promote recovery and eliminate symptoms. | | | | | | |
| 2 | <p>Light Routine Activity:</p> <table border="1"> <thead> <tr> <th>Activity</th> <th>Rest</th> </tr> </thead> <tbody> <tr> <td>Physical</td> <td>30 min 4 hrs.</td> </tr> <tr> <td>Cognitive</td> <td>30 min 60 min</td> </tr> </tbody> </table> <ul style="list-style-type: none"> Light physical activities to include walking, stationary bike, elliptical at low pace and resistance Balance activities: climb stairs, put on boots and bending tasks | Activity | Rest | Physical | 30 min 4 hrs. | Cognitive | 30 min 60 min | <ul style="list-style-type: none"> Cognitive activity limited to computer use, leisure reading and simple board games | <ul style="list-style-type: none"> No alcohol No video games, resistance training, repetitive lifting, sit-ups, push-ups or pull-ups No driving until vision & vestibular symptoms resolve | <p>Introduce and promote limited effort.</p> <p>Determine tolerance to mild exertion without vestibulo-ocular load.</p> |
| Activity | Rest | | | | | | | | | |
| Physical | 30 min 4 hrs. | | | | | | | | | |
| Cognitive | 30 min 60 min | | | | | | | | | |
| 3 | <p>Light Occupation-oriented Activity:</p> <table border="1"> <thead> <tr> <th>Activity</th> <th>Rest</th> </tr> </thead> <tbody> <tr> <td>Physical</td> <td>60 min 4 hrs.</td> </tr> <tr> <td>Cognitive</td> <td>30 min 60 min</td> </tr> </tbody> </table> <ul style="list-style-type: none"> Balance activity: walking on uneven terrain, swimming with no flip turns May wear helmet and equipment Lift/carry objects less than 20 lbs Integrated with RAW staff | Activity | Rest | Physical | 60 min 4 hrs. | Cognitive | 30 min 60 min | <ul style="list-style-type: none"> Task-oriented simple tasks; such as disassemble, clean and re-assemble weapon | <ul style="list-style-type: none"> No video games Alcohol may worsen symptoms; avoid or minimize to speed full recovery No combatives or collision sports No activities that create excessive head movements | Increase intensity and complexity of exercise and cognitive activity. |
| Activity | Rest | | | | | | | | | |
| Physical | 60 min 4 hrs. | | | | | | | | | |
| Cognitive | 30 min 60 min | | | | | | | | | |
| 4 | <p>Moderate Activity:</p> <table border="1"> <thead> <tr> <th>Activity</th> <th>Rest</th> </tr> </thead> <tbody> <tr> <td>Physical</td> <td>30 min 60 min 90 min 20 min 30 min 40 min</td> </tr> <tr> <td>Cognitive</td> <td>2 hrs. 4 hrs. 6 hrs. 40 min 60 min 80 min</td> </tr> </tbody> </table> <ul style="list-style-type: none"> Resistance training (NO vestibular load) Use elliptical and stair climber Balance activities: include NVGs, jump rope, swimming with NO flip turns Cleared for Olympic weight lifting for technique only | Activity | Rest | Physical | 30 min 60 min 90 min 20 min 30 min 40 min | Cognitive | 2 hrs. 4 hrs. 6 hrs. 40 min 60 min 80 min | <ul style="list-style-type: none"> Cleared to play video games if tolerated Any cognition or mood issues should be evaluated by cognitive performance coach and behavioral health | <ul style="list-style-type: none"> No combatives or collision sports No weapons firing | Increase intensity and complexity of physical, cognitive and balance activities to match demand of occupation |
| Activity | Rest | | | | | | | | | |
| Physical | 30 min 60 min 90 min 20 min 30 min 40 min | | | | | | | | | |
| Cognitive | 2 hrs. 4 hrs. 6 hrs. 40 min 60 min 80 min | | | | | | | | | |

Progression to the next stage may occur at different rates for each domain (physical, cognitive, vestibular, etc)

TBI RTD Protocol

Ranger TBI Return to Duty Protocol

| <p>5 Moderate Activity Amplified:</p> <table border="1" data-bbox="305 394 381 493"> <thead> <tr> <th>Activity</th> <th>Rest</th> </tr> </thead> <tbody> <tr> <td>30 min.</td> <td>2 hrs.</td> </tr> <tr> <td>60 min.</td> <td>4 hrs.</td> </tr> <tr> <td>90 min.</td> <td>6 hrs.</td> </tr> </tbody> </table> <p>Physical</p> | Activity | Rest | 30 min. | 2 hrs. | 60 min. | 4 hrs. | 90 min. | 6 hrs. | <ul style="list-style-type: none"> Use driving and weapon simulators May perform movements that create large changes in head movement (burpees, squat thrusts) | <ul style="list-style-type: none"> Cognitive activity: moderate concentration tasks i.e. mission planning for no more than 2 hours with a 6090 mental break | <ul style="list-style-type: none"> No combatives or collision sports No weapons fire | <p>***To advance beyond Stage 5, SM must complete a multisystem based (vestibulo-ocular + exertion) battery.</p> |
|--|--|---|---|--|---------|--------|---------|--------|--|--|--|--|
| Activity | Rest | | | | | | | | | | | |
| 30 min. | 2 hrs. | | | | | | | | | | | |
| 60 min. | 4 hrs. | | | | | | | | | | | |
| 90 min. | 6 hrs. | | | | | | | | | | | |
| <p>6 Intense Activity:</p> <p>May begin Return to Shoot Protocol* AFTER successful completion of Stage 5 multisystem exertion battery</p> | <ul style="list-style-type: none"> Start range time with small arms fire only; no movement Start running, jump landing, full use of NVGs Start CQB crawl-walk-run reintegration | <ul style="list-style-type: none"> Assess for tolerance to small arms blast exposure | <ul style="list-style-type: none"> No combatives or collision sports | <p>Introduce activity of duration and intensity that parallels the SMs typical job</p> | | | | | | | | |
| <p>7 Intense Activity Amplified:</p> | <ul style="list-style-type: none"> CQB crawl-walk-run reintegration with weapons fire Start TECHNIQUE ONLY combatives | <ul style="list-style-type: none"> Cognitive activity: high concentration tasks i.e. target acquisition, mission planning | <ul style="list-style-type: none"> No crew-served weapons, mortars, breaching No live sparring | <p>*Stage 6 Return to Shoot Protocol begins with shooting only to assess tolerance to small arms blast before stepwise integration of movement and vestibulo-ocular systems</p> | | | | | | | | |
| <p>8 Intense Occupation-oriented Activity:</p> | <ul style="list-style-type: none"> Cleared for moderate paced combatives Start small obstacle course | <ul style="list-style-type: none"> Any ongoing cognitive or mood issues (irritability/concentration) require medical specialist reassessment | <ul style="list-style-type: none"> No live sparring or striking | <p>Graded return to duty</p> | | | | | | | | |
| <p>9 Restricted Duty:</p> <p>(Must be cleared by Medical Team MD/PA/PT/Psych in conjunction with command team)</p> | <ul style="list-style-type: none"> Cleared to fast-rope, climb, live combatives; Cleared for ARN activities Cleared to slowly increase exposure to larger munition and blasts | <ul style="list-style-type: none"> Cleared for full cognitive duties | <ul style="list-style-type: none"> Blast exposure limited for 30 days or longer based on medical clearance | <p>Graded return to duty</p> | | | | | | | | |
| <p>–</p> | <ul style="list-style-type: none"> Normal occupational duties | <ul style="list-style-type: none"> Normal duties | <ul style="list-style-type: none"> Normal duties | <p>Graded return to duty</p> | | | | | | | | |
| <p><input type="checkbox"/> If experiencing symptoms, SM should halt activities for the day and report symptoms to their medical team</p> | | | | | | | | | | | | |

Progression to the next stage may occur at different rates for each domain (physical, cognitive, vestibular, etc)

